"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals' Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr.",52,"Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals' Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr. Michael Aberman, Senior Vice President of Strategy and Investor Relations. You may begin, sir."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals' Fourth Quarter and Year-end 2015 Conference Call. An archive of this webcast will be available on our webcast under Events & Presentations for 30 days. Joining me on t",332,"Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals' Fourth Quarter and Year-end 2015 Conference Call. An archive of this webcast will be available on our webcast under Events & Presentations for 30 days. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George and Coppola's, Founding Scientist, President of Regeneron Laboratories and Chief Financial Officer; Bob Terifay, Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we'll open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter-ended September 30, 2015, and Form 10-K for the year-ended December 31, 2015, which is expected to be filed with the SEC later this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement or -- whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and the reconciliation of those measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com.
Once our call concludes, our CFO, Bob Landry and the IR team, will be able to answer further questions. With that, let me turn the call over to President and Chief Executive Officer, Dr. Len Schleifer."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael. Good morning to everyone who has joined us on the call and webcast today. 2015 was another successful and productive year for Regeneron. EYLEA delivered expressive global growth, and we received approval for and launch Praluent, which is",557,"Thanks, Michael. Good morning to everyone who has joined us on the call and webcast today. 2015 was another successful and productive year for Regeneron. EYLEA delivered expressive global growth, and we received approval for and launch Praluent, which is indicated in the U.S. as an agent to diet and maximum tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical cardiovascular disease who require additional lowering of LDL cholesterol. We made significant advances in our late-stage pipeline, submitting a biological license application, or BLA, for sarilumab in rheumatoid arthritis and advancing Phase III clinical development for dupilumab in atopic dermatitis and asthma. In 2015, we also advanced 2 new antibodies into Phase III. Regeneron 2222 for the prevention of SingTel virus or RSV infection and our anti-NGF body for osteoarthritis pain. 
We've also advanced our early-stage pipeline with progress across multiple therapeutic areas, including retinal diseases, cancer, infectious diseases and cardiovascular diseases. 
Turning to EYLEA performance. EYLEA is now the market-leading brand in anti- VEGF therapy for retinal disease in the United States and continue to exhibit strong growth, both in the U.S. and worldwide. We saw approximately 54% growth year-over-year in the U.S., with sales of $2.68 billion. On a worldwide basis, EYLEA sales were approximately $4.1 billion for the full year. 
For the full year 2016, we estimate U.S. EYLEA net sales to grow approximately 20% over full year 2015 U.S. net sales. We are focused on maintaining our leadership in the retinal space. We are continuing clinical development with EYLEA where we have ongoing combination programs with PDGF and with Ang2 and are pursuing important additional indications for EYLEA that George will review later in the 
call. Turning out to Praluent. We're proud to first PCSK9 inhibitor to the market in the United States for patients with uncontrolled LDL cholesterol, which was approved and launch in July of last year. We are still in the early stages of this launch and have been working diligently to provide broad access to eligible patients and educated physicians and patients in order to increase adoption. Bob Terifay will provide some additional metrics on how the launch is progressing. Our mission at Regeneron for 25-plus years has been to consistently and repeatedly bring important new medicines to patients in need, and we feel that we are well-positioned to deliver on this mission with our innovative pipeline. Building on last year's approval of Praluent, we anticipate at least 1 approval each year for the coming years. In 2016, we anticipate the approval of sarilumab for the treatment of rheumatoid arthritis. Our breakthrough product, dupilumab in atopic dermatitis, is progressing and expect to report top line Phase III data and submitted BLA in the U.S. during this year. Beyond dupilumab, we have a rapidly developing late- and early-stage pipeline that now consist of 13 product candidates that were all discovered by the scientists at Regeneron. And we expect to put additional candidates into the clinic this year. George will provide some perspective on this during his remarks. 
In summary, we are in the midst of a very exciting time with Regeneron with many important events anticipated in 2016. With that, let me turn the call over to George Yancopoulos, Regeneron's Chief Scientific Officer. He will be followed by Bob Terifay, and then by Bob Landry."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. I would like to begin with EYLEA. Diabetic retinopathy is the common cause of vision loss in patie",937,"Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. I would like to begin with EYLEA. Diabetic retinopathy is the common cause of vision loss in patients with diabetes and as a result of microvascular damage to the blood vessels in the retina. When left untreated, diabetic retinopathy can progress sometimes acute vision loss. While EYLEA is a very medical retinopathy would diabetic macular edema, or DME, we believe that it could benefit much broader patient population diabetic retinopathy who do not have no proof anti-VEGF therapy. Therefore, in the first quarter of this year we plan to initiate, Phase III study of EYLEA in patients with non-diabetic retinopathy without diabetic macular edema. The National Institute of Health will also independently investigate the potential role of anti-VEGF therapy in the treatment of diabetic retinopathy. This study called, will be sponsored by the Diabetic Retinopathy Clinical Research Network or DRCR and will compare EYLEA Titian in phases with severe, non-proliferative diabetic retinopathy. 
Protocol W is expected to begin in the first quarter. A Phase II study of EYLEA in combination with our antibody delivered a powerful related injection macular degeneration, or Wet AMD, is ongoing, and we expect some top line data from the study by year-end. This program has been granted fast track designation by the FDA. Data from the Phase I study of EYLEA in combination with antibody, delivered co- formulated injection, which was presented just last week at the conference. This data show that the combination of EYLEA with and well tolerated with patients with AMD and patients with DMD. We plan to initiate Phase II studies that will include both this patient population in the first half of the year. 
As Len mentioned, our Praluent launch is underway, and you'll hear further details from Bob Terifay on the commercial front. Our 18,000-patient outcomes trial is ongoing, and we expect the first interim analysis, which will utility later this year based upon 50% of the expected events from the trial. Also, what a potential to have our second interim analysis, which occurs after 75% of the targeted primary event that have accrued by the end of this year. And this interim analysis overwhelming efficacy and fertility. As we previously disclosed, analysis with a hazard ratio of 0.802, favoring Praluent, as well as consistency across subgroups and regions, positive for secondary implants including all mortality and no cardiovascular mortality. These last points are all important as we do not want to unblind a trial early because its efficacy in the primary endpoint at the cost of not reaching significant and important secondary endpoints. 
In addition to the outcomes trial, we plan to submit a supplemental BLA in the first half of the year with the Praluent mostly dosing regiment. 
Turning now to sarilumab, our IL-6 receptor for rheumatoid arthritis. The regulatory submissions accepted by the FDA and has been granted an action date of October 30, 2016. The Phase III MONARCH trial, which is a superiority study of sarilumab monotherapy versus alirocumab, which fully enrolled and we expect top line data from this study in the first half of 2016. A European regulatory submission for sarilumab is expected to be made in the second half of 2016. I share enthusiasm for dupilumab, our IL-4-13 pathway blocking antibody, which is currently in Phase III clinical studies in asthma and in adults with moderate to severe atopic dermatitis where it's been granted breakthrough designation. We because there are no FDA approved systemic therapy for adult patients with moderate to severe atopic dermatitis. We expect  to report top line data from the Phase III atopic dermatitis study, solo 1, solo 2 and in the first half of this year, which will complete rolling DLS submission in the second half of the year. Approximately 1,700-patient pivotal Phase III study of dupilumab in asthma is also in order. We also continued to explore other indications for dupilumab, which is nasal polyps and the eosinophilic esophagitis as well as other allergic or IL-4-13 mediated diseases. 
Our Nerve Growth Factor antibody or NGF antibody, , is another late-stage pipeline candidate. Pain is one of the leading reasons that patients visit their doctors, and osteoarthritis is one of the major source of the pain in adults, particularly older adults. The increase in use of prescription to treat pains has led to a growing epidemic of drug addiction and overdose-related fatalities as well as other opioid-related side effects. 
Blocking NGF has already shown the ability to improve pain compared to placebo or active such as nonsterile anti-inflammatory drugs or in Phase II and Phase III trials. We now have a clear path forward from the FDA and will be starting with 10,000-patient long-term treatment Phase II clinical study of dupilumab in the first half of the year. We anticipate reporting data from the 16-week study in osteoarthritis pain in the first half of the year. In our early-stage pipeline, we plan to share data from our Phase I/II study of , our antibody to ANGPTL3 with from the first half as well as data from our ongoing immuno-oncology program such as our PD-1 program and the CD20 by CD3 by specific program. We have obviously been very busy in production. In fact, this year, we expect to submit a record number of IND, and we look forward to sharing more details with you as these programs move into the clinic. And with that, I would like to turn the call over to Bob Terifay."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continue to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantial",813,"Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continue to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantial progress in securing access and reimbursement for Praluent or alirocumab, among U.S. payors. In addition, the European launch for Praluent commenced. 
Starting with EYLEA. Fourth quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the fourth quarter were $746 million. Full year, U.S. EYLEA sales were $2.68 billion, which represented 54% year-over-year growth. A survey of 201 U.S. retinal specialists, who evaluated their reported usage of VEGF inhibitors in the fourth quarter 2015, indicates that EYLEA continues to be the market-leading product among FDA-approved anti-VEGF agents in all of our labeled indications. In terms of market share treated eyes. Importantly, the market share of treated eyes for EYLEA and DME is roughly double that for and similar to that to off-label 
Turning now to Praluent. As reported by Sanofi, net sales in the fourth quarter were $7 million, which understates the actual position in patient demand. As we reminded you last quarter, we anticipate that it would take some time for commercial and government payers to conduct formulary reviews, make reimbursement coverage decisions and begin to process patient claims. Given these reasons, as well as strict utilization management criteria, we continue to expect a gradual uptake. In response to potential delays and formulary reimbursement decisions, we're offering free product to appropriate patients consistent with our labeled indication. We are waiting an insurance coverage position. These delays uptake in commercial sales reporting. 
For example, much of Medicare part D are government pay patients are receiving pre-drug spending formulary coverage, which is expected later in the quarter. So performance cannot be solely judged on sales or filled prescriptions. As a reminder, the reimbursement environment is complex and is carefully managed by payers. Our goal has been to ensure the payers and health care providers understand the value that Praluent can offer the patients. And to that end, we have been and are still actively engaged in discussions with payers. There are approximately 240 million lives in the United States that have a drug benefit covered by commercial insurance or Medicare part D plans. Published decisions have already been made for approximately 90% of these lives. However, implementation is ongoing, and we expect continued rollout of the coverage over the next several months. Overall, for approximately 50% of the recovered lives, a single PCSK9 antibody has been chosen an exclusive of preferred physician. In this exclusive of preferred cases, we estimate that Praluent was chosen for about 60% of the lives. The preference for Praluent was particularly evident in the Medicare Part D decisions. In Medicare, 80% of the lives have a single PCSK9 antibody in an exclusive or preferred position. For these exclusive or preferred Medicare Part B lives, Praluent was selected approximately 95% of the time. We believe these Medicare coverage decisions are particularly important because a major indication for Praluent is for patients with history of atherosclerotic cardiovascular disease, and these patients tend to be older. According to our estimates, about 28% of statin patients in the United States are Medicare Part B patients. We're pleased to see that Praluent is resonating well with payers. As plans begin to activate the coverage, we anticipate a potential uptake in prescription volume. Importantly, almost 90% of all prescriptions processed by the hub are for our lower 75-milligram every-other-week dose. As a reminder, and our Phase III clinical studies, the vast majority of Praluent patients achieve their LDL-cholesterol goals with 75 milligrams every-other-week dose. We continue our efforts to educate both patients and physicians on the benefits of using PCSK9 inhibitor therapy. Outside of the United States, Praluent was approved in the EU in September, with product available in several countries. Reimbursement discussions are currently underway with several governments across Europe. 
In the fourth quarter, we submitted a BLA for U.S. Food and Drug Administration for sarilumab, our interleukin 6 or IL-6 receptor inhibitor for rheumatoid arthritis. We will be co-promoting sarilumab with Sanofi in the United States and are actively recruiting our field-based team. Co-promotion decisions for other countries were made -- will be made over time. We also continue to pay for the potential U.S. launch of dupilumab, our IL-4 and IL-13 inhibitor in 2017. We've recently informed Sanofi of our intent to co-promote dupilumab in the United States. Co-promotion decisions will be made at a later date. Next month, we will have a significant presence in the American College -- or American Academy of Allergy, Asthma and Immunology meeting in Los Angeles and the American Academy of Dermatology meeting in Washington, DC. With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This",1277,"Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This represents a year-over-year growth in non-GAAP diluted EPS with net income of 21% and 19%, respectively, for the full year 2015. In the fourth quarter of 2015, non-GAAP net income per diluted share increased 1% to $2.83 versus fourth quarter of 2014 and non-GAAP net income of $327 million was unchanged versus fourth quarter of 2014. Regeneron's 2015 non-GAAP net income excludes noncash share-based opposition expense, noncash interest expense related to our senior convertible notes, loss on extinguishment of debt in connection with conversions of a portion of convertible notes during 2015 and adjustment for income taxes. Non-GAAP income tax expense is based upon cash, income tax paid or payable for 2015. A full reconciliation of GAAP and non-GAAP earnings is set forth in our earnings release. 
Total revenues in the fourth quarter of 2015 were $1.1 billion and $4.1 billion for the full year 2015, which represented year-over-year growth of 37% for the 3 months and 46% for the full year. Net product sales were $750 million in the fourth quarter of 2015 and $2.69 billion for the full year of 2015 compared to $522 million in the fourth quarter of 2014 and $1.75 billion for the full year of 2014. EYLEA net product sales in the United States were $746 million in the fourth quarter and $2.68 billion in 2015, compared to $518 million in the fourth quarter of 2014 and $1.74 billion for the full year of 2014, which represents an increase of 44% and 54%, respectively. 
During the fourth quarter of 2015, EYLEA experienced a slight increase in U.S. distributary inventory levels as compared to the third quarter 2015. And overall, a slight decrease in comparison to the fourth quarter 2014 but remains within our normal 1- to 2-week targeted range. As Len mentioned earlier, our U.S. EYLEA net sales growth guidance for full year 2016  over 2015 is approximately 20%. x U.S. EYLEA sales were $413 million in the fourth quarter of 2015 as compared to $297 million in the fourth quarter of 2014, representing a 39% increase on a reported basis. x U.S. EYLEA sales for the full year of 2015 were $1.41 billion compared to $1.04 billion for 2014, representing a 36% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 54% for the 3 months and 58% for the full year 2015. Product revenues from x U.S. EYLEA sales is recorded by our collaborator, Bayer HealthCare. 
In the fourth quarter of 2015, Regeneron recognized $140 million from our share of net profits from EYLEA sales outside the United States and $467 million for the full year 2015. Total Bayer HealthCare collaboration revenue for the fourth quarter was $165 million and $580 million for the full year 2015. 
Total Sanofi collaboration revenue was $166 million for the fourth quarter and $759 million for the full year 2015. The Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the fourth quarter of 2015, our share of losses in connection with commercialization of antibodies, primarily Praluent, was $96 million for the full year 2015 was $240 million, which can be found in Table 4 of our earnings release. 
Netting with these losses were the global sales of Praluent as recognized by our partner, Sanofi, of $7 million for the fourth quarter 2015 and $11 million for the full year of 2015. Recall that Praluent was launched in the third quarter of 2015. 
Turning now to expenses. Non-GAAP R&D expenses were $389 million for the fourth quarter and $1.37 billion for the full year 2015. Our unreimbursed R&D expenses have collated as a total GAAP R&D expense less R&D reimbursements from our collaborators and R&D non-cash share based compensation expense was $214 million for the 3 months and $570 million for the full year 2015. We note that this comes in slightly above our 2015 non-GAAP unreimbursed R&D expense guidance of $540 million to $560 million, primarily due to higher expenditures for our NGF programs. Our press release includes all the information required to calculate unreimbursed non-GAAP R&D expenses. For 2016, we'd like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in the range of $875 million to $950 million. Our non-GAAP unreimbursed R&D expense is driven by 3 factors: advancing our pipeline outside of the Sanofi and Bayer collaboration, particularly our programs for NGF, RSV and CD20 by CD3; our obligation to pay for 20% of the Phase III clinical development expense following a first positive Phase III results of our partnered antibodies, primarily driven by the potential positive dupilumab Phase III read out in the first half of 2016; the advancement of our immuno-oncology pipeline in collaboration with Sanofi and proprietary R&D initiatives such as those in the area of human genomics. Non-GAAP SG&A expenses were $213 million for the fourth quarter and $646 million for the full year 2015. We expect non-GAAP SG&A expense in 2016 to be in a range of $925 million and $1 billion. The increase in our SG&A expense is primarily driven by the ongoing Praluent launch, which is entering its first full year of lunch and prepare for the potential commercial launches of both sarilumab and dupilumab. As we've mentioned previously, in 2015, we began paying significant cash that is compared to prior periods. Cash tax as a percentage of non-GAAP pretax net income for this quarter as well as for all of 2015 is based on an estimated cash tax paid or payable for the full year. This amount continues to be substantially lower than our GAAP effective tax rate. On a GAAP basis, cash tax is a percentage of non-GAAP pretax net income for the fourth quarter of 2015 and for the 12 months ended December 31, 2015, was approximately 16% and 18%, respectively. 
For 2016, our guidance for cash tax as a percentage of non-GAAP pretax income is 35% to 45%. This includes a onetime tax of approximately $222 million related to $600 million of our December 31, 2015, deferred revenue balance remaining from the immuno-oncology up from payment from Sanofi that we received in the third quarter of 2015. The cash tax impact in the immuno-oncology upfront payment would be spread equally throughout the year. Our capital expenditures for the 12 months ended December 31, 2015, were $678 million. We expect our capital expenditures to be between $580 million and $680 million for 2016. These expenses continue -- these expenses continue to build on a manufacturing expansion made in 2015, which include expanding our facilities in Rensselaer, New York; Ireland; as well as it exceeded expansion of our Tarrytown, New York headquarters. We ended the fourth quarter of 2015 with cash and marketable securities of $1.7 billion. As we have previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt. In the fourth quarter of 2015, we paid $50 million to reduce these outstanding warrants. And in January 2016, we paid an additional $135 million to reduce more outstanding warrants. We intend to continue seeking opportunities to further reduce these outstanding warrants into 2016. With that, I'd like to turn the call back to Michael."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A.",32,"Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] Our first question comes from with Bank of America.",11,"[Operator Instructions] Our first question comes from with Bank of America."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","First of all, we know that trial would likely to read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially in commercial market? Or actually you'll get in fact because the same time Sec",97,"First of all, we know that trial would likely to read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially in commercial market? Or actually you'll get in fact because the same time Secondly, maybe for Bob. Some investors about the cost trends here. So can you like a lay out in for the outer year for the next 3 to 5 years? What are your thoughts for the year on SG&A and R&D? And also maybe some trends in income tax."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And let me just remind people, one question. Thank you.",10,"And let me just remind people, one question. Thank you."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Go ahead, Bob.",3,"Go ahead, Bob."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that it's not only do we meet the primary endpoint but to ensure that if they are key secondary endpoints that we allow them to come to fruition so",93,"I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that it's not only do we meet the primary endpoint but to ensure that if they are key secondary endpoints that we allow them to come to fruition so that we ensure that we have a robust data package. In terms of the impact of Amgen coming earlier than us, it would be speculative to really state what that means. But we do think that Amgen having positive data will be positive for the overall class."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable oppon",230,"Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable opponent. And on top of that, we are in the midst of launching sarilumab in the fourth quarter of 2016. And we're also preparing for first half 2017 for dupilumab. So for those 3 launches, it's putting stress on our SG&A number. With regards to R&D, we've highlighted some drivers with regards to the increase and unreimbursed R&D. The biggest one probably the NGF program as you heard from Len and George earlier that program is full speed ahead with regards to entering Phase III very, very shortly We're also moving forward with RSD. Now these are both on partnered products. And then again, we get our first positive Phase III readout for dupilumab in the first half of 2016. And as you know and as we've said before, that's a driver with regards to us picking up 20% of the program cost associated with that. So that would not only include atopic dermatitis, that would also include the asthma indications associated with that. So all of these things associated are putting some stress in our expenses. And maybe Len may have a few additional comments."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The space is usually too wide with lots of white space and lots of early and what to do with the next going to come from. Or ve",175,"Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The space is usually too wide with lots of white space and lots of early and what to do with the next going to come from. Or very infrequently, as in the case of Regeneron, this a lot going on. It's very compacted in time. We, of course, would rather have the latter than the former. And that's why it think that we're managing through at this exciting time. And approval in 2015 for Praluent. 2016, we hope for sarilumab. 2017, the first approval for dupilumab. And beyond that, approval for dupilumab and asthma. Perhaps NGF coming up, RAC, progress and perhaps approval down the line there and immuno-oncology. So we have a very intensely compacted pipeline that we have to manage, both from a technical point of view, from an operational point of view, a manufacturing point of view, and of course, as Bob said, from a financial point of view."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn from Goldman Sachs.",10,"Our next question comes from Terence Flynn from Goldman Sachs."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On Praluent, just wondering if you do additional commentary on the citation, I mean, on the therapy I know what percentage of scripts are actually getting filled versus rejected?",29,"On Praluent, just wondering if you do additional commentary on the citation, I mean, on the therapy I know what percentage of scripts are actually getting filled versus rejected?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I do think we get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points  take this up too, emphasize some of the points that Bob made, which is t",284,"Yes. I do think we get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points  take this up too, emphasize some of the points that Bob made, which is that we feel on the contracting side, that process is starting to wind down in terms of about 90% of the lives who have maybe a commercial or medicated part B coverage have a made. They haven't been fully implemented in fact to roll out at Cisco to going over the next several months and even into the second quarter of this year. So coverage won't begin. We did particularly well in those cases where there was an exclusive or preferred decision made. We won that business over 60% of the time. And as Bob said in the Medicare business, where it's a large proportion of the statin use, a large proportion of our patients, we were able when there was an exclusive or preferred decision made and that was 80% of the time. And it was exclusive or preferred decision made, that went 95% of the lives went to Praluent. So we're very pleased that our product offering is resonating well and that people, I think, are getting our message. In terms of the patient types, as we mentioned, there's a very strict utilization management criteria in the category. So it is strictly within the label population, which is patients with heterozygous hypercholesterolemia and patients with a history of coronary disease. So we're seeing myocardial infarctions, patients and very, very high baseline LDL-C. Patients who have FH. These are the patient published for which the products were saying."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we're hoping in the elderly population what would they bring some of that business that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps wanting to start on a",48,"And we're hoping in the elderly population what would they bring some of that business that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps wanting to start on a lower dose. Next question, Michael?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Next question?",2,"Next question?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Jennifer Teague is from The Ring.",11,"Our next question comes from Jennifer Teague is from The Ring."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'm a little confused about a quarterly results and by your guidance. You grew up 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% next year. If I run 1.5% sequential growth fo",99,"I'm a little confused about a quarterly results and by your guidance. You grew up 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% next year. If I run 1.5% sequential growth forward, it only gets to about 15% for the year. Can you give us a sense of whether any onetime items out of Q4 our Q3 or their dissipative for next year or you just taken a cautious approach on how was the underlying demand trend from Q3 to Q4?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Right. So no. I think -- Jeff, thanks for the question. One point, this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter and year-over-year inventory actually decrease a little bi",139,"Right. So no. I think -- Jeff, thanks for the question. One point, this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter and year-over-year inventory actually decrease a little bit. So there really wasn't -- that wasn't a driver. There is some -- when you look sequentially, you do have to be careful. There are seasonality trends. Fourth quarter, lots of holidays. Fourth and first quarter, lots of weather. You know how we feel about forecasting. It's about the most imprecise scientifically unscientific activity we do here. But it is a matter of guiding conservatively or aggressively or what have you. Just trying to give you our best guess with the information we have, which -- and looking into the future, which is, of course, difficult."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","The next question comes from Adnan Butt with RBC Capital Markets.",11,"The next question comes from Adnan Butt with RBC Capital Markets."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So I'll ask a question on the EYLEA combinations. You've now seen data from both ends PDGFR. Which one seems compelling? And in the past, you said some doubts about is the target. Has no change since the new data?",41,"So I'll ask a question on the EYLEA combinations. You've now seen data from both ends PDGFR. Which one seems compelling? And in the past, you said some doubts about is the target. Has no change since the new data?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. Too early to talk about any efficacy.",58,"George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. Too early to talk about any efficacy. But George, do you have any comments on that?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Similarly, I don't think our views have changed that much. And we do rationale we believe a little stronger for the Institute within the PDGF that way. But either way, we would, of course, we're excited if the clinic either one of these combinations",98,"Yes. Similarly, I don't think our views have changed that much. And we do rationale we believe a little stronger for the Institute within the PDGF that way. But either way, we would, of course, we're excited if the clinic either one of these combinations brought out a benefit to patients especially because we think that with our ability to combine these agents into a single -- formulation of single injection, if there is increased benefit, we'll be able to have the most convenient delivery regimen for the patients. So we're only hoping for success with these combinations."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I might say combinations that there are others we're trying to do a fix by specific approach. And I think as George talked about this and some of his previous meetings we've had, which is that the rationale they are. To us, I think would be better to come",132,"I might say combinations that there are others we're trying to do a fix by specific approach. And I think as George talked about this and some of his previous meetings we've had, which is that the rationale they are. To us, I think would be better to come by these as separate drugs and a single formulation so you can adjust the concentration of dose of each one mantle and optical level. When you see a result by specific, you don't know it has anything to do with both drugs acting or only 1 just acting better than the model-specific antibody or drug that you had compared it to. So we like the approach we are using. We like the technology. But a data will determine exactly where this goes."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Jim Birchenough from Wells Fargo.",10,"Our next question comes from Jim Birchenough from Wells Fargo."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Can I just go back to the PD-1 inhibitor. The trial has ballooned from 60 to now probably 973 patients. There's no quad arm of and GMC SS. So could you just talk a little bit about what data are we going to get from this trial and what exactly it is to tr",81,"Can I just go back to the PD-1 inhibitor. The trial has ballooned from 60 to now probably 973 patients. There's no quad arm of and GMC SS. So could you just talk a little bit about what data are we going to get from this trial and what exactly it is to try to show in this trial and perhaps conceptualize that with what competitors are doing with their PD-1 inhibitors. It's obviously, a very large and complex trial."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We're not going to give out the data. But George, maybe you want to comment general approach here.",19,"Yes. We're not going to give out the data. But George, maybe you want to comment general approach here."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Right. The first point was just to convince demonstrate activity and where we think it sits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notes of any novel combinations which have been",90,"Right. The first point was just to convince demonstrate activity and where we think it sits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notes of any novel combinations which have been direct us to both settings and combinations where there might be opportunities. And I think we've said, and Michael said throughout this meeting we will be talking about some of these data it or not too distant future. Mike, when are we going to talk about?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just said later this year.",6,"I just said later this year."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. And so the programs are going well. Thereof is leaving large because we're pleased with the initial results that we're seeing. And will be sharing some of that with you at the upcoming appropriate meetings.",36,"Yes. And so the programs are going well. Thereof is leaving large because we're pleased with the initial results that we're seeing. And will be sharing some of that with you at the upcoming appropriate meetings."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Chris Raymond with Raymond James.",10,"Our next question comes from Chris Raymond with Raymond James."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back on Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other brother had was we should we",53,"This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back on Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other brother had was we should we think about in 2016?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. It's always hard to anticipate trend that will go or will drive a drug at this point. I mean, remember, we're in the 50 or if the launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the product",233,"Yes. It's always hard to anticipate trend that will go or will drive a drug at this point. I mean, remember, we're in the 50 or if the launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the product still growing, which is I think the most important, if not quantitative, it's the most important qualitative statement. We become the leading branded anti-VEGF in the market. And we take this franchise very seriously as we think there are additional growth drivers. So let's talk about the fact that we want to develop diabetic retinopathy and talk about looking at combinations with PDGF and Ang2. So we're still committed to developing this market to both in the United States and with our partner Bayer, outside of the United States. We should note that the growth we've demonstrated in the United States was purely volume. We did not take any price increases. Now from a macro sense, if there are payer changes or housing or reimbursed or things like that, what we can say now is there are non-in place. But as things change, I think there'll be more this year during election year than actual action. But we monitor this very closely. We think our drug is a site-saving and important therapy. And we're going continue to try and grow this franchise."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matt Roden with UBS.",9,"Our next question comes from Matt Roden with UBS."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Regarding the protocol, when should we expect your data to be presented? And then secondly, in terms of when we made it looks like the EYLEA acuity curve in the 2015 [ph] your less worse trending a bit higher as you approach the 1 year mark. So this bring",71,"Regarding the protocol, when should we expect your data to be presented? And then secondly, in terms of when we made it looks like the EYLEA acuity curve in the 2015 [ph] your less worse trending a bit higher as you approach the 1 year mark. So this brings the question, could the data get better versus in the second year? And how much would you frame the 2-year data for?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think we can frame the 2-year data because we just have to wait and expected to come sometime the first half of this year. And we don't control the data, obviously, the data is controlled by our friends at DRCR. I will say that for us, the mo",127,"Yes. I don't think we can frame the 2-year data because we just have to wait and expected to come sometime the first half of this year. And we don't control the data, obviously, the data is controlled by our friends at DRCR. I will say that for us, the most important data set for the primary endpoint is 1 year where we did show superiority to the other therapies, and we showed a very strong safety profile. As we go up to the second year when you have less patients, some dropouts and what have you. We'll have to see debate is it the most overly to show our project is to have a strong safety profile as it has in all of our studies today."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to build on what Len is saying. We're the direct comparison would be in the first year because that's when the drug really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get our confab relate",80,"Just to build on what Len is saying. We're the direct comparison would be in the first year because that's when the drug really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get our confab related with the fact that those regiments change. There's a lot more PR and usage. A lot more laser usage and so forth. So it's going to be very hard to be convoluted I think the data."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Geoff Meacham with Barclays.",9,"Our next question comes from Geoff Meacham with Barclays."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So last year with EYLEA, Protocol T, obviously, a big driver of the adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And maybe w",82,"So last year with EYLEA, Protocol T, obviously, a big driver of the adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And maybe what is the driver of that is? Just more blocking and tackling of the market place? Is there a following data sets that you feel like could be more meaningful to retinal specialists?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So Jeff, obviously, we have seen of as we a lot of our growth this year coming from the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exam, don't get into the re",114,"So Jeff, obviously, we have seen of as we a lot of our growth this year coming from the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exam, don't get into the retinal specialists. And so DME is currently still undertreated. Although VEGF inhibitors are being used more broadly to patients who are diagnosed with DME. The opportunity for us is to make patients aware that they've got to get their eye exam and get into a retinal specialist if they do have any problems with their vision. And that really is a major focus of our promotion this year."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And as George mentioned in his talk. Remember, we haven't diabetic retinopathy for the setting of DME. But a much broader diabetic retinopathy without DME in terms of number patients is something that we would like to get added to the label. And that's wh",143,"And as George mentioned in his talk. Remember, we haven't diabetic retinopathy for the setting of DME. But a much broader diabetic retinopathy without DME in terms of number patients is something that we would like to get added to the label. And that's why we are conducting pivotal studies to broaden the label of that indication. So I think it sort of the same, Jeff. We see growth and demographic. Moped patients getting older and more patients with diabetes. We see strength in potential marketshare, both from off label and coming from the off label Avastin and perhaps from Lucentis. We see geographic growth with more room to grow outside the United States. Our ratio outside United States is not as high as it's inside of United States in terms of market share. And finally, new indications that potentially, as I mentioned."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true, but unfortunately, this data shown anti-VEGF therapy can provide much better vision results than laser therapy. Our laser is still the preferred i",99,"And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true, but unfortunately, this data shown anti-VEGF therapy can provide much better vision results than laser therapy. Our laser is still the preferred in the DME population. There's a lot of patient education and doctor education there. And as Len said, that's just for the approved setting DME diabetic population. There's at least 3x as many patients population diabetic retinopathy without DME. So the current studies really show their results. I mean, there's an opportunity there as well."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Cory Kasimov with JPMorgan.",9,"Our next question comes from Cory Kasimov with JPMorgan."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? Is it something specific to the drugs profile such as the building options you mentioned primarily to lower dose or does this have to do pricing discounts being offe",53,"I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? Is it something specific to the drugs profile such as the building options you mentioned primarily to lower dose or does this have to do pricing discounts being offered. I'm just trying to understand the dynamics there."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people and the payers abo",149,"Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people and the payers about the product profile. We do believe that the low dose particularly in elderly patients, might be of something of value for physicians to choose. Remember, a vast majority of patients are able to get to their desired level using the lower dose. Now whether or not the attitude doesn't matter how low you go and it's too complicated for doctors to be able to understand the use of low and high dose, I think that puts not quite enough faith in doctors and my colleagues in the medical profession. They get the difference. And I think this may be resonating well."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from March Schoenebaum with Evercore ISI.",10,"Our next question comes from March Schoenebaum with Evercore ISI."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a",123,"I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a 20% reduction as overwhelming after fee. Maybe can you give us what your base case assumption is at the final analysis for risk reduction. And just related, Amgen talked a lot about their ibis trial and now they think is very important. To my knowledge, you guys aren't conducting one I just like to hear you speak about your decision there And your thoughts on that data will be meaningful in the marketplace."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Were not talking about the base case. But talking about exactly what the study is actually hour to pick up. So that's the numbers that we are giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob said, I mean, we certai",106,"Were not talking about the base case. But talking about exactly what the study is actually hour to pick up. So that's the numbers that we are giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob said, I mean, we certainly realize and recognize that a lot of the outcomes data Andy's imaging studies and so forth. They're going to speak to the class effect. And so we're hoping that their results would be positive and we're also going to be looking at what studies that we can do during our addition to outcomes study in terms of imaging."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it does seem you may be one of the only people in the planet who remember each and every outcomes study with the statins and which statin was shown that was used in the outcomes trial. But I do think, for the most part, there is some generisization. Bu",261,"So it does seem you may be one of the only people in the planet who remember each and every outcomes study with the statins and which statin was shown that was used in the outcomes trial. But I do think, for the most part, there is some generisization. But I think it will be settle differences. And just to emphasize what Georgia is saying about the power. I mean, what Amgen is basically telling you, which is correct, which is that in previous studies, the amount of risk reduction you get is proportional to the absolute number of milligrams per deciliter that you lower LDL cholesterol. Now of course, in their Phase IIb/III studies, and I should say they're faced to none outcome studies as well as ours, were starting LDL cholesterol was higher. And so the overall LDL absolutely reduction was a lot. And therefore, the risk reduction was a lot. When you start out with more modest LDL, which we are both doing in our outcomes trial, you have less LDL lowering and on average, you should have less risk reduction that we think a every get robust results and will be able to look at various pet terms of peoples starting LDL and so on and so forth. So we're very confident in the LDL hypothesis. Remember, we're the first people to the LDL receptor, our Board of Directors. So we have been something we are very close to forever a long time. We believe LDL month and we believed outcomes trials and continue to support that."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from Does that is I think it would be more qualitative than quantitative as the FDA was cautioned possible to co",108,"I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from Does that is I think it would be more qualitative than quantitative as the FDA was cautioned possible to compare between studies bit and that's because there's so many inherent differences. The type of compilation starting LDL reason events or whether it's more secondary prevention type of the setting and so forth and so on. So there's many differences between the population. So I think one is looking  more for qualitative messages here as opposed to specific quantitative differentiators."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Alethea Young with Credit Suisse.",10,"Our next question comes from Alethea Young with Credit Suisse."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on DB. I know it's on the pediatric trial but it was a small trial that was ongoing. This wondered if you could give us your updated thoughts and fast-forward.",32,"Just one on DB. I know it's on the pediatric trial but it was a small trial that was ongoing. This wondered if you could give us your updated thoughts and fast-forward."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal",209,"Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal way that this is done is that you wait till you've completed your Phase III studies in adults before moving more aggressively into children. But after, I think, looking at our program and an advisory panel on the subject, the FDA and the advisory panel I think pushed us, and we agreed that we should be looking even before we had the final Phase III data because the data was on phase to be were so strong. And remember, it was designated a breakthrough therapy by agency. So we have -- we've moved into pediatrics. We have a Phase II study that's ongoing in patients between ages of 6 and 17, and we expect to be able to get you data from that perhaps later this year. And we have a Phase III pediatric study plan as well. So we see the need. We see the children who suffer and don't have good alternatives, would very much like to be able to treat them."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Next question?",2,"Next question?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matthew Harrison from Morgan Stanley.",10,"Our next question comes from Matthew Harrison from Morgan Stanley."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just want to ask on both Ang2 and the PDF following. You obviously, are now going to be running 2 large Phase II studies for both of those drugs. One will readout I guess at the end of this year and the next one I assume sometime next year. I mean, how",110,"I just want to ask on both Ang2 and the PDF following. You obviously, are now going to be running 2 large Phase II studies for both of those drugs. One will readout I guess at the end of this year and the next one I assume sometime next year. I mean, how are you thinking about bringing both of those into Phase III? Will you decide on them independently? Or will you wait for both data set to decide how to move forward and anything you could say around what kind of bar you think is relevant from an efficacy standpoint there to be able to move those forward?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of the combination approaches. And will make the decision based on the data. I th",146,"Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of the combination approaches. And will make the decision based on the data. I think certain advantages that we would have is the efficacy advantage or the interval differentiation is sufficient, we'll be able to conveniently and in a cost effective manner, be providing both agents to the patients. So we're not really limited by sort of saying, ""Well, yes, there is an advantage, but it's so moderate."" How to justify all new biologics year. Wherein the unique position to being able to provide both agents in a very cost-effective manner regardless of what the benefit if there is definitive, convincing additional benefits. But it's all going to depend on the data."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I can't over emphasize what George just said, so I'll repeat it which is about -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the risk becau",189,"Yes. I can't over emphasize what George just said, so I'll repeat it which is about -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the risk because injections in the eye, although probably none have -- there's no injections that I can imagine with EYLEA around the world. But the injections in the eye still carry a small but real risk each time a physician sticks a needle in the eye without putting anything in there. And so if we're going to have a very small benefit, 2 needles fix probably won't be justified. And as George said, the cost. We can deliver these at the same cost if necessary in a single injection. So we have both the financial burden as well as the injection burden really under our control. So therefore, we can be driven by any -- we can be driven to go to market with smaller benefits than you might have to hold yourself up to a failed to do a multiple injections and add-on costs."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Operator, we have time for one last question.",8,"Operator, we have time for one last question."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Philip Nadeau with Cowen and Company.",11,"Our next question comes from Philip Nadeau with Cowen and Company."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on how you think we should model Praluent uptake through 2016. I know  in the past you've said that you'll take several quarters for sales to reflect end-user demand. Is there a point in 2016 where you think that reimbursement negotiations",78,"Just a question on how you think we should model Praluent uptake through 2016. I know  in the past you've said that you'll take several quarters for sales to reflect end-user demand. Is there a point in 2016 where you think that reimbursement negotiations will be finished and sampling will begin to subside where we can begin to see end-user demand reflected in sales? Or is 2016 really a proprietary here for the postevent study uptake of Praluent?"
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months",108,"Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months. Once that coverage comes on board, there is going to be sometime for physicians to understand what utilization management criteria and how to really document the prior authorization to get these patients through the entire process to get a prescription. So I would say you're going to see very gradual uptake for several months until we get to some kind of a steady state."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great, operator. With that, this concludes our call. I want to thank everybody. As for usual, myself, DIR team and Bob Landry, our CFO, are available to follow-up questions as needed at our office. Please let us know  if you want to talk. Thank you.",45,"Great, operator. With that, this concludes our call. I want to thank everybody. As for usual, myself, DIR team and Bob Landry, our CFO, are available to follow-up questions as needed at our office. Please let us know  if you want to talk. Thank you."
33715,323449305,928896,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day.",17,"Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr. M",52,"Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr. Michael Aberman, Senior Vice President of Strategy and Investor Relations. You may begin, sir."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals fourth quarter and year end 2015 conference call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on th",332,"Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals fourth quarter and year end 2015 conference call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2015, and Form 10-K for the year-ended December 31, 2015, which is expected to be filed with the SEC later this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statements or whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and reconciliation of those measures to GAAP are available on our financial results press release, which can be accessed on our website at www.regeneron.com.
Once our call concludes, our CFO, Bob Landry and the IR team will be available to answer further questions. With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael. A very good morning to everyone who has joined us on the call and webcast today. 2015 was another successful and productive year for Regeneron. EYLEA delivered impressive global growth. And we received approval for and launched Praluent",568,"Thanks, Michael. A very good morning to everyone who has joined us on the call and webcast today. 
2015 was another successful and productive year for Regeneron. EYLEA delivered impressive global growth. And we received approval for and launched Praluent, which is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol. We made significant advances in our late-stage pipeline, submitting a biologic license application, or BLA, for sarilumab in rheumatoid arthritis and advancing Phase III clinical development for dupilumab in atopic dermatitis and asthma. In 2015, we also advanced 2 new antibodies into Phase III. Regeneron 2222 for the prevention of  Respiratory Syncytial Virus or RSV infection infants and our anti-NGF antibody for osteoarthritis pain. We also advanced our early-stage pipeline with progress across multiple therapeutic areas, including retinal diseases, cancer, infectious diseases and cardiovascular diseases. 
Turning to EYLEA performance. EYLEA is now the market-leading brand in anti-VEGF therapy for retinal disease in the United States and continue to exhibit strong growth, both in the U.S. and worldwide. We saw approximately 54% growth year-over-year in the U.S., with sales of $2.68 billion. On a worldwide basis, EYLEA sales were approximately $4.1 billion for the full year. 
For the full year 2016, we estimate U.S. EYLEA net sales to grow approximately 20% over full year 2015 U.S. net sales. We are focused on maintaining our leadership in the retinal space. We are continuing clinical development with EYLEA where we have ongoing combination programs with PDGF and with ANG2 and are pursuing important additional indications for EYLEA that George will review later in the call.
Turning now to Praluent. We are proud to have brought the first PCSK9 inhibitor to the market in the United States for patients with uncontrolled LDL cholesterol, which was approved and launched in July of last year. We are still in the early stages of this launch and have been working diligently to provide broad access to eligible patients and educating physicians and patients in order to increase adoption. Bob Terifay will provide some additional metrics on how the launch is progressing. 
Our mission at Regeneron for 25 plus years has been to consistently and repeatedly bring important new medicines to patients in need. And we feel that we are well-positioned to deliver on this mission with our innovative pipeline. Building on last year's approval of Praluent, we anticipate at least 1 approval each year for the coming years. In 2016, we anticipate the approval of sarilumab for the treatment of rheumatoid arthritis. Our breakthrough product, dupilumab and atopic dermatitis, is progressing. And we expect to report top line Phase III data and submitted BLA in the U.S. during this year. Beyond dupilumab, we have a rapidly developing late and early-stage pipeline that now consists of 13 product candidates that were all discovered by the scientists at Regeneron. And we expect to put additional new candidates into the clinic this year. George will provide some perspective on this during his remarks. 
In summary, we are in the midst of a very exciting time with Regeneron with many important events anticipated in 2016. With that, let me turn the call over to George Yancopoulos, Regeneron's Chief Scientific Officer. He will be followed by Bob Terifay and then by Bob Landry."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. I would like to begin with EYLEA. Diabetic retinopathy is the most common cause of vision loss i",990,"Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. 
I would like to begin with EYLEA. Diabetic retinopathy is the most common cause of vision loss in patients with diabetes and as a result of microvascular damage to the blood vessels in the retina. If left untreated, diabetic retinopathy can progress to profound and sometimes acute vision loss. While EYLEA is a approved to treat diabetic retinopathy in patients with diabetic macular edema, or DME, we believe that it could benefit much broader patient population with diabetic retinopathy who do not have DME where there is no approved anti-VEGF therapy. Therefore, in the first quarter of this year, we plan to initiate Panorama, a Phase III study of EYLEA in patients with nonproliferative diabetic retinopathy without diabetic macular edema. The National Institute of Health will also independently investigate the potential role of anti-VEGF therapy in the treatment of diabetic retinopathy. This study called, Protocol-W, will be sponsored by the Diabetic Retinopathy Clinical Research Network, or DRCR, and will compare EYLEA to sham in phases with severe, nonproliferative diabetic retinopathy. Protocol-W is expected to begin in the first quarter. 
A Phase II study of EYLEA in combination with our PDGF receptor antibody delivered as a co-formulated injection in wet age-related macular degeneration, or Wet AMD, is ongoing. And we expect to see top line data from this study by year end. This program had been granted fast track designation by the FDA. Data from the Phase I study of EYLEA in combination with Nesvacumab, our ANG2 antibody, delivered as a co-formulated injection, was presented just last week at the Angiogenesis Conference. This data shows that the combination of EYLEA with Nesvacumab was safe and well tolerated in patients with AMD and patients with DME. We plan to initiate Phase II studies that will include both these patient populations in the first half of the year. 
As Len mentioned, our Praluent launch is underway, and you'll hear further details from Bob Terifay on the commercial front. Our 18,000-patient outcomes trial is ongoing. And we expect the first interim analysis, which will test for futility will occur later this year based upon 50% of the expected events from the trial. Also, we could potentially have our second interim analysis, which occurs after 75% of the targeted primary events that have accrued by the end of this year. And this interim analysis will test for overwhelming efficacy and futility. As we previously disclosed, the stopping rule for this efficacy analysis with a hazard ratio of 0.802 favoring Praluent, as well as consistency across subgroups and regions, positive trends for secondary endpoints including all caused mortality and no excess noncardiovascular mortality. These last points are all important as we would not want to unblind a trial early because its efficacy in the primary endpoint at the cost of not reaching significant and important secondary endpoints. In addition to the outcomes trial, we plan to submit a supplemental BLA in the first half of the year with the Praluent monthly dosing regimen.
Turning now to sarilumab, our IL-6 receptor anitbody for rheumatoid arthritis. Our regulatory submissions was accepted by the FDA and has been granted an action date of October 30, 2016. The Phase III MONARCH trial, which is a superiority study of sarilumab monotherapy versus adalimumab, which fully enrolled, and we expect top line data from this study in the first half of 2016. A European regulatory submission for sarilumab is expected to be made in the second half of 2016. 
I share Len's enthusiasm for dupilumab, our IL-4/13 pathway blocking antibody, which is currently in Phase III clinical studies in asthma and in adults with moderate to severe atopic dermatitis where it's been granted breakthrough designation, in part because there are no FDA-approved systemic therapy for adult patients with moderate to severe atopic dermatitis. We expect to report top line data from the Phase III atopic dermatitis study, Solo-1, Solo-2 and CHRONOS in the first half of this year and to complete rolling BLS submission in the second half of the year. Our approximately 1,700-patient pivotal Phase III study of dupilumab in asthma is also enrolled. We also continued to explore other indications for dupilumab, which is nasal polyps and the eosinophilic esophagitis as well as other allergic or IL-4/13 mediated diseases. 
Our Nerve Growth Factor antibody, or NGF antibody,  fasinumab, is another late-stage pipeline candidate. Pain is one of the leading reasons that patients visit the doctor, and osteoarthritis is one of the major source of the pain in adults, particularly older adults. The increasing use of prescription opioids to treat pains has led to a growing epidemic of drug addiction and overdose-related fatalities as well as other opioid-related side effects. 
Blocking NGF has already shown the ability to improve pain compared to placebo or an active comparator such as nonsteroidal anti-inflammatory drugs, or NSAIDs, in Phase II and Phase III trials. We now have a clear path forward from the FDA and will be starting with 10,000 patient long-term treatment Phase II clinical study of fasinumab in the first half of the year. We anticipate reporting data from a 16-week study in osteoarthritis pain in the first half of the year. 
In our early-stage pipeline, we plan to share data from our Phase I/II study of  [indiscernible], our antibody to ANGPTL3 with Dyslipidemia from the first half as well as data from our ongoing immuno-oncology program such as our PD-1 program and the CD20 by CD3 by specific program. We have obviously been very busy and productive. In fact, this year, we expect to submit a record number of IND, and we look forward to sharing more details with you as these programs move into the clinic. And with that, I would like to turn the call over to Bob Terifay."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantia",824,"Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantial progress in securing access and reimbursement for Praluent or alirocumab, among U.S. payors. In addition, the European launch for Praluent commenced. 
Starting with EYLEA. Fourth quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the fourth quarter were $746 million. Full year, U.S. EYLEA sales were $2.68 billion, which represented 54% year-over-year growth. A survey of 201 U.S. retinal specialists, who evaluated their reported usage of VEGF inhibitors in the fourth quarter of 2015, indicates that EYLEA continues to be the market-leading product among FDA-approved anti-VEGF agents in all of our labeled indications in terms of market share of treated eyes. Importantly, the market share of treated eyes for EYLEA and DME is roughly double that for ranibizumab and similar to that -- for off-label bevacizumab.
Turning now to Praluent. As reported by Sanofi, net sales in the fourth quarter were $7 million, which understates actual position in patient demand. As we reminded you last quarter, we anticipate that it would take some time for commercial and government payers to conduct formulary reviews, make reimbursement coverage decisions and begin to process patient claims. Given these reasons, as well as strict utilization management criteria, we continue to expect a gradual uptake. In response to potential delays and formulary reimbursement decisions, we're offering free product to appropriate patients consistent with our labeled indication. We are waiting an insurance coverage decision. These delays uptake in commercial sales reporting. 
For example, much of Medicare Part D are government-paid patients are receiving free drug pending formulary coverage, which is expected later in the quarter. So performance cannot be solely judged on sales or filled prescriptions. As a reminder, the reimbursement environment is complex and is carefully managed by payers. Our goal has been to ensure that payers and health care providers understand the value that Praluent can offer to patients. And to that end, we have been and are still actively engaged in discussions with payers. 
There are approximately 240 million lives in the United States that have a drug benefit covered by commercial insurance or Medicare part D plans. Coverage decisions have already been made for approximately 90% of these lives. However, implementation is ongoing. And we expect continued rollout of the coverage over the next several months. Overall, for approximately 50% of the covered lives, a single PCSK9 antibody has been chosen an exclusive or preferred physician. In these exclusive or preferred cases, we estimate that Praluent was chosen for about 60% of the lives. The preference for Praluent was particularly evident in the Medicare Part D decisions. In Medicare, 80% of the lives have a single PCSK9 antibody in an exclusive or preferred position. For these exclusive or preferred Medicare Part B lives, Praluent was selected approximately 95% of the time. We believe these Medicare coverage decisions are particularly important because our major indications for Praluent is for patients with a history of atherosclerotic cardiovascular disease. And these patients tend to be older. According to our estimates, about 28% of statin patients in the United States are Medicare Part B patients. We are pleased to see that Praluent is resonating well with payers. As plans begin to activate their coverage, we anticipate a potential uptake in prescription volume. Importantly, almost 90% of all prescriptions processed by the hub are for our lower 75-milligram every-other-week dose. As a reminder, in our Phase III clinical studies, the vast majority of Praluent patients achieved their LDL-cholesterol goals with a 75-milligram every-other-week dose. We continue our efforts to educate both patients and physicians on the benefit of using PCSK9 inhibitor therapy. Outside of the United States, Praluent was approved in the EU in September with product available in several countries. Reimbursement discussions are currently underway with several governments across Europe. 
In the fourth quarter, we submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our interleukin 6 or IL-6 receptor inhibitor for rheumatoid arthritis. We will be co-promoting sarilumab with Sanofi in the United States and are actively recruiting our field-based team. Co-promotion decisions for other countries were made -- will be made over time. We also continue to pay for the potential U.S. launch of dupilumab, our IL-4 and IL-13 inhibitor in 2017. We've recently informed Sanofi of our intent to co-promote dupilumab in the United States. Co-promotion decisions for other countries will be made at a later date. Next month, we will have a significant presence at the American College -- or the American Academy of Allergy, Asthma and Immunology meeting in Los Angeles and the American Academy of Dermatology meeting in Washington, DC. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This",1281,"Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This represents a year-over-year growth in non-GAAP diluted EPS and net income of 21% and 19%, respectively, for the full year 2015. 
In the fourth quarter of 2015, non-GAAP net income per diluted share increased 1% to $2.83 versus fourth quarter of 2014, and non-GAAP net income of $327 million was unchanged versus fourth quarter of 2014. Regeneron's 2015 non-GAAP net income excludes noncash share-based compensation expense, noncash interest expense related to our senior convertible notes, loss on extinguishment of debt in connection with conversions of a portion of our convertible notes during 2015 and in adjustment for income taxes. Non-GAAP income tax expense is based upon cash, income taxes paid or payable for 2015. A full reconciliation of GAAP and non-GAAP earnings is set forth in our earnings release. 
Total revenues in the fourth quarter of 2015 were $1.1 billion and $4.1 billion for the full year 2015, which represented year-over-year growth of 37% for the 3 months and 46% for the full year. Net product sales were $750 million in the fourth quarter of 2015 and $2.69 billion for the full year of 2015 compared to $522 million in the fourth quarter of 2014 and $1.75 billion for the full year of 2014. EYLEA net product sales in the United States were $746 million in the fourth quarter and $2.68 billion in 2015, compared to $518 million in the fourth quarter of 2014 and $1.74 billion for the full year of 2014, which represents an increase of 44% and 54%, respectively. 
During the fourth quarter of 2015, EYLEA experienced a slight increase in U.S. distributary inventory levels as compared to the third quarter 2015. And overall, a slight decrease in comparison to the fourth quarter 2014 but remains within our normal 1- to 2-week targeted range. As Len mentioned earlier, our U.S. EYLEA net sales growth guidance for full year 2016  over 2015 is approximately 20%. Ex U.S. EYLEA sales were $413 million in the fourth quarter of 2015 as compared to $297 million in the fourth quarter of 2014, representing a 39% increase on a reported basis. Ex U.S. EYLEA sales for the full year of 2015 were $1.41 billion compared to $1.04 billion for 2014, representing a 36% increase on a reported basis. 
On an operational basis or constant currency basis, sales increased approximately 54% for the 3 months and 58% for the full year 2015. Product revenues from ex U.S. EYLEA sales is recorded by our collaborator, Bayer HealthCare. 
In the fourth quarter of 2015, Regeneron recognized $140 million from our share of net profits from EYLEA sales outside the United States and $467 million for the full year 2015. Total Bayer HealthCare collaboration revenue for the fourth quarter was $165 million and $580 million for the full year 2015. 
Total Sanofi collaboration revenue was $166 million for the fourth quarter and $759 million for the full year 2015. The Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the fourth quarter of 2015, our share of losses in connection with commercialization of antibodies, primarily Praluent, was $96 million for the full year 2015 was $240 million, which can be found in Table 4 of our earnings release. 
Netting with these losses were the global sales of Praluent as recognized by our partner, Sanofi, of $7 million for the fourth quarter 2015 and $11 million for the full year 2015. Recall that Praluent was launched in the third quarter of 2015. 
Turning now to expenses. Non-GAAP R&D expenses were $389 million for the fourth quarter and $1.37 billion for the full year 2015. Our unreimbursed R&D expense, which is calculated as the total GAAP R&D expense less R&D reimbursements from our collaborators and R&D noncash share based compensation expense, was $214 million for the 3 months and $570 million for the full year 2015. We note that this comes in slightly above our 2015 non-GAAP unreimbursed R&D expense guidance of $540 million to $560 million, primarily due to higher expenditures for our NGF program. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. 
For 2016, we'd like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in the range of $875 million to $950 million. Our non-GAAP unreimbursed R&D spend is driven by 3 factors: advancing our pipeline outside of the Sanofi and Bayer collaboration, particularly our programs for NGF, RSV and CD20 by CD3; our obligation to pay for 20% of the Phase III clinical development expense following a first positive Phase III results of our partnered antibodies, primarily driven by the potential positive dupilumab Phase III readout in the first half of 2016; the advancement of our immuno-oncology pipeline in collaboration with Sanofi and proprietary R&D initiatives such as those in the area of human genomics. Non-GAAP SG&A expenses were $213 million for the fourth quarter and $646 million for the full year 2015. We expect non-GAAP SG&A expense in 2016 to be in the range of $925 million and $1 billion. The increase in our SG&A expense is primarily driven by the ongoing Praluent launch, which is entering its first full year of launch and preparing for the potential commercial launches of both sarilumab and dupilumab. As we've mentioned previously, in 2015, we began paying significant cash income taxes as compared to prior periods. Cash tax, as a percentage of non-GAAP pretax net income for this quarter as well as for all of 2015, is based on an estimated cash tax paid or payable for the full year. This amount continues to be substantially lower than our GAAP effective tax rate. On a non-GAAP basis, cash tax, as a percentage of non-GAAP pretax net income for the fourth quarter of 2015 and for the 12 months ended December 31, 2015, was approximately 16% and 18%, respectively. 
For 2016, our guidance for cash tax, as a percentage of non-GAAP pretax income, is 35% to 45%. This includes a onetime tax of approximately $222 million related to $600 million of our December 31, 2015, deferred revenue balance remaining from the immuno-oncology upfront payment from Sanofi that we received in the third quarter of 2015. The cash tax impact of the immuno-oncology upfront payment would be spread equally throughout the year. 
Our capital expenditures for the 12 months ended December 31, 2015, were $678 million. We expect our capital expenditures to be between $580 million and $680 million for 2016. These expenses continue -- these expenses continue to build on the manufacturing expansions made in 2015, which include expanding our facilities in Rensselaer, New York; in Limerick, Ireland; as well as the continued expansion of our Tarrytown, New York headquarters. We ended the fourth quarter of 2015 with cash and marketable securities of $1.7 billion. As we have previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt. In the fourth quarter of 2015, we paid $50 million to reduce these outstanding warrants. And in January 2016, we paid an additional $135 million to reduce more outstanding warrants. We intend to continue seeking opportunities to further reduce these outstanding warrants into 2016. 
With that, I'd like to turn the call back to Michael."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A.",32,"Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] Our first question comes from Ying Huang with Bank of America.",13,"[Operator Instructions] Our first question comes from Ying Huang with Bank of America."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","First of all, we know that Amgen's CD outcome trial would likely read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially at a disadvantage in the commercial markets? Or actually you'l",117,"First of all, we know that Amgen's CD outcome trial would likely read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially at a disadvantage in the commercial markets? Or actually you'll get a ripple effect because both drugs are in the same class of PCSK9 inhibitors. Secondly, maybe for Bob. Some investors are a little concerned about the cost trends here. So can you kind of like lay out in the outer years, for the next 3 to 5 years? What are your thoughts for the year on SG&A and also R&D cost? And also maybe some trends in long-term tax."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And let me just remind people, one question. Thank you.",10,"And let me just remind people, one question. Thank you."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Go ahead, Bob.",3,"Go ahead, Bob."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that not only do we meet the primary endpoint, but we ensure that if they are key secondary endpoints, that we allow them to come to fruition so th",92,"I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that not only do we meet the primary endpoint, but we ensure that if they are key secondary endpoints, that we allow them to come to fruition so that we ensure that we have a robust data package. In terms of the impact of Amgen coming earlier than us, it would be speculative to really state what that means. But we do think that Amgen having positive data will be positive for the overall class."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable oppon",230,"Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable opponent. And on top of that, we are in the midst of launching sarilumab in the fourth quarter of 2016. And we're also preparing for first half 2017 for dupilumab. So for those 3 launches, it's putting stress on our SG&A number. With regards to R&D, we've highlighted some drivers with regards to the increase and unreimbursed R&D. The biggest one probably being the NGF program, as you heard from Len and George earlier. That program is full speed ahead with regards to entering Phase III very, very shortly. We're also moving forward with RSV. Now these are both unpartnered products. And then again, we get our first positive Phase III readout for dupilumab in the first half of 2016. And as you know and as we've said before, that's a driver with regards to us picking up 20% of the program cost associated with that. So that would not only include atopic dermatitis, that would also include the asthma indications associated with that. So all of these things associated are putting some stress on our expenses. And maybe Len may have a few additional comments."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The spaces are usually too wide with lots of white space and lots of worry, what to do, where's the next drug going to come fro",180,"Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The spaces are usually too wide with lots of white space and lots of worry, what to do, where's the next drug going to come from? Or very infrequently, as is the case here of Regeneron, there's a lot going on. It's very compacted in time. We, of course, would rather have the latter than the former. And that's why I think that we're managing through. And it's an exciting time: an approval in 2015 for Praluent; 2016, we hope for sarilumab; 2017, the first approval for dupilumab; and beyond that, approvals for dupilumab in asthma; perhaps NGF coming up; RSV; progress in the -- and perhaps approval down the line there; and immuno-oncology. So we have a very intensely compacted pipeline that we have to manage both from a technical point of view, from an operational point of view, a manufacturing point of view, and of course, as Bob says, from a financial point of view."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn for Goldman Sachs.",10,"Our next question comes from Terence Flynn for Goldman Sachs."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On Praluent, just wondering if you can give us any additional commentary on the types of patients coming on to therapy? And maybe what percentage of scrips are actually getting filled versus rejected?",33,"On Praluent, just wondering if you can give us any additional commentary on the types of patients coming on to therapy? And maybe what percentage of scrips are actually getting filled versus rejected?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think we can get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points -- take this opportunity. We emphasize some of the points that Bob",300,"Yes. I don't think we can get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points -- take this opportunity. We emphasize some of the points that Bob made, which is that we feel on the contracting side, that process is starting to wind down in terms of about 90% of the lives who have, either commercial or a Medicare Part D coverage, decisions have been made. They haven't been fully implemented on many of them. And in fact, the rollout is just going to keep going over the next several months. And even into the second quarter of this year, some coverage won't begin. We did particularly well in those cases where there was an exclusive or preferred decision made. We won that business over 60% of the time. And as Bob said in the Medicare business, where there's a large proportion of the statin use, a large proportion of our patients, we were able when there was an exclusive or preferred decision made, and that was 80% of the time when there was an exclusive or preferred decision made, that went -- 95% of the lives went to Praluent. So we're very pleased that our product offering is resonating well. And that people, I think, are getting our message. In terms of the patient types, as we mentioned, there's a very strict utilization management criteria in the category. So it is strictly within the label population, which is patients with heterozygous familial  hypercholesterolemia and patients with a history of coronary disease. So we're seeing patients who had myocardial infarctions; patients with very, very high baseline LDL-C; patients who have FH. These are the patient populations for which the products is being dispensed."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we're hoping in the elderly population, where we did win so much of that business, that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps, wanting to start on",49,"And we're hoping in the elderly population, where we did win so much of that business, that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps, wanting to start on a lower dose. Next question, Michael?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Next question?",2,"Next question?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Geoffrey Porges with Leerink.",9,"Our next question comes from Geoffrey Porges with Leerink."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I might go back to EYLEA, if I could. I'm a little confused both by the quarterly results and by your guidance. You grew 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% next y",108,"I might go back to EYLEA, if I could. I'm a little confused both by the quarterly results and by your guidance. You grew 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% next year. If I run 1.5% sequential growth forward, it only gets to about 15% for the year. Can you give us a sense of whether any onetime items in our Q4 or Q3 or that you're anticipating for next year or you're just taking a cautious approach? And how is the underlying demand trend from Q3 to Q4?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So no. I think -- Jeff, thanks for your question. One point is that this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter, and year-over-year inventory actually decreased a little",143,"So no. I think -- Jeff, thanks for your question. One point is that this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter, and year-over-year inventory actually decreased a little bit. So there really wasn't -- that wasn't a driver. There is some -- when you look sequentially, you do have to be careful. There are seasonality trends: fourth quarter, lots of holidays; fourth and first quarter, lots of weather. And so you know how we feel about forecasting. It's about the most imprecise scientifically unscientific activity we do here. But it isn't a matter of guiding conservatively or aggressively or what have you. It's just trying to give you our best guess with the information we have which -- and looking into the future, which is of course, difficult."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","The next question comes from Adnan Butt with RBC Capital Markets.",11,"The next question comes from Adnan Butt with RBC Capital Markets."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So I'll ask a question on the EYLEA combinations. You've now seen data from both ends doing PDGFR. Which one seems more compelling? And in the past, you've shed some doubts about PDGF as a target. Has that view changed since seeing new data?",45,"So I'll ask a question on the EYLEA combinations. You've now seen data from both ends doing PDGFR. Which one seems more compelling? And in the past, you've shed some doubts about PDGF as a target. Has that view changed since seeing new data?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. It's too early to talk about our -- a",61,"George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. It's too early to talk about our -- any efficacy. But George, do you have any comments on that?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Similarly, I don't think our views have changed that much. Mechanistically, the rationale, we believe, is a little stronger for the ANG2  than the PDGF pathway. But either way, we would, of course, be excited if in the clinic, either one of these com",98,"Yes. Similarly, I don't think our views have changed that much. Mechanistically, the rationale, we believe, is a little stronger for the ANG2  than the PDGF pathway. But either way, we would, of course, be excited if in the clinic, either one of these combinations brought out a benefit to patients, especially because we think that with our ability to combine these agents into a single -- formulation of single injection, if there is increased benefit, we'll be able to have the most convenient delivery regimen for the patients. So we're only hoping for success with these combinations."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I might say on combinations that there are others we're trying to do a fix by specific approach. And I think as George has talked about this in some of his previous meetings we've had, which is that the rationale, they're, to us, seems better to be able t",135,"I might say on combinations that there are others we're trying to do a fix by specific approach. And I think as George has talked about this in some of his previous meetings we've had, which is that the rationale, they're, to us, seems better to be able to combine these as separate drugs in a single formulation so you can adjust the concentration and dose of each one to an optimal level. When you see a result by specific, you don't know whether or not it's got anything to do with both drugs acting or only 1 just acting better than the mono-specific antibody or drugs that you had compared it to. So we like the approach we're using. We like the technology, but the data's going to determine exactly where this goes."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Jim Birchenough with Wells Fargo.",10,"Our next question comes from Jim Birchenough with Wells Fargo."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's Nick in for Jim this morning. Can I just go back to the PD-1 inhibitor? The trial has ballooned from 60 to now, apparently 973 patients. There's now a quad arm of chemo, RT and GMCSS. So can you just talk a little bit about what data are we going to",90,"It's Nick in for Jim this morning. Can I just go back to the PD-1 inhibitor? The trial has ballooned from 60 to now, apparently 973 patients. There's now a quad arm of chemo, RT and GMCSS. So can you just talk a little bit about what data are we going to get from this trial? And what exactly it is you're trying to show in this trial? And perhaps, contextualize that with what competitors are doing with their PD-1 inhibitors. It's obviously a very large and complex trial."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We're not going to give out the data. But George, you might want to comment on what the approach here.",21,"Yes. We're not going to give out the data. But George, you might want to comment on what the approach here."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Right. I mean the first point was just to convincingly demonstrate the activity and where we think it sits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notion of any novel combinations,",94,"Right. I mean the first point was just to convincingly demonstrate the activity and where we think it sits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notion of any novel combinations, which could then direct us to both settings and combinations where there might be opportunities. And I think we've said and Michael didn't say exactly when that we will be talking about some of this data in the not-too-distant future. Michael, when are we going to be talking about it?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We just said later this year.",6,"We just said later this year."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. And so the programs are going well. They've obviously been enlarged because we're pleased with the initial results that we're seeing. And we'll be sharing some of that with you at the upcoming appropriate cancer meetings.",37,"Yes. And so the programs are going well. They've obviously been enlarged because we're pleased with the initial results that we're seeing. And we'll be sharing some of that with you at the upcoming appropriate cancer meetings."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Chris Raymond with Raymond James.",10,"Our next question comes from Chris Raymond with Raymond James."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back to Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other broader headwinds we should",52,"This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back to Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other broader headwinds we should be thinking about in 2016?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's always hard to anticipate trend that will go or will drive a drug at this point. I mean remember, we're in the fifth year of a launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the pr",238,"Yes. So it's always hard to anticipate trend that will go or will drive a drug at this point. I mean remember, we're in the fifth year of a launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the product still growing, which is, I think, the most important, if not quantitative. It's the most important qualitative statement. We've become the leading branded anti-VEGF in the market. And we take this franchise very seriously as we think there are additional growth drivers. George talked about the fact that we want to develop a diabetic retinopathy. And he's talked about looking at combinations with PDGF and ANG2. So we're still committed to developing this market to both in the United States and with our partner, Bayer, outside of the United States. We should note that the growth we demonstrated in the United States was purely volume. We did not take any price increases. Now from a macro sense, if there are payer changes on housings or reimbursed or things like that, what we can say now cause there are not in place, but if things change, I think there'll be more rhetoric this year during election year than actual action. But we monitor this very closely. We think our drug is a site-saving and important therapy. And we're going to continue to try and grow this franchise."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matt Roden with UBS.",9,"Our next question comes from Matt Roden with UBS."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Jeff Hung here for Matt. Regarding the Protocol C trial, when should we expect the 2-year data to be presented? And then secondly, in terms of when we may expect it to see it, it looked like the EYLEA acuity curve in the [indiscernible] or worst group is",84,"Jeff Hung here for Matt. Regarding the Protocol C trial, when should we expect the 2-year data to be presented? And then secondly, in terms of when we may expect it to see it, it looked like the EYLEA acuity curve in the [indiscernible] or worst group is trending a bit higher as you approach the 1 year mark. So this brings the question, could the data get better versus competitors in the second year? And how would you frame the 2-year data for?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think we can frame the 2-year data because we'll just have to wait and we expect it to come some time the first half of this year. And we don't control the data obviously. The data is controlled by our friends at DRCR. I will say that for us,",138,"Yes. I don't think we can frame the 2-year data because we'll just have to wait and we expect it to come some time the first half of this year. And we don't control the data obviously. The data is controlled by our friends at DRCR. I will say that for us, the most important data set was -- at the primary endpoint is 1 year where we did show superiority to the other therapies. And we showed a very strong safety profile. As you go up to the second year when you have less patients, some dropouts and what have you, we'll have to see the data set. And we'll have to look at carefully at, hopefully, to show our drug continues to have a strong safety profile as it has in all of our studies today."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to build on what Len is saying. Really, We're the the direct comparison would be in the first year because that's when the drugs were really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get",82,"Just to build on what Len is saying. Really, We're the the direct comparison would be in the first year because that's when the drugs were really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get hopelessly confabulated by the fact that the dosing regimens change. There's a lot more PR and usage, a lot more laser usage and so forth. So it's going to be very hard to deconvolute, I think, the data."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Geoff Meacham with Barclays.",9,"Our next question comes from Geoff Meacham with Barclays."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So last year with EYLEA, Protocol T, obviously, a big driver of the DME adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And may",83,"So last year with EYLEA, Protocol T, obviously, a big driver of the DME adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And maybe what the driver of that is? Is it just more blocking and tackling of the market place? Are there follow-on data sets that you feel like could be more meaningful to retinal specialists?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So Jeff, obviously, we have seen a lot of our growth this year coming in the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exams, don't get into the retinal spec",111,"So Jeff, obviously, we have seen a lot of our growth this year coming in the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exams, don't get into the retinal specialists. And so DME is currently still undertreated. Although VEGF inhibitors are being used more broadly for patients who are diagnosed with DME. The opportunity for us is to make patients aware that they've got to get their eye exam and get into a retinal specialist if they do have any problems with their vision. And that really is a major focus of our promotion this year."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And as George mentioned in his talk. Remember, we haven't diabetic retinopathy for the setting of DME. But the much broader indication of diabetic retinopathy without DME in terms of number of patients is something that we would like to get added to the l",151,"And as George mentioned in his talk. Remember, we haven't diabetic retinopathy for the setting of DME. But the much broader indication of diabetic retinopathy without DME in terms of number of patients is something that we would like to get added to the label. And that's why we are conducting pivotal studies to broaden the label of that indication. So I think it's sort of the same, Jeff, but it's -- we see growth in demographic. More patients getting older, more patients with diabetes. We see strength in potential market share, both from off label and from, coming from the off-label Avastin and perhaps from Lucentis. We see geographic growth with more room to grow outside the United States. Our ratio outside the United States is not as high as it is inside the United States in terms of market share. And finally, new indications that potentially, as I mentioned."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true that unfortunately, despite the data showing that anti-VEGF therapy can provide much better vision results than laser therapy, our laser is still t",102,"And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true that unfortunately, despite the data showing that anti-VEGF therapy can provide much better vision results than laser therapy, our laser is still the preferred in the DME population. There's a lot of patient education and doctor education there. And as Len said, that's just for the approved setting DME diabetic population. There's at least 3x as many patients who have diabetic retinopathy without DME. So if current studies really show their results, I mean there's an opportunity there as well."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Cory Kasimov with JPMorgan.",9,"Our next question comes from Cory Kasimov with JPMorgan."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? It's something specific to the drugs profile, such as the dosing options you mentioned. It's primarily the lower dose. Or does this have more to do with pricing disc",55,"I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? It's something specific to the drugs profile, such as the dosing options you mentioned. It's primarily the lower dose. Or does this have more to do with pricing discounts being offered? I'm just trying to understand the dynamics there."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people with the payers ab",150,"Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people with the payers about the product profile. We do believe that the low dose, particularly in elderly patients, might be of something of value for physicians to choose. Remember, a vast majority of patients are able to get to their desired level using the lower dose. Now whether or not the attitude of doesn't matter how low you go and it's too complicated for doctors to be able to understand the use of low and high dose, I think that puts not quite enough faith in doctors and my colleagues in the medical profession. They get the difference. And I think this may be resonating frankly."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Mark Schoenebaum with Evercore ISI.",10,"Our next question comes from Mark Schoenebaum with Evercore ISI."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a",121,"I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a 20% reduction as overwhelming efficacy. Maybe can you give us what your base case assumption is at the final analysis for risk reduction? And just related, Amgen talks a lot about their IBIS trial and how they think that's very important. To my knowledge, you guys aren't conducting one. I'd just like to hear you speak about your decision there, and your thoughts if that data will be meaningful to marketplace."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I guess we're not talking about a base case. We're telling you exactly what the study is actually is trial -- is powered to pick up. So that's the numbers that we're giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob",116,"I guess we're not talking about a base case. We're telling you exactly what the study is actually is trial -- is powered to pick up. So that's the numbers that we're giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob said, I mean we certainly realize and recognize that a lot of the outcome data and these imaging studies and so forth, they are going to speak to the class effects. And so we're hoping that their results will be positive, and we're also going to be looking at what studies that we can be doing in addition to our outcomes study and in terms of imaging."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it does seem, Mark, you may be one of the only people in the planet who can remember each and every outcomes study with the statins and which statin that it was shown that was used in the outcomes trial. But I do think, for the most part, there is some",276,"So it does seem, Mark, you may be one of the only people in the planet who can remember each and every outcomes study with the statins and which statin that it was shown that was used in the outcomes trial. But I do think, for the most part, there is some genericization. But I think it will be settled differences. And just to emphasize what George was saying about the power. I mean I think what Amgen is basically telling you, which is correct, which is that in previous studies, the amount of risk reduction you get is proportional to the absolute number of milligrams per deciliter that you lower LDL cholesterol. Now of course, in their Phase IIb/III studies -- I should say they're Phase III nonoutcome studies as well as ours, the starting LDL cholesterol was higher. And so the overall LDL absolutely reduction was a lot. And therefore, the risk reduction was a lot. When you start out with a more modest LDL, which we're both doing in our outcomes trial, you have less LDL lowering. And on average, you should have less risk reduction, but we think a every robust results. And we'll be able to look across the various spectrums of peoples who had this starting LDL and so on and so forth. So we're very confident in the LDL hypothesis. Remember, Brown and Goldstein were the first people to understand the LDL receptor, our Board of Directors. So this is something we have been very close to for a very long time. We believe in the LDL hypothesis, and we believe the outcomes trials should continue to support that."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from these studies, I think it's going to be more qualitative than quantitative as the FDA has cautioned. It's i",119,"I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from these studies, I think it's going to be more qualitative than quantitative as the FDA has cautioned. It's impossible to compare between studies, and that's because there are so many inherent differences. And the type of the population is the starting LDL, whether the had recent events or whether it's more of a secondary prevention type of a setting and so forth and so on. So there's so many differences between the population. So I think one is looking  more for qualitative messages here as opposed to specific quantitative differentiators."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Alethia Young with Credit Suisse.",10,"Our next question comes from Alethia Young with Credit Suisse."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on DB. I know -- I thought I saw like a pediatric trial. There was a small trial that was ongoing. Just wondered if you could give us your updated thoughts and fast forward on peds for DB please.",41,"Just one on DB. I know -- I thought I saw like a pediatric trial. There was a small trial that was ongoing. Just wondered if you could give us your updated thoughts and fast forward on peds for DB please."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal",213,"Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal way that this is done is that you wait till you've completed your Phase III studies in adults before moving more aggressively into children. But after, I think, looking at our program and an advisory panel on the subject, the FDA and the advisory panel, I think, pushed us. And we agreed that we should be looking even before we had the final Phase III data because the data we saw on Phase IIB were so strong. And remember, it was designated a breakthrough therapy by the agency. So we have -- we've moved into pediatrics. We have a Phase II study that's ongoing in patients between the ages of 6 and 17. And we expect to be able to get you data from that perhaps later this year. And we have a Phase III pediatric study plan as well. So we see the need. We see the children who suffer and don't have good alternatives. And we would very much like to be able to treat them."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matthew Harrison with Morgan Stanley.",10,"Our next question comes from Matthew Harrison with Morgan Stanley."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just want to ask on both the ANG2 and the PDGF following. You obviously are now going to be running 2 large Phase II studies for both of those drugs. One will read out, I guess, end of this year, and the next one I assume sometime next year. I mean how",111,"I just want to ask on both the ANG2 and the PDGF following. You obviously are now going to be running 2 large Phase II studies for both of those drugs. One will read out, I guess, end of this year, and the next one I assume sometime next year. I mean how are you thinking about bringing both of those into Phase III? Will you decide on them independently? Or will you wait for both data set to decide how to move them forward? And anything you can say around what kind of bar you think is relevant from an efficacy standpoint there to be able to move those forward?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of the combination approaches. And we'll make the decision based on the data. I t",150,"Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of the combination approaches. And we'll make the decision based on the data. I think certain advantages that we would have is that if the efficacy advantage or the interval differentiation is sufficient, we'll be able to conveniently and in a cost-effective manner, be providing both agents to the patients. So we're not really limited by sort of saying, ""Well yes, there is an advantage, but it's so modest."" How do you justify a whole new biologic here? We're in the unique position to being able to provide both agents in a very cost-effective manner regardless of what the benefit, if there is definitive, convincing additional benefits. But it's all going to depend on the data."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I can't over emphasize what George just said, so I'll repeat it which is that, when the -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the r",196,"Yes. I can't over emphasize what George just said, so I'll repeat it which is that, when the -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the risk because injections in the eye, although probably none have -- there's been no more injections, then I can imagine has been with EYLEA around the world. But the injections in the eye still carry a small but real risk each time a physician sticks a needle in the eye without putting anything in there. And so if you're going to have a very small benefit, 2 needles fixed probably won't be justified. And as George said, the cost. We can deliver these at the same cost if necessary in a single injection. So we have both the financial burden as well as the injection burden really under our control. So therefore, we can be driven by any -- we can be driven to go to market with smaller benefits than you might have to hold yourself up to if you have to do a multiple injections and add-on costs."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Operator, we have time for one last question.",8,"Operator, we have time for one last question."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Phil Nadeau with Cowen and Company.",11,"Our next question comes from Phil Nadeau with Cowen and Company."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on how you think we should model Praluent uptake through 2016. I know  in the past you've said that you'll take several quarters for sales to reflect end user demand. Is there a point in 2016 where you think that reimbursement negotiations",79,"Just a question on how you think we should model Praluent uptake through 2016. I know  in the past you've said that you'll take several quarters for sales to reflect end user demand. Is there a point in 2016 where you think that reimbursement negotiations will be finished, and sampling will begin to subside where we can begin to see end-user demand reflected in sales? Or is 2016 really a proprietary year for the postevent study uptake of Praluent?"
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months",111,"Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months. Once that coverage comes on board, there is going to be some time for physicians to understand what utilization management criteria are and how to really document the prior authorization to get these patients through the entire process to get a defense prescription. So I would say you're going to see very gradual uptake for several months until we get to some kind of a steady state."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great, operator. With that, this concludes our call. I want to thank everybody. As per usual, myself, the IR team and Bob Landry, our CFO, are available for; follow-up questions as needed at our office. Please let us know if you want to talk. Thank you.",46,"Great, operator. With that, this concludes our call. I want to thank everybody. As per usual, myself, the IR team and Bob Landry, our CFO, are available for; follow-up questions as needed at our office. Please let us know if you want to talk. Thank you."
33715,323449305,929206,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day.",17,"Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr. M",52,"Good day, ladies and gentlemen, and welcome to the Regeneron Pharmaceuticals Q4 2015 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would like to introduce your host for this conference call, Dr. Michael Aberman, Senior Vice President of Strategy and Investor Relations. You may begin, sir."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals fourth quarter and year end 2015 conference call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on th",332,"Thank you very much. Good morning, everybody, and welcome to Regeneron Pharmaceuticals fourth quarter and year end 2015 conference call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2015, and Form 10-K for the year-ended December 31, 2015, which is expected to be filed with the SEC later this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statements or whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and reconciliation of those measures to GAAP are available on our financial results press release, which can be accessed on our website at www.regeneron.com.
Once our call concludes, our CFO, Bob Landry and the IR team will be available to answer further questions. With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael. A very good morning to everyone who has joined us on the call and webcast today. 2015 was another successful and productive year for Regeneron. EYLEA delivered impressive global growth. And we received approval for and launched Praluent",570,"Thanks, Michael. A very good morning to everyone who has joined us on the call and webcast today. 
2015 was another successful and productive year for Regeneron. EYLEA delivered impressive global growth. And we received approval for and launched Praluent, which is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol. We made significant advances in our late-stage pipeline, submitting a biologic license application, or BLA, for sarilumab in rheumatoid arthritis and advancing Phase III clinical development for dupilumab in atopic dermatitis and asthma. In 2015, we also advanced 2 new antibodies into Phase III. Regeneron 2222 for the prevention of Respiratory Syncytial Virus or RSV infection infants and our anti-NGF antibody for osteoarthritis pain. We also advanced our early-stage pipeline with progress across multiple therapeutic areas, including retinal diseases, cancer, infectious diseases and cardiovascular diseases. 
Turning to EYLEA performance. EYLEA is now the market-leading brand in anti-VEGF therapy for retinal disease in the United States and continue to exhibit strong growth, both in the U.S. and worldwide. We saw approximately 54% growth year-over-year in the U.S., with sales of $2.68 billion. On a worldwide basis, EYLEA sales were approximately $4.1 billion for the full year. 
For the full year 2016, we estimate U.S. EYLEA net sales to grow approximately 20% over full year 2015 U.S. net sales. We are focused on maintaining our leadership in the retinal space. We are continuing clinical development with EYLEA where we have ongoing combination programs with PDGF and with ANG2 and are pursuing important additional indications for EYLEA that George will review later in the call.
Turning now to Praluent. We are proud to have brought the first PCSK9 inhibitor to the market in the United States for patients with uncontrolled LDL cholesterol, which was approved and launched in July of last year. We are still in the early stages of this launch and have been working diligently to provide broad access to eligible patients and educating physicians and patients in order to increase adoption. Bob Terifay will provide some additional metrics on how the launch is progressing. 
Our mission at Regeneron for 25 plus years has been to consistently and repeatedly bring important new medicines to patients in need. And we feel that we are well-positioned to deliver on this mission with our innovative pipeline. Building on last year's approval of Praluent, we anticipate at least 1 approval each year for the coming years. In 2016, we anticipate the approval of sarilumab for the treatment of rheumatoid arthritis. Our breakthrough product, dupilumab and atopic dermatitis, is progressing. And we expect to report top line Phase III data and submit a BLA in the U.S. during this year. Beyond dupilumab, we have a rapidly developing late and early-stage pipeline that now consists of 13 product candidates that were all discovered by the scientists at Regeneron. And we expect to put additional new candidates into the clinic this year. George will provide some perspective on this during his remarks. 
In summary, we are in the midst of a very exciting time with Regeneron with many important events anticipated in 2016. With that, let me turn the call over to Dr. George Yancopoulos, Regeneron's Chief Scientific Officer. He will be followed by Bob Terifay and then by Bob Landry."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. I would like to begin with EYLEA. Diabetic retinopathy is the most common cause of vision loss i",990,"Thank you, Len, and a very good morning to everyone who has joined us today. As Len said, 2015 was a very successful and exciting year for R&D at Regeneron. 
I would like to begin with EYLEA. Diabetic retinopathy is the most common cause of vision loss in patients with diabetes and as a result of microvascular damage to the blood vessels in the retina. If left untreated, diabetic retinopathy can progress to profound and sometimes acute vision loss. While EYLEA is approved to treat diabetic retinopathy in patients with diabetic macular edema, or DME, we believe that it could benefit much broader patient population with diabetic retinopathy who do not have DME where there is no approved anti-VEGF therapy. Therefore, in the first quarter of this year, we plan to initiate Panorama, a Phase III study of EYLEA in patients with nonproliferative diabetic retinopathy without diabetic macular edema. The National Institute of Health will also independently investigate the potential role of anti-VEGF therapy in the treatment of diabetic retinopathy. This study called, Protocol-W, will be sponsored by the Diabetic Retinopathy Clinical Research Network, or DRCR, and will compare EYLEA to sham in phases with severe, nonproliferative diabetic retinopathy. Protocol-W is expected to begin in the first quarter. 
A Phase II study of EYLEA in combination with our PDGF receptor antibody delivered as a co-formulated injection in wet age-related macular degeneration, or Wet AMD, is ongoing. And we expect to see top line data from this study by year end. This program had been granted fast track designation by the FDA. Data from the Phase I study of EYLEA in combination with Nesvacumab, our ANG2 antibody, delivered as a co-formulated injection, was presented just last week at the Angiogenesis Conference. These data shows that the combination of EYLEA with Nesvacumab was safe and well tolerated in patients with AMD and patients with DME. We plan to initiate Phase II studies that will include both these patient populations in the first half of the year. 
As Len mentioned, our Praluent launch is underway, and you'll hear further details from Bob Terifay on the commercial front. Our 18,000-patient outcomes trial is ongoing. And we expect the first interim analysis, which will test for futility to occur later this year based upon 50% of the expected events from the trial. Also, we could potentially have our second interim analysis, which occurs after 75% of the targeted primary events that have accrued by the end of this year. And this interim analysis will test for overwhelming efficacy and futility. As we previously disclosed, the stopping rule for this efficacy analysis is a hazard ratio of 0.802 favoring Praluent, as well as consistency across subgroups and regions, positive trends for secondary endpoints including all caused mortality and no excess noncardiovascular mortality. These last points are all important as we would not want to unblind a trial early because its efficacy in the primary endpoint at the cost of not reaching significant and important secondary endpoints. In addition to the outcomes trial, we plan to submit a supplemental BLA in the first half of the year with the Praluent monthly dosing regimen.
Turning now to sarilumab, our IL-6 receptor anitbody for rheumatoid arthritis. Our regulatory submissions were accepted by the FDA and has been granted an action date of October 30, 2016. The Phase III MONARCH trial, which is a superiority study of sarilumab monotherapy versus adalimumab, which fully enrolled, and we expect top line data from this study in the first half of 2016. A European regulatory submission for sarilumab is expected to be made in the second half of 2016. 
I share Len's enthusiasm for dupilumab, our IL-4/13 pathway blocking antibody, which is currently in Phase III clinical studies in asthma and in adults with moderate to severe atopic dermatitis where it's been granted breakthrough designation, in part because there are no FDA-approved systemic therapy for adult patients with moderate to severe atopic dermatitis. We expect to report top line data from the Phase III atopic dermatitis study, Solo-1, Solo-2 and CHRONOS in the first half of this year and to complete rolling BLS submission in the second half of the year. Our approximately 1,700-patient pivotal Phase III study of dupilumab in asthma is also enrolled. We also continue to explore other indications for dupilumab, such as nasal polyps and the eosinophilic esophagitis as well as other allergic or IL-4/13 mediated diseases. 
Our Nerve Growth Factor antibody, or NGF antibody,  fasinumab, is another late-stage pipeline candidate. Pain is one of the leading reasons that patients visit the doctor, and osteoarthritis is one of the major source of the pain in adults, particularly older adults. The increasing use of prescription opioids to treat pains has led to a growing epidemic of drug addiction and overdose-related fatalities as well as other opioid-related side effects. 
Blocking NGF has already shown the ability to improve pain compared to placebo or an active comparator such as nonsteroidal anti-inflammatory drugs, or NSAIDs, in Phase II and Phase III trials. We now have a clear path forward from the FDA and will be starting with 10,000 patient long-term treatment Phase III clinical study of fasinumab in the first half of the year. We anticipate reporting data from a 16-week study in osteoarthritis pain in the first half of the year. 
In our early-stage pipeline, we plan to share data from our Phase I/II study of anivacumab [indiscernible], our antibody to ANGPTL3 with Dyslipidemia from the first half as well as data from our ongoing immuno-oncology program such as our PD-1 program and the CD20 by CD3 by specific program. We have obviously been very busy and productive. In fact, this year, we expect to submit a record number of IND, and we look forward to sharing more details with you as these programs move into the clinic. And with that, I would like to turn the call over to Bob Terifay."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantia",825,"Thank you, George, and good morning, everyone. Fourth quarter 2015 was a productive one for Regeneron. We continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We also made substantial progress in securing access and reimbursement for Praluent or alirocumab, among U.S. payors. In addition, the European launch for Praluent commenced. 
Starting with EYLEA. Fourth quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the fourth quarter were $746 million. Full year, U.S. EYLEA sales were $2.68 billion, which represented 54% year-over-year growth. A survey of 201 U.S. retinal specialists, who evaluated their reported usage of VEGF inhibitors in the fourth quarter of 2015, indicates that EYLEA continues to be the market-leading product among FDA-approved anti-VEGF agents in all of our labeled indications in terms of market share of treated eyes. Importantly, the market share of treated eyes for EYLEA and DME is roughly double that for ranibizumab and similar to that -- for off-label bevacizumab.
Turning now to Praluent. As reported by Sanofi, net sales in the fourth quarter were $7 million, which understates actual position in patient demand. As we reminded you last quarter, we anticipate that it would take some time for commercial and government payers to conduct formulary reviews, make reimbursement coverage decisions and begin to process patient claims. Given these reasons, as well as strict utilization management criteria, we continue to expect a gradual uptake. In response to potential delays and formulary reimbursement decisions, we're offering free product to appropriate patients consistent with our labeled indication. We are waiting an insurance coverage decision. This delays uptake in commercial sales reporting. 
For example, much of Medicare Part D are government-paid patients are receiving free drug pending formulary coverage, which is expected later in the quarter. So performance cannot be solely judged on sales or filled prescriptions. As a reminder, the reimbursement environment is complex and is carefully managed by payers. Our goal has been to ensure that payers and health care providers understand the value that Praluent can offer to patients. And to that end, we have been and are still actively engaged in discussions with payers. 
There are approximately 240 million lives in the United States that have a drug benefit covered by commercial insurance or Medicare part D plans. Coverage decisions have already been made for approximately 90% of these lives. However, implementation is ongoing. And we expect continued rollout of the coverage over the next several months. Overall, for approximately 50% of the covered lives, a single PCSK9 antibody has been chosen an exclusive or preferred physician. In these exclusive or preferred cases, we estimate that Praluent was chosen for about 60% of the lives. The preference for Praluent was particularly evident in the mart Medicare Part D decisions. In Medicare, 80% of the lives have a single PCSK9 antibody in an exclusive or preferred position. For these exclusive or preferred Medicare Part B lives, Praluent was selected approximately 95% of the time. We believe these Medicare coverage decisions are particularly important because our major indications for Praluent is for patients with a history of atherosclerotic cardiovascular disease. And these patients tend to be older. According to our estimates, about 28% of statin patients in the United States are Medicare Part D patients. We are pleased to see that Praluent is resonating well with payers. As plans begin to activate their coverage, we anticipate a potential uptake in prescription volume. Importantly, almost 90% of all prescriptions processed by the hub are for our lower 75-milligram every-other-week dose. As a reminder, in our Phase III clinical studies, the vast majority of Praluent patients achieved their LDL-cholesterol goals with a 75-milligram every-other-week dose. We continue our efforts to educate both patients and physicians on the benefit of using PCSK9 inhibitor therapy. Outside of the United States, Praluent was approved in the EU in September with product available in several countries. Reimbursement discussions are currently underway with several governments across Europe. 
In the fourth quarter, we submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our interleukin 6 or IL-6 receptor inhibitor for rheumatoid arthritis. We will be co-promoting sarilumab with Sanofi in the United States and are actively recruiting our field-based team. Co-promotion decisions for other countries were made -- will be made over time. We also continue to pay for the potential U.S. launch of dupilumab, our IL-4 and IL-13 inhibitor in 2017. We've recently informed Sanofi of our intent to co-promote dupilumab in the United States. Co-promotion decisions for other countries will be made at a later date. Next month, we will have a significant presence at the American College -- or the American Academy of Allergy, Asthma and Immunology meeting in Los Angeles and the American Academy of Dermatology meeting in Washington, DC. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This",1281,"Thanks, Bob, and good morning to everyone who has joined us today. Overall, we are please with the full year performance Regeneron delivered in 2015. For the full year 2015, we earned $12.07 per diluted share from non-GAAP net income of $1.4 billion. This represents a year-over-year growth in non-GAAP diluted EPS and net income of 21% and 19%, respectively, for the full year 2015. 
In the fourth quarter of 2015, non-GAAP net income per diluted share increased 1% to $2.83 versus fourth quarter of 2014, and non-GAAP net income of $327 million was unchanged versus fourth quarter of 2014. Regeneron's 2015 non-GAAP net income excludes noncash share-based compensation expense, noncash interest expense related to our senior convertible notes, loss on extinguishment of debt in connection with conversions of a portion of our convertible notes during 2015 and in adjustment for income taxes. Non-GAAP income tax expense is based upon cash, income taxes paid or payable for 2015. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the fourth quarter of 2015 were $1.1 billion and $4.1 billion for the full year 2015, which represented year-over-year growth of 37% for the 3 months and 46% for the full year. Net product sales were $750 million in the fourth quarter of 2015 and $2.69 billion for the full year of 2015 compared to $522 million in the fourth quarter of 2014 and $1.75 billion for the full year of 2014. EYLEA net product sales in the United States were $746 million in the fourth quarter and $2.68 billion in 2015, compared to $518 million in the fourth quarter of 2014 and $1.74 billion for the full year of 2014, which represents an increase of 44% and 54%, respectively. 
During the fourth quarter of 2015, EYLEA experienced a slight increase in U.S. distributary inventory levels as compared to the third quarter 2015. And overall, a slight decrease in comparison to the fourth quarter 2014 but remains within our normal 1- to 2-week targeted range. As Len mentioned earlier, our U.S. EYLEA net sales growth guidance for full year 2016 over 2015 is approximately 20%. Ex U.S. EYLEA sales were $413 million in the fourth quarter of 2015 as compared to $297 million in the fourth quarter of 2014, representing a 39% increase on a reported basis. Ex U.S. EYLEA sales for the full year of 2015 were $1.41 billion compared to $1.04 billion for 2014, representing a 36% increase on a reported basis. 
On an operational basis or constant currency basis, sales increased approximately 54% for the 3 months and 58% for the full year 2015. Product revenues from ex U.S. EYLEA sales is recorded by our collaborator, Bayer HealthCare. 
In the fourth quarter of 2015, Regeneron recognized $140 million from our share of net profits from EYLEA sales outside the United States and $467 million for the full year 2015. Total Bayer HealthCare collaboration revenue for the fourth quarter was $165 million and $580 million for the full year 2015. 
Total Sanofi collaboration revenue was $166 million for the fourth quarter and $759 million for the full year 2015. The Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the fourth quarter of 2015, our share of losses in connection with commercialization of antibodies, primarily Praluent, was $96 million for the full year 2015 was $240 million, which can be found in Table 4 of our earnings release. 
Netting within these losses were the global sales of Praluent as recognized by our partner, Sanofi, of $7 million for the fourth quarter 2015 and $11 million for the full year 2015. Recall that Praluent was launched in the third quarter of 2015. 
Turning now to expenses. Non-GAAP R&D expenses were $389 million for the fourth quarter and $1.37 billion for the full year 2015. Our unreimbursed R&D expense, which is calculated as the total GAAP R&D expense less R&D reimbursements from our collaborators and R&D noncash share based compensation expense, was $214 million for the 3 months and $570 million for the full year 2015. We note that this comes in slightly above our 2015 non-GAAP unreimbursed R&D expense guidance of $540 million to $560 million, primarily due to higher expenditures for our NGF program. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. 
For 2016, we'd like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in the range of $875 million to $950 million. Our non-GAAP unreimbursed R&D spend is driven by 3 factors: advancing our pipeline outside of the Sanofi and Bayer collaboration, particularly our programs for NGF, RSV and CD20 by CD3; our obligation to pay for 20% of the Phase III clinical development expense following a first positive Phase III results of our partnered antibodies, primarily driven by the potential positive dupilumab Phase III readout in the first half of 2016; the advancement of our immuno-oncology pipeline in collaboration with Sanofi and proprietary R&D initiatives such as those in the area of human genomics. Non-GAAP SG&A expenses were $213 million for the fourth quarter and $646 million for the full year 2015. We expect non-GAAP SG&A expense in 2016 to be in the range of $925 million and $1 billion. The increase in our SG&A expense is primarily driven by the ongoing Praluent launch, which is entering its first full year of launch and preparing for the potential commercial launches of both sarilumab and dupilumab. As we've mentioned previously, in 2015, we began paying significant cash income taxes as compared to prior periods. Cash tax, as a percentage of non-GAAP pretax net income for this quarter as well as for all of 2015, is based on an estimated cash tax paid or payable for the full year. This amount continues to be substantially lower than our GAAP effective tax rate. On a non-GAAP basis, cash tax, as a percentage of non-GAAP pretax net income for the fourth quarter of 2015 and for the 12 months ended December 31, 2015, was approximately 16% and 18%, respectively. 
For 2016, our guidance for cash tax, as a percentage of non-GAAP pretax income, is 35% to 45%. This includes a onetime tax of approximately $222 million related to $600 million of our December 31, 2015, deferred revenue balance remaining from the immuno-oncology upfront payment from Sanofi that we received in the third quarter of 2015. The cash tax impact of the immuno-oncology upfront payment would be spread equally throughout the year. 
Our capital expenditures for the 12 months ended December 31, 2015, were $678 million. We expect our capital expenditures to be between $580 million and $680 million for 2016. These expenses continue -- these expenses continue to build on the manufacturing expansions made in 2015, which include expanding our facilities in Rensselaer, New York; in Limerick, Ireland; as well as the continued expansion of our Tarrytown, New York headquarters. We ended the fourth quarter of 2015 with cash and marketable securities of $1.7 billion. As we have previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt. In the fourth quarter of 2015, we paid $50 million to reduce these outstanding warrants. And in January 2016, we paid an additional $135 million to reduce more outstanding warrants. We intend to continue seeking opportunities to further reduce these outstanding warrants into 2016. 
With that, I'd like to turn the call back to Michael."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A.",32,"Thanks, Bob. Before starting the Q&A, I just want to correct that our 10-K will be filed later this week, not later this morning. With that, operator, we can start the Q&A."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] Our first question comes from Ying Huang with Bank of America.",13,"[Operator Instructions] Our first question comes from Ying Huang with Bank of America."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","First of all, we know that Amgen's CD outcome trial would likely read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially at a disadvantage in the commercial markets? Or actually you'l",117,"First of all, we know that Amgen's CD outcome trial would likely read out earlier than you guys. I want to ask you about the thought on that. So do you think that will put Praluent potentially at a disadvantage in the commercial markets? Or actually you'll get a ripple effect because both drugs are in the same class of PCSK9 inhibitors. Secondly, maybe for Bob. Some investors are a little concerned about the cost trends here. So can you kind of like lay out in the outer years, for the next 3 to 5 years? What are your thoughts for the year on SG&A and also R&D cost? And also maybe some trends in long-term tax."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And let me just remind people, one question. Thank you.",10,"And let me just remind people, one question. Thank you."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Go ahead, Bob.",3,"Go ahead, Bob."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that not only do we meet the primary endpoint, but that we ensure that if they are key secondary endpoints, that we allow them to come to fruition",93,"I think on the cardiovascular outcomes trial. Obviously, as George pointed out, we feel it's very important that not only do we meet the primary endpoint, but that we ensure that if they are key secondary endpoints, that we allow them to come to fruition so that we ensure that we have a robust data package. In terms of the impact of Amgen coming earlier than us, it would be speculative to really say what that means. But we do think that Amgen having positive data will be positive for the overall class."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable oppon",230,"Yes. It's Bob. With regards to your question on cost. Certainly, it's something that we take very serious about this. As we mentioned several times in the quarters last year, we are in the midst of a sizable Praluent launch against a very formidable opponent. And on top of that, we are in the midst of launching sarilumab in the fourth quarter of 2016. And we're also preparing for first half 2017 for dupilumab. So for those 3 launches, it's putting stress on our SG&A number. With regards to R&D, we've highlighted some drivers with regards to the increase and unreimbursed R&D. The biggest one probably being the NGF program, as you heard from Len and George earlier. That program is full speed ahead with regards to entering Phase III very, very shortly. We're also moving forward with RSV. Now these are both unpartnered products. And then again, we get our first positive Phase III readout for dupilumab in the first half of 2016. And as you know and as we've said before, that's a driver with regards to us picking up 20% of the program cost associated with that. So that would not only include atopic dermatitis, that would also include the asthma indications associated with that. So all of these things associated are putting some stress on our expenses. And maybe Len may have a few additional comments."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The spaces are usually too wide with lots of white space and lots of worry, what to do, where's the next drug going to come fro",180,"Thanks, Bob. I would just say that if you study this industry and companies in it, nobody ever has a perfectly spaced pipeline. The spaces are usually too wide with lots of white space and lots of worry, what to do, where's the next drug going to come from? Or very infrequently, as is the case here of Regeneron, there's a lot going on. It's very compacted in time. We, of course, would rather have the latter than the former. And that's what I think that we're managing through. And it's an exciting time: an approval in 2015 for Praluent; 2016, we hope for sarilumab; 2017, the first approval for dupilumab; and beyond that, approvals for dupilumab in asthma; perhaps NGF coming up; RSV; progress in the -- and perhaps approval down the line there; and immuno-oncology. So we have a very intensely compacted pipeline that we have to manage both from a technical point of view, from an operational point of view, a manufacturing point of view, and of course, as Bob says, from a financial point of view."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn for Goldman Sachs.",10,"Our next question comes from Terence Flynn for Goldman Sachs."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On Praluent, just wondering if you can give us any additional commentary on the types of patients coming on to therapy? And maybe what percentage of scrips are actually getting filled versus rejected?",33,"On Praluent, just wondering if you can give us any additional commentary on the types of patients coming on to therapy? And maybe what percentage of scrips are actually getting filled versus rejected?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think we can get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points -- take this opportunity. We emphasize some of the points that Bob",300,"Yes. I don't think we can get into the metrics in terms of those things, Terence. Unfortunately, it's a fairly competitive marketplace out there. I will reemphasize that some of the points -- take this opportunity. We emphasize some of the points that Bob made, which is that we feel on the contracting side, that process is starting to wind down in terms of about 90% of the lives who have, either commercial or a Medicare Part D coverage, decisions have been made. They haven't been fully implemented on many of them. And in fact, the rollout is just going to keep going over the next several months. And even into the second quarter of this year, some coverage won't begin. We did particularly well in those cases where there was an exclusive or preferred decision made. We won that business over 60% of the time. And as Bob said in the Medicare business, where there's a large proportion of the statin use, a large proportion of our patients, we were able when there was an exclusive or preferred decision made, and that was 80% of the time when there was an exclusive or preferred decision made, that went -- 95% of the lives went to Praluent. So we're very pleased that our product offering is resonating well. And that people, I think, are getting our message. In terms of the patient types, as we mentioned, there are very strict utilization management criteria in the category. So it is strictly within the label population, which is patients with heterozygous familial  hypercholesterolemia and patients with a history of coronary disease. So we're seeing patients who've had myocardial infarctions; patients with very, very high baseline LDL-C; patients who have FH. These are the patient populations for which the products is being dispensed."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we're hoping in the elderly population, where we did win so much of that business, that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps, wanting to start on",49,"And we're hoping in the elderly population, where we did win so much of that business, that the availability of our low dose accompanying that will resonate well with doctors, especially as they're treating elderly people and perhaps, wanting to start on a lower dose. Next question, Michael?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Next question?",2,"Next question?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Geoffrey Porges with Leerink.",9,"Our next question comes from Geoffrey Porges with Leerink."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I might go back to EYLEA, if I could. I'm a little confused both by the quarterly results and then by your guidance. You grew 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% n",109,"I might go back to EYLEA, if I could. I'm a little confused both by the quarterly results and then by your guidance. You grew 1.5% sequentially Q3 to Q4. And you originally guided this year for 25% to 30% and you grew 54%. And now you're guiding for 20% next year. If I run 1.5% sequential growth forward, it only gets to about 15% for the year. Can you give us a sense of whether any onetime items in our Q4 or Q3 or that you're anticipating for next year or you're just taking a cautious approach? And how is the underlying demand trend from Q3 to Q4?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So no. I think -- Jeff, thanks for your question. One point is that this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter, and year-over-year inventory actually decreased a little",143,"So no. I think -- Jeff, thanks for your question. One point is that this is not driven by inventory or things like that. Inventory increased very slightly but within our range in the fourth quarter, and year-over-year inventory actually decreased a little bit. So there really wasn't -- that wasn't a driver. There is some -- when you look sequentially, you do have to be careful. There are seasonality trends: fourth quarter, lots of holidays; fourth and first quarter, lots of weather. And so you know how we feel about forecasting. It's about the most imprecise scientifically unscientific activity we do here. But it isn't a matter of guiding conservatively or aggressively or what have you. It's just trying to give you our best guess with the information we have which -- and looking into the future, which is of course, difficult."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","The next question comes from Adnan Butt with RBC Capital Markets.",11,"The next question comes from Adnan Butt with RBC Capital Markets."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So I'll ask a question on the EYLEA combinations. You've now seen data from both ends doing PDGFR. Which one seems more compelling? And in the past, you've shed some doubts about PDGF as a target. Has that view changed since seeing data?",44,"So I'll ask a question on the EYLEA combinations. You've now seen data from both ends doing PDGFR. Which one seems more compelling? And in the past, you've shed some doubts about PDGF as a target. Has that view changed since seeing data?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. It's too early to talk about our -- a",61,"George can comment. But there isn't much to change our view because the only thing we've really seen thus far is that we can deliver these products in combination, and we can do that and what appears to be a safe way. It's too early to talk about our -- any efficacy. But George, do you have any comments on that?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Similarly, I don't think our views have changed that much. Mechanistically, the rationale, we believe, is a little stronger for the ANG2 than the PDGF pathway. But either way, we would, of course, be excited if in the clinic, either one of these comb",98,"Yes. Similarly, I don't think our views have changed that much. Mechanistically, the rationale, we believe, is a little stronger for the ANG2 than the PDGF pathway. But either way, we would, of course, be excited if in the clinic, either one of these combinations brought out a benefit to patients, especially because we think that with our ability to combine these agents into a single -- formulation of single injection, if there is increased benefit, we'll be able to have the most convenient delivery regimen for the patients. So we're only hoping for success with these combinations."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I might say on combinations that there are others we're trying to do a fix by specific approach. And I think as George has talked about this in some of his previous meetings we've had, which is that the rationale, they're, to us, seems better to be able t",135,"I might say on combinations that there are others we're trying to do a fix by specific approach. And I think as George has talked about this in some of his previous meetings we've had, which is that the rationale, they're, to us, seems better to be able to combine these as separate drugs in a single formulation so you can adjust the concentration and dose of each one to an optimal level. When you see a result by specific, you don't know whether or not it's got anything to do with both drugs acting or only 1 just acting better than the mono-specific antibody or drugs that you had compared it to. So we like the approach we're using. We like the technology, but the data's going to determine exactly where this goes."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Jim Birchenough with Wells Fargo.",10,"Our next question comes from Jim Birchenough with Wells Fargo."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's Nick in for Jim this morning. Can I just go back to the PD-1 inhibitor? The trial has ballooned from 60 to now, apparently 973 patients. There's now a quad arm of chemo, RT and GMCSS. So can you just talk a little bit about what data are we going to",90,"It's Nick in for Jim this morning. Can I just go back to the PD-1 inhibitor? The trial has ballooned from 60 to now, apparently 973 patients. There's now a quad arm of chemo, RT and GMCSS. So can you just talk a little bit about what data are we going to get from this trial? And what exactly it is you're trying to show in this trial? And perhaps, contextualize that with what competitors are doing with their PD-1 inhibitors. It's obviously a very large and complex trial."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We're not going to give out the data. But George, you might want to comment on what the general approach is.",22,"Yes. We're not going to give out the data. But George, you might want to comment on what the general approach is."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Right. I mean the first point was just to convincingly demonstrate the activity and where we think it fits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notion of any novel combinations,",94,"Right. I mean the first point was just to convincingly demonstrate the activity and where we think it fits compared to our competitors. Second was to get a broad idea of which settings and which indications. But also, the notion of any novel combinations, which could then direct us to both settings and combinations where there might be opportunities. And I think we've said and Michael didn't say exactly when that we will be talking about some of this data in the not-too-distant future. Michael, when are we going to be talking about it?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We just said later this year.",6,"We just said later this year."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. And so the programs are going well. They've obviously been enlarged because we're pleased with the initial results that we're seeing. And we'll be sharing some of that with you at the upcoming appropriate cancer meetings.",37,"Yes. And so the programs are going well. They've obviously been enlarged because we're pleased with the initial results that we're seeing. And we'll be sharing some of that with you at the upcoming appropriate cancer meetings."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Chris Raymond with Raymond James.",10,"Our next question comes from Chris Raymond with Raymond James."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back to Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other broader headwinds we should",52,"This is Laura Chico in for Chris Raymond today. I guess I'd like to just go back to Jeff's question on the EYLEA guidance for a moment. I know you mentioned seasonal and weather potential impacts in Q1. But are there any other broader headwinds we should be thinking about in 2016?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's always hard to anticipate trends that will go or will drive a drug at this point. I mean remember, we're in the fifth year of a launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the p",238,"Yes. So it's always hard to anticipate trends that will go or will drive a drug at this point. I mean remember, we're in the fifth year of a launch, which is a pretty big deal to be expecting 20% year-over-year growth on a very large base. So we see the product still growing, which is, I think, the most important, if not quantitative. It's the most important qualitative statement. We've become the leading branded anti-VEGF in the market. And we take this franchise very seriously as we think there are additional growth drivers. George talked about the fact that we want to develop a diabetic retinopathy. And he's talked about looking at combinations with PDGF and ANG2. So we're still committed to developing this market to both in the United States and with our partner, Bayer, outside of the United States. We should note that the growth we demonstrated in the United States was purely volume. We did not take any price increases. Now from a macro sense, if there are payer changes on housings or reimbursed or things like that, what we can say now cause there are not in place, but if things change, I think there'll be more rhetoric this year during election year than actual action. But we monitor this very closely. We think our drug is a site-saving and important therapy. And we're going to continue to try and grow this franchise."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matt Roden with UBS.",9,"Our next question comes from Matt Roden with UBS."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Jeff Hung here for Matt. Regarding the Protocol C trial, when should we expect the 2-year data to be presented? And then secondly, in terms of when we may expect it to see it, it looked like the EYLEA acuity curve in the 2050[indiscernible] or worst group",84,"Jeff Hung here for Matt. Regarding the Protocol C trial, when should we expect the 2-year data to be presented? And then secondly, in terms of when we may expect it to see it, it looked like the EYLEA acuity curve in the 2050[indiscernible] or worst group is trending a bit higher as you approach the 1 year mark. So this breeds the question, could the data get better versus competitors in the second year? And how would you frame the 2-year data for?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think we can frame the 2-year data because we'll just have to wait and we expect it to come some time the first half of this year. And we don't control the data obviously. The data is controlled by our friends at DRCR. I will say that for us,",139,"Yes. I don't think we can frame the 2-year data because we'll just have to wait and we expect it to come some time the first half of this year. And we don't control the data obviously. The data is controlled by our friends at DRCR. I will say that for us, the most important data set was -- at the primary endpoint is 1 year where we did show superiority to the other therapies. And we showed a very strong safety profile. As you go up to the second year when you have less patients, some dropouts and what have you, we'll have to see the data set. And we'll have to look at carefully at, hopefully, to show our drug continues to have a strong safety profile as it has in all of our studies to date."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to build on what Len is saying. Really, were the direct comparison would be in the first year because that's when the drugs were really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get h",83,"Just to build on what Len is saying. Really, were the direct comparison would be in the first year because that's when the drugs were really tried side-by-side using very similar paradigms, dosing regimens and so forth. In the second year, things get hopelessly confabulated by the fact that the dosing regimens change. There's a lot more PR end usage, a lot more laser usage and so forth. So it's going to be very hard to deconvolute, I think, the second year data."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Geoff Meacham with Barclays.",9,"Our next question comes from Geoff Meacham with Barclays."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So last year with EYLEA, Protocol T, obviously, a big driver of the DME adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And may",83,"So last year with EYLEA, Protocol T, obviously, a big driver of the DME adoption. I wanted to see if you guys could talk sort of qualitatively about where you think VEGF share of the overall DME market is? What you think the next leg of growth is? And maybe what the driver of that is? Is it just more blocking and tackling of the market place? Are there follow-on data sets that you feel like could be more meaningful to retinal specialists?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So Jeff, obviously, we have seen a lot of our growth this year coming in the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exams, don't get into the retinal spec",111,"So Jeff, obviously, we have seen a lot of our growth this year coming in the DME segment of the marketplace. Unfortunately, there's still a large number of patients who have diabetes that don't get yearly dilated eye exams, don't get into the retinal specialists. And so DME is currently still undertreated. Although VEGF inhibitors are being used more broadly for patients who are diagnosed with DME. The opportunity for us is to make patients aware that they've got to get their eye exam and get into a retinal specialist if they do have any problems with their vision. And that really is a major focus of our promotion this year."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And as George mentioned in his talk. Remember, we have an indication for diabetic retinopathy in the setting of DME. But the much broader indication of diabetic retinopathy without DME in terms of number of patients is something that we would like to get",154,"And as George mentioned in his talk. Remember, we have an indication for diabetic retinopathy in the setting of DME. But the much broader indication of diabetic retinopathy without DME in terms of number of patients is something that we would like to get added to the label. And that's why we are conducting pivotal studies to broaden the label of that indication. So I think it's sort of the same, Jeff, but it's -- we see growth in demographics. More patients getting older, more patients with diabetes. We see strength in potential market share, both from off label and from, coming from the off-label Avastin and perhaps from Lucentis. We see geographic growth with more room to grow outside the United States. Our ratio outside the United States is not as high as it is inside the United States in terms of market share. And finally, new indications that potentially, as I mentioned."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true that unfortunately, despite the data showing that anti-VEGF therapy can provide much better vision results than laser therapy, our laser is still t",104,"And just add to that. There is a lot of patient and doctor education that needs to be done. It's still true that unfortunately, despite the data showing that anti-VEGF therapy can provide much better vision results than laser therapy, our laser is still the preferred therapy in the DME population. There's a lot of patient education and doctor education there. And as Len said, that's just for the approved setting DME diabetic population. There's at least 3x as many patients who have diabetic retinopathy without DME. So if the current studies really show their results, I mean there's an opportunity there as well."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Cory Kasimov with JPMorgan.",9,"Our next question comes from Cory Kasimov with JPMorgan."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? It's something specific to the drugs profile, such as the dosing options you mentioned. It's primarily the lower dose. Or does this have more to do with pricing disc",55,"I'm curious what you think is driving the impressive Medicare uptake so far for Praluent? It's something specific to the drugs profile, such as the dosing options you mentioned. It's primarily the lower dose. Or does this have more to do with pricing discounts being offered? I'm just trying to understand the dynamics there."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people with the payers ab",150,"Yes. That's always hard to know because we, of course, don't know what the other sides of financial offerings are. We only know ours. But we believe in all of these meetings, we spent a lot of time trying to educate the technical people with the payers about the product profile. We do believe that the low dose, particularly in elderly patients, might be of something of value for physicians to choose. Remember, a vast majority of patients are able to get to their desired level using the lower dose. Now whether or not the attitude of doesn't matter how low you go and it's too complicated for doctors to be able to understand the use of low and high dose, I think that puts not quite enough faith in doctors and my colleagues in the medical profession. They get the difference. And I think this may be resonating frankly."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Mark Schoenebaum with Evercore ISI.",10,"Our next question comes from Mark Schoenebaum with Evercore ISI."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a",122,"I'll follow Michael's rule of no more than 7 questions. Amgen has actually said that their base case at the final analysis for the CVOT trial is a risk reduction of about 25% to 35%. So I was struck by your statement that your DSMB would consider about a 20% reduction as overwhelming efficacy. Maybe can you give us what your base case assumption is at the final analysis for risk reduction? And just related, Amgen talks a lot about their IBIS trial and how they think that's very important. To my knowledge, you guys aren't conducting one. I'd just like to hear you speak about your decision there, and your thoughts on if that data will be meaningful to marketplace."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I guess we're not talking about a base case. We're telling you exactly what the study is actually is trial -- is powered to pick up. So that's the numbers that we're giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob",116,"I guess we're not talking about a base case. We're telling you exactly what the study is actually is trial -- is powered to pick up. So that's the numbers that we're giving. And certainly, we're looking at a variety of imaging studies and so forth. As Bob said, I mean we certainly realize and recognize that a lot of the outcome data and these imaging studies and so forth, they are going to speak to the class effects. And so we're hoping that their results will be positive, and we're also going to be looking at what studies that we can be doing in addition to our outcomes study and in terms of imaging."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it does seem, Mark, you may be one of the only people in the planet who can remember each and every outcomes study with the statins and which statin that it was shown that was used in the outcomes trial. But I do think, for the most part, there is some",277,"So it does seem, Mark, you may be one of the only people in the planet who can remember each and every outcomes study with the statins and which statin that it was shown that was used in the outcomes trial. But I do think, for the most part, there is some genericization. But I think it will be settled differences. And just to emphasize what George was saying about the power. I mean I think what Amgen is basically telling you, which is correct, which is that in previous studies, the amount of risk reduction you get is proportional to the absolute number of milligrams per deciliter that you lower LDL cholesterol. Now of course, in their Phase IIb/III studies -- I should say they're Phase III nonoutcome studies as well as ours, the starting LDL cholesterol was higher. And so the overall LDL absolutely reduction was a lot. And therefore, the risk reduction was a lot. When you start out with a more modest LDL, which we're both doing in our outcomes trial, you have less LDL lowering. And on average, you should have less risk reduction, but we think a very robust result. And we'll be able to look across the various spectrums of peoples who had this starting LDL and so on and so forth. So we're very confident in the LDL hypothesis. Remember, Brown and Goldstein were the first people to understand the LDL receptor, on our Board of Directors. So this is something we have been very close to for a very long time. We believe in the LDL hypothesis, and we believe the outcomes trials should continue to support that."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from these studies, I think it's going to be more qualitative than quantitative as the FDA has cautioned. It's i",119,"I think Len said it very well, but it was a little complicated even for me to understand. I think the point is that the important message here from these studies, I think it's going to be more qualitative than quantitative as the FDA has cautioned. It's impossible to compare between studies, and that's because there are so many inherent differences. And the type of the population is the starting LDL, whether the had recent events or whether it's more of a secondary prevention type of a setting and so forth and so on. So there's so many differences between the population. So I think one is looking  more for qualitative messages here as opposed to specific quantitative differentiators."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Alethia Young with Credit Suisse.",10,"Our next question comes from Alethia Young with Credit Suisse."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on DB. I know -- I thought I saw like a pediatric trial. There was a small trial that was ongoing. Just wondered if you could give us your updated thoughts and fast forward on peds for DB please.",41,"Just one on DB. I know -- I thought I saw like a pediatric trial. There was a small trial that was ongoing. Just wondered if you could give us your updated thoughts and fast forward on peds for DB please."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal",218,"Well, as you know, pediatric patients with atopic dermatitis are a very large population of people. And these children and many of them suffered greatly. So we would love to see our drug program expanded to be able to treat children. Of course, the normal way that this is done is that you wait till you've completed your Phase III studies in adults before moving more aggressively into children. But after, I think, looking at our program and an advisory panel on the subject, the FDA and the advisory panel, I think, pushed us. And we agreed that we should be looking even before we had the final Phase III data because the data we saw on Phase IIB were so strong. And remember, it was designated a breakthrough therapy by the agency. So we have -- we've moved into pediatrics. We have a Phase II study that's ongoing in patients between the ages of 6 and 17. And we expect to be able to get you data from that perhaps later this year. And we have a Phase III pediatric study plan as well. So we see the need. We see the children who suffer and don't have good alternatives. And we would very much like to be able to expand to be able to treat them."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Matthew Harrison with Morgan Stanley.",10,"Our next question comes from Matthew Harrison with Morgan Stanley."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just want to ask on both the ANG2 and the PDGF following. You obviously are now going to be running 2 large Phase II studies for both of those drugs. One will read out, I guess, end of this year, and the next one I assume sometime next year. I mean how",111,"I just want to ask on both the ANG2 and the PDGF following. You obviously are now going to be running 2 large Phase II studies for both of those drugs. One will read out, I guess, end of this year, and the next one I assume sometime next year. I mean how are you thinking about bringing both of those into Phase III? Will you decide on them independently? Or will you wait for both data set to decide how to move them forward? And anything you can say around what kind of bar you think is relevant from an efficacy standpoint there to be able to move those forward?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of these combination approaches. And we'll make the decision based on the data. I",150,"Well, I think data always speaks for us and to us and that's how we make our decision. So we, I think have designed a very robust and comprehensive Phase II program for both of these combination approaches. And we'll make the decision based on the data. I think certain advantages that we would have is that if the efficacy advantage or the interval differentiation is sufficient, we'll be able to conveniently and in a cost-effective manner, be providing both agents to the patients. So we're not really limited by sort of saying, ""Well yes, there is an advantage, but it's so modest."" How do you justify a whole new biologic here? We're in the unique position of being able to provide both agents in a very cost-effective manner regardless of what the benefit, if there is definitive, convincing additional benefits. But it's all going to depend on the data."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I can't over emphasize what George just said, so I'll repeat it which is that, when the -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the r",196,"Yes. I can't over emphasize what George just said, so I'll repeat it which is that, when the -- some people are trying to develop add-ons as 2 separate injections, which really means that you must have a robust efficacy and safety profile to justify the risk because injections in the eye, although probably none have -- there's been no more injections, then I can imagine has been with EYLEA around the world. But the injections in the eye still carry a small but real risk each time a physician sticks a needle in the eye without putting anything in there. And so if you're going to have a very small benefit, 2 needles fixed probably won't be justified. And as George said, the cost. We can deliver these at the same cost if necessary in a single injection. So we have both the financial burden as well as the injection burden really under our control. So therefore, we can be driven by any -- we can be driven to go to market with smaller benefits than you might have to hold yourself up to if you have to do a multiple injections and add-on costs."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Operator, we have time for one last question.",8,"Operator, we have time for one last question."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Phil Nadeau with Cowen and Company.",11,"Our next question comes from Phil Nadeau with Cowen and Company."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on how you think we should model Praluent uptake through 2016. I know in the past you've said that you'll take several quarters for sales to reflect end user demand. Is there a point in 2016 where you think that reimbursement negotiations",80,"Just a question on how you think we should model Praluent uptake through 2016. I know in the past you've said that you'll take several quarters for sales to reflect end user demand. Is there a point in 2016 where you think that reimbursement negotiations will be finished, and sampling will begin to subside where we can begin to see end-user demand reflected in sales? Or is 2016 really a proprietary year for the post event study uptake of Praluent?"
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months",112,"Just to clarify. Although as we discussed, the class currently has penetrated 90% of covered lives. Many of the payers have yet to implement their insurance coverage. So we expect to see that coverage continue to come on board over the next several months. Once that coverage comes on board, there is going to be some time for physicians to understand what the utilization management criteria are and how to really document the prior authorization to get these patients through the entire process to get a defense prescription. So I would say you're going to see very gradual uptake for several months until we get to some kind of a steady state."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great, operator. With that, this concludes our call. I want to thank everybody. As per usual, myself, the IR team and Bob Landry, our CFO, are available for; follow-up questions as needed at our office. Please let us know if you want to talk. Thank you.",46,"Great, operator. With that, this concludes our call. I want to thank everybody. As per usual, myself, the IR team and Bob Landry, our CFO, are available for; follow-up questions as needed at our office. Please let us know if you want to talk. Thank you."
33715,323449305,929326,"Regeneron Pharmaceuticals, Inc., Q4 2015 Earnings Call, Feb 09, 2016",2016-02-09,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day.",17,"Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. Now, I'll turn the call over to Dr. Mike Aberman",41,"Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. Now, I'll turn the call over to Dr. Mike Aberman."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, operator, and good morning, and welcome to Regeneron Pharmaceutical's First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.Joining me on the call today are Dr",313,"Thank you, operator, and good morning, and welcome to Regeneron Pharmaceutical's First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer.
After our prepared remarks, we will open the call for Q&A.  I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended March 31, 60 oh, which was filed with the SEC this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com.
Once the call concludes, Bob Landry and IR team will be available to answer further questions. 
With that, let me turn the call over toward the President and Chief Executive Officer, Dr. Len Schleifer."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Michael. A very good morning to everyone who was joined us on the call and webcast today. The first quarter of 2016 was busy and we've a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities and drug d",321,"Thank you, Michael. A very good morning to everyone who was joined us on the call and webcast today. 
The first quarter of 2016 was busy and we've a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities and drug discovery and development on bringing important new medicines to patients in need. George will provide you with some of the recent exciting progress we've made in that regard. 
From a high-level perspective, we had positive data readouts from 3 Phase III programs, Praluent for lowering LDL cholesterol in the setting, sarilumab in rheumatoid arthritis, and dupilumab in atopic dermatitis. 
We also reported positive data from a Phase II/III study in osteoarthritis for fasinumab, our NGF for pain. And we continue to make good progress with our early stage assets and discovery efforts. 
Turning to our marketed products, EYLEA has continued to deliver solid growth and we are able to increase our guidance for the year. Praluent's launch is still ongoing and it's obviously faced with difficult reimbursement environment. 
While we fully understand payers' efforts to control costs, we do have serious concerns that appropriate patients are having undue difficulty getting approval for Praluent. We continue to be optimistic over the long term that Praluent will provide an important cholesterol-lowering option to many patients. 
Bob Terifay will provide more detail on EYLEA and Praluent. Following that, Bob Landry will provide more detail on financial results for the first quarter of 2016 as well as updated guidance. 
Finally, we are approaching the potential approval and launch of 2 new products, sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis, is under review with the FDA. Dupilumab is being developed for a number of indications and we are targeting completion of our rolling BLA submission for moderate-to-severe atopic dermatitis in the third quarter of 2016. 
With that, let me turn the call over to George."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who was joined us today. Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combination of EYLEA with [indiscernible], an antibody to the PDGF receptor and nesvacumab, an a",1556,"Thank you, Len, and a very good morning to everyone who was joined us today. 
Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combination of EYLEA with [indiscernible], an antibody to the PDGF receptor and nesvacumab, an antibody to angiopoietin-2, we have also commenced Panorama, a Phase III study of EYLEA in non-proliferative diabetic retinopathy I patients without diabetic macular edema, or DME, which will evaluate whether EYLEA can improve retinopathy. 
Additionally, the Diabetic Retinopathy Clinical Research Network, or DRCR, initiated a related clinical study called Protocol W to evaluate the potential of anti-VEGF therapy in preventing worsening of severe non-proliferative diabetic retinopathy. 
The study will explore every 16-week dosing of EYLEA, which the only anti-VEGF treatment being investigated in this study. 
In February, we received 2 new results from Protocol T, a government-sponsored study in patients with DME, comparing the safety and efficacy of EYLEA versus Lucentis and Avastin. The primary efficacy endpoint for that study was at 1 year, which showed significant better vision gain with EYLEA in either with Lucentis or Avastin. 
The second year of the study was not designed to rigorously compare the anti-VEGF agents as the second year results were increasingly confounded by variable dosing frequencies as well as additional adjunctive therapies such as laser. 
Along these lines, it is important to point out that there was a greater number of injections substantially more use of laser associated with Avastin treatment in the overall population. 
Despite this, when compared with Avastin, EYLEA demonstrated a statistically significant 5-letter gain or an entire line of vision in patients with poor vision at baseline. 
At 2 years, the rates of most ocular adverse events were similar across 3 study groups. There was, however, statistical given lower rate of arterial events, including nonfatal stroke, nonfatal myocardial infarction and vascular death in the EYLEA group compared with the ranibizumab group. 
A probably launch is underway and Bob Terifay will provide further details on the commercial front. 
Our 18,000 patient ODYSSEY OUTCOMES study is ongoing. The data monitoring committee for this study has completed the first interim analysis with 50% of the total events had accrued based on unblinded study data. 
In addition to reviewing the safety data, the DMC performed the futility assessment and recommended the study continue with no changes. 
We remain blinded to the actual results of this analysis and the study is ongoing. A second interim analysis for futility as well as overwhelming efficacy can potentially occur in the second half of 2016, when 75% of the targeted primary events have occurred. 
In March, we reported positive data from the Phase III ODYSSEY ESCAPE study in patients with heterozygous familial hypercholesterolemia, who required chronic weekly or biweekly apheresis. Apheresis is an invasive, expensive and time-consuming therapy given to the patients with the highest cholesterol levels in the greatest need. 
Our study showed that Praluent reduced the need for apheresis by 75% compared to placebo. And 63% of Praluent patients no longer require apheresis compared to 0% of the patients with placebo arm. Praluent is the only PCSK9 inhibitor that has been studied in a apheresis study, which represents some of the most severe hypercholesterolemic patients. The adverse events had occurred more frequently in the Praluent-treated patients where injected sites reactions in [indiscernible]. 
We expect  a supplemental BLA for the once monthly dosing of regimen of Praluent to be filed in the second quarter, which if approved, will expand our dosing flexibility options.
Turning now to our late stage pipeline, where we had some very positive news. I'd like to start with sarilumab, our IL-6 receptor antibody, which is under review by the FDA for the treatment of rheumatoid arthritis. 
In March, we announced positive data from the Phase III MONARCH study of sarilumab versus Humira, which demonstrated sarilumab was superior to Humira in the monotherapy setting improving signs and symptoms of rheumatoid arthritis at 24 weeks. This was the first head-to-head study in the monotherapy study using a subcutaneously administered IL-6 inhibitor. 
The use of IL-6 inhibitions of monotherapy setting has been growing and this data provide us with a competitive product profile. Data from the MONARCH study will be included in our European submission and is expected midyear of 2016. 
Turning now to dupilumab, our IL-4 13 blocking antibody, where we recently announced positive top line data from Solo-1 and Solo-2 monotherapy Phase III studies in adults with moderate-to-severe atopic dermatitis. 
These were the first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis and confirm the positive data we have seen in our Phase IIb study. 
Overall, the study demonstrates significant improvements in measures of disease severity, skin clearing, itching, quality-of-life and mental health. We expect to present detailed data from the solo studies in the upcoming medical conference. 
We continue to expect top line data from the Phase III CHRONO study, which explores dupilumab in combination with topical corticosteroids in the second quarter of 2016. We expect to complete the rolling BLA submission for dupilumab in atopic dermatitis in the third quarter of 2016. Remind you that dupilumab has received breakthrough designation from the FDA for this indication in adults. 
In the first quarter of 2016, we initiated liver AD Caf, a Phase II study of dupilumab to support our European submission. This study invest dupilumab with common topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or intolerant to an intelligible form systemic [indiscernible] treatment. 
In addition to the studies in the adult setting, we also plan to initiate a Phase III study in the atopic dermatitis indication in the pediatric population once we have data from the ongoing Phase II pediatric study that is now fully enrolled. We expect this Phase II data in the second half of the year. 
We're also investigating dupilumab and other indications, including asthma, where we are currently enrolling our 1,700 patients pivotal study. 
We're also advancing critical development in indications such as nasal polyps and eosinophilic esophagitis. 
For fasinumab, our NGF antibody, earlier this week, we announced positive data from our Phase II/III study in osteoarthritis, which provides us with our first safety and efficacy data with our subcutaneous dosing regiment. This was the first completed study using the antibody to NGF that performs extensive imaging of knee, hip and shoulder joints at screening and throughout the trial. 
Interestingly, we found that sub inter-efficiency fraction and even osteoarthritis were present in this population at screening. 
Further, our findings in patients fasinumab treatment are consistent with prior data suggesting that they may not be a substantial increase in rapidly progressing osteoarthritis when an NGF antibody is using the monotherapy setting. 
That said, it's a relatively small trial and we look forward to data from a much larger clinical studies that are underway. 
We have also seen some exciting developments in an earlier stage program. I'd like to spend a few minutes in 2 areas. Our efforts in genetics and our recent collaboration in the arena of gene editing. In March, we published a paper in the New England Journal of Medicine based on research that was conducted at the Regeneron Genetics Center, or the RGC. The publication showed that inactivating the patients in the gene called angiopoietin like 4 were associated with a significantly reduced risk of coronary artery diseases in humans. This is a great example that demonstrates how our efforts in the area of position medicine can link genetic mutations information with real-world health outcomes to make actionable discoveries. 
Many of the findings the RGC are already being used to inform Regeneron's robust and integrated R&D programs and give us the ability to incorporate large-scale sequencing into discovery and pipeline approaches. 
We also demonstrate the advantages of our unique combination of technologies. Using our proprietary VelociGene Technology, we developed animal models that collaborate the human genetics findings. We're able to use VelociGene platform to create a fully human monoclonal antibody inhibitor of ANGPTL4 that reduce triglyceride levels in mice and nonhuman primate. 
We're also advancing the Phase II program of Regeneron 1500, an antibody that ANGPTL3. ANGPTL3 play a central role of lipoprotein metabolism and our genetic data show that patients with homozygous activation mutations of this gene report greater than 50% lower levels of LDL, HDL and triglycerides. 
Initial data from the small study in homozygous patients will be presented at the upcoming annual meeting of the National Lipid Association. We 
recently entered into collaboration with Intellia Therapeutics with the aim of advancing [indiscernible] genetic technology into in vivo therapeutic development. This was a logical fit for us given our long-standing expertise on genetic engineering, combined with our industry-leading human genetics research with the RGC, which is already identifying important generic target. 
We believe that combining these capabilities with Intellia technology holds real promise for serious diseases that have been historically difficult to address. It expands our ability to help patients with antibody-base therapies may not be the optimal approach. 
We continue to make progress in immuno-oncology. REGN2810, our PD-1 antibody program has entered a Phase II potentially registrational study in cutaneous sub carcinoma. We'll be presenting some preliminary Phase I data at the upcoming annual ASCO conference. 
With that, I'd like to turn over to call to Bob Terifay."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. During the first quarter of 2016, we continue to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We made substantial progress in securing a",974,"Thank you, George, and good morning, everyone. 
During the first quarter of 2016, we continue to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. 
We made substantial progress in securing access and reimbursement for Praluent or alirocumab, among U.S. payers. 
In addition, the European launch of Praluent continues to progress. 
We also are now preparing for the potential U.S. launch of sarilumab and dupilumab over the next 12 to 15 months. 
Starting with EYLEA. First quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the first quarter were $781 million. Net ex-U.S. EYLEA sales in the first quarter were $419 million, which represents 44% growth year-over-year on a reported basis. 
We continue to see quarter-over-quarter increases in our U.S. market shares leadership for EYLEA in the FDA approved anti-VEGF market, both in terms of dollar sales as well as injections as reported by 207 retinal specialist in our quarterly market research survey. 
We're encouraged about Q2 growth opportunities for EYLEA based upon the recently recorded 2-year results of the independently conducted Protocol T comparative study of EYLEA versus ranibizumab versus [indiscernible] in patients with diabetes macular edema. 
However, I should point out that we are closely monitoring pressures on EYLEA sales as the year progresses. They're currently a series of proposals for the centers for Medicare and Medicaid services regarding physician reimbursement for physician administered Medicare Part D buy and bill drugs, which could lead towards physicians favoring the use of off label repackaged bevacizumab or in large volume retinal practice ranibizumab due to provision of direct to physician financial incentives from the manufacturer. 
Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed inappropriate. Therefore, we and scores of other manufacturers, patient ethics groups and industry associations, will or have already submitted objections to CMS and Congress, recommending the physicians' choice be preserved an alternative scheme to reduce health care be explored. 
Turning now to Praluent. As reported by Sanofi, net sales in the first quarter were $13 million, which understates the actual position of patient demand. 
As a reminder, over the last several quarters, we anticipated that it will take some time for commercial and government payers to conduct formulary reviews, make reimbursement covers decisions to begin to process patient claims. 
I'm pleased to tell you that as of April 1, approximately 74% of commercially insured lives and 91% of Medicare insured lives have access to Praluent. 
We've recently seen an improvement in a number of prescriptions that are successfully being filled. Highlighting our approved coverage as well as our share of voice among health care professionals, the most recent nationally syndicated prescription audit for the week ended April 22, 2016, indicates that Praluent captured approximately 50% of new prescriptions in the class. 
Unfortunately, due to unprecedented strict management utilization management criteria and very tedious prior authorization paperwork and documentation that the pharmacy benefit managers and health plans have put in place, many patients who are eligible for treatment with PCSK9 inhibitor have not had their prescriptions filled. Frustrated by this process, health care professionals are limiting the prescriptions to the sickest of patients, a prescription volume for the PCSK9 inhibitor class is limited. 
We're focusing our efforts in improving the prescription process through the payers and specialty pharmacies. We're also working with physicians offices to ensure that the prescription process is better understood on a pair by pair basis. 
Over the last several weeks, we've seen 2 payers loosen their utilization management criteria, removing a requirement for prior therapy. 
ODYSSEY OUTCOMES data is positive will be a key driver in shaping the future success of Praluent. 
Outside of the United States, Praluent was approved in the EU in September of 2015, with product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. 
Outside the United States, it remains a difficult reimbursement market with some countries awaiting outcomes data.
We submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our interleukin 6 inhibitor for rheumatoid arthritis and have been granted a PDUFA date of October 30, 2016. 
We will be co-promoting sarilumab with Sanofi Genzyme in the United States and are actively recruiting our field-based team. Copromotion decisions for other countries will be made over time. 
We're excited about the potential U.S. launch for sarilumab. Given the essential role of interleukin 6 in the inflammation contributed to the signs and symptoms of rheumatoid arthritis, and more importantly, disabling joint destruction, we believe that IL-6 inhibitors should be used early following tumor necrosis factor or TNF inhibitor failure. 
Recently issued U.S. and European guidelines support the use of IL-6 inhibitor class in earlier lines of treatment. This is particularly relevant for those patients who cannot take combination therapies with methotrexate. 
With multiple players competing in the anti-IL-6 market place, this should contribute to improved physician awareness and understanding of the inadequacy of TNF inhibitor cycling and the need for early IL-6 inhibitor treatment. 
Subcutaneously administered sarilumab has strong clinical data in terms of improved signs and symptoms of rheumatoid arthritis and prevention of bone damage in methotrexate in inadequate responders. 
Similar improvements in the signs and symptoms of RA have been reported in the TNF inhibitor in adequate responder population. 
We continue to prepare for the potential U.S. launch of dupilumab, our IL-4 and 13 inhibitor, which we expect in 2017. There are approximately 1.6 million patients with inadequately controlled moderate-to-severe atopic dermatitis in the United States. We've been co-promoting dupilumab in the United States. Co-promotion decisions for other countries will be made at a later date. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, good morning to everyone who has joined us today. In the first quarter 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2016 and non-GAAP net income of $293 million decreased 13% versus first quarte",1219,"Thanks, Bob, good morning to everyone who has joined us today. 
In the first quarter 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2016 and non-GAAP net income of $293 million decreased 13% versus first quarter of 2015. 
Regeneron's 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and includes an adjustment for income taxes.  A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the first quarter of 2016 were $1.2 billion, which represent year-over-year growth of 38% over the first quarter of 2015. 
Net product sales were $784 million in the first quarter 2016 compared to $545 million in the first quarter of 2015. EYLEA net product sales into United States were $781 million in the first quarter of 2016 compared to $541 million in the first quarter of 2015, which represents an increase of 44%. 
Sequential quarter-over-quarter growth was an increase of 5%. During the first quarter 2016, EYLEA experienced a slight decrease in U.S. distributor inventory levels as compared to the fourth quarter 2015 but continues to be within our normal 1- to 2-week targeted range. 
As Len mentioned, we are updating our full year 2016 U.S. EYLEA guidance to be year-over-year growth of between 20% and 25% from the previously provided guidance of approximately 20% growth. 
Ex-U.S. EYLEA sales were $419 million in the first quarter of 2016 as compared to $292 million in the first quarter 2015, representing a 44% increase in a reported basis. 
On an operational basis, our constant currency basis, sales increased approximately 48%. 
Product revenue from ex-U.S. EYLEA sales is recorded by our collaborator, Bayer. 
In the first quarter of 2016, Regeneron recognized $146 million from our share net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the first quarter of 2016 was $180 million. I also like to take this moment to highlight our recently expanded collaboration with Bayer, following our agreement to jointly develop the co-formulation of our antibody to Ang2 in EYLEA. 
In connection with this agreement, Bayer made a $50 million upfront payment to us which was a receivable at March 31, 2016, and Regeneron has the potential to earn up to $80 million in development milestones. 
The $50 million upfront payment has been deferred and will be recognized over the estimated performance period. Similar to our EYLEA agreement, Regeneron has exclusive commercial rights within the U.S. and will retain all of the profits from any U.S. sales. 
Finally, a reminder for the EYLEA franchise. The second quarter of 2016 will be the final quarter in which we incur the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. In fact, I'm pleased to announce that this royalty will officially end in 2 more days.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $220 million for the first quarter of '16. The Sanofi collaboration revenue line primarily consists of reimbursements of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercial related expenses and our share of profits and losses in connection with commercialization of antibodies. 
In the first quarter of 2016, our share of the collaborations losses in connection with commercial with antibodies, primarily Praluent, was $99 million, which can be found in Table 4 of our earnings release. 
Netted within the collaboration losses where the global sales of Praluent has recognized by our collaborator, Sanofi, of $13 million for the first quarter 2016. 
Turning now to expenses. Non-GAAP R&D expense was $392 million for the first quarter. Our unreimburse R&D expense, which is calculated as total GAAP R&D, expense less R&D reimbursements from our collaborators and R&D noncash share-based compensation expense was $164 million for the first 3 months of 2016. 
Our press release includes all the information that's required to calculate unreimbursed non-GAAP R&D expense. 
For 2016, we like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in a range of $875 million to $950 million. 
Non-GAAP SG&A expense was $230 million for the first quarter of 2016. We continue to expect non-GAAP SG&A expense in 2016 to be in the range of $925 million and $1 billion. 
Before I move on from our operating expenses, I'd like to take a moment to discuss the new guidance component we announced this morning. Sanofi reimbursement of Regeneron commercialization related expenses, which represents reimbursement of internal and external cost in connection with preparing to commercialize, are commercializing, as applicable, Praluent and sarilumab, effective in the first quarter 2016, dupilumab. This is the line item found within Sanofi collaboration revenue and is referenced in Table 4 of our press release. 
Going forward, we believe that providing guidance for this number will help modeling the Sanofi collaboration revenue line item. 
For the first quarter of 2016, the reimbursement of Regeneron commercialization related expenses was $73 million, and we expect this expense in 2016 to be in the range $320 million and $370 million. 
Turning now to our non-GAAP tax adjustment. Cash tax, as a percentage of non-GAAP pretax net income for this quarter, continues to be lower than our GAAP effective tax rate, primarily due to the tax impact of noncash share-based compensation. 
On a non-GAAP basis, cash tax as a percentage of non-GAAP pretax net income for the first quarter of 2016 was approximately 38%. 
For 2016, our guidance for cash tax as a percentage of non-GAAP pretax income remains at 35% to 45%. As previously reported, this includes a onetime tax of approximately $222 million related to the Sanofi immuno-oncology agreement. 
I'd also like to reiterate that the non-GAAP tax impact of the immuno-oncology upfront payment will be spread equally throughout 2016. 
Our capital expenditures for the first quarter of 2016 were $104 million. Given our latest review of capital expenditures, we are tightening and lowering our full year 2016 capital expenditures guidance to a range of $550 million to $625 million from $580 million to $680 million. 
These expenditures continue to build on our manufacturing expansions in 2015, which include expanding our facilities in Rensselaer, New York and Ireland as well as the continued expansion of our Tarrytown, New York headquarters. 
We ended the first quarter of 2016 with cash and marketable securities of $1.4 billion. As we previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt.  In the first quarter of 2016, we paid $242 million to reduce these outstanding warrants. 
Before I conclude my remarks, I would briefly like to highlight certain financial companies of the recent collaboration with Intellia Therapeutics. 
The April 2016 agreement grants Regeneron access to Intellia's CRISPR technology platform as well as the right to discover and develop up to 10 targets on an exclusive basis over the course of the 6-year agreement. 
In return, we paid a $75 million upfront payment to Intellia, which we anticipate recording as R&D expense in the second quarter of 2016, but plan to exclude from non-GAAP net income. The agreement also requires Regeneron's to purchase up to $50 million of Intellia's shares contingent upon Intellia consummating its initial public offering. 
With that, I'd like to turn the call back over to Michael."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period.",16,"Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners.",13,"[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","As opposed, couple of questions. George, post on dupilumab. Now you have the first Phase III readout. What incrementally have you learned from that in terms of the profile of dupilumab and how does that alter what you might focus on and potentially invest",113,"As opposed, couple of questions. George, post on dupilumab. Now you have the first Phase III readout. What incrementally have you learned from that in terms of the profile of dupilumab and how does that alter what you might focus on and potentially invest in for that molecule in the future? And then secondly, just on Medicare Part D, you alluded to that and called it out in your in the Q. What are you learning in the comment period and will you be submitting comments or are you aware of other comments and do you think there's any chance that this is going to be modified or altered or scheduled or scoped?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","This is George. I'll take the dupilumab question. I guess, the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy the important benefit to patients in essential",244,"This is George. I'll take the dupilumab question. I guess, the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy the important benefit to patients in essentially every single efficacy readout that we explored, where obviously that's very gratifying and comforting when one actually sees data that is as promising as your earlier data and suggest it can really make an important difference to moderate-to-severe patients real need these therapies to this disease. In addition, the safety profile was also very comforting. And we reported extensively and it really does suggest that it's going to have a very important benefit risk profile for patients. I think that basically for atopic dermatitis, it really means that it's all green light and all speed ahead. And that we're really excited that we can really bring forward, as the FDA has designated, a breakthrough therapy for these patients need. As you know, we also have a pivotal study in asthma, and that's already been read out. And we're in the midst of our first base through, which is now our second confirmatory study in that indication as well. So Dupilumab is a very, very exciting program. As I already told you about today, I told you that in terms of the atopic dermatitis population, we're also moving to the pediatric population there as well, which is also an important unmet need area."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","In terms of the Part D, we fully understand that health care cost need to be appropriately controlled in this country. However, the approach that it has been proposed by Medicare Part D would limit options for physicians and patients to give appropriate t",159,"In terms of the Part D, we fully understand that health care cost need to be appropriately controlled in this country. However, the approach that it has been proposed by Medicare Part D would limit options for physicians and patients to give appropriate therapies to patients who need them. For example, in the case of the retinal space, you could lead to physicians being required simply by the economics that are in place to force them to use an off label repackaged bevacizumab, which at least in the Protocol T trial was shown in DME not to be as effective as the other therapies. They could be forced to use this for economic reasons. We see that a number of manufacturers as well as a number of congressmen and patient advocacy groups recognize that you have to preserve physician choice and so there will be a number of complaints and whether it's going to the Congress, including our own."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I mean, just to add, literally, hundreds of Congressman have said that they should not be done. There are others have said that unintended consequences that were concerned about it must be managed, the retinal groups, the etymology groups and not to",89,"Yes. I mean, just to add, literally, hundreds of Congressman have said that they should not be done. There are others have said that unintended consequences that were concerned about it must be managed, the retinal groups, the etymology groups and not to mention all the other interested parties such as cancer and what have you. So I think many observers, which were not experts but many observers in Washington would suggest that this seems unlikely. But we were certainly going to do our best on this as well."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our next question is from Chris Raymond from Raymond James.",11,"And our next question is from Chris Raymond from Raymond James."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just 1 question here. So just kind of the PD-1, kind of struck by the news that this cutaneous squamous sub trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more color on where t",101,"So just 1 question here. So just kind of the PD-1, kind of struck by the news that this cutaneous squamous sub trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more color on where those trial fits in with the overall development plan. Just looking at clinicaltrials.gov, there's not a ton of detail. Obviously, there's a lot of breadth of labeling potential in that type of molecule. If you could maybe sort of talk about where you plan to take this, that will be great."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we are implementing a highly integrated very comprehensive effort in immunotherapy. And this obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to patien",128,"Well, we are implementing a highly integrated very comprehensive effort in immunotherapy. And this obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to patients and really make a difference in certain disease settings. And how we're going to do that and how we hope to bring the best results to patients with the best combination is something that, at this point, I think, or thinking behind in this very competitive space is rather largely to ourselves. So sorry for not informing you more, but we just think that we have a very robust and highly integrated comprehensive effort here and we intend to fully deliver important new approaches to patients."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Terence Flynn from Goldman Sachs.",10,"Our next question is from Terence Flynn from Goldman Sachs."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just wondering for dupi, I know it's a little bit early, but as we think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent type launch or more like EYLEA? And if you want to answer that",70,"So just wondering for dupi, I know it's a little bit early, but as we think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent type launch or more like EYLEA? And if you want to answer that directly, maybe you just walk us through some of the factors we should consider as we think about the ramp."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. It's Len. Since we were all -- both you guys and us were spot on in EYLEA and Praluent, otherwise we wont take a shot at dupilumab. I think the fact is obviously, we can't answer that directly, Terence, and since we've been -- we and of us, everybod",332,"Sure. It's Len. Since we were all -- both you guys and us were spot on in EYLEA and Praluent, otherwise we wont take a shot at dupilumab. I think the fact is obviously, we can't answer that directly, Terence, and since we've been -- we and of us, everybody's been wrong multiple times, these things unfold as they unfold. The factors to consider obviously is that you're already always obviously see the PBM taking a notice of this. I saw this in somebody's report that this is the next big class that they're worried about. There are a lot of patients out there that might fit our label assuming we get the label. But I'm sure they're going to be -- there's going to be utilization management, make sure the topical steroids or whatever that they really have the right diagnosis, et cetera, et cetera. Whether there would be ""warehousing of patients"", people lining up to get it, it's just really impossible for us to tell. But I would suspect that this would be one of those launches that would be patient-driven that -- as people get on the drug if the results in the real world or anywhere is close to the results we've seen in our Phase III trials so far, I'm sure that patient drive would be tremendous because this is a terrible disease that people have been suffering with for decades. Adults now have it without anything at all new to really help to make a difference. And if you look at -- whether you measure this by quality of life metrics, the increase risk of suicide, just the terrible burden that this puts in patients, we're optimistic that this drug can make a difference for them. So we're hopeful for a good launch. But how that -- the actual ramp and whether it takes us a while to get it going and what the coverage looks like and all that, it's just too early to tell."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Adnan Butt from RBC Capital Market.",11,"Our next question is from Adnan Butt from RBC Capital Market."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is John for Adnan. Could you please put the fasinumab safety data kind of in the context given that the FDA seems to have already been focused on safety in general?",32,"This is John for Adnan. Could you please put the fasinumab safety data kind of in the context given that the FDA seems to have already been focused on safety in general?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Maybe I'll make a brief comment and if George has anything to add, obviously, he's welcome. Our feeling is that, as George said in his talk, is that we did something in which we think is pretty important, which is we did an extensive and detailed scr",253,"Yes. Maybe I'll make a brief comment and if George has anything to add, obviously, he's welcome. Our feeling is that, as George said in his talk, is that we did something in which we think is pretty important, which is we did an extensive and detailed screening of patients with x-rays and MRIs before they were ever exposed to drug. And that demonstrated that some of these things that people are concerned about might be somewhat induced by drugs. But really fairly prevalent in the population whether they be insufficiency fractures or whether they be osteoarthritis and so on. So I think that that was important. And I do think that the FDA has come around to thinking that this had to be looked at carefully. And that's what we're doing. And the right patients have to be studied, and that's also what we're doing. And they also have had concerns about whether or not any one of these drugs individually or as a class could affect on sympathetic nerves and sympathetic nervous system function. We also looked at that pretty well and we have more to tell you about that in upcoming meetings. But we didn't see any evidence at all. So that so far, as things look reasonable. But, I mean, as George said, it is a small study and we're underpowered to pick up very small increases in some of these things. And that's why we're going to study thousands and thousands of patients in our Phase III program."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, and to add to that, I think that one of the biggest underlying fears for this class certainly -- outside people, but also by ourselves, was that the very small increase in certain aeropathy events, certain joint pathologies that were seen, particular",347,"Yes, and to add to that, I think that one of the biggest underlying fears for this class certainly -- outside people, but also by ourselves, was that the very small increase in certain aeropathy events, certain joint pathologies that were seen, particularly in combination with but also a small increase even in monotherapy might actually be reflecting a much bigger, somewhat invisible problem that there was a bigger, disruptive process that was in the scene over longer periods in time and so forth. And this is why we did this, as Len said, this extensive imaging of both the index joints but also non-index joints to see whether overall, the skeleton was really changing. And as we've already said, the thing that was very gratifying was that unfortunately, for these patients suffering from this important problem, there is it already significant skeletal pathology at baseline. These patients have these so-called sub sufficiency fraction. You could even see undiagnosed osteo necrosis in patients and so forth. And these events, both in the index and non-index joints, were not dramatically increased by treating with NGF. And 1 year for example would that be these subchondral efficiency fractures may be happening much more frequently with drug and eventually leading to much higher incidences of events down the line. And so it's very comforting not to see this. That said, there remain, as with any drug, and certainly with the drug this active, they will continue to be a risk associated with treatment. But one has to balance that would all the benefits that could be provided. Pain is a very serious problem for a lot of people, especially people suffering from osteoarthritis. And the options, obviously, as you know, are quite limiting with no new action drugs added to this field for decades. And so the possibility and the opportunity and new mechanism action subclass that might have different profiles. And also, different risk profile as compared to, for example, opioids and [indiscernible] and other drugs with serious risks. We think it can offer an important option for patients."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And Mike, I just want to make sure I add because in talking about pain, you really have to keep in the context of really what is an epidemic in the United States in terms of the drug opioid abuse and overdose with quadrupling in a number opioid death in t",107,"And Mike, I just want to make sure I add because in talking about pain, you really have to keep in the context of really what is an epidemic in the United States in terms of the drug opioid abuse and overdose with quadrupling in a number opioid death in the past number of years as well as from the CDC website. Nearly half a million people died from drug overdoses from 2000 to 2014. Almost 80 Americans die everyday from an opioid overdose. I just think that you get in the context that pain remain -- having new pain medicines can really -- is really important."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question is from Yin Huang from Bank of America.",10,"Next question is from Yin Huang from Bank of America."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just first on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called therap",109,"Just first on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called therapeutically similar cost and therefore, to be subject to a reference pricing in the second phase of that demo. And then also on the ODYSSEY OUTCOMES trials, I know the trial is powered 15 -- I don't know power to show 15% CDR risk reduction. Maybe you guys can provide us whether you think the payers would be excited about that 15% risk reduction?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","To which question you want to answer because Michael's holding up the sign that says 1 question. Even though he loves you, which one does he want?",28,"To which question you want to answer because Michael's holding up the sign that says 1 question. Even though he loves you, which one does he want?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Len, you're the boss.",4,"Len, you're the boss."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Not true.",2,"Not true."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","All right, maybe second. It's probably more important from my perspective.",11,"All right, maybe second. It's probably more important from my perspective."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. I think the outcomes data, as we showed at the, it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the data set, et cetera, et cetera. Certainly, we power the study base",143,"Okay. I think the outcomes data, as we showed at the, it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the data set, et cetera, et cetera. Certainly, we power the study based on expert input of where they thought that would be if we saw results, that would be a meaningful result for patients. But of course, it's not just one number. Not just statistical significance. You want to see how all the data set looks like and I think somebody said, [indiscernible] has statistical significance. But if you blink, you could miss it. And we tried to design study and set the parameters such that if we saw the result, we can feel comfortable about it, that we were making a difference in the outcomes to patients."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Ying, I can't leave the EYLEA one hang out there. I'm sorry. If you remember back to the VIEW 1 and View 2 studies, we actually designed studies that compared ourselves to what was a standard of care branded agent, which was ranibizumab monthly and we stu",171,"Ying, I can't leave the EYLEA one hang out there. I'm sorry. If you remember back to the VIEW 1 and View 2 studies, we actually designed studies that compared ourselves to what was a standard of care branded agent, which was ranibizumab monthly and we studied EYLEA, both those monthly as well as every 8 weeks. And what we saw is very similar results with the EYLEA every eight-week dosing to the Lucentis, every four-week dosing. This is a major advantage to elderly patients who can't get into the physician's office on a regular basis. And so they are not therapeutically equivalent. EYLEA has longer durability of effect. I would also point out there are data in a subset of patients in the VIEW studies that indicate that there are patients who are more refractory to anti-VEGF  therapies, especially those who received prior anti-VEGF  therapies who may need more anti-VEGF  treatment and what we're seeing in those treatments, we're able to dry them up better with EYLEA than with Lucent."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I also have to make a few comments here. And I think really Bob touched on important point that our drug showed, compared to -- at the time optimum standard of care that doubling the interval could produce -- at least as good results from the terms of vis",435,"I also have to make a few comments here. And I think really Bob touched on important point that our drug showed, compared to -- at the time optimum standard of care that doubling the interval could produce -- at least as good results from the terms of visual acuity but also even better results in terms of controlling vascular leak and retinal slowing and so forth. And I think that we all have to really consider that maybe, and I hate to say it because some people are going to say, hey, don't challenge the physicians here. But I think the physicians here, and we understand the limitations of the real world and practice, doing a huge disservice to patients. In terms of the systematic under treatment that is probably occurring in this field, there's an enormous drive to try to get patients less trips to the office, less injections. And you're probably seen the release of recent data with long, 4 or 5-year follow on. And after you take the patients over the more controlled phases of the study, where they're getting, in general, in most studies, monthly treatment of very carefully monitored treatment, they essentially lose almost all their vision gain over this later years of 4- and 5-year follow-ups. And we believe that the data and evidence suggest that this is really due to systematic under treatment, patients getting less and less treatment, particularly in that setting. If you want to deliver the best care to patients, you should be delivering the best agents that has the longest duration of action. And we think that the only agent that's really demonstrated that convincingly is EYLEA. And so I think to save patients missions, you saw the long-term trials. Patients are losing vision. Physicians are not doing the right things by their patients. They're systematically under treating and particularly in those setting, they should be getting the best drug that protects patients against this vision loss. And it will be a disservice if, in fact, incentives and so forth are driven to the use of agent which will cause patients -- think about it, your patient, who can't drive, your patient who can't read, you're now given a drug all of a sudden, you gain 2, 3 lines of vision. That changes the world literally for you. Okay. You could do things you can't do before. And now, we developed a system that allows you to lose that, I think we have to think about how we want to practice medicine in this country if we create a situation that allows that."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think the physician -- George, right there with you. And it's hard to imagine that once the physicians heard on the subject that Avastin, an off label in theory of product based on a government  study could be set of standards.",43,"Yes. I think the physician -- George, right there with you. And it's hard to imagine that once the physicians heard on the subject that Avastin, an off label in theory of product based on a government  study could be set of standards."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Robyn Karnauskas from Citigroup.",9,"Our next question is from Robyn Karnauskas from Citigroup."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I feel like you're one of the few companies rather so much going on in the call and you provide clarity. I guess, I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does highlight this a lot. And I feel like, those",120,"I feel like you're one of the few companies rather so much going on in the call and you provide clarity. I guess, I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does highlight this a lot. And I feel like, those of us on the street are more skeptical about the opportunity. Help us understand what your view is of sarilumab and how you think about this. It's a competitive space. There are stuff coming up from Avi. How are you thinking about the strength of that data and you have any understanding of the strategy and how you could take share from the current market or expand the current market?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build the company over the last 3 decades that is driven by -- truly driven by science innovation. So we appreciate you, of you taking note of that. And Bob, can",64,"Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build the company over the last 3 decades that is driven by -- truly driven by science innovation. So we appreciate you, of you taking note of that. And Bob, can comment to that giving away all of our intricate strategy on what the opportunity for assets might be."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Robyn, as I pointed out earlier, I think that when Genentech launched [indiscernible] into the U.S. market place, it was very much a market dominated by growing TNF inhibitors. And they were a single company trying to educate on the role of IL-6 in rheuma",188,"Robyn, as I pointed out earlier, I think that when Genentech launched [indiscernible] into the U.S. market place, it was very much a market dominated by growing TNF inhibitors. And they were a single company trying to educate on the role of IL-6 in rheumatoid arthritis and the potential benefit of using an IL-6 inhibitor earlier. It is always more beneficial. We've seen this, for example, in the statins class where as more and more statins become more available, they grew the market. We believe that this is the opportunity for this class that we can educate physicians more. One, as I said earlier, on the central role of IL-6, in both the signs and symptoms of RA but as well as in joint destruction, which we feel is very important. Physicians need to understand they shouldn't stay with the TNF innovator, which over time, each additional TNF inhibitor does not deliver the efficacy that they receive with the first TNF inhibitor. So there's a benefit of moving to a new class, an IL-6 really does have a central role, both in symptoms as well as bone destruction."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I also just to add. There's something historical accidents have occurred here in the order of the drugs that came along and how we do pricing and with the methotrexate being so the main stage very cheap drug. It's effective. But it's not the most oculus d",145,"I also just to add. There's something historical accidents have occurred here in the order of the drugs that came along and how we do pricing and with the methotrexate being so the main stage very cheap drug. It's effective. But it's not the most oculus drug in the world from its side effects and what have you. And many people, particularly women, who don't  like being on the product. And there seems to be movement towards monotherapy. And remember, methotrexate -- some may argue that this drug, methotrexate provides immunosuppression for the biologics so that any immune-related, if you will, blockade effect, doesn't appear as quickly. Suffice it to say, maybe, George, can comment on that more. But I could say that one will look head-to-head against the market leader, Avi, in the monotherapy setting, you've seen our data. We had a superior result."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","But I also do -- just finish the story, sarilumab is not a me to drug. I don't  want to do a cross comparison trial data right now. But I think if you look to at the prescribing information for subcutaneous and you look at the results, we reported with ou",86,"But I also do -- just finish the story, sarilumab is not a me to drug. I don't  want to do a cross comparison trial data right now. But I think if you look to at the prescribing information for subcutaneous and you look at the results, we reported with our product, we are very encouraged about the product profile that our product, which had higher binding affinity to IL-6 is going to offer in the market place. Maybe, George, you want to comment on that."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's important to just highlight a few things. Because once again, it all comes down to the patients doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense to",292,"Yes. I think it's important to just highlight a few things. Because once again, it all comes down to the patients doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense to start all patients, particularly patients in monotherapy settings with the TNF and that maybe historical accident. It also doesn't make sense to just continue patients cycling on TNF if there is an alternative. It can deliver them better symptomatic relief. And so we think there's an enormous opportunity for this class. And importantly, in this class, and as Bob said, the most -- one of the most important things that I said it patients and physicians are concerned about is irreversible bone loss. That's one thing that you can't get back. And that's one thing that's left that in this field. And as you know, a tumor is now growing through a subcutaneous formulation. And if you look in the label, there's less, according to the subcutaneous formulation that's used there in terms of innovation of the irreversible bone loss, there's less than 50% inhibition by the subcutaneous formulation in terms of the bone loss. If you look at our study, we offered 2 doses. And if they both get approved, our higher subcutaneous dose gives greater than 90% inhibition of irreversible bone loss. So as Bob said, these are not identical agents. This is not a me to. This important differences. And there is an important opportunity to do better by patients in terms of the monotherapy settings and in terms of not just cycling through drugs that maybe aren't working for the patients and putting them in a different mechanism action drug."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I'd also say that there have been, let me call it, commercial gains that have been played out there in that negotiations that have gone on with the PBMs where people have used certain multiple indications as a way to drive use and other indications from w",168,"I'd also say that there have been, let me call it, commercial gains that have been played out there in that negotiations that have gone on with the PBMs where people have used certain multiple indications as a way to drive use and other indications from what we can tell. And I think the PBMs are sort of wise up to that and move into indications specific pricing and negotiations. And so we actually feel that we might be entering the market at a reasonably good time where a lot of dynamics are going on and a good product, you can make good inroads. Now I don't think this is going to be an easy road, and I wouldn't be -- I don't thank you can just assume that were going to jump in and grab huge market share right off the bat. But I think we can build this into a significant opportunity over time. It's more of going to be like a slow and steady."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question is from Alethia Young from Credit Suisse.",9,"Next question is from Alethia Young from Credit Suisse."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to the trial trends that you said in your script. Again, you said that 50% of new -- you filed at 50% of the new scripts. Could you guys had a talk about what kind of behavior driving kind of that 50%. Is that something that you're kind of",60,"Just going back to the trial trends that you said in your script. Again, you said that 50% of new -- you filed at 50% of the new scripts. Could you guys had a talk about what kind of behavior driving kind of that 50%. Is that something that you're kind of adjusting or changing that's resounding in the profile?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's hard to know for sure. We don't  have another minute here so I do want to head into great detail. But one thing that is important is new coverage this coming into play, particularly in the Medicare space, which was really only recently c",201,"Yes. I think it's hard to know for sure. We don't  have another minute here so I do want to head into great detail. But one thing that is important is new coverage this coming into play, particularly in the Medicare space, which was really only recently coming on, where in those plans that chose -- which is both of them, a single agent as priority drug. We were, I think, selected about 90% of the time. So I think that there is some new coverage, new management. And honestly, we're working hard it is. But I don't think you can consider 1 week a trend, whether it's only 1 direction. It's just the data point. Right now to market seems to be split, roughly more or less equally based on that data point, how that goes over time, obviously, that's what the competitive marketplace is all about. But I think our most important effort right now has to be on making sure that the right patients get access to drugs. And that's really where both companies are focused.   It's an important thing for the class. The patients who need drug have to get an opportunity to have access to it."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our last question is from Matthew Harrison for Morgan Stanley.",11,"And our last question is from Matthew Harrison for Morgan Stanley."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just have 2 related Praluent questions. You said that 2 pairs have loosened their criteria. I'm wondering if you could just be more specific about that, who they were and what exactly what they loosened? And then you were talking about an improvement in",74,"I just have 2 related Praluent questions. You said that 2 pairs have loosened their criteria. I'm wondering if you could just be more specific about that, who they were and what exactly what they loosened? And then you were talking about an improvement in the number of Rxs that were filled. Is just that more people getting through the utilization management criteria? Could you just be more specific about that comment as well?"
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Our contacts with the payers don't allow us to disclose the specific ones who have changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of [indiscernible] after",185,"Sure. Our contacts with the payers don't allow us to disclose the specific ones who have changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of [indiscernible] after maximally tolerated statin therapy for the utilization management criteria. That was setting up a delay in access to PCSK9 inhibition. The physicians were having to put them [indiscernible] and then wait and it was causing a backlog for the doctors. So that has been removed with 2 of the payers. In terms of the improvement of a number of people going through the hub, I think what I could say is, one, as Len said, payers have come on board now. So especially Medicare patients now are getting access to therapy. I think the other thing is that the physicians as well as the specialty pharmacies are better understanding how to make the prescription process better. That's not -- it's not easy right now. We continue to work on improving it, but at least it has gotten better for some patients."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So just one last comment. This is Len. In our efforts to answer your questions, what we're trying to do is give you some insight into thinking why we went forward with something. We're not trying to make costs trial comparisons per se. We're try to give y",167,"So just one last comment. This is Len. In our efforts to answer your questions, what we're trying to do is give you some insight into thinking why we went forward with something. We're not trying to make costs trial comparisons per se. We're try to give you an idea of why we went forward and what we saw and how we felt we were differentiated. What we can say in the marketplace obviously will be limited based on what we actually get in our various labels out of penny. 
And with that, I would just say that we're pleased that the innovation machine continues to turn and produce lots of exciting things that we hope to update you in the scientific literature and the presentations that are upcoming. Lots of things that George did not get a chance to talk about that are exciting. So we appreciate your interest, and we hope to continue to be able to update you over time. Thank you very much."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks.",1,"Thanks."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you.",2,"Thank you."
33715,331187536,973634,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. And I will now turn the call over to Dr. Micha",43,"Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. 
And I will now turn the call over to Dr. Michael Aberman."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, operator. And good morning, and welcome to Regeneron Pharmaceuticals First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.Joining me on the call today are Dr.",313,"Thank you, operator. And good morning, and welcome to Regeneron Pharmaceuticals First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.  
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. 
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission or SEC, including its Form 10-Q for the quarter ended March 31, 2016, which was filed with the SEC this morning.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Michael, and a very good morning to everyone who has joined us on the call and webcast today. The first quarter of 2016 was busy, and we have a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities in dr",327,"Thank you, Michael, and a very good morning to everyone who has joined us on the call and webcast today. The first quarter of 2016 was busy, and we have a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities in drug discovery and development on bringing important new medicines to patients in need. 
George will provide you with some of the recent exciting progress we have made in that regard. From a high-level perspective, we had positive data readouts from 3 Phase III programs, Praluent for lowering LDL cholesterol in the apheresis setting, sarilumab in rheumatoid arthritis and dupilumab in atopic dermatitis. We also reported positive data from a Phase II/III study in osteoarthritis for fasinumab, our NGF antibody for pain. And we continue to make good progress with our earlier-stage assets and discovery efforts. 
Turning to our marketed products. EYLEA has continued to deliver solid growth, and we are able to increase our guidance for the year. Praluent's launch is still ongoing, and it's obviously faced a difficult reimbursement environment. While we fully understand payers' efforts to control costs, we do have serious concerns that appropriate patients are having undue difficulty getting approval for Praluent. We continue to be optimistic over the long term that Praluent will provide an important cholesterol-lowering option to many patients.  Bob Terifay will provide more detail on EYLEA and Praluent. Following that, Bob Landry will provide more detail on financial results for the first quarter of 2016 as well as updated guidance. 
Finally, we are approaching the potential approval and launch of 2 new products. Sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis, is under review with the FDA. Dupilumab is being developed for a number of indications, and we are targeting completion of our rolling BLA submission for moderate to severe atopic dermatitis in the third quarter of 2016. 
With that, let me turn the call over to George."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combinations of EYLEA with rinucumab, an antibody to the PDGF receptor, and Nesvacumab, an antibod",1580,"Thank you, Len, and a very good morning to everyone who has joined us today. Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combinations of EYLEA with rinucumab, an antibody to the PDGF receptor, and Nesvacumab, an antibody to angiopoietin-2, we have also commenced Panorama, a Phase III study of EYLEA in non-proliferative diabetic retinopathy in patients without diabetic macular edema or DME, which will evaluate whether EYLEA can improve the retinopathy. 
Additionally, the Diabetic Retinopathy Clinical Research Network or the DRCR initiated a related clinical study called Protocol-W to evaluate the potential of anti-VEGF therapy in preventing worsening of severe non-proliferative diabetic retinopathy. This study will explore every 16-week dosing of EYLEA, which the only anti-VEGF treatment being investigated in this study. 
In February, we received 2 new results from Protocol T, a government-sponsored study in patients with DME, comparing the safety and efficacy of EYLEA versus Lucentis and Avastin. The primary efficacy endpoint for that study was at 1 year, which showed significantly better vision gain with EYLEA than either with Lucentis or Avastin. The second year of the study was not designed to rigorously compare the anti-VEGF agents as the second year results were increasingly confounded by variable dosing frequencies as well as additional or adjunctive therapies such as laser. 
Along these lines, it is important to point out there was a greater number of injections and substantially more use of laser associated with Avastin treatment in the overall population. Despite this, when compared with Avastin, EYLEA demonstrated a statistically significant 5-letter gain or an entire line of vision in patients with poor vision at baseline. At 2 years, the rate of most ocular adverse events were similar across the 3 study groups. There was, however, statistically significant lower rate of arterial thromboembolic events , including nonfatal stroke, nonfatal myocardial infarction and vascular death in the EYLEA group compared with the ranibizumab group. 
Our Praluent launch is underway, and Bob Terifay will provide further details on the commercial front. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. The data monitoring committee for this study has completed the first interim analysis, with 50% of the total events had accrued (sic) [occurred] based on unblinded study data. In addition to reviewing the safety data, the DMC performed a futility assessment and recommended the study continue with no changes. We remain blinded to the actual results of this analysis, and the study is ongoing. A second interim analysis for futility as well as overwhelming efficacy could potentially occur in the second half of 2016 when 75% of the targeted primary events have occurred. 
In March, we reported positive data from the Phase III ODYSSEY ESCAPE study in patients with heterozygous familial hypercholesterolemia, who require chronic weekly or biweekly apheresis. Apheresis is an invasive, expensive and time-consuming therapy given to the patients with the highest cholesterol levels and the greatest need. Our study showed that Praluent reduced the need for apheresis by 75% compared to placebo, and 63% of Praluent patients no longer required apheresis compared to 0% of the patients in the placebo arm. 
Praluent is the only PCSK9 inhibitor that has been studied in an apheresis setting, which represents some of the most severe hypercholesterolemic patients. The adverse events that occurred more frequently in the Praluent-treated patients were injection site reactions and myalgia. We expect our supplemental BLA for the once-monthly dosing regimen of Praluent to be filed in the second quarter, which, if approved, will expand our dosing flexibility options. 
Turning now to our late-stage pipeline, where we had some very positive news. I'd like to start with sarilumab, our IL-6 receptor antibody which is under review by the FDA for the treatment of rheumatoid arthritis. In March, we announced positive data from the Phase III MONARCH study of sarilumab versus Humira, which demonstrated that sarilumab was superior to Humira in the monotherapy setting in improving signs and symptoms of rheumatoid arthritis at 24 weeks. This was the first head-to-head study in the monotherapy setting using a subcutaneously administered IL-6 inhibitor. The use of IL-6 inhibition in the monotherapy setting has been growing, and these data provide us with a competitive product profile. Data from the MONARCH study will be included in our European submission that is expected midyear of 2016. 
Turning now to dupilumab, our IL-4/13 blocking antibody, where we recently announced positive top line data from the Solo-1 and Solo-2 monotherapy Phase III studies in adults with moderate to severe atopic dermatitis. These were the first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate to severe atopic dermatitis and confirm the positive data we have seen in our Phase IIb study. Overall, the studies demonstrate significant improvements in measures of disease severity, skin clearing, itching, quality of life and mental health. We expect to present detailed data from the Solo studies in an upcoming medical conference. 
We continue to expect top line data from the Phase III CHRONOS study, which explores dupilumab in combination with topical corticosteroids, in the second quarter of 2016. We expect to complete the rolling BLA submission for dupilumab in atopic dermatitis in the third quarter of 2016. We remind you that dupilumab has received breakthrough designation from the FDA for this indication in adults. 
In the first quarter of 2016, we initiated LIBERTY AD CAFE, a Phase III study of dupilumab to support our European submission. This study investigates dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or intolerant to or ineligible for systemic cyclosporine A treatment. In addition to the studies in the adult setting, we also plan to initiate a Phase III study in the atopic dermatitis indication in the pediatric population once we have data from the ongoing Phase II pediatric study that is now fully enrolled. We expect this Phase II data in the second half of the year. 
We're also investigating dupilumab in other indications, including asthma, where we are currently enrolling our 1,700-patient pivotal study. We're also advancing clinical development in indications such as nasal polyps and eosinophilic esophagitis. 
For fasinumab, our NGF antibody, earlier this week, we announced positive data from our Phase II/III study in osteoarthritis, which provides us with our first safety and efficacy data with our subcutaneous dosing regimen. This was the first completed study using an antibody to NGF that performs extensive imaging of knee, hip and shoulder joints at screening and throughout the trial. Interestingly, we found that  subchondral insufficiency fracture and even osteonecrosis were present in this population at screening. 
Further, our findings in patients following fasinumab treatment are consistent with prior data, suggesting that there may not be a substantial increase in rapidly progressing osteoarthritis when an NGF antibody is used in the monotherapy setting. That said, it's a relatively small trial, and we look forward to data from the much larger clinical studies that are underway. 
We have also seen some exciting developments in our earlier-stage programs. I'd like to spend a few minutes on 2 areas: our efforts in genetics and our recent collaboration in the arena of gene editing. In March, we published a paper in the New England Journal of Medicine based on research that was conducted at the Regeneron Genetics Center or the RGC. The publication showed that inactivating mutations in a gene called angiopoeitin-like 4 were associated with a significantly reduced risk of coronary artery disease in humans. This is a great example that demonstrates how our efforts in the area of precision medicine can link genetic mutation information with real-world health outcomes to make actionable discoveries. 
Many of the findings from the RGC are already being used to inform Regeneron's robust and integrated R&D programs and give us the ability to incorporate large-scale sequencing into our discovery and pipeline approaches. It also demonstrates the advantages of our unique combination of technologies. Using our proprietary VelociGene Technology, we develop animal models that corroborate the human genetics findings. And we were able to use our VelocImmune platform to create a fully human monoclonal antibody inhibitor of ANGPTL4 that reduce triglyceride levels in mice and nonhuman primates. 
We are also advancing a Phase II program of REGN1500, an antibody to ANGPTL3. ANGPTL3 is thought to play a central role in lipoprotein metabolism, and our genetic data show that patients with homozygous inactivating mutations of this gene report greater than 50% lower levels of LDL, HDL and triglycerides. Initial data from a small study in homozygous patients will be presented at the upcoming Annual meeting of the National Lipid Association. 
We recently entered into collaboration with Intellia Therapeutics with the aim of advancing CRISPR/Cas gene editing technology into in vivo therapeutic development. This was a logical fit for us given our long-standing expertise on genetic engineering, combined with our industry-leading human genetics research with the RGC, which is already identifying important genetic targets. We believe that combining these capabilities with Intellia's technology holds real promise for serious diseases that have been historically difficult to address and expands our ability to help patients where antibody-based therapies may not be the optimal approach. 
We continue to make progress in immuno-oncology. REGN2810, our PD-1 antibody program, has entered a Phase II potential registrational study in cutaneous squamous cell carcinoma. We'll be presenting some preliminary Phase I data at the upcoming annual ASCO conference. 
With that, I would like to turn over the call to Bob Terifay."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. During the first quarter of 2016, we continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We've made substantial progress in securing a",972,"Thank you, George, and good morning, everyone. During the first quarter of 2016, we continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We've made substantial progress in securing access and reimbursement for Praluent or alirocumab among U.S. payers. In addition, the European launch of Praluent continues to progress. 
We also are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next 12 to 15 months. 
Starting with EYLEA. First quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the first quarter were $781 million. Net ex-U.S. EYLEA sales in the first quarter were $419 million, which represents 44% growth year-over-year on a reported basis. We continue to see quarter-over-quarter increases in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market, both in terms of dollar sales as well as injections as reported by 207 retinal specialists in our quarterly market research survey. 
We're encouraged about Q2 growth opportunities for EYLEA based upon the recently reported 2-year results of the independently conducted Protocol T comparative study of EYLEA versus ranibizumab versus bevacizumab in patients with diabetic macular edema. However, I should point out that we are closely monitoring pressures on EYLEA sales as the year progresses. There are currently a series of proposals for the Centers for Medicare and Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B buy-and-bill drugs, which could lead towards physicians favoring the use of off-label, repackaged bevacizumab or, in large-volume retinal practices, ranibizumab due to the provision of direct-to-physician financial incentives from the manufacturer. 
Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. Therefore, we and scores of other manufacturers, patient ethics groups and industry associations will or have already submitted objections to CMS and Congress, recommending the physicians' choice be preserved and alternative schemas to reduce health care costs should be explored. 
Turning now to Praluent. As reported by Sanofi, net sales in the first quarter were $13 million, which understates the actual position of patient demand. As a reminder, over the last several quarters, we anticipated that it would take some time for commercial and government payers to conduct formulary reviews, make reimbursement coverage decisions and begin to process patient claims. I'm pleased to tell you that as of April 1, approximately 74% of commercially insured lives and 91% of Medicare-insured  lives have access to Praluent. We've recently seen an improvement in the number of prescriptions that are successfully being filled. 
Highlighting our improved coverage as well as our share of voice among health care professionals, the most recent nationally syndicated prescription audit for the week ended April 22, 2016, indicates that Praluent captured approximately 50% of new prescriptions in the class.  Unfortunately, due to unprecedented strict management -- utilization management criteria and very tedious prior authorization paperwork and documentation that the pharmacy benefits managers and health plans have put in place, many patients who are eligible for treatment with a PS -- PCSK9 inhibitor have not had their prescriptions filled. Frustrated by this process, health care professionals are limiting the prescriptions to the sickest of patients. The prescription volume for the PCSK9 inhibitor class is limited. 
We're focusing our efforts on improving the prescription process through the payers and specialty pharmacies. We're also working with physicians' offices to ensure that the prescription process is better understood on a payer-by-payer basis. Over the last several weeks, we've seen 2 payers loosen their utilization management criteria, removing the requirement for prior ezetimibe therapy. ODYSSEY OUTCOMES data, if positive, will be a key driver in shaping the future success of Praluent. 
Outside of the United States, Praluent was approved in the EU in September of 2015, with product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Outside the United States, it remains a difficult reimbursement market, with some countries awaiting OUTCOMES data. 
We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our interleukin 6 receptor inhibitor for rheumatoid arthritis, and have been granted a PDUFA date of October 30, 2016. 
We will be co-promoting sarilumab with Sanofi-Genzyme in the United States and are actively recruiting our field-based team. Co-promotion decisions for other countries will be made over time. We're excited about the potential U.S. launch for sarilumab. Given the central role of interleukin 6 in the inflammation contributed (sic) [attributed] to the signs and symptoms of rheumatoid arthritis and, more importantly, disabling joint destruction, we believe that IL-6 inhibitors should be used early following tumor necrosis factor or TNF inhibitor failure. 
Recently issued U.S. and European guidelines support the use of IL-6 inhibitor class in earlier lines of treatments, and this is particularly relevant for those patients who cannot take combination therapies with methotrexate. With multiple players competing in the anti-IL-6 marketplace, this should contribute to improved physician awareness and understanding of the inadequacy of TNF inhibitor cycling and the need for early IL-6 inhibitor treatment. Subcutaneously administered sarilumab has strong clinical data in terms of the improved signs and symptoms of rheumatoid arthritis and prevention of bone damage in methotrexate-inadequate responders. Similar improvements in the signs and symptoms of RA have been reported in TNF inhibitor-inadequate responder population. 
We continue to prepare for the potential U.S. launch of dupilumab, our IL-4 and 13 inhibitor, which we expect in 2017. There are approximately 1.6 million patients with inadequately controlled moderate to severe atopic dermatitis in the United States. We'll be co-promoting dupilumab in the United States. Co-promotion decisions for other countries will be made at a later date. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone who has joined us today. In the first quarter of 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2015 and non-GAAP net income of $293 million decreased 13% versus first",1221,"Thanks, Bob, and good morning to everyone who has joined us today. 
In the first quarter of 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2015 and non-GAAP net income of $293 million decreased 13% versus first quarter of 2015.  Regeneron's 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and includes an adjustment for income taxes. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the first quarter of 2016 were $1.2 billion, which represented year-over-year growth of 38% over the first quarter of 2015. Net product sales were $784 million in the first quarter of 2016 compared to $545 million in the first quarter of 2015. EYLEA net product sales in the United States were $781 million in the first quarter of 2016 compared to $541 million in the first quarter of 2015, which represents an increase of 44%. Sequential quarter-over-quarter growth was an increase of 5%. 
During the first quarter 2016, EYLEA experienced a slight decrease in U.S. distributor inventory levels as compared to the fourth quarter 2015, but continues to be within our normal 1- to 2-week targeted range. As Len mentioned, we are updating our full year 2016 U.S. EYLEA guidance to be year-over-year growth of between 20% and 25% from the previously provided guidance of approximately 20% growth. 
Ex-U.S. EYLEA sales were $419 million in the first quarter of 2016 as compared to $292 million in the first quarter 2015, representing a 44% increase on a reported basis. On an operational basis or constant-currency basis, sales increased approximately 48%. Product revenue from ex-U.S. EYLEA sales is recorded by our collaborator, Bayer. In the first quarter of 2016, Regeneron recognized $146 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the first quarter of 2016 was $180 million. 
I'd also like to take this moment to highlight our recently expanded collaboration with Bayer, following our agreement to jointly develop the co-formulation of our antibody to ANG2 and EYLEA. In connection with this agreement, Bayer made a $50 million upfront payment to us, which was a receivable at March 31, 2016, and Regeneron has the potential to earn up to $80 million in development milestones. The $50 million upfront payment has been deferred and will be recognized over the estimated performance period. Similar to our EYLEA agreement, Regeneron has exclusive commercial rights within the U.S. and will retain all of the profits from any U.S. sales. 
Finally, a reminder for the EYLEA franchise. The second quarter of 2016 will be the final quarter in which we incur the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. In fact, I'm pleased to announce that this royalty will officially end in 2 more days.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $220 million for the first quarter of '16. The Sanofi collaboration revenue line primarily consists of reimbursements of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the first quarter of 2016, our share of the collaboration's losses in connection with commercialization with antibodies, primarily Praluent, was $99 million, which can be found in Table 4 of our earnings release. 
Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $13 million for the first quarter 2016. 
Turning now to expenses. Non-GAAP R&D expense was $392 million for the first quarter. Our unreimbursed R&D expense, which is calculated as total GAAP R&D expense less R&D reimbursements from our collaborators and R&D noncash share-based compensation expense, was $164 million for the first 3 months of 2016. Our press release includes all the information that's required to calculate unreimbursed non-GAAP R&D expense. For 2016, we'd like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in the range of $875 million to $950 million. 
Non-GAAP SG&A expense was $230 million for the first quarter 2016. We continue to expect non-GAAP SG&A expense in 2016 to be in the range of $925 million and $1 billion. 
Before I move on from our operating expenses, I'd like to take a moment to discuss the new guidance component we announced this morning, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs in connection with preparing to commercialize or commercializing, as applicable, Praluent, sarilumab and, effective in the first quarter of 2016, dupilumab. This is a line item found within Sanofi collaboration revenue and is referenced in Table 4 of our press release. Going forward, we believe that providing guidance for this number will help in modeling the Sanofi collaboration revenue line item. For the first quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $73 million, and we expect this expense in 2016 to be in the range $320 million and $370 million. 
Turning now to our non-GAAP tax adjustment. Cash tax as a percentage of non-GAAP pretax net income for this quarter continues to be lower than our GAAP effective tax rate, primarily due to the tax impact of noncash share-based compensation. On a non-GAAP basis, cash tax as a percentage of non-GAAP pretax net income for the first quarter of 2016 was approximately 38%. 
For 2016, our guidance for cash tax as a percentage of non-GAAP pretax income remains at 35% to 45%. As previously reported, this includes a onetime tax of approximately $222 million related to the Sanofi immuno-oncology agreement. I'd also like to reiterate that the non-GAAP tax impact of the immuno-oncology upfront payment will be spread equally throughout 2016. 
Our capital expenditures for the first quarter of 2016 were $104 million. Given our latest review of capital expenditures, we are tightening and lowering our full year 2016 capital expenditures guidance to a range of $550 million to $625 million from $580 million to $680 million. These expenditures continue to build on our manufacturing expansions in 2015, which include expanding our facilities in Rensselaer, New York and Limerick, Ireland as well as the continued expansion of our Tarrytown, New York headquarters. 
We ended the first quarter of 2016 with cash and marketable securities of $1.4 billion. As we previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt.  In the first quarter of 2016, we paid $242 million to reduce these outstanding warrants. 
Before I conclude my remarks, I would briefly like to highlight certain financial components of the recent collaboration with Intellia Therapeutics. The April 2016 agreement grants Regeneron access to Intellia's CRISPR technology platform as well as the right to discover and develop up to 10 targets on an exclusive basis over the course of the 6-year agreement. In return, we paid a $75 million upfront payment to Intellia, which we anticipate recording as R&D expense in the second quarter of 2016, but plan to exclude from non-GAAP net income. The agreement also requires Regeneron to purchase up to $50 million of Intellia's shares, contingent upon Intellia consummating its initial public offering. 
With that, I'd like to turn the call back to Michael."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period.",16,"Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners.",13,"[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","The 10-Q being filed today is very helpful with all the detail. I suppose, a couple of questions. George, first on dupilumab. Now that you have the first Phase III readout, what incrementally have you learned from that in terms of the profile of dupilumab",131,"The 10-Q being filed today is very helpful with all the detail. I suppose, a couple of questions. George, first on dupilumab. Now that you have the first Phase III readout, what incrementally have you learned from that in terms of the profile of dupilumab? And how does that alter what you might focus on and potentially invest in for that molecule in the future? And then secondly, just on Medicare Part B, you alluded to that and called it out in your script [ph] and in the Q. What are you learning in the comment period? And will you be submitting comments? Or are you aware of other comments? And do you think there's any chance that this is going to be modified or altered in schedule or scope?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, this is George. I'll take the dupilumab question. I guess the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy and the important benefit to patients in",249,"Well, this is George. I'll take the dupilumab question. I guess the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy and the important benefit to patients in essentially every single efficacy readout that we explored. So obviously, that's very gratifying and comforting when one actually sees data that is as promising as your earlier data and suggests it can really make an important difference to moderate to severe patients who really need new therapies to attack their disease. In addition, the safety profile was also very comforting. And we reported extensively and it really does suggest that it's going to have a very important benefit/risk profile for patients. I think that, basically, for atopic dermatitis, it really means that it's all greenlights and all speed ahead and that we're really excited that we could be really bringing forward, as the FDA has designated, a breakthrough therapy for these patients' need. As you know, we also have a pivotal study in asthma, and that's already been read out. And we're in the midst of our first breakthrough, which is now our second confirmatory study in that indication as well. So dupilumab is a very, very exciting program. And as I already told you about today, I told you that in terms of the atopic dermatitis population, we're also moving to the pediatric population there as well, which is also an important unmet need area."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","In terms of the Part B, we fully understand that health care costs need to be appropriately controlled in this country. However, the approach that has been proposed by Medicare Part B would limit options for physicians and patients to give appropriate the",158,"In terms of the Part B, we fully understand that health care costs need to be appropriately controlled in this country. However, the approach that has been proposed by Medicare Part B would limit options for physicians and patients to give appropriate therapies to patients who need them. For example, in the case of the retinal space, you could lead to physicians being required simply by the economics that are in place to force them to use an off-label repackaged bevacizumab, which, at least in the Protocol 3 -- T trial, was shown in DME not to be as effective as the other therapies. They could be forced to use this for economic reasons. We see that a number of manufacturers as well as a number of congressmen and patient advocacy groups recognize that you have to preserve physician choice, and so there will be a number of complaints and letters going into the Congress, including our own."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I mean, just to add, there are literally hundreds of congressmen who have said that this should not be done. There are others who've said that the unintended consequences that we're concerned about must be managed, the retinal groups, the ophthalmolo",97,"Yes. I mean, just to add, there are literally hundreds of congressmen who have said that this should not be done. There are others who've said that the unintended consequences that we're concerned about must be managed, the retinal groups, the ophthalmology groups and, not to mention, all the other interested parties, such as cancer and what have you. So I think many observers, which we're not experts on -- but many observers in Washington would suggest that this seems unlikely. But we'll have -- we are certainly going to do our best on this as well."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","[Operator Instructions]",2,"[Operator Instructions]"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our next question is from Chris Raymond from Raymond James.",11,"And our next question is from Chris Raymond from Raymond James."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just one question here. So just kind of on the PD-1, kind of sort of struck by the news that this cutaneous squamous cell trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more co",104,"So just one question here. So just kind of on the PD-1, kind of sort of struck by the news that this cutaneous squamous cell trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more color on where those trial fits in with the overall development plan. Just looking at clinicaltrials.gov, there's not a ton of detail. And obviously, there's a lot of breadth of labeling potential with that type of molecule. If you could maybe sort of talk about where you plan to take this, that'd be great."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we are implementing a highly integrated and very comprehensive effort in immunotherapy. And this is obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to",134,"Well, we are implementing a highly integrated and very comprehensive effort in immunotherapy. And this is obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to patients and really make a difference in certain disease settings. And how we're going to do that and how we hope to bring the best results to patients with the best combination is something that, at this point, I think -- our thinking behind -- in this very competitive space is rather keep largely to ourselves. So sorry for not informing you more, but we just think that we have a very robust and highly integrated and comprehensive effort here, and we intend to hopefully deliver important new approaches to patients."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Terence Flynn from Goldman Sachs.",10,"Our next question is from Terence Flynn from Goldman Sachs."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just wondering -- for dupi, I know it's a little bit early, but as we just think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent-type launch or more like EYLEA? And if you won't answer",71,"So just wondering -- for dupi, I know it's a little bit early, but as we just think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent-type launch or more like EYLEA? And if you won't answer that directly, maybe you can just walk us through some of the factors we should consider as we think about the ramp."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. It's Len. Since we were all -- both you guys and us were spot on, on EYLEA and Praluent, I don't know why we wouldn't take a shot at dupilumab. I think the fact is, obviously, we can't answer that directly, Terence. And since we've been -- we and al",338,"Sure. It's Len. Since we were all -- both you guys and us were spot on, on EYLEA and Praluent, I don't know why we wouldn't take a shot at dupilumab. I think the fact is, obviously, we can't answer that directly, Terence. And since we've been -- we and all of us, everybody has been wrong multiple times, these things unfold as they unfold. The factors to consider obviously is that you're already obviously seeing the PBMs taking a notice of this. I saw this in somebody's report, that this is the next big class that they're worried about. There are a lot of patients out there that might fit our label, assuming we get the label. But I'm sure they're going to be -- there's going to be utilization management, make sure they've tried the topical steroids or whatever, that they really have the right diagnosis, et cetera, et cetera. Now whether there will be ""warehousing of patients"", people lining up to get it, it's just really impossible for us to tell. But I would suspect that this would be one of those launches that will be patient-driven. That -- as people get on the drug, if the results in the real world or anywhere is close to the results we've seen in our Phase III trials so far, I'm sure that, that patient drive will be tremendous because this is a terrible disease that people have been suffering with for decades. Adults now have it without anything at all new to really help them and make a difference. And if you look at -- whether you measure this by quality-of-life metrics, the increased risk of suicide, just the terrible burden that this puts on patients, we're optimistic that this drug can make a difference for them. So we're hopeful for a good launch. But how that -- the actual ramp and whether it takes us a while to get it going and what the coverage looks like and all that, just too early to tell."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Adnan Butt from RBC Capital Markets.",11,"Our next question is from Adnan Butt from RBC Capital Markets."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Arshad [ph] on for Adnan. Could you please put the fasinumab safety data kind of in the context, given that the FDA seems to have already been focused on safety in general?",34,"This is Arshad [ph] on for Adnan. Could you please put the fasinumab safety data kind of in the context, given that the FDA seems to have already been focused on safety in general?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Well, maybe I'll make a brief comment. And if George has anything to add, obviously, he's welcome. The -- our feeling is that -- as George said in his talk, is that we did something which we think was pretty important, which is we did an extensive an",259,"Yes. Well, maybe I'll make a brief comment. And if George has anything to add, obviously, he's welcome. The -- our feeling is that -- as George said in his talk, is that we did something which we think was pretty important, which is we did an extensive and detailed screening of patients with x-rays and MRIs before they were ever exposed to drug. And that demonstrated that some of these things that people were concerned about might be somewhat induced by drugs, were really fairly prevalent in the population, whether they be insufficiency fractures or whether they be osteonecrosis and so on. So I think that, that was important. And I do think that the FDA has come around to thinking that this has to be looked at carefully, and we -- and that's what we're doing. And the right patients have to be studied, and that's also what we're doing. They also have had concerns about whether or not any one of these drugs individually or as a class could have effect on sympathetic nerves and sympathetic nervous system function. We also looked at that pretty well, and we'll have more to tell you about that in upcoming meetings. But we didn't see any evidence at all so that, so far, things look reasonable. But as -- I think as George said, it's a small study, and we're underpowered to pick up very small increases in some of these things. And that's why we're going to study thousands and thousands of patients in our Phase III program."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. And to add to that, I think that the -- one of the biggest underlying fears for this class, certainly by outside people but also by ourselves, was that the very small increase in certain arthropathy events, certain joint pathologies that was seen, pa",352,"Yes. And to add to that, I think that the -- one of the biggest underlying fears for this class, certainly by outside people but also by ourselves, was that the very small increase in certain arthropathy events, certain joint pathologies that was seen, particularly in combination with NSAIDs but also a small increase even in monotherapy might actually be reflecting a much bigger, somewhat invisible problem that there was a bigger, destructive process that would then be seen over longer periods in time and so forth. And this is why we did this -- as Len said, this extensive imaging of both the index joints but also non-index joints to see whether, overall, the skeleton was really changing. And as we've already said, the thing that was very gratifying was that, unfortunately, for these patients suffering from this important problem, there is already significant skeletal pathology at baseline. These patients have these so-called subchondral insufficiency fractures, and you could even see undiagnosed osteonecrosis in these patients and so forth. And these events, both in the index and the non-index joints, were not dramatically increased by treating with NGF. And one fear, for example, was that these asymptomatic subchondral insufficiency fractures may be happening much more frequently with drug and then eventually leading to much higher incidences of events down the line. And so it's very comforting not to see this. That said, there remain -- as with any drug and, certainly, with a drug this active, there will continue to be risks associated with treatment. But one has to balance that with all the benefits that could be provided. Pain is a very serious problem for a lot of people, especially people suffering from osteoarthritis. And the options, obviously, as you know, are quite limiting with no new mechanism-of-action drugs added to this field for decades. And so the possibility and the opportunity that a new mechanism-of-action class that might have different profile and also different risk profile as compared to, for example, opiates and NSAIDs and other drugs with serious risks, we think can offer an important option for patients."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","This is Michael. I just want to make sure we -- I add it because when talking about pain, you really have to keep into context of really what is an epidemic in the United States in terms of drug -- opioid abuse and overdose, with quadrupling in the number",111,"This is Michael. I just want to make sure we -- I add it because when talking about pain, you really have to keep into context of really what is an epidemic in the United States in terms of drug -- opioid abuse and overdose, with quadrupling in the number opioid death in the past number of years as well as -- from the CDC website. Nearly 0.5 million people died from drug overdoses from 2000 to 2014. Almost 80 Americans die every day from an opioid overdose. So I just think that could keep into context that pain remain -- having new pain medicines can really -- is really important."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Yin Huang from Bank of America.",11,"Our next question is from Yin Huang from Bank of America."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just first, on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called thera",109,"Just first, on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called therapeutically similar class, and therefore, it should be subject to a reference pricing in the second phase of that demo. And then also on the ODYSSEY OUTCOMES trial, I know the trial is powered -- 90% power to show 15% CV risk reduction. Maybe you guys can provide thoughts on whether you think the payers would be excited about that 15% CV risk reduction."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So Ying, which question do you want to answer because Michael's holding up a sign that says 1 question. Even though he loves you, he said, ""Which one does he want?""",31,"So Ying, which question do you want to answer because Michael's holding up a sign that says 1 question. Even though he loves you, he said, ""Which one does he want?"""
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Len, you're the boss.",4,"Len, you're the boss."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Not true. Which question, Ying?",5,"Not true. Which question, Ying?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","All right. Maybe second. It's probably more important from my perspective.",11,"All right. Maybe second. It's probably more important from my perspective."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, I think that the OUTCOMES data, as we saw with ezetimibe it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the dataset, et cetera, et cetera. Certainly, we power",147,"Okay. Well, I think that the OUTCOMES data, as we saw with ezetimibe it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the dataset, et cetera, et cetera. Certainly, we power the study based on expert input of where they thought that would be -- if we saw the results, that would be a meaningful result for patients. But of course, it's not just one number, not just statistical significance. You want to see how all the dataset looks like. And I think somebody said, well, ezetimibe has statistical significance. But if you blink, you could miss it. And we tried to design a study and set the parameters such that if we saw the result, we could feel confident about it, that we were making a difference in these outcomes to patients."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Ying, I can't leave the EYLEA one hanging out there, I'm sorry. If you remember back to the VIEW 1 and VIEW 2 studies, we actually designed studies that compared ourselves to what was the standard-of-care branded agent, which was ranibizumab monthly, and",172,"Ying, I can't leave the EYLEA one hanging out there, I'm sorry. If you remember back to the VIEW 1 and VIEW 2 studies, we actually designed studies that compared ourselves to what was the standard-of-care branded agent, which was ranibizumab monthly, and we studied EYLEA, both -- dose, both monthly as well as every 8 weeks. And what we saw is very similar results with the EYLEA every 8-week dosing to the Lucentis every 4-week dosing. This is a major advantage to elderly patients who can't get into the physician's office on a regular basis. And so they are not therapeutically equivalent. EYLEA has a longer durability of effect. I would also point out, there are data in a subset of patients in the VIEW studies that indicates that there are patients who are more refractory to anti-VEGF therapy, especially those who've received prior anti-VEGF therapies who may need more anti-VEGF treatment. And what we're seeing in those patients, we're able to dry them up better with EYLEA than with Lucentis."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And George also. I also have to make a few comments here. And I think, really, Bob touched on an important point, that our drug showed, compared to the, at the time, optimum standard of care, that doubling the interval could produce at least as good resul",445,"And George also. I also have to make a few comments here. And I think, really, Bob touched on an important point, that our drug showed, compared to the, at the time, optimum standard of care, that doubling the interval could produce at least as good results from -- in terms of visual acuity but also even better results in terms of controlling vascular leak and retinal slowing and so forth. And I think that we all have to really consider that maybe -- and I hate to say it because some people are going to say, ""Hey, don't challenge the physicians here."" But I think the physicians here, and we understand the limitations of the real world and practice, are doing a huge disservice to patients, in terms of the systematic under-treatment that is probably occurring in this field. There's an enormous drive to try to get patients less trips to the office, less injections. And you've probably seen the release of recent data with long 4- or 5-year follow-on. And after you take the patients over the more controlled phases of the study, where they're getting, in general, in most studies, monthly treatment, a very carefully monitored treatment, they essentially lose almost all their vision gain over these later years of 4- and 5-year follow-ups. And we believe that the data and the evidence suggest that this is really due to systematic under-treatment, patients getting less and less treatment. And particularly in that setting, if you want to deliver the best care to patients, you should be delivering the best agent that has the longest duration of action, and we think that the only agent that's really demonstrated that convincingly is EYLEA. And so I think to save patients' visions -- you saw the long-term trials. Patients are losing visions. Physicians are not doing the right things by their patients. They're systematically under-treating. And particularly in those setting, they should be getting the best drug that protects patients against this vision loss. And it would be a disservice if, in fact, incentives and so forth are driven to the use of an inferior agent, which will cause patients -- think about it. You're a patient who can't drive, you're a patient who can't read, you're now given a drug. All of a sudden, you gain 2, 3 lines of vision. That changes the world literally for you. Okay. You could do things you can't do before. And now we developed a system that allows you to lose that. I think that we have to think about how we want to practice medicine in this country if we create a situation that allows that."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think the physicians, George, are right there with you. And it'd be hard for me to imagine that once the physicians heard on this subject that Avastin could -- an off-label, inferior product based on the government's study could be set to standard.",45,"Yes. I think the physicians, George, are right there with you. And it'd be hard for me to imagine that once the physicians heard on this subject that Avastin could -- an off-label, inferior product based on the government's study could be set to standard."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Robyn Karnauskas from Citigroup.",9,"Our next question is from Robyn Karnauskas from Citigroup."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Congratulations on all the innovation. I feel like you're one of the few companies where there's so much going on, on the call and you provide clarity. I guess I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does",133,"Congratulations on all the innovation. I feel like you're one of the few companies where there's so much going on, on the call and you provide clarity. I guess I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does highlight this a lot. And I feel like it's -- those of us on The Street are more skeptical about the opportunity. Help us understand how you -- what your view is of sarilumab and how you think about this. It's a competitive space. There are stuff coming up behind it from AbbVie. How are you thinking about the strength of that data? And do you have any understanding of the strategy and how you could take share from the current market or expand the current market?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build a company for the last 3 decades that is driven by -- truly driven by science and innovation, so we appreciate you taking note of that. Bob, can you commen",63,"Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build a company for the last 3 decades that is driven by -- truly driven by science and innovation, so we appreciate you taking note of that. Bob, can you comment without giving away all of our intricate strategy on what the opportunity for our assets might be?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Robyn, as I pointed out earlier, I think that when Genentech launched Actemra into the U.S. marketplace, it was very much a market dominated by growing TNF inhibitors, and they were a single company trying to educate on the role of IL-6 in rheumatoid arth",187,"Robyn, as I pointed out earlier, I think that when Genentech launched Actemra into the U.S. marketplace, it was very much a market dominated by growing TNF inhibitors, and they were a single company trying to educate on the role of IL-6 in rheumatoid arthritis and the potential benefit of using an IL-6 inhibitor earlier. It is always more beneficial -- we've seen this, for example, in the statin class, where as more and more statins became available, they grew the market. We believe that this is the opportunity for this class, that we can educate physicians more, one, as I said earlier, on the central role of IL-6 in both the signs and symptoms of RA but as well as in joint destruction, which we feel is very important. Physicians need to understand they shouldn't stay with a TNF inhibitor, which, over time, each additional TNF inhibitor does not deliver the efficacy that they received with the first TNF inhibitor. So there's a benefit of moving to a new class, and IL-6 really does have a central role both in symptoms as well as bone destruction."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I also -- just to add that there's something about the -- some historical accidents have occurred here in the order that drugs came along and having to do with pricing and with methotrexate being sort of the main stay. It's a very cheap drug. It's effecti",163,"I also -- just to add that there's something about the -- some historical accidents have occurred here in the order that drugs came along and having to do with pricing and with methotrexate being sort of the main stay. It's a very cheap drug. It's effective. But it's the not most innocuous drug in the world from its side effects and what have you. And there are many people, particularly women, who don't  like being on the product, and there seems to be movement towards monotherapy. And remember, methotrexate -- some have argued that for some drugs methotrexate provides the immunosuppression for the biologics so that any immune-related, if you will, blockade of effect doesn't appear as quickly. Suffice it to say, we -- and maybe George can comment on that more. But I can say that when we look head to head against the market leader, AbbVie, in the monotherapy setting, you've seen our data, we had a superior result. So..."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","But I also do -- just to finish the story. Sarilumab is not a me-too drug. I don't want to do cross-comparison trial data right now. But I think if you look at the prescribing information for subcutaneous Actemra and you look at the results we reported wi",82,"But I also do -- just to finish the story. Sarilumab is not a me-too drug. I don't want to do cross-comparison trial data right now. But I think if you look at the prescribing information for subcutaneous Actemra and you look at the results we reported with our product, we are very encouraged about the product profile that our product, which had higher binding affinity to IL-6, is going to offer in the marketplace. Maybe George wants to comment on that."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's important to just highlight a few things because, once again, it all comes down to the patients and doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense",298,"Yes. I think it's important to just highlight a few things because, once again, it all comes down to the patients and doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense to start all patients, particularly patients in monotherapy settings, with the TNF. And that may be a historical accident. It also doesn't make sense to just continue patients cycling on TNF if there is an alternative that can deliver them better symptomatic relief. And so we think that there's enormous opportunity for this class. And importantly, in this class, and as Bob said, the most -- one of the most important things that I think that patients and physicians are concerned about is irreversible bone loss. That's one thing that you can't get back, and that's one thing that's looked at in this field. And as you know, Actemra is now growing through a subcutaneous formulation. And if you look in the label, there's less -- according to the subcutaneous formulation that's used there in terms of the inhibition of the irreversible bone loss, there's less than 50% inhibition by the subcutaneous formulation in terms of Actemra in terms of the irreversible bone loss. If you look at our study, we offer 2 doses. And if they both get approved, our higher subcutaneous dose gives greater than 90% inhibition of irreversible bone loss. So as Bob said, these are not identical agents. This is not a me-too. There's important differences, and there's an important opportunity to do better by patients in terms of the monotherapy setting and in terms of not just cycling through drugs that maybe aren't working for the patients and putting them on a different mechanism-of-action drug."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I'll also say that there have been, let me call it, commercial games that have been played out there in that -- in negotiations that have gone on with the PBMs, where people have used certain multiple indications as a way to drive use in other indications",169,"I'll also say that there have been, let me call it, commercial games that have been played out there in that -- in negotiations that have gone on with the PBMs, where people have used certain multiple indications as a way to drive use in other indications from what we can tell. And I think the PBMs are sort of wising up to that and moving to indication-specific pricing negotiations. And so we actually feel that we might be entering the market at a reasonably good time, where, with a lot of dynamics going on and a good product, you can make inroads. Now I don't think this is going to be an easy road, and I wouldn't be -- I don't think you can just assume that we're going to jump in and grab huge market share right off the bat. But I think it's -- we can build this into a significant opportunity over time. It's more of going to be like a slow and steady."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Alethia Young from Crdit  Suisse.",10,"Our next question is from Alethia Young from Crdit  Suisse."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to the Praluent trends that you said in your script. I guess, you said that 50% of new -- you finally got 50% of the new scripts. Can you guys kind of talk about what behavior might be driving kind of that 50%? Is it something that you're",61,"Just going back to the Praluent trends that you said in your script. I guess, you said that 50% of new -- you finally got 50% of the new scripts. Can you guys kind of talk about what behavior might be driving kind of that 50%? Is it something that you're kind of adjusting or changing that's resounding in the profile?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's hard to know for sure, and we only have another minute here so I don't want to get into great detail. But one thing that is important is that there's new coverage that's coming to play, particularly in the Medicare space, which was reall",208,"Yes. I think it's hard to know for sure, and we only have another minute here so I don't want to get into great detail. But one thing that is important is that there's new coverage that's coming to play, particularly in the Medicare space, which was really only recently coming on, where in those plans that chose -- which was most of them, a single agent as the priority drug, we were, I think, selected about 90% of the time. So I think that there's some new coverage, new utilization management. And obviously, we're working hard at this. But I don't think you can consider 1 week a trend, whether it's one -- going one direction. It's just a data point. But right now, the market seems to be split roughly, more or less, equally based on that data point. How that goes over time, obviously, that's what the competitive marketplace is all about. But I think our most important effort right now has to be on making sure that the right patients get access to drugs, and that's really where both companies are focused. It's an important thing for the class. The patients who need drug have to get an opportunity to have access to it."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our last question is from Matthew Harrison from Morgan Stanley.",11,"And our last question is from Matthew Harrison from Morgan Stanley."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just had 2 related Praluent questions. You said that 2 payers have loosened their criteria. I'm wondering if you can just be more specific about that, who they were and exactly what they loosened. And then you were talking about an improvement in the nu",73,"I just had 2 related Praluent questions. You said that 2 payers have loosened their criteria. I'm wondering if you can just be more specific about that, who they were and exactly what they loosened. And then you were talking about an improvement in the number of Rxs that were filled. Is that just more people getting through the utilization management criteria? Could you just be more specific about that comment as well?"
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Our contracts with the payers don't allow us to disclose the specific ones who've changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of Zetia after maximally",189,"Sure. Our contracts with the payers don't allow us to disclose the specific ones who've changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of Zetia after maximally tolerated statin therapy from their the utilization management criteria. That was setting up a delay in access to PCSK9 inhibition. The physicians were having to put them on Zetia and then wait, and it was causing a real backlog for the doctors. So that has been removed by 2 of the payers. In terms of the improvement of the number of people going through the hub, I think what I could say is, one, the -- as Len said, payers have come onboard now, and so especially Medicare patients now are getting access to therapy. I think the other thing is that the physicians as well as the specialty pharmacies are better understanding how to make the prescription process better. That's not -- it's not easy right now. We continue to work on improving it, but at least it has gotten better for some patients."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So just one last comment from -- it's Len. So in our effort to answer all your questions, what we're trying to do is give you some insight into our thinking, like why we went forward with something. We're not trying to make cross-trial comparisons per se.",173,"So just one last comment from -- it's Len. So in our effort to answer all your questions, what we're trying to do is give you some insight into our thinking, like why we went forward with something. We're not trying to make cross-trial comparisons per se. We're trying to give you an idea of why we went forward and what we saw, how we felt we were differentiated. What we can say out in the marketplace obviously will be limited based on what we actually get in our various labels that are pending. 
And with that, I would just say that we're pleased that the innovation machine continues to turn and produce lots of exciting things that we hope to update you in the scientific literature and in presentations that are upcoming. Lots of things that we -- George did not get a chance to talk about that are exciting. So we appreciate your interest, and we hope to continue to be able to update you over time. Thank you very much."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks.",1,"Thanks."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you.",2,"Thank you."
33715,331187536,974052,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect.",15,"Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. And I will now turn the call over to Dr. Micha",43,"Welcome to the Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions] Please note, the conference is being recorded. 
And I will now turn the call over to Dr. Michael Aberman."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, operator. And good morning, and welcome to Regeneron Pharmaceuticals First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.Joining me on the call today are Dr.",313,"Thank you, operator. And good morning, and welcome to Regeneron Pharmaceuticals First Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.  
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. 
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission or SEC, including its Form 10-Q for the quarter ended March 31, 2016, which was filed with the SEC this morning.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Michael, and a very good morning to everyone who has joined us on the call and webcast today. The first quarter of 2016 was busy, and we have a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities in dr",327,"Thank you, Michael, and a very good morning to everyone who has joined us on the call and webcast today. The first quarter of 2016 was busy, and we have a lot to share with you today. Our strategy remains, as always, to focus our unique capabilities in drug discovery and development on bringing important new medicines to patients in need. 
George will provide you with some of the recent exciting progress we have made in that regard. From a high-level perspective, we had positive data readouts from 3 Phase III programs, Praluent for lowering LDL cholesterol in the apheresis setting, sarilumab in rheumatoid arthritis and dupilumab in atopic dermatitis. We also reported positive data from a Phase II/III study in osteoarthritis for fasinumab, our NGF antibody for pain. And we continue to make good progress with our earlier-stage assets and discovery efforts. 
Turning to our marketed products. EYLEA has continued to deliver solid growth, and we are able to increase our guidance for the year. Praluent's launch is still ongoing, and it's obviously faced a difficult reimbursement environment. While we fully understand payers' efforts to control costs, we do have serious concerns that appropriate patients are having undue difficulty getting approval for Praluent. We continue to be optimistic over the long term that Praluent will provide an important cholesterol-lowering option to many patients.  Bob Terifay will provide more detail on EYLEA and Praluent. Following that, Bob Landry will provide more detail on financial results for the first quarter of 2016 as well as updated guidance. 
Finally, we are approaching the potential approval and launch of 2 new products. Sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis, is under review with the FDA. Dupilumab is being developed for a number of indications, and we are targeting completion of our rolling BLA submission for moderate to severe atopic dermatitis in the third quarter of 2016. 
With that, let me turn the call over to George."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combinations of EYLEA with rinucumab, an antibody to the PDGF receptor, and Nesvacumab, an antibod",1581,"Thank you, Len, and a very good morning to everyone who has joined us today. Let me begin with an update on EYLEA. In addition to the Phase II co-formulated combinations of EYLEA with rinucumab, an antibody to the PDGF receptor, and Nesvacumab, an antibody to angiopoietin-2, we have also commenced Panorama, a Phase III study of EYLEA in non-proliferative diabetic retinopathy in patients without diabetic macular edema or DME, which will evaluate whether EYLEA can improve the retinopathy. 
Additionally, the Diabetic Retinopathy Clinical Research Network or the DRCR initiated a related clinical study called Protocol-W to evaluate the potential of anti-VEGF therapy in preventing worsening of severe non-proliferative diabetic retinopathy. This study will explore every 16-week dosing of EYLEA, which is the only anti-VEGF treatment being investigated in this study. 
In February, we received 2 new results from Protocol T, a government-sponsored study in patients with DME, comparing the safety and efficacy of EYLEA versus Lucentis and Avastin. The primary efficacy endpoint for that study was at 1 year, which showed significantly better vision gain with EYLEA than either with Lucentis or Avastin. The second year of the study was not designed to rigorously compare the anti-VEGF agents as the second year results were increasingly confounded by variable dosing frequencies as well as additional or adjunctive therapies such as laser. 
Along these lines, it is important to point out there was a greater number of injections and substantially more use of laser associated with Avastin treatment in the overall population. Despite this, when compared with Avastin, EYLEA demonstrated a statistically significant 5-letter gain or an entire line of vision in patients with poor vision at baseline. At 2 years, the rate of most ocular adverse events were similar across the 3 study groups. There was, however, statistically significant lower rate of arterial thromboembolic events , including nonfatal stroke, nonfatal myocardial infarction and vascular death in the EYLEA group compared with the ranibizumab group. 
Our Praluent launch is underway, and Bob Terifay will provide further details on the commercial front. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. The data monitoring committee for this study has completed the first interim analysis, with 50% of the total events had accrued (sic) [occurred] based on unblinded study data. In addition to reviewing the safety data, the DMC performed a futility assessment and recommended the study continue with no changes. We remain blinded to the actual results of this analysis, and the study is ongoing. A second interim analysis for futility as well as overwhelming efficacy could potentially occur in the second half of 2016 when 75% of the targeted primary events have occurred. 
In March, we reported positive data from the Phase III ODYSSEY ESCAPE study in patients with heterozygous familial hypercholesterolemia, who require chronic weekly or biweekly apheresis. Apheresis is an invasive, expensive and time-consuming therapy given to the patients with the highest cholesterol levels and the greatest need. Our study showed that Praluent reduced the need for apheresis by 75% compared to placebo, and 63% of Praluent patients no longer required apheresis compared to 0% of the patients in the placebo arm. 
Praluent is the only PCSK9 inhibitor that has been studied in an apheresis setting, which represents some of the most severe hypercholesterolemic patients. The adverse events that occurred more frequently in the Praluent-treated patients were injection site reactions and myalgia. We expect our supplemental BLA for the once-monthly dosing regimen of Praluent to be filed in the second quarter, which, if approved, will expand our dosing flexibility options. 
Turning now to our late-stage pipeline, where we had some very positive news. I'd like to start with sarilumab, our IL-6 receptor antibody which is under review by the FDA for the treatment of rheumatoid arthritis. In March, we announced positive data from the Phase III MONARCH study of sarilumab versus Humira, which demonstrated that sarilumab was superior to Humira in the monotherapy setting in improving signs and symptoms of rheumatoid arthritis at 24 weeks. This was the first head-to-head study in the monotherapy setting using a subcutaneously administered IL-6 inhibitor. The use of IL-6 inhibition in the monotherapy setting has been growing, and these data provide us with a competitive product profile. Data from the MONARCH study will be included in our European submission that is expected midyear of 2016. 
Turning now to dupilumab, our IL-4/13 blocking antibody, where we recently announced positive top line data from the Solo-1 and Solo-2 monotherapy Phase III studies in adults with moderate to severe atopic dermatitis. These were the first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate to severe atopic dermatitis and confirm the positive data we have seen in our Phase IIb study. Overall, the studies demonstrate significant improvements in measures of disease severity, skin clearing, itching, quality of life and mental health. We expect to present detailed data from the Solo studies in an upcoming medical conference. 
We continue to expect top line data from the Phase III CHRONOS study, which explores dupilumab in combination with topical corticosteroids, in the second quarter of 2016. We expect to complete the rolling BLA submission for dupilumab in atopic dermatitis in the third quarter of 2016. We remind you that dupilumab has received breakthrough designation from the FDA for this indication in adults. 
In the first quarter of 2016, we initiated LIBERTY AD CAFE, a Phase II study of dupilumab to support our European submission. This study investigates dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or intolerant to or ineligible for systemic cyclosporine A treatment. In addition to the studies in the adult setting, we also plan to initiate a Phase III study in the atopic dermatitis indication in the pediatric population once we have data from the ongoing Phase II pediatric study that is now fully enrolled. We expect this Phase II data in the second half of the year. 
We're also investigating dupilumab in other indications, including asthma, where we are currently enrolling our 1,700-patient pivotal study. We're also advancing clinical development in indications such as nasal polyps and eosinophilic esophagitis. 
For fasinumab, our NGF antibody, earlier this week, we announced positive data from our Phase II/III study in osteoarthritis, which provides us with our first safety and efficacy data with our subcutaneous dosing regimen. This was the first completed study using an antibody to NGF that performs extensive imaging of knee, hip and shoulder joints at screening and throughout the trial. Interestingly, we found that  subchondral insufficiency fracture and even osteonecrosis were present in this population at screening. 
Further, our findings in patients following fasinumab treatment are consistent with prior data, suggesting that there may not be a substantial increase in rapidly progressing osteoarthritis when an NGF antibody is used in the monotherapy setting. That said, it's a relatively small trial, and we look forward to data from the much larger clinical studies that are underway. 
We have also seen some exciting developments in our earlier-stage programs. I'd like to spend a few minutes on 2 areas: our efforts in genetics and our recent collaboration in the arena of gene editing. In March, we published a paper in the New England Journal of Medicine based on research that was conducted at the Regeneron Genetics Center or the RGC. The publication showed that inactivating mutations in a gene called angiopoeitin-like 4 were associated with a significantly reduced risk of coronary artery disease in humans. This is a great example that demonstrates how our efforts in the area of precision medicine can link genetic mutation information with real-world health outcomes to make actionable discoveries. 
Many of the findings from the RGC are already being used to inform Regeneron's robust and integrated R&D programs and give us the ability to incorporate large-scale sequencing into our discovery and pipeline approaches. It also demonstrates the advantages of our unique combination of technologies. Using our proprietary VelociGene Technology, we develop animal models that corroborate the human genetics findings. And we were able to use our VelocImmune platform to create a fully human monoclonal antibody inhibitor of ANGPTL4 that reduce triglyceride levels in mice and nonhuman primates. 
We are also advancing a Phase II program of REGN1500, an antibody to ANGPTL3. ANGPTL3 is thought to play a central role in lipoprotein metabolism, and our genetic data show that patients with homozygous inactivating mutations of this gene report greater than 50% lower levels of LDL, HDL and triglycerides. Initial data from a small study in homozygous patients will be presented at the upcoming Annual meeting of the National Lipid Association. 
We recently entered into collaboration with Intellia Therapeutics with the aim of advancing CRISPR/Cas gene editing technology into in vivo therapeutic development. This was a logical fit for us given our long-standing expertise on genetic engineering, combined with our industry-leading human genetics research with the RGC, which is already identifying important genetic targets. We believe that combining these capabilities with Intellia's technology holds real promise for serious diseases that have been historically difficult to address and expands our ability to help patients where antibody-based therapies may not be the optimal approach. 
We continue to make progress in immuno-oncology. REGN2810, our PD-1 antibody program, has entered a Phase II potential registrational study in cutaneous squamous cell carcinoma. We'll be presenting some preliminary Phase I data at the upcoming annual ASCO conference. 
With that, I would like to turn over the call to Bob Terifay."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. During the first quarter of 2016, we continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We've made substantial progress in securing a",972,"Thank you, George, and good morning, everyone. During the first quarter of 2016, we continued to see strong sales growth for EYLEA or aflibercept injection, both in the United States and the rest of the world. We've made substantial progress in securing access and reimbursement for Praluent or alirocumab among U.S. payers. In addition, the European launch of Praluent continues to progress. 
We also are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next 12 to 15 months. 
Starting with EYLEA. First quarter U.S. net sales grew 44% year-over-year. Net U.S. EYLEA sales in the first quarter were $781 million. Net ex-U.S. EYLEA sales in the first quarter were $419 million, which represents 44% growth year-over-year on a reported basis. We continue to see quarter-over-quarter increases in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market, both in terms of dollar sales as well as injections as reported by 207 retinal specialists in our quarterly market research survey. 
We're encouraged about future growth opportunities for EYLEA based upon the recently reported 2-year results of the independently conducted Protocol T comparative study of EYLEA versus ranibizumab versus bevacizumab in patients with diabetic macular edema. However, I should point out that we are closely monitoring pressures on EYLEA sales as the year progresses. There are currently a series of proposals for the Centers for Medicare and Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B buy-and-bill drugs, which could lead towards physicians favoring the use of off-label, repackaged bevacizumab or, in large-volume retinal practices, ranibizumab due to the provision of direct-to-physician financial incentives from the manufacturer. 
Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. Therefore, we and scores of other manufacturers, patient ethics groups and industry associations will or have already submitted objections to CMS and Congress, recommending the physicians' choice be preserved and alternative schemas to reduce health care costs should be explored. 
Turning now to Praluent. As reported by Sanofi, net sales in the first quarter were $13 million, which understates the actual position of patient demand. As a reminder, over the last several quarters, we anticipated that it would take some time for commercial and government payers to conduct formulary reviews, make reimbursement coverage decisions and begin to process patient claims. I'm pleased to tell you that as of April 1, approximately 74% of commercially insured lives and 91% of Medicare-insured  lives have access to Praluent. We've recently seen an improvement in the number of prescriptions that are successfully being filled. 
Highlighting our improved coverage as well as our share of voice among health care professionals, the most recent nationally syndicated prescription audit for the week ended April 22, 2016, indicates that Praluent captured approximately 50% of new prescriptions in the class.  Unfortunately, due to unprecedented strict management -- utilization management criteria and very tedious prior authorization paperwork and documentation that the pharmacy benefits managers and health plans have put in place, many patients who are eligible for treatment with a PS -- PCSK9 inhibitor have not had their prescriptions filled. Frustrated by this process, health care professionals are limiting the prescriptions to the sickest of patients. The prescription volume for the PCSK9 inhibitor class is limited. 
We're focusing our efforts on improving the prescription process through the payers and specialty pharmacies. We're also working with physicians' offices to ensure that the prescription process is better understood on a payer-by-payer basis. Over the last several weeks, we've seen 2 payers loosen their utilization management criteria, removing the requirement for prior ezetimibe therapy. ODYSSEY OUTCOMES data, if positive, will be a key driver in shaping the future success of Praluent. 
Outside of the United States, Praluent was approved in the EU in September of 2015, with product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Outside the United States, it remains a difficult reimbursement market, with some countries awaiting OUTCOMES data. 
We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our interleukin 6 receptor inhibitor for rheumatoid arthritis, and have been granted a PDUFA date of October 30, 2016. 
We will be co-promoting sarilumab with Sanofi-Genzyme in the United States and are actively recruiting our field-based team. Co-promotion decisions for other countries will be made over time. We're excited about the potential U.S. launch for sarilumab. Given the central role of interleukin 6 in the inflammation contributed (sic) [attributed] to the signs and symptoms of rheumatoid arthritis and, more importantly, disabling joint destruction, we believe that IL-6 inhibitors should be used early following tumor necrosis factor or TNF inhibitor failure. 
Recently issued U.S. and European guidelines support the use of IL-6 inhibitor class in earlier lines of treatments, and this is particularly relevant for those patients who cannot take combination therapies with methotrexate. With multiple players competing in the anti-IL-6 marketplace, this should contribute to improved physician awareness and understanding of the inadequacy of TNF inhibitor cycling and the need for early IL-6 inhibitor treatment. Subcutaneously administered sarilumab has strong clinical data in terms of the improved signs and symptoms of rheumatoid arthritis and prevention of bone damage in methotrexate-inadequate responders. Similar improvements in the signs and symptoms of RA have been reported in TNF inhibitor-inadequate responder population. 
We continue to prepare for the potential U.S. launch of dupilumab, our IL-4 and 13 inhibitor, which we expect in 2017. There are approximately 1.6 million patients with inadequately controlled moderate to severe atopic dermatitis in the United States. We'll be co-promoting dupilumab in the United States. Co-promotion decisions for other countries will be made at a later date. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone who has joined us today. In the first quarter of 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2015 and non-GAAP net income of $293 million decreased 13% versus first",1222,"Thanks, Bob, and good morning to everyone who has joined us today. 
In the first quarter of 2016, non-GAAP net income per diluted share decreased 11% to $2.57 versus first quarter of 2015 and non-GAAP net income of $293 million decreased 13% versus first quarter of 2015.  Regeneron's 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and includes an adjustment for income taxes. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the first quarter of 2016 were $1.2 billion, which represented year-over-year growth of 38% over the first quarter of 2015. Net product sales were $784 million in the first quarter of 2016 compared to $545 million in the first quarter of 2015. EYLEA net product sales in the United States were $781 million in the first quarter of 2016 compared to $541 million in the first quarter of 2015, which represents an increase of 44%. Sequential quarter-over-quarter growth was an increase of 5%. 
During the first quarter 2016, EYLEA experienced a slight decrease in U.S. distributor inventory levels as compared to the fourth quarter 2015, but continues to be within our normal 1- to 2-week targeted range. As Len mentioned, we are updating our full year 2016 U.S. EYLEA guidance to be year-over-year growth of between 20% and 25% from the previously provided guidance of approximately 20% growth. 
Ex-U.S. EYLEA sales were $419 million in the first quarter of 2016 as compared to $292 million in the first quarter 2015, representing a 44% increase on a reported basis. On an operational basis or constant-currency basis, sales increased approximately 48%. Product revenue from ex-U.S. EYLEA sales is recorded by our collaborator, Bayer. In the first quarter of 2016, Regeneron recognized $146 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the first quarter of 2016 was $180 million. 
I'd also like to take this moment to highlight our recently expanded collaboration with Bayer, following our agreement to jointly develop the co-formulation of our antibody to ANG2 and EYLEA. In connection with this agreement, Bayer made a $50 million upfront payment to us, which was a receivable at March 31, 2016, and Regeneron has the potential to earn up to $80 million in development milestones. The $50 million upfront payment has been deferred and will be recognized over the estimated performance period. Similar to our EYLEA agreement, Regeneron has exclusive commercial rights within the U.S. and will retain all of the profits from any U.S. sales. 
Finally, a reminder for the EYLEA franchise. The second quarter of 2016 will be the final quarter in which we incur the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. In fact, I'm pleased to announce that this royalty will officially end in 2 more days.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $220 million for the first quarter of '16. The Sanofi collaboration revenue line primarily consists of reimbursements of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the first quarter of 2016, our share of the collaboration's losses in connection with commercialization with antibodies, primarily Praluent, was $99 million, which can be found in Table 4 of our earnings release. 
Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $13 million for the first quarter 2016. 
Turning now to expenses. Non-GAAP R&D expense was $392 million for the first quarter. Our unreimbursed R&D expense, which is calculated as total GAAP R&D expense less R&D reimbursements from our collaborators and R&D noncash share-based compensation expense, was $164 million for the first 3 months of 2016. Our press release includes all the information that's required to calculate unreimbursed non-GAAP R&D expense. For 2016, we'd like to reiterate our previously provided guidance for non-GAAP unreimbursed R&D to be in the range of $875 million to $950 million. 
Non-GAAP SG&A expense was $230 million for the first quarter 2016. We continue to expect non-GAAP SG&A expense in 2016 to be in the range of $925 million and $1 billion. 
Before I move on from our operating expenses, I'd like to take a moment to discuss the new guidance component we announced this morning, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs in connection with preparing to commercialize or commercializing, as applicable, Praluent, sarilumab and, effective in the first quarter of 2016, dupilumab. This is a line item found within Sanofi collaboration revenue and is referenced in Table 4 of our press release. Going forward, we believe that providing guidance for this number will help in modeling the Sanofi collaboration revenue line item. For the first quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $73 million, and we expect this expense in 2016 to be in the range of $320 million and $370 million. 
Turning now to our non-GAAP tax adjustment. Cash tax as a percentage of non-GAAP pretax net income for this quarter continues to be lower than our GAAP effective tax rate, primarily due to the tax impact of noncash share-based compensation. On a non-GAAP basis, cash tax as a percentage of non-GAAP pretax net income for the first quarter of 2016 was approximately 38%. 
For 2016, our guidance for cash tax as a percentage of non-GAAP pretax income remains at 35% to 45%. As previously reported, this includes a onetime tax of approximately $222 million related to the Sanofi immuno-oncology agreement. I'd also like to reiterate that the non-GAAP tax impact of the immuno-oncology upfront payment will be spread equally throughout 2016. 
Our capital expenditures for the first quarter of 2016 were $104 million. Given our latest review of capital expenditures, we are tightening and lowering our full year 2016 capital expenditures guidance to a range of $550 million to $625 million from $580 million to $680 million. These expenditures continue to build on our manufacturing expansions in 2015, which include expanding our facilities in Rensselaer, New York and Limerick, Ireland as well as the continued expansion of our Tarrytown, New York headquarters. 
We ended the first quarter of 2016 with cash and marketable securities of $1.4 billion. As we previously mentioned, we have been opportunistically entering into agreements to reduce the number of our outstanding warrants that we issued in 2011 in connection with our convertible debt.  In the first quarter of 2016, we paid $242 million to reduce these outstanding warrants. 
Before I conclude my remarks, I would briefly like to highlight certain financial components of the recent collaboration with Intellia Therapeutics. The April 2016 agreement grants Regeneron access to Intellia's CRISPR technology platform as well as the right to discover and develop up to 10 targets on an exclusive basis over the course of the 6-year agreement. In return, we paid a $75 million upfront payment to Intellia, which we anticipate recording as R&D expense in the second quarter of 2016, but plan to exclude from non-GAAP net income. The agreement also requires Regeneron to purchase up to $50 million of Intellia's shares, contingent upon Intellia consummating its initial public offering. 
With that, I'd like to turn the call back to Michael."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period.",16,"Thanks, Bob. Operator, at this time, we will open up the call for our Q&A period."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners.",13,"[Operator Instructions] And our first question is from Geoffrey Porges from Leerink Partners."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","The 10-Q being filed today is very helpful with all the detail. I suppose, a couple of questions. George, first on dupilumab. Now that you have the first Phase III readout, what incrementally have you learned from that in terms of the profile of dupilumab",130,"The 10-Q being filed today is very helpful with all the detail. I suppose, a couple of questions. George, first on dupilumab. Now that you have the first Phase III readout, what incrementally have you learned from that in terms of the profile of dupilumab? And how does that alter what you might focus on and potentially invest in for that molecule in the future? And then secondly, just on Medicare Part B, you alluded to that and called it out in your risk and in the Q. What are you learning in the comment period? And will you be submitting comments? Or are you aware of other comments? And do you think there's any chance that this is going to be modified or altered in schedule or scope?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, this is George. I'll take the dupilumab question. I guess the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy and the important benefit to patients in",249,"Well, this is George. I'll take the dupilumab question. I guess the most important thing that we learned from the 2 Phase III studies in atopic dermatitis was, number one, that we confirmed the impressive efficacy and the important benefit to patients in essentially every single efficacy readout that we explored. So obviously, that's very gratifying and comforting when one actually sees data that is as promising as your earlier data and suggests it can really make an important difference to moderate to severe patients who really need new therapies to attack their disease. In addition, the safety profile was also very comforting. And we reported extensively and it really does suggest that it's going to have a very important benefit/risk profile for patients. I think that, basically, for atopic dermatitis, it really means that it's all greenlights and all speed ahead and that we're really excited that we could be really bringing forward, as the FDA has designated, a breakthrough therapy for these patients' need. As you know, we also have a pivotal study in asthma, and that's already been read out. And we're in the midst of our first breakthrough, which is now our second confirmatory study in that indication as well. So dupilumab is a very, very exciting program. And as I already told you about today, I told you that in terms of the atopic dermatitis population, we're also moving to the pediatric population there as well, which is also an important unmet need area."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","In terms of the Part B, we fully understand that health care costs need to be appropriately controlled in this country. However, the approach that has been proposed by Medicare Part B would limit options for physicians and patients to give appropriate the",158,"In terms of the Part B, we fully understand that health care costs need to be appropriately controlled in this country. However, the approach that has been proposed by Medicare Part B would limit options for physicians and patients to give appropriate therapies to patients who need them. For example, in the case of the retinal space, you could lead to physicians being required simply by the economics that are in place to force them to use an off-label repackaged bevacizumab, which, at least in the Protocol 3 -- T trial, was shown in DME not to be as effective as the other therapies. They could be forced to use this for economic reasons. We see that a number of manufacturers as well as a number of congressmen and patient advocacy groups recognize that you have to preserve physician choice, and so there will be a number of complaints and letters going into the Congress, including our own."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I mean, just to add, there are literally hundreds of congressmen who have said that this should not be done. There are others who've said that the unintended consequences that we're concerned about must be managed, the retinal groups, the ophthalmolo",97,"Yes. I mean, just to add, there are literally hundreds of congressmen who have said that this should not be done. There are others who've said that the unintended consequences that we're concerned about must be managed, the retinal groups, the ophthalmology groups and, not to mention, all the other interested parties, such as cancer and what have you. So I think many observers, which we're not experts on -- but many observers in Washington would suggest that this seems unlikely. But we'll have -- we are certainly going to do our best on this as well."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","[Operator Instructions]",2,"[Operator Instructions]"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our next question is from Chris Raymond from Raymond James.",11,"And our next question is from Chris Raymond from Raymond James."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just one question here. So just kind of on the PD-1, kind of sort of struck by the news that this cutaneous squamous cell trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more co",104,"So just one question here. So just kind of on the PD-1, kind of sort of struck by the news that this cutaneous squamous cell trial could be pivotal. I know Sanofi kind of broke that news last week. But I was wondering if you could provide a little more color on where those trial fits in with the overall development plan. Just looking at clinicaltrials.gov, there's not a ton of detail. And obviously, there's a lot of breadth of labeling potential with that type of molecule. If you could maybe sort of talk about where you plan to take this, that'd be great."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we are implementing a highly integrated and very comprehensive effort in immunotherapy. And this is obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to",134,"Well, we are implementing a highly integrated and very comprehensive effort in immunotherapy. And this is obviously a very competitive area, and I think that there's a lot of room for people to make inroads here, provide new approaches and new benefits to patients and really make a difference in certain disease settings. And how we're going to do that and how we hope to bring the best results to patients with the best combination is something that, at this point, I think -- our thinking behind -- in this very competitive space is rather keep largely to ourselves. So sorry for not informing you more, but we just think that we have a very robust and highly integrated and comprehensive effort here, and we intend to hopefully deliver important new approaches to patients."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Terence Flynn from Goldman Sachs.",10,"Our next question is from Terence Flynn from Goldman Sachs."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just wondering -- for dupi, I know it's a little bit early, but as we just think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent-type launch or more like EYLEA? And if you won't answer",71,"So just wondering -- for dupi, I know it's a little bit early, but as we just think about the launch trajectory here, maybe you can just give us your perspective. Is this more likely to be a Praluent-type launch or more like EYLEA? And if you won't answer that directly, maybe you can just walk us through some of the factors we should consider as we think about the ramp."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. It's Len. Since we were all -- both you guys and us were spot on, on EYLEA and Praluent, I don't know why we wouldn't take a shot at dupilumab. I think the fact is, obviously, we can't answer that directly, Terence. And since we've been -- we and al",338,"Sure. It's Len. Since we were all -- both you guys and us were spot on, on EYLEA and Praluent, I don't know why we wouldn't take a shot at dupilumab. I think the fact is, obviously, we can't answer that directly, Terence. And since we've been -- we and all of us, everybody has been wrong multiple times, these things unfold as they unfold. The factors to consider obviously is that you're already obviously seeing the PBMs taking a notice of this. I saw this in somebody's report, that this is the next big class that they're worried about. There are a lot of patients out there that might fit our label, assuming we get the label. But I'm sure they're going to be -- there's going to be utilization management, make sure they've tried the topical steroids or whatever, that they really have the right diagnosis, et cetera, et cetera. Now whether there will be ""warehousing of patients"", people lining up to get it, it's just really impossible for us to tell. But I would suspect that this would be one of those launches that will be patient-driven. That -- as people get on the drug, if the results in the real world or anywhere is close to the results we've seen in our Phase III trials so far, I'm sure that, that patient drive will be tremendous because this is a terrible disease that people have been suffering with for decades. Adults now have it without anything at all new to really help them and make a difference. And if you look at -- whether you measure this by quality-of-life metrics, the increased risk of suicide, just the terrible burden that this puts on patients, we're optimistic that this drug can make a difference for them. So we're hopeful for a good launch. But how that -- the actual ramp and whether it takes us a while to get it going and what the coverage looks like and all that, just too early to tell."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Adnan Butt from RBC Capital Markets.",11,"Our next question is from Adnan Butt from RBC Capital Markets."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Arshad [ph] on for Adnan. Could you please put the fasinumab safety data kind of in the context, given that the FDA seems to have already been focused on safety in general?",34,"This is Arshad [ph] on for Adnan. Could you please put the fasinumab safety data kind of in the context, given that the FDA seems to have already been focused on safety in general?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Well, maybe I'll make a brief comment. And if George has anything to add, obviously, he's welcome. The -- our feeling is that -- as George said in his talk, is that we did something which we think was pretty important, which is we did an extensive an",259,"Yes. Well, maybe I'll make a brief comment. And if George has anything to add, obviously, he's welcome. The -- our feeling is that -- as George said in his talk, is that we did something which we think was pretty important, which is we did an extensive and detailed screening of patients with x-rays and MRIs before they were ever exposed to drug. And that demonstrated that some of these things that people were concerned about might be somewhat induced by drugs, were really fairly prevalent in the population, whether they be insufficiency fractures or whether they be osteonecrosis and so on. So I think that, that was important. And I do think that the FDA has come around to thinking that this has to be looked at carefully, and we -- and that's what we're doing. And the right patients have to be studied, and that's also what we're doing. They also have had concerns about whether or not any one of these drugs individually or as a class could have effect on sympathetic nerves and sympathetic nervous system function. We also looked at that pretty well, and we'll have more to tell you about that in upcoming meetings. But we didn't see any evidence at all so that, so far, things look reasonable. But as -- I think as George said, it's a small study, and we're underpowered to pick up very small increases in some of these things. And that's why we're going to study thousands and thousands of patients in our Phase III program."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. And to add to that, I think that the -- one of the biggest underlying fears for this class, certainly by outside people but also by ourselves, was that the very small increase in certain arthropathy events, certain joint pathologies that was seen, pa",352,"Yes. And to add to that, I think that the -- one of the biggest underlying fears for this class, certainly by outside people but also by ourselves, was that the very small increase in certain arthropathy events, certain joint pathologies that was seen, particularly in combination with NSAIDs but also a small increase even in monotherapy might actually be reflecting a much bigger, somewhat invisible problem that there was a bigger, destructive process that would then be seen over longer periods in time and so forth. And this is why we did this -- as Len said, this extensive imaging of both the index joints but also non-index joints to see whether, overall, the skeleton was really changing. And as we've already said, the thing that was very gratifying was that, unfortunately, for these patients suffering from this important problem, there is already significant skeletal pathology at baseline. These patients have these so-called subchondral insufficiency fractures, and you could even see undiagnosed osteonecrosis in these patients and so forth. And these events, both in the index and the non-index joints, were not dramatically increased by treating with NGF. And one fear, for example, was that these asymptomatic subchondral insufficiency fractures may be happening much more frequently with drug and then eventually leading to much higher incidences of events down the line. And so it's very comforting not to see this. That said, there remain -- as with any drug and, certainly, with a drug this active, there will continue to be risks associated with treatment. But one has to balance that with all the benefits that could be provided. Pain is a very serious problem for a lot of people, especially people suffering from osteoarthritis. And the options, obviously, as you know, are quite limiting with no new mechanism-of-action drugs added to this field for decades. And so the possibility and the opportunity that a new mechanism-of-action class that might have different profile and also different risk profile as compared to, for example, opiates and NSAIDs and other drugs with serious risks, we think can offer an important option for patients."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","This is Michael. I just want to make sure we -- I add it because when talking about pain, you really have to keep into context of really what is an epidemic in the United States in terms of drug -- opioid abuse and overdose, with quadrupling in the number",111,"This is Michael. I just want to make sure we -- I add it because when talking about pain, you really have to keep into context of really what is an epidemic in the United States in terms of drug -- opioid abuse and overdose, with quadrupling in the number opioid death in the past number of years as well as -- from the CDC website. Nearly 0.5 million people died from drug overdoses from 2000 to 2014. Almost 80 Americans die every day from an opioid overdose. So I just think that could keep into context that pain remain -- having new pain medicines can really -- is really important."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Yin Huang from Bank of America.",11,"Our next question is from Yin Huang from Bank of America."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just first, on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called thera",109,"Just first, on the CMS proposal again. I think you guys mentioned in DME, you do have superiority against some of the other medications. But in AMD, I was wondering if you guys can provide your thoughts on whether it could be classified as so-called therapeutically similar class, and therefore, it should be subject to a reference pricing in the second phase of that demo. And then also on the ODYSSEY OUTCOMES trial, I know the trial is powered -- 90% power to show 15% CV risk reduction. Maybe you guys can provide thoughts on whether you think the payers would be excited about that 15% CV risk reduction."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So Ying, which question do you want to answer because Michael's holding up a sign that says 1 question. Even though he loves you, he said, ""Which one does he want?""",31,"So Ying, which question do you want to answer because Michael's holding up a sign that says 1 question. Even though he loves you, he said, ""Which one does he want?"""
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Len, you're the boss.",4,"Len, you're the boss."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Not true. Which question, Ying?",5,"Not true. Which question, Ying?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","All right. Maybe second. It's probably more important from my perspective.",11,"All right. Maybe second. It's probably more important from my perspective."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, I think that the OUTCOMES data, as we saw with ezetimibe it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the dataset, et cetera, et cetera. Certainly, we power",147,"Okay. Well, I think that the OUTCOMES data, as we saw with ezetimibe it's not simply a matter of statistical significance. I think what people will be looking for is the robustness and the quality of the dataset, et cetera, et cetera. Certainly, we power the study based on expert input of where they thought that would be -- if we saw the results, that would be a meaningful result for patients. But of course, it's not just one number, not just statistical significance. You want to see how all the dataset looks like. And I think somebody said, well, ezetimibe has statistical significance. But if you blink, you could miss it. And we tried to design a study and set the parameters such that if we saw the result, we could feel confident about it, that we were making a difference in these outcomes to patients."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Ying, I can't leave the EYLEA one hanging out there, I'm sorry. If you remember back to the VIEW 1 and VIEW 2 studies, we actually designed studies that compared ourselves to what was the standard-of-care branded agent, which was ranibizumab monthly, and",172,"Ying, I can't leave the EYLEA one hanging out there, I'm sorry. If you remember back to the VIEW 1 and VIEW 2 studies, we actually designed studies that compared ourselves to what was the standard-of-care branded agent, which was ranibizumab monthly, and we studied EYLEA, both -- dose, both monthly as well as every 8 weeks. And what we saw is very similar results with the EYLEA every 8-week dosing to the Lucentis every 4-week dosing. This is a major advantage to elderly patients who can't get into the physician's office on a regular basis. And so they are not therapeutically equivalent. EYLEA has a longer durability of effect. I would also point out, there are data in a subset of patients in the VIEW studies that indicates that there are patients who are more refractory to anti-VEGF therapy, especially those who've received prior anti-VEGF therapies who may need more anti-VEGF treatment. And what we're seeing in those patients, we're able to dry them up better with EYLEA than with Lucentis."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And George also. I also have to make a few comments here. And I think, really, Bob touched on an important point, that our drug showed, compared to the, at the time, optimum standard of care, that doubling the interval could produce at least as good resul",445,"And George also. I also have to make a few comments here. And I think, really, Bob touched on an important point, that our drug showed, compared to the, at the time, optimum standard of care, that doubling the interval could produce at least as good results from -- in terms of visual acuity but also even better results in terms of controlling vascular leak and retinal slowing and so forth. And I think that we all have to really consider that maybe -- and I hate to say it because some people are going to say, ""Hey, don't challenge the physicians here."" But I think the physicians here, and we understand the limitations of the real world and practice, are doing a huge disservice to patients, in terms of the systematic under-treatment that is probably occurring in this field. There's an enormous drive to try to get patients less trips to the office, less injections. And you've probably seen the release of recent data with long 4- or 5-year follow-on. And after you take the patients over the more controlled phases of the study, where they're getting, in general, in most studies, monthly treatment, a very carefully monitored treatment, they essentially lose almost all their vision gain over these later years of 4- and 5-year follow-ups. And we believe that the data and the evidence suggest that this is really due to systematic under-treatment, patients getting less and less treatment. And particularly in that setting, if you want to deliver the best care to patients, you should be delivering the best agent that has the longest duration of action, and we think that the only agent that's really demonstrated that convincingly is EYLEA. And so I think to save patients' visions -- you saw the long-term trials. Patients are losing visions. Physicians are not doing the right things by their patients. They're systematically under-treating. And particularly in those setting, they should be getting the best drug that protects patients against this vision loss. And it would be a disservice if, in fact, incentives and so forth are driven to the use of an inferior agent, which will cause patients -- think about it. You're a patient who can't drive, you're a patient who can't read, you're now given a drug. All of a sudden, you gain 2, 3 lines of vision. That changes the world literally for you. Okay. You could do things you can't do before. And now we developed a system that allows you to lose that. I think that we have to think about how we want to practice medicine in this country if we create a situation that allows that."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think the physicians, George, are right there with you. And it'd be hard for me to imagine that once the physicians heard on this subject that Avastin could -- an off-label, inferior product based on the government's study could be set to standard.",45,"Yes. I think the physicians, George, are right there with you. And it'd be hard for me to imagine that once the physicians heard on this subject that Avastin could -- an off-label, inferior product based on the government's study could be set to standard."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Robyn Karnauskas from Citigroup.",9,"Our next question is from Robyn Karnauskas from Citigroup."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Congratulations on all the innovation. I feel like you're one of the few companies where there's so much going on, on the call and you provide clarity. I guess I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does",133,"Congratulations on all the innovation. I feel like you're one of the few companies where there's so much going on, on the call and you provide clarity. I guess I'm going to go with the sarilumab and ask a question about the opportunity because Sanofi does highlight this a lot. And I feel like it's -- those of us on The Street are more skeptical about the opportunity. Help us understand how you -- what your view is of sarilumab and how you think about this. It's a competitive space. There are stuff coming up behind it from AbbVie. How are you thinking about the strength of that data? And do you have any understanding of the strategy and how you could take share from the current market or expand the current market?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build a company for the last 3 decades that is driven by -- truly driven by science and innovation, so we appreciate you taking note of that. Bob, can you commen",63,"Sure. Robyn, thanks for your comments about innovation. Obviously, George and I have tried to build a company for the last 3 decades that is driven by -- truly driven by science and innovation, so we appreciate you taking note of that. Bob, can you comment without giving away all of our intricate strategy on what the opportunity for our assets might be?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Robyn, as I pointed out earlier, I think that when Genentech launched Actemra into the U.S. marketplace, it was very much a market dominated by growing TNF inhibitors, and they were a single company trying to educate on the role of IL-6 in rheumatoid arth",187,"Robyn, as I pointed out earlier, I think that when Genentech launched Actemra into the U.S. marketplace, it was very much a market dominated by growing TNF inhibitors, and they were a single company trying to educate on the role of IL-6 in rheumatoid arthritis and the potential benefit of using an IL-6 inhibitor earlier. It is always more beneficial -- we've seen this, for example, in the statin class, where as more and more statins became available, they grew the market. We believe that this is the opportunity for this class, that we can educate physicians more, one, as I said earlier, on the central role of IL-6 in both the signs and symptoms of RA but as well as in joint destruction, which we feel is very important. Physicians need to understand they shouldn't stay with a TNF inhibitor, which, over time, each additional TNF inhibitor does not deliver the efficacy that they received with the first TNF inhibitor. So there's a benefit of moving to a new class, and IL-6 really does have a central role both in symptoms as well as bone destruction."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I also -- just to add that there's something about the -- some historical accidents have occurred here in the order that drugs came along and having to do with pricing and with methotrexate being sort of the main stay. It's a very cheap drug. It's effecti",163,"I also -- just to add that there's something about the -- some historical accidents have occurred here in the order that drugs came along and having to do with pricing and with methotrexate being sort of the main stay. It's a very cheap drug. It's effective. But it's  not the most  innocuous drug in the world from its side effects and what have you. And there are many people, particularly women, who don't  like being on the product, and there seems to be movement towards monotherapy. And remember, methotrexate -- some have argued that for some drugs methotrexate provides the immunosuppression for the biologics so that any immune-related, if you will, blockade of effect doesn't appear as quickly. Suffice it to say, we -- and maybe George can comment on that more. But I can say that when we look head to head against the market leader, AbbVie, in the monotherapy setting, you've seen our data, we had a superior result. So..."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","But I also do -- just to finish the story. Sarilumab is not a me-too drug. I don't want to do cross-comparison trial data right now. But I think if you look at the prescribing information for subcutaneous Actemra and you look at the results we reported wi",82,"But I also do -- just to finish the story. Sarilumab is not a me-too drug. I don't want to do cross-comparison trial data right now. But I think if you look at the prescribing information for subcutaneous Actemra and you look at the results we reported with our product, we are very encouraged about the product profile that our product, which had higher binding affinity to IL-6, is going to offer in the marketplace. Maybe George wants to comment on that."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's important to just highlight a few things because, once again, it all comes down to the patients and doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense",298,"Yes. I think it's important to just highlight a few things because, once again, it all comes down to the patients and doing the best by the patients. And I think as Bob and Len already mentioned, if you look at the signs, it doesn't necessarily make sense to start all patients, particularly patients in monotherapy settings, with the TNF. And that may be a historical accident. It also doesn't make sense to just continue patients cycling on TNF if there is an alternative that can deliver them better symptomatic relief. And so we think that there's enormous opportunity for this class. And importantly, in this class, and as Bob said, the most -- one of the most important things that I think that patients and physicians are concerned about is irreversible bone loss. That's one thing that you can't get back, and that's one thing that's looked at in this field. And as you know, Actemra is now growing through a subcutaneous formulation. And if you look in the label, there's less -- according to the subcutaneous formulation that's used there in terms of the inhibition of the irreversible bone loss, there's less than 50% inhibition by the subcutaneous formulation in terms of Actemra in terms of the irreversible bone loss. If you look at our study, we offer 2 doses. And if they both get approved, our higher subcutaneous dose gives greater than 90% inhibition of irreversible bone loss. So as Bob said, these are not identical agents. This is not a me-too. There's important differences, and there's an important opportunity to do better by patients in terms of the monotherapy setting and in terms of not just cycling through drugs that maybe aren't working for the patients and putting them on a different mechanism-of-action drug."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I'll also say that there have been, let me call it, commercial games that have been played out there in that -- in negotiations that have gone on with the PBMs, where people have used certain multiple indications as a way to drive use in other indications",170,"I'll also say that there have been, let me call it, commercial games that have been played out there in that -- in negotiations that have gone on with the PBMs, where people have used certain multiple indications as a way to drive use in other indications from what we can tell. And I think the PBMs are sort of wising up to that and moving to indication-specific pricing and negotiations. And so we actually feel that we might be entering the market at a reasonably good time, where, with a lot of dynamics going on and a good product, you can make inroads. Now I don't think this is going to be an easy road, and I wouldn't be -- I don't think you can just assume that we're going to jump in and grab huge market share right off the bat. But I think it's -- we can build this into a significant opportunity over time. It's more of going to be like a slow and steady."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question is from Alethia Young from Crdit  Suisse.",10,"Our next question is from Alethia Young from Crdit  Suisse."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to the Praluent trends that you said in your script. I guess, you said that 50% of new -- you finally got 50% of the new scripts. Can you guys kind of talk about what behavior might be driving kind of that 50%? Is it something that you're",61,"Just going back to the Praluent trends that you said in your script. I guess, you said that 50% of new -- you finally got 50% of the new scripts. Can you guys kind of talk about what behavior might be driving kind of that 50%? Is it something that you're kind of adjusting or changing that's resounding in the profile?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think it's hard to know for sure, and we only have another minute here so I don't want to get into great detail. But one thing that is important is that there's new coverage that's coming to play, particularly in the Medicare space, which was reall",208,"Yes. I think it's hard to know for sure, and we only have another minute here so I don't want to get into great detail. But one thing that is important is that there's new coverage that's coming to play, particularly in the Medicare space, which was really only recently coming on, where in those plans that chose -- which was most of them, a single agent as the priority drug, we were, I think, selected about 90% of the time. So I think that there's some new coverage, new utilization management. And obviously, we're working hard at this. But I don't think you can consider 1 week a trend, whether it's one -- going one direction. It's just a data point. But right now, the market seems to be split roughly, more or less, equally based on that data point. How that goes over time, obviously, that's what the competitive marketplace is all about. But I think our most important effort right now has to be on making sure that the right patients get access to drugs, and that's really where both companies are focused. It's an important thing for the class. The patients who need drug have to get an opportunity to have access to it."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","And our last question is from Matthew Harrison from Morgan Stanley.",11,"And our last question is from Matthew Harrison from Morgan Stanley."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I just had 2 related Praluent questions. You said that 2 payers have loosened their criteria. I'm wondering if you can just be more specific about that, who they were and exactly what they loosened. And then you were talking about an improvement in the nu",73,"I just had 2 related Praluent questions. You said that 2 payers have loosened their criteria. I'm wondering if you can just be more specific about that, who they were and exactly what they loosened. And then you were talking about an improvement in the number of Rxs that were filled. Is that just more people getting through the utilization management criteria? Could you just be more specific about that comment as well?"
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. Our contracts with the payers don't allow us to disclose the specific ones who've changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of Zetia after maximally",189,"Sure. Our contracts with the payers don't allow us to disclose the specific ones who've changed their utilization management criteria. But what I can say, as I did earlier, what they did is removed a trial period of 12-plus weeks of Zetia after maximally tolerated statin therapy from their the utilization management criteria. That was setting up a delay in access to PCSK9 inhibition. The physicians were having to put them on Zetia and then wait, and it was causing a real backlog for the doctors. So that has been removed by 2 of the payers. In terms of the improvement of the number of people going through the hub, I think what I could say is, one, the -- as Len said, payers have come onboard now, and so especially Medicare patients now are getting access to therapy. I think the other thing is that the physicians as well as the specialty pharmacies are better understanding how to make the prescription process better. That's not -- it's not easy right now. We continue to work on improving it, but at least it has gotten better for some patients."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So just one last comment from -- it's Len. So in our effort to answer all your questions, what we're trying to do is give you some insight into our thinking, like why we went forward with something. We're not trying to make cross-trial comparisons per se.",173,"So just one last comment from -- it's Len. So in our effort to answer all your questions, what we're trying to do is give you some insight into our thinking, like why we went forward with something. We're not trying to make cross-trial comparisons per se. We're trying to give you an idea of why we went forward and what we saw, how we felt we were differentiated. What we can say out in the marketplace obviously will be limited based on what we actually get in our various labels that are pending. 
And with that, I would just say that we're pleased that the innovation machine continues to turn and produce lots of exciting things that we hope to update you in the scientific literature and in presentations that are upcoming. Lots of things that we -- George did not get a chance to talk about that are exciting. So we appreciate your interest, and we hope to continue to be able to update you over time. Thank you very much."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks.",1,"Thanks."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you.",2,"Thank you."
33715,331187536,974531,"Regeneron Pharmaceuticals, Inc., Q1 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect.",15,"Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded. I would now turn the call",50,"Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded. I would now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this will webcast will be available in our website under Events and presentation for 30 days. Joining me on the call today are Dr. Leo",313,"Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this will webcast will be available in our website under Events and presentation for 30 days. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay,  Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. 
After our prepared remarks, we'll open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, intellectual property and competition.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com.
Once or call concludes, Bob Landry and the IR team will be available to answer further questions. With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to giv",538,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to give you some broader perspective on Regeneron and our business. Regeneron continues to advance its mission to bring important new medicines to patients in need. EYLEA is our drug used to treating a number of potentially blinding diseases. And with million's of injections administered each year, it is one of our most important approved products and continuous grow well globally. EYLEA is at an annual global net sales run rate that exceeds $5 billion. This has been driven both by the approval of EYLEA in new indications as well as new data that have further increased the confidence of physicians in this product. Thanks to our long-standing belief and investment in science and technology, we are now in the midst of a new product cycle, which has the potential to impact multiple disease settings. This investment in science has resulted in Praluent, our PCSK9 antibody, for lowering LDL cholesterol, an additional potential near-term approvals that could address rheumatoid arthritis and atopic dermatitis. Our late-stage pipeline also includes program and asthma, pain, respiratory and virus and immunotherapy of cancer. Our area pipeline opportunities continue to grow with a total of 15 product candidates currently in clinical development, including 7 that we are developing independently, with several more expected to enter the clinic in the near-term, making for pipeline that can address potential opportunities ranging from there or for diseases such as fiber , [indiscernible] or FOP, to emerging affecting diseases epidemic, such as Zika. George will provide specific details and some of these programs later in this call. All of these opportunities are the results of investments we made in science and technology over the last 20 years, yielding a pipeline that is entirely home-grown. Our commitment to the long-term is unwavering as we invest in the next generation of technologies to support our feature pipeline. For example, our Regeneron Genetics Center and our investment technologies with companies in the areas of gene-editing and cell therapies, such us which is synergistic with our existing capabilities. I should also mention that we recognize that we operate in a rapidly changing environment that poses new challenges to the commercialization of our products, and we continue to try and develop innovative solutions to address these issues. Lastly, we believe it's absolutely essential to attract the best and brightest minds to scientific careers and to elevate the place of science in our society. Therefore, we were thrilled to announce in May that Regeneron was selected as new sponsors for these new science talent search. Regeneron is only the third sponsor in this renowned 75-year history of this high school science talent competition, which was previously sponsored by Intel. And before that, by Westinghouse. George and I are both alumni of the Science Talent Search and we believe the program plays a vital role encouraging national encouraging talented young people to pursue a path in science and engineering. With that introduction, let me turn the call over to George."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline. In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 blo",1493,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline. 
In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 blocker in patients with uncontrolled moderate to severe atopic dermatitis, which is a chronic inflammatory skin disease. Dupilumab is the first systemic therapy to show positive Phase II results in this indications. 
On our last earnings call, we talked about the positive data from the first 2 Phase III studies, Solo-1 and Solo-2, which studied dupilumab as a monotherapy. 
In June, we just recently reported the results from the third study, LIBERTY AD CHRONOS, which was a long-term study that invest dupilumab in combination with topical corticosteroids, which is currently the standard of care in the United States for the treatment of this difficult disease. Overall, the efficacy observed in the CHRONOS study was very consistent with the previously reported positive Phase III Solo-1 and Solo-2 studies of dupilumab in the monotherapy setting. When the primary endpoint of the CHRONOS study was assessed at 16 weeks, the studies continued until 52 weeks and efficacy was sustained in both the dupilumab 300-milligram weekly as well as the 300-milligram every other week dose group through this 1 year mark. 
At 16 weeks, about 40% of the patients in both dupilumab dose groups achieved clear or almost clear skin status as measured by the investigator's global assessment score compared to about 12% of the patients in the topical-steroid-only on. Nearly 2/3 of the patients receiving dupilumab achieved a 75% improvement in the average improvement in the overall skin score as excess by the eczema area severe index easy score, compared to about 23% of patients in the topical-steroid-only on. 
This was the first long-term Phase III study to show that dupilumab in combination with topical steroids was superior to topical steroids alone and provided sustained efficacy and significantly improve measures of overall disease severity, skin clearing, itching and quality of life through 1 year of treatment.
The overall rate of adverse events and serious adverse events was comparable between the group's treated with dupilumab in combination with topical steroid and the topical steroids alone. Serious and/or severe infections were numerically higher in the topical steroid alone. Adverse events that were noted to have a higher rate with sarilumab treatment included injection site reactions, which was seen in 20% of the patients on the dupilumab weekly arm, 16% of the patients in dupilumab every 2-week arm and 9% of the patients with placebo plus topical steroid alone arm. And conjunctivitis, which was observed in 19% of the patients with dupilumab weekly arm, 13% of patients in the dupilumab every other week arm and 8% of patients in the topical steroid alone arm. About 22% of the patients in the placebo group, 23% of the patients in the dupilumab weekly group and 28% of the dupilumab every other weekly group had a reported history of allergic conjunctivitis coming into the study.
These 1 year results from the CHRONOS study further suggest that dupilumab impact the activation of the interleukin-4 13 pathway and result in significant efficacy without the side effects associated with immuno suppressing therapies. 
In this regard, and very importantly, we have not observed an increasing overall infections or serious infections in our atopic dermatitis program to date. The U.S. BLA submission has been completed, and we look forward to working with the FDA to bringing this important breakthrough therapy to patients as soon as possible. 
We were also developing dupilumab in other allergic diseases such as asthma, nasal polyps, esophagitis. As a reminder, our first pivotal study in asthma show that 2 doses of dupilumab, 200 milligram and 300 milligram every other week, in combination with inhaled steroids and long-acting beta agonist, demonstrated a statistically significant 12% to 15% improvement in lung function as measured by FEV1 over placebo at week 12, at a 64% to 75% reduction in the annualized rate of severe asthma exacerbations over placebo. The most common adverse event with injection site reactions, which are more frequent and dupilumab dose groups at 13% to 25% compared to 12% in the placebo group. The of infections was bound across treatment groups at 42% to 45% of dupilumab arms and 46% in the placebo arm as with the serious adverse events, which were seen in 3% to 7% of the dupilumab groups and 5% in the placebo group. We expect our confirmatory 1 year Phase III study of dupilumab in this indication of complete enrollment in the third quarter of 2016. 
As a reminder, we are the only late-stage biologic that targets both IL-4 and IL-13, and recent competitor developments in the late-stage asthma space are consistent with our preclinical data and our hypothesis that it is important to block both of these interleukins.
Turning to Praluent. Our 18,000 patient ODYSSEY OUTCOMES study is ongoing. As we previously disclosed data monitoring committee for this study completed the first interim analysis with 50% of the total had accrued based on unblinded study data. In addition to reviewing the safety study, the DMC performed the fertility assessment recommended for the study continues with no changes. A second interim analysis for fertility as well as for overall efficacy when 75% of the targeted primary incidents occurred is expected later this year. As Len mentioned, we also have 3 other late-stage programs: Sarilumab, our interleukin-6 receptor antibody for rheumatoid arthritis, where we expect FDA action by October 30; fasinumab, our NGF antibody for pain associated with osteoarthritis; and the Regeneron 2222, for respiratory virus or RSV.
Turning now to our earlier-stage pipeline. In May, reported positive interim proof-of-concept data from a Phase II study of , and the antibody angiopoietin-PTL3 in patients with homozygous form of familial hypercholesterolemia. These patients continue to have a major unmet need as they are typically not as responsive to standard lipid-lowering therapy such as states or even PCSK9 inhibition. And some of the other treatment options available are limited by the accompanying safety and tolerability concerns. Although these data were from a small number of patients, we're encouraged by the additional 55% reduction in LDL cholesterol levels at week 4 on top of standard of care compared to baseline.
In this study, alirocumab was generally well tolerated with no adverse event leading to discontinuation. The most common drug-related adverse events were injections site reactions, which were mild in severity. 
Our Phase II study of EYLEA in a co-formulated combination with rinucumab, GDF8 receptor antibody and what age Mac other the generation or wet AMD, which has been granted Fast Track designation, is fully enrolled and we expect top line data from the study in the fourth quarter of 2016. This is a 3-arm, 2-stage study with patients randomized to receive 1 of 3 dosing regiments: EYLEA alone; EYLEA in combination with low-dose PDGF block antibody; or EYLEA in combination with high-dose PDGF blocking antibody. Our primary efficacy endpoint of the first stage of this study is the mean change in visual acuity at week 12 from baseline. The second stage of this study is designed to confirm and extend these findings from the first stage of the study. Our Phase II combination studies of EYLEA in a co-formulated combination with nesvacumab, our antibody to angiopoietin-2 and AMD and DME continue to enroll patients. We are very excited by our earlier-stage pipeline in immuno-oncology, where both our PD-1 antibody and our CD20 by CD3 bispecific antibody have demonstrated promising activity in early clinical trials. A potential pivotal study with our PD-1 antibody in squamous cell carcinoma, continues to enroll patients, and we hope to be in that additional accommodations over the next 6 to 12 months. We have also expanded our capability in the area of precision immunotherapy with our recently announced collaboration with Adicet, which will allow us to discover and develop engineered next-generation immuno cell therapies. This collaboration takes advantage over our unique VelocImmune and VelociNext technologies that will allow us to use cell-based therapies to target tumor cells. 
We also recently initiated Phase I study in healthy volunteers of Regeneron 2477, an active antibody being treatment of viral dysplasia, or FLP, and other musculoskeletal disorders. We remain committed to using our technologies and approaches to help address emerging infectious diseases such as Ebola, MERS and Zika. For Zika, we have identified several fully human monoclonal antibody candidates that were able to potentially block the virus -- to potently block the virus from infecting cells in the future. An early date these antibodies are protected in the animal model. We're now in the process of scaling up for human trials. We also recently initiated our first and human study in healthy volunteers in our Ebola program, which has been granted orphan drug designation by the FDA. With that, let me turn the call over to Bob Terifay."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and hello, everyone. We're pleased with the sales growth up EYLEA or aflibercept injection, both in the United States and x U.S. in the first half of 2016. We've made progress in improving access in reimbursement for Praluent, or aliroc",805,"Thank you, George, and hello, everyone. We're pleased with the sales growth up EYLEA or aflibercept injection, both in the United States and x U.S. in the first half of 2016. We've made progress in improving access in reimbursement for Praluent, or alirocumab, among U.S. payers. In addition, the European and Japanese launches for Praluent continue to progress. And we are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next year. 
Starting with EYLEA. Second quarter U.S. net sales grew 27% year-over-year. Net U.S. EYLEA sales in the second quarter were $831 million. Net  x U.S. EYLEA sales in the second quarter were $486 million, which represents 44% growth year-over-year on a reported basis. We continue to have a strong position in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market in terms of injections as reported by 203 retinal specialists in our quarterly market research survey. According to our survey results, in the overall anti-VEGF market, EYLEA has a 37% share of injections as compared to 19% for ranibizumab and 44% for off-label repackaged bevacizumab. On the other hand, with our growing market share, our expenses to support reimbursement activities, including patient support services and reimbursement systems have also increased, impacting both our gross-to-net ratio as well as our profit margin. I should note that there are currently a series of proposals for the -- from the centers for Medicare and Medicaid services regarding physician reimbursement for physician administered Medicare Part B  by inbuilt drugs, which leads to positions favoring the use of bevacizumab or large breasted, ranibizumab due to the provision of increased directive physician financial from the manufacturer and group purchasing organization. The impact of any changes is difficult to predict. Though we are monitoring the situation very closely. Regeneron believes that EYLEA is clearly differentiated from both beneficial to map and ranibizumab. The positions of patients are not be denied access to any drug therapy this is deemed appropriate. We believe that position joint should be preserved an alternative scheme is to be reduce health care cost should be explored. 
Turning now to probably win. As reported by Sanofi, net sales in the second quarter were $24 million worldwide, with the U.S. accounting for $21 million of the total. I'm pleased to share that as of July 1, approximately 74% of commercially insured lives and approximately 91% of Medicare-insured lives have access to Praluent. We continue to see improvement in the number of prescriptions that are I successfully being filled, with both Praluent and generally splitting market share. However, only approximately 25% of our prescriptions written actually get dispensed. Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork that a pharmacy benefits managers and health plans have put in place, many patients were eligible for treatment with a PCSK9 inhibitor have not have the prescriptions filled. We continue to focus our efforts on improving access -- improving the Scripture process through the payers and the specialty pharmacies. Over the last several months, we've seen some payers losing their utilization management criteria, removing a requirement in prior therapy. Others have streamlined the prior authorization processes. ODYSSEY OUTCOMES data, if positive, is anticipated to be a key driver in shaping the future success of Praluent. 
Outside of the United States, Praluent was approved in the EU in September of 2015, with a product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K. and Spain among others. It still remains a difficult reimbursement market with some countries awaiting outcomes data. And the United States, we've submitted the supplemental BLA for the 300-milligram monthly dose of Praluent and have been granted a PDUFA date of January 24, 2017. We have also submitted a regulatory application for Praluent monthly dosing in the EU. Also in July, Praluent was approved in Japan. We've submitted the BLA to the U.S. Food and Drug Administration for sarilumab, our IL-6 receptor inhibitor for rheumatoid arthritis and had been granted a PDUFA date of October 30, 2016. Earlier this week, the European Marketing Authorization Application, or MAA, for sarilumab was accepted for review by the European Medicines Agency. We will be co-promoting sarilumab with Sanofi Genzyme in the United States, and we have completed hiring of our field-based team. Training began this week. Co-promotion decisions for other countries will be made over time. We're currently preparing for dupilumab commercialization with potential U.S. approval in the first half 2017. We'll be co-promoting dupilumab in the United States with Sanofi Genzyme and began improving our sales management team. Co-promotion decisions for other countries will be made on a later date. With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented a",1426,"Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented an increase of 24% in both non-GAAP net income per diluted share as well as non-GAAP net income in the second quarter of 2016 compared to the second quarter of 2015. 
Regeneron's second quarter 2016 non-GAAP net income excludes noncash share-based compensation expense and a $75 million up front payment made in connection with our April 2016 license in collaboration agreement with Intellia. It also includes the income tax effect of these non-GAAP adjustments. A full resolution of GAAP and on GAAP earnings is set forth in our earnings release. I will describe in further detail shortly effective this quarter, our non-GAAP net income is no longer included an adjustment from GAAP tax expense to the amount of taxes that were estimated to be paid or payable in cash. Total revenues in the second quarter of 2016 were $1.2 billion, which represented a year-over-year growth of 21% over the second quarter of 2015. Net product sales were $834 million in the second quarter 2016 compared to $658 million in the second quarter of 2015. EYLEA U.S. net product sales were $831 million compared to $655 million in the second quarter of 2015, representing a 27% year-over-year growth. Sequential quarter-over-quarter growth was 6%. 
EYLEA distributor inventory levels continue to be within our 1- to 2-week targeted range, and the June 30 levels were very similar to our large March 31, 2016 levels. 
Please note that we are reaffirming our 2016 U.S. EYLEA net sales guidance to be year-over-year growth of between 20% and 25%.
X U.S. EYLEA sales, where product revenue was recorded by our collaborator, Bayer, were $486 million in the second quarter of 2016, compared to $338 million in the second quarter of 2015, representing a 24% increase on a reported basis. On an operational basis, or constant currency basis, sales increased approximately 42%. In the second quarter 2016, Regeneron recognized $167 million from our share in net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the second quarter of 2016 was $192 million. As a reminder, for the EYLEA franchise, during May 26, 2016, we stopped incurring the relative expense in connection with our agreement with Genentech related to global EYLEA sales. This benefited our cost of goods sold and cost of collaboration line items. 
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $163 million for the second quarter of 2016. Sanofi collaboration revenue line primarily consists of reimbursement average Enron incurred R&D expense. Reimbursement of Regeneron commercialization related expenses and our share of profits or losses in connection with commercialization of antibodies. In the second quarter of 2016, our share of the collaborations losses in connection with commercialization of antibodies, primarily Praluent, was $122 million, which can be found in table 4 of our earnings release. Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborators, Sanofi, of $24 million for the second quarter 2016.
Turning now to expenses. Non-GAAP R&D expense was $406 million for the second quarter 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as a total GAAP R&D expense, less R&D reimbursement from our collaborators, R&D noncash share-based compensation expense and the Intellia upfront payment was $222 million for the 3 months ended June 30, 2016. Our press release includes all the information that is required to calculate non-GAAP R&D expense. Given our forecasted spend in associate reimbursement levels in the second half of 2016, we are increasing and tightening our full year guidance for non-GAAP unreimbursed R&D to be in the range of between $970 million to just over $1 billion from the previously provided range of $875 million to $950 million. This increase is a result of 2 factors: A forecasted increase in spending shift from partnered and unpartnered antibody development programs. We now have 7 antibodies that we're developing independently, including 2 that are in late stage,  RSV and fasinumab; and a greater allocation of unreimbursed manufacturing cost within our Rensselaer New York facility to R&D as opposed to inventory due to less demand for Praluent than was anticipated. Non-GAAP expense was $244 million for the second quarter of 2016. We are increasing and tightening non-GAAP SG&A expense in 2016 to $980 million to $1.02 billion from the range of $925 million to $1 billion. This increase is primarily driven by our expenses to support EYLEA reimbursement activities, including patients support services and reimbursement assistance along with additional investments in EYLEA commercialization. This increase is partially offset by lower commercialization prelaunch and associated with our collaboration antibodies with Sanofi. As you may recall, last quarter, we introduced a new guidance component, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs that Regeneron incurred in connection with preparing to commercialize or commercializing as applicable Praluent, sarilumab and dupilumab. Again, this is a line item found within the Sanofi collaboration revenue referenced in table 4 of our press release. 
For the second quarter 2016, the reimbursement of Regeneron commercialization related expenses was $86 million. We are lowering and tightening this guidance for 2016 to be in the range of $310 million and $340 million from $320 million to $370 million. 
Turning now to taxes. Prior to the quarter ended June 30, 2016, our non-GAAP measures included income tax expense adjustments from GAAP tax expense to the amount of taxes that were paid or payable in cash for the respective period. Historically, it was a significant difference between the companies GAAP effective tax rate and the actual facts income taxes paid or payable probably due to tax benefits related to employee exercises and stock options. The tax benefits related to employee exercises and stock options were strictly recorded in additional paid in capital for GAAP reporting purposes. 
During the second quarter of 2016, the company early adopted accounting standards update 2016-09, the new standard requires companies to recognize tax benefits in connection with employee exercises of stock options in the income statement. In other words, we'll account for tax reductions related to stock options exercises in a period of exercise as a discrete item the quarter with early adoption of the new standard, the company chose to discontinue its non-GAAP income excess by adopting the new standard in limiting one of our primarily differences between the company's effective tax rate and cash income taxes paid or payable. As a result, our second quarter 2016 and 2015 non-GAAP financial results included in our earnings release were comparison now reflect discontinuance over our non-GAAP income tax expense adjustment.
This new standard will result in variability in our effective tax rate from quarter-to-quarter as based on GAAP rules, these items are not forecasted in our estimated annual effective tax rate. These deductions are based on the company's stock price and individual employees decisions on when to exercise their stock options. The carbon tax adjustment in the reconciliation of GAAP net income to non-GAAP net income table 3  of our earnings release, solely represents income tax effects related to our non-GAAP pretax adjustments. Our effective tax rate for the second quarter of 2016 was approximately 33%, which is 8% lower compared to the second quarter of 2015. This decrease was primarily due to the impact of the changes in the geographic mix of earnings and share base compensation as compared to the same quarter of last year. 
For 2016, our guidance for our GAAP effective tax rate for the full year will be 33% to 41%. Our capital expenditures for the second quarter of 2016 and for the 6 months ended June 30, 2016 was $139 million and $243 million, respectively. We are lowering our full year 2016 capital expenditure guidance to a range of $480 million to $530 million from the previously provided range of $550 million to $625 million. These 2016 expenditures include expansion of our manufacturing capabilities and both Rensselaer, New York, Island as well as growth in our TarryTarrytown, New York headquarters as we continue to grow our employee base. Regeneron's balance sheet had $1.64 billion of cash and marketable securities as of June 30, 2016. Less than $500,000 of our originally issued $400 million of convertible senior notes due October 1, 2016, remain outstanding. With that, I would now like to turn the call back to Michael."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, can now open the call for questi",44,"Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, can now open the call for questions."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II of EYLEA combined with your PDGF, it looks like that we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you'r",70,"This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II of EYLEA combined with your PDGF, it looks like that we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're hoping to see with respect to efficacy in order to make a go, no go decision on the Phase III?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the firs",211,"It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the first stage. As you know, even in studies with hundreds of patients in them, as we of course abstain we have much experience as anybody alone with our collaborators doing these large studies, there can be a lot of variability in letters gained. So we designed the study to include a second stage as well that actually shows the effects of adding our therapy on top in the same groups. That we predict to be a more powerful way of confirming if there are added benefits of the PDGF therapies. So we'll have the first type of comparison, which we consider perhaps to be slightly less powerful in the time frame that I just described. And then will also be getting the second stage of data. So depending on how strong the first set of data is, we will either be able to make a decision at that point, or we'll be awaiting the results from the second stage to help us make that decision."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that we don't have to have a gigantic benefit. We just have to have something that's clearly beneficial because the hurdl",69,"I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that we don't have to have a gigantic benefit. We just have to have something that's clearly beneficial because the hurdle for us to move forward is that great because there's no additional burden on patients having to take on additional injection."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Robyn Karnak is from Citigroup.",10,"Our next question comes from Robyn Karnak is from Citigroup."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So you mentioned that [indiscernible] is opening up a little bit for PCSK9. Can you talk a little bit about what percentage of the peers had higher prescriptions initially this year? And then how did that change? And what percent of people are not requiri",95,"So you mentioned that [indiscernible] is opening up a little bit for PCSK9. Can you talk a little bit about what percentage of the peers had higher prescriptions initially this year? And then how did that change? And what percent of people are not requiring prior off or reduce the requirements for filling up forms, et cetera? And then going to that, what do you think the trigger point was towards doing that? And what are the timing for these events? Third quarter? What triggers these things and that we think about that going forward?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So there have been some payers that based upon the FDA's decision, not to improve based upon their outcomes data that I've said that it might does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice",154,"So there have been some payers that based upon the FDA's decision, not to improve based upon their outcomes data that I've said that it might does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice of some of their position medical directors, they have removed the is at a might step at it. And that has happened in that few plans already. With regards to the prior authorization paper works, some of the payers had prior authorizations that required 10s -- almost up to 40 questions. It became very tedious for the physicians. So some of the plans have begun to change their prior authorization to be simpler. And again, that is in place in a few payers now. I think the real driver that's going to change things is going to be when we get the outcomes data for the product."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. It's Len. Just to amplify all that. It seems to me there are 3 ways -- 3 important factors that you could consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lower and toler",240,"Thanks, Bob. It's Len. Just to amplify all that. It seems to me there are 3 ways -- 3 important factors that you could consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lower and tolerated drug. This is not like market. There should be long-term patients so we begin to accumulate them as opposed to constantly having to find them to replace as you would, that said, in a Pepsi environment. Secondly, as Bob said, the cardiologists are not like the rheumatologists where they have people in their office who are very expensive dealing with this prior authorizations and paper work. And I think that they are getting more efficient at it. There are somewhat frustrated by insurance. Some of them are giving up. Some say, well, wait for outcomes before I go to the map things like that. But I do believe that the experience that the doctors in picking the patients that they know that each PBM for each patient or each payer, if you will, they kind of know or getting better at knowing how to get this done as they get more experience. And then, of course, finally, as George mentioned, we hope that the outcomes data later this year will change the dynamic out there in terms of the filling, the compelling need to go on these products if we show an outcomes benefit."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Your final question comes from Ronnie from Bernstein.",8,"Your final question comes from Ronnie from Bernstein."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Actually, nevermind.",2,"Actually, nevermind."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","The following question comes from Ying Huang from Bank of America Merrill Lynch.",13,"The following question comes from Ying Huang from Bank of America Merrill Lynch."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one more on PDGF. So if you look at [indiscernible] plus Lucentis, it seems like there's a fallout of defense. Can you help us frame the expectations for your formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does t",58,"Just one more on PDGF. So if you look at [indiscernible] plus Lucentis, it seems like there's a fallout of defense. Can you help us frame the expectations for your formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that apply in this case? And what are you expecting for the outcome?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seeing with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early fi",167,"Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seeing with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early field. And based on a lot of the science. It's really very, very hard to predict. What if any benefit will be seen here. Would you think that our unique two-stage design will end up given is probably the best data and most convincing perspective on whether there is another benefit are not and as Len pointed out, the fact that if there is an added benefit, we'll be able to do it with a single injection. And assuming appropriate safety, we'll make it easier to deliver that benefit to patients with this approach. And remember, our approach here, we are combining to very similar antibody-based drugs into a single formulated injection as opposed to giving 2 different types of drugs with separate injections."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Are following question comes from Geoffrey Porges from Leerink Swann.",10,"Are following question comes from Geoffrey Porges from Leerink Swann."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just on dupilumab. George, could you just comment first from the conjunctivitis. Is that signal real in are you saying in the other studies for example in asthma or [indiscernible] And then related to that, can you talk a little bit about the launch of lu",70,"Just on dupilumab. George, could you just comment first from the conjunctivitis. Is that signal real in are you saying in the other studies for example in asthma or [indiscernible] And then related to that, can you talk a little bit about the launch of luck. What are the parallels and differences to the Praluent experience? And how much you get payers to let some patients through in this case?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, and these differences, for example, in the way topical st",623,"Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, and these differences, for example, in the way topical steroids are used in the populations and so forth. And we have various ideas about why this may be the case. That said, even though it seems specific to the weighted drug is being used in this particular patient population and perhaps either use or actually do less use of topical steroids in the treated patients. The comforting thing is that these patients do have, as we pointed out in the call, they do have already a lot of history of conjunctivitis. So this is not really something brand-new to the patient now patients. And the conjunctivitis that are seen here on dupilumab seems to be of mild to moderate severity and is limited. Most cases actually resolve during treatment. And very few, if any, cases actually lead to discontinuation. So it seems as if the benefit risk is really maintained in the phase of this. That said also, in terms of the second part of your question about dupilumab. We think it's a very different situation compared to Praluent. I mean there is a huge unmet need here. Patients are really suffering from ongoing symptomatology. And the data actually shows add that this symptomatology is actually markedly improved with the dupilumab treatment. So that it seems to us that there's going to be a lot of patients who really are -- and we already know, who was going to be possibly impacted their lives that they're going to be demanding this drug. And it seems to offset -- of these patients will deserve to have this first systemic therapy that could really make a difference in their lives. Let me remind you that we're talking about the most moderate to severe class of patients here, which are more than 1 million patients in the United States alone. And these patients really have very few other alternatives. And as you see with our data in CHRONOS, where we treat on top of topical steroids, the standard of care, very few, only about 10% of the patients or so, become clear or almost with topical steroids as opposed to about 40% on the drug. And there's not only, of course, the cosmetic effects of having these skin lesions and so forth  and the associated infections and so forth that they get. But there's an enormous amount of itch that drives a lot of behavioral problems associated depressive and psychological symptomatology here and so forth. And we've actually shown that much of this is actually impacted in our studies. So we've been a very important drug for this population of patients, and we think that there's going to be a very important opportunity to make a lot of difference in a lot of people's lives, which is what should count in this business. But beyond that, I think that we also have to remember that dupilumab is really a franchise onto itself. The data really suggested that we have hit upon here with blocking both interleukin-4 and 13, the critical levels of allergic disease in general. We're hoping to extend the findings from our first pivotal study in asthma by confirming in the second pivotal study. And we'll also be continuing to study in other allergic diseases where as you've already seen, we already have some positive data in other allergic diseases in the early-stage studies as well. So this can benefit not only the allergic and atopic disease and atopical dermatitis studies that confirm it to additional diseases as well."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just want to add one thing, Geoff. In terms of the difference between Praluent, just to emphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like them to take a cholesterol-lowering drug",154,"I just want to add one thing, Geoff. In terms of the difference between Praluent, just to emphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like them to take a cholesterol-lowering drug or fix it with diet or I'll take my statin or what have you. But patients with atopic dermatitis really suffer. It's really made its way to pop-culture. There's a new series on HBO. I do know if seen it. It's called the Night Of. And the actor, John Turturro, who trained as a lawyer and suffers terribly from atopic dermatitis. He has to wear sandals. He has to go to groups to discuss all this. And really is a terrible impact on the site. And I don't think this is just a TV portrayal. I think this is what we've seen and people really suffer from this disease."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think one last point to just add as well is that unlike most other Biologics that are immunomodulators where you see, in general, whether it's the DNS or a variety of other than generally see serious risk rate. This appears to be a amino modulator that",121,"I think one last point to just add as well is that unlike most other Biologics that are immunomodulators where you see, in general, whether it's the DNS or a variety of other than generally see serious risk rate. This appears to be a amino modulator that is correcting and immune deviation. And actually, as we reported it as we summarized during this call, there is no increase in infections and in serious infections year. So once again, it is an important option that's being offered to the patients in contrast to other alternatives which were immuno suppressing. And to have this sort of efficacy with a non-immuno suppressing agent, I think, is also offering a lot of hope to patients."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Chris Raymond from Raymond James.",9,"Next question comes from Chris Raymond from Raymond James."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just another question  here, I guess, on dupilumab. So in atopic dermatitis, maybe for Bob if possible. So I'd imagine  that your marketing preps pretty underway now with the BLA submitted. And I know we know the vast majority of intervention here is t",83,"So just another question  here, I guess, on dupilumab. So in atopic dermatitis, maybe for Bob if possible. So I'd imagine  that your marketing preps pretty underway now with the BLA submitted. And I know we know the vast majority of intervention here is topical, corticosteroids. But just curious, what has your work uncovered in terms of the use of other biologics' off-label and physician's satisfaction with these agents? Can you talk about how you think about this earlier formulating your launch plans?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other thera",130,"Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therapies, immunosuppressant agents, generally not biologics with things like cyclosporine and methotrexate. The challenge with those therapies is a can't use them or long term. They've got some toxicities that really interfere with the patient's long-term use of the therapy. And thus, their symptoms will come back, their itch will come back and their quality of life will decrease. So there is a huge opportunity for dupilumab in this uncontrolled severe patients. The pent-up demand of among patients and physicians to get the patients on therapy and to improve their lives."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promis",69,"And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promising in this area. So this really has a chance to really be providing something to patients that  don't really have any other alternatives at this point."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would add also to make sure you think about these other diseases and other significant opportunities. It has been a desire to have a drug like a Biologics that could affect and asthma, for example, that could treat all patients, that could have an effec",145,"I would add also to make sure you think about these other diseases and other significant opportunities. It has been a desire to have a drug like a Biologics that could affect and asthma, for example, that could treat all patients, that could have an effect both on FEV1 and on exacerbations. And that -- no such drug has been forthcoming as yet, and we're excited that our first pivotal trial demonstrated in the broad population of fact, both on FEV1 and on exacerbation. So hopefully, if we can confirm that in a trial that's just about to be completed in enrollment. So think of about 1 year for the trial and then the data, we could be onto something a whole new opportunity which people really are looking for. Something that can treat all the patients and can treat both the FEV1 Andy exacerbations."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or type p",93,"As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or type patients, and it's the only places where substantial efficacy has been noted. As Len said, mostly with exacerbations and none on lung functions. So if we can confirm the results of the first pivotal, it could provide another major hope for patients who really need these types of therapies."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And the last point on that George likes to make when he speaks about this at meetings is we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlap",69,"And the last point on that George likes to make when he speaks about this at meetings is we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlapping syndromes because they are scientifically related in -- if I should say path of Fisher logically related, we think, to the IL-4 13 pathway."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Mark Sherman barred from Evercore ISR.",10,"Next question comes from Mark Sherman barred from Evercore ISR."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","John Scotti on for Mark. I will just ask a quick one on the Abbasid collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And I guess how that approach differ those that are already in develop",65,"John Scotti on for Mark. I will just ask a quick one on the Abbasid collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And I guess how that approach differ those that are already in development such as selective? And then I guess, may be what it was he some of those assets entering the clinic?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think...",3,"Well, I think..."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Before you answer that, George. I just want to make one comment that is, if I went to Broadway and had so many standing actors, that would be mortified.",29,"Before you answer that, George. I just want to make one comment that is, if I went to Broadway and had so many standing actors, that would be mortified."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think an important point to make is we really believe in people, and we believe in synergies and we've had long-standing interest to be working with IE Jacobowitz who's really leading Adicet. And obviously, she's been in areas that we've been in. We hav",196,"I think an important point to make is we really believe in people, and we believe in synergies and we've had long-standing interest to be working with IE Jacobowitz who's really leading Adicet. And obviously, she's been in areas that we've been in. We have enormous respect for her and her capabilities. And so we really feel that we can work well together with her and her team. And number two, is that synergies with our existing programs. This is why we make these sorts of deals. We believe that we have a lot of potential tools and starting points for making the sorts of targeting reagents that would be introduced to sell therapies losing our existing technologies such as VelocImmune and our velocity next technology, which really nobody else in the field has access to right now. So we're hoping that we put together our unique capabilities that nobody else in the cell therapy space had, together with a pioneer in a-determithe leader in this area such as IE Jacobowitz and her team that we could really do a special thing. And I think at this point, that's what want to say about this collaboration."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Adnan Butt from RBC Capital.",10,"Our next question comes from Adnan Butt from RBC Capital."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So let me ask a 10-Q question. Less PD-1 embarking on potentially pivotal studies over the next year. Are there unique indications or are combinations that you selected already? Any details there, please?",34,"So let me ask a 10-Q question. Less PD-1 embarking on potentially pivotal studies over the next year. Are there unique indications or are combinations that you selected already? Any details there, please?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies,",90,"Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies, which is cutaneous squamous cell carcinoma. And so that is, for example, one setting. We've also identified additional setting that has been publicly disclosed. Of also identified additional setting that will be going into, we hope, both and to potentially as a monotherapy but also with new combinations."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we have time for one last question.",8,"And we have time for one last question."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Alethia Young from Credit Suisse.",10,"Our final question comes from Alethia Young from Credit Suisse."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to your prepared remarks. I was just wondering with EYLEA like is it something that you're kind of starting to experience as part of the dynamic for why kind of the financial the manufacturing is providing are increasing repurchasing speci",53,"Just going back to your prepared remarks. I was just wondering with EYLEA like is it something that you're kind of starting to experience as part of the dynamic for why kind of the financial the manufacturing is providing are increasing repurchasing specifically kind of bring that a lot of attention this quarter?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think that Bob is highlighting what's going on in the marketplace and we're seeing more of these things than we have in years past. Is not been any drastic change. But it's just to get in front of these things, we monitor them and we have responses prep",60,"I think that Bob is highlighting what's going on in the marketplace and we're seeing more of these things than we have in years past. Is not been any drastic change. But it's just to get in front of these things, we monitor them and we have responses prepared should they be necessary. Bob comedy want to add anything?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","No, I mean, it's a dynamic and the marketplace that impacts the growth of EYLEA and we just wanted to discuss it.",22,"No, I mean, it's a dynamic and the marketplace that impacts the growth of EYLEA and we just wanted to discuss it."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Well, that  concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry in the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?",42,"Great. Well, that  concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry in the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?"
33715,372870908,1024685,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.I will now turn the call",50,"Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.Joining me on the call today are Dr. Leonar",317,"Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer.
After our prepared remarks, we'll open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions.
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to gi",545,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to give you some broader perspective on Regeneron and our business. Regeneron continues to advance its mission to bring important new medicines to patients in need. EYLEA is our drug used to treating a number of potentially blinding diseases. And with millions of injections administered each year, it is one of our most important approved products and continuous grow well globally. EYLEA is now at an annual global net sales run rate that exceeds $5 billion. This has been driven both by the approval of EYLEA in new indications as well as new data that have further increased the confidence of physicians in this product. Thanks to our long-standing belief and investment in science and technology, we are now in the midst of a new product cycle, which has the potential to impact multiple disease settings. This investment in science has resulted in Praluent, our PCSK9 antibody, for lowering LDL cholesterol, and additional potential near-term approvals that could address rheumatoid arthritis and atopic dermatitis. Our late-stage pipeline also includes programs in asthma, pain, respiratory syncytial virus and the immunotherapy of cancer. Our earlier pipeline opportunities continue to grow with a total of 15 product candidates currently in clinical development, including 7 that we are developing independently, with several more expected to enter the clinic in the near term, making for pipeline that can address potential opportunities ranging from rare often diseases such as fibrodysplasia ossificans progressiva, or FOP, to emerging infectious diseases epidemic, such as Zika. George will provide specific details on some of these programs later in this call. All of these opportunities are the results of investments we made in science and technology over the last 20 years, yielding a pipeline that is entirely home-grown. Our commitment to the long-term is unwavering as we invest in the next generation of technologies to support our feature pipeline. For example, our Regeneron Genetics Center and our investment in technologies with companies in the areas of gene-editing and cell therapy, such as Intellia and Adicet, which are synergistic with our existing capabilities. I should also mention that we recognize that we operate in a rapidly changing environment that poses new challenges to the commercialization of our products, and we continue to try and develop innovative solutions to address these issues. Lastly, we believe it's absolutely essential to attract the best and brightest minds to scientific careers and to elevate the place of science in our society. Therefore, we were thrilled to announce in May that Regeneron was selected as the new sponsor of the Science Talent Search. Regeneron is only the third sponsor in this renowned 75-year history of this high school science talent competition, which was previously sponsored by Intel and before that, by Westinghouse. George and I are both alumni of the Science Talent Search, and we believe the program plays a vital role encouraging -- in encouraging talented young people to pursue a path in science and engineering.
With that introduction, let me turn the call over to George."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 bloc",1499,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.
In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 blocker in patients with uncontrolled moderate to severe atopic dermatitis, which is a chronic inflammatory skin disease. Dupilumab is the first systemic therapy to show positive Phase III results in this indication.
On our last earnings call, we talked about the positive data from the first 2 Phase III studies, Solo-1 and Solo-2, which studied dupilumab as a monotherapy.
In June, we just recently reported the results from the third study, LIBERTY AD CHRONOS, which was a long-term study that investigated dupilumab in combination with topical corticosteroids, which are currently the standard of care in the United States for the treatment of this difficult disease. Overall, the efficacy observed in the CHRONOS study was very consistent with the previously reported positive Phase III Solo-1 and Solo-2 studies of dupilumab in the monotherapy setting. While the primary endpoint of the CHRONOS study was assessed at 16 weeks, the study continued until 52 weeks and efficacy was sustained in both the dupilumab 300-milligram weekly as well as the 300-milligram every-other-week dose groups through this 1-year mark. At 16 weeks, about 40% of the patients in both dupilumab dose groups achieved clear or almost clear skin status as measured by the investigator global assessment score compared to about 12% of the patients in the topical-steroid-only arm. Nearly 2/3 of the patients receiving dupilumab achieved a 75% improvement in the average improvement in the overall skin score as assessed by the eczema area and severity index or the EASI score, compared to about 23% of patients in the topical-steroid-only arm.
This was the first long-term Phase III study to show that dupilumab in combination with topical steroids was superior to topical steroids alone and provided sustained efficacy and significantly improved measures of overall disease severity, skin clearing, itching and quality of life through 1 year of treatment.
The overall rate of adverse events and serious adverse events was comparable between the groups treated with dupilumab in combination with topical steroid and the topical steroids alone. Serious and/or severe infections were numerically higher in the topical-steroid-alone group. Adverse events that were noted to have a higher rate with dupilumab treatment included injection-site reactions, which were seen in 20% of the patients on the dupilumab weekly arm, 16% of the patients in dupilumab every-2-week arm and 9% of the patients in the placebo plus topical-steroid-alone arm. And conjunctivitis, which was observed in 19% of the patients in the dupilumab weekly arm, 13% of patients in the dupilumab every-other-week arm and 8% of patients in the topical-steroid-alone arm. About 22% of the patients in the placebo group, 23% of the patients in the dupilumab weekly group and 28% in the dupilumab every-other-weekly group had a reported history of allergic conjunctivitis coming into the study.
These 1-year results from the CHRONOS study further suggested dupilumab impacts the aberrant activation of the interleukin-4/13 pathway and results in significant efficacy without the side effects associated with immune-suppressing therapies.
In this regard, and very importantly, we have not observed an increase in overall infections or serious infections in our atopic dermatitis program to date. The U.S. BLA submission has been completed, and we look forward to working with the FDA to bringing this important breakthrough therapy to patients as soon as possible.
We are also developing dupilumab in other allergic diseases, such as asthma, nasal polyps, and eosinophilic esophagitis. As a reminder, our first pivotal study in asthma show that 2 doses of dupilumab, 200 milligram and 300 milligram every other week, in combination with inhaled steroids and long-acting beta-agonist, demonstrated a statistically significant 12% to 15% improvement in lung function as measured by FEV1 over placebo at week 12, and a 64% to 75% reduction in the annualized rate of severe asthma exacerbations over placebo. The most common adverse event was injection-site reaction, which are more frequent in the dupilumab dose groups at 13% to 25% compared to 12% in the placebo group. The incident of infections was balance across treatment groups at 42% to 45% of dupilumab arms and 46% in the placebo arm as was the incidence of serious adverse events, which were seen in 3% to 7% of the dupilumab groups and 5% in the placebo group. We expect our confirmatory 1-year Phase III study of dupilumab in this indication to complete enrollment in the third quarter of 2016.
As a reminder, we are the only late-stage biologic that targets both IL-4 and IL-13, and recent competitor [ph] developments in the late-stage asthma space are consistent with our preclinical data and our hypothesis that it is important to block both of these interleukins.
Turning to Praluent. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. As we had previously disclosed, the data-monitoring committee for this study completed the first interim analysis with 50% of the total events had accrued based on unblinded study data. In addition to reviewing the safety study, the DMC performed a futility assessment and recommended that the study continue with no changes. A second interim analysis for futility as well as for overwhelming efficacy when 75% of the targeted primary events has occurred is expected later this year.
As Len mentioned, we also have 3 other late-stage programs: Sarilumab, our interleukin-6 receptor antibody for rheumatoid arthritis, where we expect FDA action by October 30; fasinumab, our NGF antibody for pain associated with osteoarthritis; and the Regeneron 2222, for respiratory syncytial virus, or RSV.
Turning now to our earlier-stage pipeline. In May, we reported positive interim proof-of-concept data from a Phase II study of evinacumab and the antibody to angiopoietin-PTL3 in patients with homozygous form of familial hypercholesterolemia. These patients continue to have a major unmet need as they are typically not as responsive to standard lipid-lowering therapy, such as statins or even to PCSK9 inhibition. And some of the other treatment options available to them are limited by the accompanying safety and tolerability concerns. Although these data were from a small number of patients, we're encouraged by the additional 55% reduction in LDL cholesterol levels at week 4 on top of standard of care compared to baseline.
In this study, evinacumab was generally well tolerated and there were no adverse events leading to discontinuation. The most common drug-related adverse events were injection-site reactions, which were mild in severity.
Our Phase II study of EYLEA in a co-formulated combination with rinucumab, our PDGF-receptor antibody, in wet age-related macular degeneration, or wet AMD, which has been granted fast-track designation, is fully enrolled, and we expect top line data from the study in the fourth quarter of 2016. This is a 3-arm, 2-stage study with patients randomized to receive 1 of 3 dosing regimens: EYLEA alone; EYLEA in combination with low-dose PDGF-blocking antibody; or EYLEA in combination with high-dose PDGF-blocking antibody. The primary efficacy endpoint of the first stage of this study is the mean change in visual acuity at week 12 from baseline. The second stage of the study is designed to confirm and extend the findings from the first stage of the study. Our Phase II combination studies of EYLEA in a co-formulated combination with Nesvacumab, our antibody to angiopoietin-2, in AMD and DME, continue to enroll patients. We are very excited by our earlier-stage pipeline in immuno-oncology, where both our PD-1 antibody and our CD20 by CD3 bispecific antibody have demonstrated promising activity in early clinical trials. A potential pivotal study with our PD-1 antibody in cutaneous squamous cell carcinoma continues to enroll patients, and we hope to be investigating additional agents and combinations over the next 6 to 12 months. We have also expanded our capability in the area of precision immunotherapy with our recently announced collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapies. This collaboration takes advantage over our unique VelocImmune and Veloci-Next technologies that will allow us to use cell-based therapies to target tumor cells.
We also recently initiated Phase I study in healthy volunteers of Regeneron 2477, an Activin A antibody, being developed for the treatment of fibrodysplasia ossificans progressiva, or FOP, and other musculoskeletal disorders. We remain committed to using our technologies and approaches to help address emerging infectious diseases, such as Ebola, MERS and Zika. For Zika, we have identified several fully human monoclonal antibody candidates that we're able to potentially block the virus -- to potently block the virus from infecting cells in vitro, and early data indicates that these antibodies are protected in an animal model. We are now in the process of scaling up for human trials. We also recently initiated our first in-human study in healthy volunteers in our Ebola program, which has been granted orphan drug designation by the FDA.
With that, let me turn the call over to Bob Terifay."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or a",804,"Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or alirocumab, among U.S. payers. In addition, the European and Japanese launches for Praluent continue to progress. And we are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next year.
Starting with EYLEA. Second quarter U.S. net sales grew 27% year-over-year. Net U.S. EYLEA sales in the second quarter were $831 million. Net ex U.S. EYLEA sales in the second quarter were $486 million, which represents 44% growth year-over-year on a reported basis. We continue to have a strong position in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market in terms of injections as reported by 203 retinal specialists in our quarterly market research survey. According to our survey results, in the overall anti-VEGF market, EYLEA has a 37% share of injections as compared to 19% for ranibizumab and 44% for off-label repackaged bevacizumab. On the other hand, with our growing market share, our expenses to support reimbursement activities, including patient support services and reimbursement assistance, have also increased, impacting both our gross-to-net ratio as well as our profit margin. I should note that there are currently a series of proposals for the -- from the Centers for Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B buy-and-bill drugs, which could lead towards positions favoring the use of bevacizumab or, in large-volume retinal practices, ranibizumab due to the provision of increased direct-to-physician financial incentives from the manufacturer and group-purchasing organizations.
The impact of any changes is difficult to predict. Though we are monitoring this situation very closely. Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. We believe that physician choice should be preserved and alternative scheme as to reduce health care cost should be explored.
Turning now to Praluent. As reported by Sanofi, net sales in the second quarter were $24 million worldwide, with the U.S. accounting for $21 million of the total. I'm pleased to share that as of July 1, approximately 74% of commercially insured lives and approximately 91% of Medicare-insured lives have access to Praluent. We continue to see improvement in the number of prescriptions that are successfully being filled, with both Praluent and evolocumab generally splitting market share evenly. However, only approximately 25% of our prescriptions written actually get dispensed. Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork that the pharmacy benefits managers and health plans have put in place, many patients who are eligible for treatment with the PCSK9 inhibitor have not had their prescriptions filled. We continue to focus our efforts on improving access -- improving the prescription process through the payers and the specialty pharmacies. Over the last several months, we've seen some payers losing their utilization management criteria, removing the requirement for prior ezetimibe therapy. Others have streamlined the prior-authorization processes. ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of Praluent.
Outside of the United States, Praluent was approved in the EU in September of 2015, with the product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K. and Spain among others. It still remains a difficult reimbursement market with some countries awaiting OUTCOMES data. In the United States, we've submitted the supplemental BLA for the 300-milligram monthly dose of Praluent and have been granted a PDUFA date of January 24, 2017. We have also submitted a regulatory application for Praluent monthly dosing in the EU. Also in July, Praluent was approved in Japan. We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our IL-6 receptor inhibitor, for rheumatoid arthritis and have been granted a PDUFA date of October 30, 2016. Earlier this week, the European Marketing Authorization Application, or MAA, for sarilumab was accepted for review by the European Medicines Agency. We will be co-promoting sarilumab with Sanofi Genzyme in the United States, and we've completed hiring of our field-based team. Training began this week. Co-promotion decisions for other countries will be made over time. We're currently preparing for dupilumab commercialization with potential U.S. approval in the first half 2017. We'll be co-promoting dupilumab in the United States with Sanofi Genzyme and they have begun interviewing our sales management team. Co-promotion decisions for other countries will be made at a later date.
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented a",1437,"Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented an increase of 24% in both non-GAAP net income per diluted share as well as non-GAAP net income in the second quarter of 2016 compared to the second quarter of 2015.
Regeneron's second quarter 2016 non-GAAP net income excludes noncash share-based compensation expense and $75 million up-front payment made in connection with our April 2016 license and collaboration agreement with Intellia. It also includes the income tax effect of these non-GAAP adjustments. A full reconciliation of GAAP and non-GAAP earnings is set forth in our earnings release. I will describe in further detail shortly, effective this quarter, our non-GAAP net income is no longer includes in adjustment from GAAP tax expense to the amount of taxes that were estimated to be paid or payable in cash. Total revenues in the second quarter of 2016 were $1.2 billion, which represented a year-over-year growth of 21% over the second quarter of 2015. Net product sales were $834 million in the second quarter of 2016 compared to $658 million in the second quarter of 2015. EYLEA U.S. net product sales were $831 million compared to $655 million in the second quarter of 2015, representing a 27% year-over-year growth. Sequential quarter-over-quarter growth was 6%. EYLEA distributor inventory levels continue to be within our normal 1- to 2-week targeted range, and the June 30 levels were very similar to our large March 31, 2016 levels.
Please note that we are reaffirming our 2016 U.S. EYLEA net sales guidance to be year-over-year growth of between 20% and 25%.
Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $486 million in the second quarter of 2016 compared to $338 million in the second quarter of 2015, representing a 44% increase on a reported basis. On an operational basis, or constant currency basis, sales increased approximately 42%. In the second quarter of 2016, Regeneron recognized $167 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the second quarter of 2016 was $192 million.
As a reminder, for the EYLEA franchise, during May 2016, we stopped incurring the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. This benefited our cost to goods sold and cost of collaboration manufacturing line items.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $163 million for the second quarter of 2016. Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the second quarter of 2016, our share of the collaboration's losses in connection with commercialization of antibodies, primarily Praluent, was $122 million, which can be found in table 4 of our earnings release. Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $24 million for the second quarter of 2016.
Turning now to expenses. Non-GAAP R&D expense was $406 million for the second quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total GAAP R&D expense, less R&D reimbursements from our collaborators, R&D noncash share-based compensation expense and the Intellia up-front payment, was $222 million for the 3 months ended June 30, 2016. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. Given our forecasted spend in associate reimbursement level for the second half of 2016, we are increasing and tightening our full year guidance for non-GAAP unreimbursed R&D to be in the range of between $970 million to just over $1 billion from the previously provided range of $875 million to $950 million. This increase is a result of 2 factors: A forecasted increase in spending shift from partnered to unpartnered antibody development programs. We now have 7 antibodies that we're developing independently, including 2 that are in late stage, RSV and fasinumab; and a greater allocation of unreimbursed manufacturing cost within our Rensselaer, New York facility to R&D as opposed to inventory due to less demand for Praluent than was anticipated. Non-GAAP SG&A expense was $244 million for the second quarter of 2016. We are increasing and tightening non-GAAP SG&A expense in 2016 to $980 million to $1.02 billion from the range of $925 million to $1 billion. This increase is primarily driven by our expenses to support EYLEA reimbursement activities, including patient support services and reimbursement assistance along with additional investments in EYLEA's commercialization. This increase is partially offset by lower commercialization and prelaunch spend associated with our collaboration antibodies with Sanofi. As you may recall, last quarter, we introduced a new guidance component, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs that Regeneron incurs in connection with preparing to commercialize or commercializing as applicable, Praluent, sarilumab and dupilumab. Again, this is the line item found within Sanofi collaboration revenue and is referenced in table 4 of our press release.
For the second quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $86 million. We are lowering and tightening this guidance in 2016 to be in the range of $310 million and $340 million from $320 million to $370 million.
Turning now to taxes. Prior to the quarter ended June 30, 2016, our non-GAAP measures included an income tax expense adjustment from GAAP tax expense to the amount of taxes that were paid or payable in cash for the respective period. Historically, there was a significant difference between the company's GAAP-effective tax rate and the actual cash income taxes paid or payable primarily due to tax benefits related to employee exercises stock options. The tax benefits related to employee exercises stock options were historically recorded in additional paid in capital for GAAP-reporting purposes.
During the second quarter of 2016, the company early adopted accounting standards update 2016-09. The new standard requires companies to recognize tax benefits in connection with employee exercises stock option in the income statement. In other words, we'll account for tax deductions related to stock option exercises in the period of exercise as a discrete item to the quarter. With the early adoption of the new standard, the company chose to discontinue its former non-GAAP income tax expense adjustment since by adopting the new standard and eliminated one of our primarily -- primary differences between the company's effective tax rate and cash income taxes paid or payable. As a result, our second quarter 2016 and 2015 non-GAAP financial results included in our earnings release for comparison now reflect discontinuance of our non-GAAP income tax expense adjustment.
This new standard will result in variability in our effective tax rate from quarter-to-quarter. As based on GAAP rules, these items are not forecasted in our estimated annual effective tax rate. These deductions are based on the company's stock price and individual employees' decisions on when to exercise their stock options. The current tax-related adjustment in our reconciliation of GAAP net income to non-GAAP net income, table 3 of our earnings release, solely represents the income tax effects related to our non-GAAP pretax adjustments. Our effective tax rate for the second quarter of 2016 was approximately 33%, which is 8% lower compared to the second quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings and share base compensation as compared to the same quarter of last year.
For 2016, our guidance for our GAAP effective tax rate for the full year will be 33% to 41%. Our capital expenditures for the second quarter of 2016 and for the 6 months ended June 30, 2016 was $139 million and $243 million, respectively. We are lowering our full year 2016 capital expenditure guidance to a range of $480 million to $530 million from the previously provided range of $550 million to $625 million. These 2016 expenditures include the expansion of our manufacturing capabilities in both Rensselaer, New York; in Limerick, Ireland; as well as growth in our Tarrytown, New York headquarters as we continue to grow our employee base. Regeneron's balance sheet had $1.64 billion of cash and marketable securities as of June 30, 2016. Less than $500,000 of our originally issued $400 million of convertible senior notes due October 1, 2016, remain outstanding.
With that, I would now like to turn the call back to Michael."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for qu",45,"Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for questions."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're ho",68,"This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're hoping to see with respect to efficacy in order to make a go, no, go decision on the Phase III?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the firs",215,"It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the first stage. As you know, even in studies with hundreds of patients in them, as we have of course seen, we have as much experience as anybody alone and with our collaborators doing these large studies, there can be a lot of variability in letters gained. So we designed the study to include a second stage as well that actually shows the effects of adding on therapy on top within the same group. That we predict to be a more powerful way of confirming if there are added benefits of the PDGF therapies. So we'll have the first type of comparison, which we consider perhaps to be slightly less powerful in the time frame that I just described, and then we will also be getting the second stage of data. So depending on how strong the first set of data is, we will either be able to make a decision at that point or we'll be awaiting the results from the second stage to help us make that decision."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hu",70,"I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hurdle for us to move forward isn't that great because there's no additional burden on patients having to take an additional injection."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Robyn Karnauskas from Citigroup.",9,"Our next question comes from Robyn Karnauskas from Citigroup."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring pr",99,"So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring prior auth or reduce the requirements for filling up forms, et cetera? And then going to that, what do you think the trigger point was for doing that? And what are the timing for these events, like the third quarter? What triggers these things and how do we think about that going forward?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at t",149,"So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice of some of their physician -- medical directors, they've removed the ezetimibe step at it. And that has happened in a few plans already. With regards to the prior authorization paperwork, some of the payers had prior authorizations that required 10s -- almost up to 40 questions. It became very tedious for the physicians. So some of the plans have begun to change their prior authorization to be simpler. And again, that is in place in a few payers now. I think the real driver that's going to change things is going to be when we get the OUTCOMES data for the product."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate th",252,"Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate the drug, this is not like hepatitis C market. Those should be long-term patients, so we begin to accumulate as opposed to constantly having to find to replace as you would, let's say in a hep C environment. Secondly, as Bob said, this is -- the cardiologists are not like the rheumatologists where they have people in their office, who are very experienced in dealing with the prior authorizations and paperwork, and I think that they are getting more efficient at it, they are somewhat frustrated by it for sure, and some of them are giving up. Some say, ""well, I'll wait for outcomes before I go to them at with fights"" and things like that. But I do believe that the experience that the doctors in picking the patients that they know that each PBM for each patient or each payer, if you will, they kind of know -- are getting better at knowing how to get this done as they get more experience. And then, of course, finally, as George mentioned, we hope that the OUTCOMES data later this year will change the dynamic out there in terms of the feeling, the compelling need to go on these products if we show an OUTCOMES benefit."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ronny Gal from Bernstein.",9,"Our following question comes from Ronny Gal from Bernstein."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","One second.",2,"One second."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Do you have a question?",5,"Do you have a question?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Yes, right here. Sorry, actually never mind.",7,"Yes, right here. Sorry, actually never mind."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ying Huang from Bank of America Merrill Lynch.",13,"Our following question comes from Ying Huang from Bank of America Merrill Lynch."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does t",60,"Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that [indiscernible] apply in this case? And what are you expecting for the outcome?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early fiel",169,"Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early field. And based on a lot of the science, it's really very, very hard to predict what, if any, benefit will be seen here. Would you think that our unique two-stage design will end up giving us probably the best data in most convincing perspective on whether there is an added benefit or not, and as Len pointed out, the fact that if there is an added benefit, we'll be able to do it with a single injection. And assuming appropriate safety, we'll make it easier to deliver that benefit to patients with this approach. And remember, our approach here, we are combining 2 very similar antibody-like drugs into a single co-formulated injection as opposed to giving 2 very different types of drugs with separate injections."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Geoffrey Porges from Leerink.",9,"Our following question comes from Geoffrey Porges from Leerink."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook.",68,"Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook. What are the parallels or differences to the Praluent experience? And how much you get payers to let some patients through in this case?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical ste",642,"Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical steroids are used in the populations and so forth, and we have various ideas about why this may be the case. That said, even though it seems specific to the way the drug is being used in this particular patient population and perhaps with either the use or actually the less use of topical steroids in the treated patients. The comforting thing is that these patients do have -- as we pointed out in the call, they do have already a lot of history of conjunctivitis. So this is not really something brand-new to the patients. And the conjunctivitis that is seen here on dupilumab seems to be of mild-to-moderate severity and is limited. Most cases actually resolve during treatment. And very few, if any, cases actually lead to discontinuation. So it seems as if the benefit/risk is really maintained in the phase of this. That said also, in terms of the second part of your question about dupilumab, we think it's a very different situation compared to Praluent. I mean there is a huge unmet need here. Patients are really suffering from ongoing symptomatology. And the data actually shows that this symptomatology is actually markedly improved with the dupilumab treatment. So that it seems to us that there's going to be a lot of patients who really are -- and we already know, who are going to be so positively impacted in their lives that they're going to be demanding this drug. And it seems to us that these patients will deserve to have this first systemic therapy that can really make a difference in their lives. Let me remind you that this is -- we're talking about the most moderate-to-severe class of the patients here, which are more than 1 million patients in the United States alone, and these patients really have very few other alternatives. And as you can see with our data in CHRONOS, where we treat on top of topical steroids, the standard of care, very few, only about 10% of the patients or so, become clear or almost clear with topical steroids as opposed to about 40% on the drug. And there's not only, of course, the cosmetic effects of having these skin lesions and so forth and the associated infections and so forth that you get, but there's an enormous amount of itch, which drives a lot of behavioral problems and so forth. There is associated depressive and psychological symptomatology here and so forth. And we've actually shown that much of this is actually impacted in our studies. So we think this can be a very important drug for this population of patients, and we think that there's going to be a very important opportunity to make a lot of difference in a lot of people's lives, which is what should count in this business. But beyond that, I think that we also have to remember that dupilumab is really a franchise onto itself. The data really suggest that we have hit upon here with blocking both interleukin-4 and 13, the critical drivers of allergic disease in general. We're hoping obviously to extend the findings from our first pivotal study in asthma by confirming them with the second pivotal study. And we'll also be continuing to study in other allergic diseases whereas you've already seen we already have some positive data in other allergic diseases in early-stage studies as well. So this can benefit not only the allergic and atopic disease of atopic dermatitis, but we hope to be able to have studies that confirm it to additional allergic diseases as well."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowe",155,"I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowering drug or fix it with diet or take my statin or what have you. But patients with atopic dermatitis really suffer. It's really made its way into pop-culture. There's a new series on HBO. I don't know if any of you have seen, it's called The Night Of, and the actor, John Turturro, portrays as lawyer, who suffers terribly from atopic dermatitis. He has to wear sandals. He goes to groups to discuss all this. And really has a terrible impact on his life. And this -- I don't think this is just a TV portrayal. I think this is what we see, the people really suffer from this disease."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This",124,"I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This appears to be more of immunomodulators correcting an immune deviation. And actually, as we reported and as we summarized during this call, there is no increase in infections and in serious infections here. So once again, this is an important option that's being offered to the patients in contrast to other alternatives which were essentially immunosuppressing. And to have this sort of efficacy with a nonimmunosuppressing agent, I think, is also offering a lot of hope to patients."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Chris Raymond from Raymond James.",9,"Next question comes from Chris Raymond from Raymond James."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is",87,"So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is topical corticosteroids. But just curious, what has your work uncovered in terms of the use of other biologics' off-label and physician satisfaction with these agents? And maybe can you talk about how you're thinking about this as you formulate your launch plans?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other thera",129,"Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therapies, immunosuppressant agents, generally not biologics, but things like cyclosporine and methotrexate. The challenge with those therapies is you can't use them long term. They've got some toxicities that really interfere with the patient's long-term use of the therapy. And thus, their symptoms will come back, their itch will come back and their quality of life will decrease. So there is a huge opportunity for dupilumab in these uncontrolled moderate-to-severe patients. There's the pent-up demand among patients and physicians to get the patients on therapy and to improve their lives."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promis",69,"And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promising in this area. So this really has a chance to really be providing something to patients that don't really have any other alternatives at this point."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effe",146,"I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effect both on FEV1 and on exacerbations. And that -- no such drug has been forthcoming as yet, and we're excited that our first pivotal trial demonstrated in the broad population effect both on FEV1 and on exacerbation. So, hopefully, if we can confirm that in our trial that's just about to be completed in enrollment. So think ahead about 1 year for the trial and then the data, we could be onto something a whole new opportunity which people really are looking for. Something that can treat all the patients and that can treat both the FEV1 and the exacerbations."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosino",95,"As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosinophilic-type patients, and it's the only places where substantial efficacy has been noted. And as Len said, mostly only with exacerbations and not on lung functions. So if we can confirm the results of the first pivotal, it could provide another major hope for patients who really need these types of therapies."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. Thes",66,"And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlapping syndromes because they are scientifically related in -- if I should say pathophysiologically related, we think, to the IL-4/13 pathway."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Mark Schoenebaum from Evercore ISI.",9,"Next question comes from Mark Schoenebaum from Evercore ISI."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that a",70,"It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that are already in development, such as selective? And then I guess, maybe when can we see some of those assets entering the clinic?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think the...",4,"Well, I think the..."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified.",29,"Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. W",196,"I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. We have enormous respect for her, her capabilities, and so we really feel that we can work well together with her and her team. And number 2 is the synergies with our existing programs. This is why we make these sorts of deals. We believe that we have a lot of potential tools and starting points for making the sorts of targeting reagents that would be introduced into these cell therapies using our existing technologies, such our VelocImmune and our Veloci-Next technologies, which really nobody else in this field has access to right now. So we're hoping that we put together our unique capabilities that nobody else in the cell therapy space has, together with a pioneer and leader in this area, such as Aya Jakobovits and her team, that we could really do a special thing. And I think at this point that's what we want to say about this collaboration."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Adnan Butt from RBC Capital.",10,"Our next question comes from Adnan Butt from RBC Capital."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please.",33,"Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies,",90,"Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies, which is cutaneous squamous cell carcinoma. And so that is, for example, one setting. We've also identified additional setting that has been publicly disclosed. We've also identified additional setting that will be going into, we hope, both potentially with it as a monotherapy but also with new combinations."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we have time for one last question.",8,"And we have time for one last question."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Alethia Young from Crdit Suisse.",10,"Our final question comes from Alethia Young from Crdit Suisse."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or",63,"Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or increasing or group purchasing. Why did you specifically kind of bring that to our attention this quarter?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and w",66,"I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and we have responses prepared should they be necessary. Bob, you want to add anything there?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it.",22,"No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?",42,"Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?"
33715,372870908,1025176,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.I will now turn the call",50,"Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.Joining me on the call today are Dr. Leonar",317,"Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer.
After our prepared remarks, we'll open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions.
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to gi",545,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to give you some broader perspective on Regeneron and our business. Regeneron continues to advance its mission to bring important new medicines to patients in need. EYLEA is our drug used to treating a number of potentially blinding diseases. And with millions of injections administered each year, it is one of our most important approved products and continuous grow well globally. EYLEA is now at an annual global net sales run rate that exceeds $5 billion. This has been driven both by the approval of EYLEA in new indications as well as new data that have further increased the confidence of physicians in this product. Thanks to our long-standing belief and investment in science and technology, we are now in the midst of a new product cycle, which has the potential to impact multiple disease settings. This investment in science has resulted in Praluent, our PCSK9 antibody, for lowering LDL cholesterol, and additional potential near-term approvals that could address rheumatoid arthritis and atopic dermatitis. Our late-stage pipeline also includes programs in asthma, pain, respiratory syncytial virus and the immunotherapy of cancer. Our earlier pipeline opportunities continue to grow with a total of 15 product candidates currently in clinical development, including 7 that we are developing independently, with several more expected to enter the clinic in the near term, making for pipeline that can address potential opportunities ranging from rare often diseases such as fibrodysplasia ossificans progressiva, or FOP, to emerging infectious diseases epidemic, such as Zika. George will provide specific details on some of these programs later in this call. All of these opportunities are the results of investments we made in science and technology over the last 20 years, yielding a pipeline that is entirely home-grown. Our commitment to the long-term is unwavering as we invest in the next generation of technologies to support our feature pipeline. For example, our Regeneron Genetics Center and our investment in technologies with companies in the areas of gene-editing and cell therapy, such as Intellia and Adicet, which are synergistic with our existing capabilities. I should also mention that we recognize that we operate in a rapidly changing environment that poses new challenges to the commercialization of our products, and we continue to try and develop innovative solutions to address these issues. Lastly, we believe it's absolutely essential to attract the best and brightest minds to scientific careers and to elevate the place of science in our society. Therefore, we were thrilled to announce in May that Regeneron was selected as the new sponsor of the Science Talent Search. Regeneron is only the third sponsor in this renowned 75-year history of this high school science talent competition, which was previously sponsored by Intel and before that, by Westinghouse. George and I are both alumni of the Science Talent Search, and we believe the program plays a vital role encouraging -- in encouraging talented young people to pursue a path in science and engineering.
With that introduction, let me turn the call over to George."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 bloc",1499,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.
In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 blocker in patients with uncontrolled moderate to severe atopic dermatitis, which is a chronic inflammatory skin disease. Dupilumab is the first systemic therapy to show positive Phase III results in this indication.
On our last earnings call, we talked about the positive data from the first 2 Phase III studies, Solo-1 and Solo-2, which studied dupilumab as a monotherapy.
In June, we just recently reported the results from the third study, LIBERTY AD CHRONOS, which was a long-term study that investigated dupilumab in combination with topical corticosteroids, which are currently the standard of care in the United States for the treatment of this difficult disease. Overall, the efficacy observed in the CHRONOS study was very consistent with the previously reported positive Phase III Solo-1 and Solo-2 studies of dupilumab in the monotherapy setting. While the primary endpoint of the CHRONOS study was assessed at 16 weeks, the study continued until 52 weeks and efficacy was sustained in both the dupilumab 300-milligram weekly as well as the 300-milligram every-other-week dose groups through this 1-year mark. At 16 weeks, about 40% of the patients in both dupilumab dose groups achieved clear or almost clear skin status as measured by the investigator global assessment score compared to about 12% of the patients in the topical-steroid-only arm. Nearly 2/3 of the patients receiving dupilumab achieved a 75% improvement in the average improvement in the overall skin score as assessed by the eczema area and severity index or the EASI score, compared to about 23% of patients in the topical-steroid-only arm.
This was the first long-term Phase III study to show that dupilumab in combination with topical steroids was superior to topical steroids alone and provided sustained efficacy and significantly improved measures of overall disease severity, skin clearing, itching and quality of life through 1 year of treatment.
The overall rate of adverse events and serious adverse events was comparable between the groups treated with dupilumab in combination with topical steroid and the topical steroids alone. Serious and/or severe infections were numerically higher in the topical-steroid-alone group. Adverse events that were noted to have a higher rate with dupilumab treatment included injection-site reactions, which were seen in 20% of the patients on the dupilumab weekly arm, 16% of the patients in dupilumab every-2-week arm and 9% of the patients in the placebo plus topical-steroid-alone arm. And conjunctivitis, which was observed in 19% of the patients in the dupilumab weekly arm, 13% of patients in the dupilumab every-other-week arm and 8% of patients in the topical-steroid-alone arm. About 22% of the patients in the placebo group, 23% of the patients in the dupilumab weekly group and 28% in the dupilumab every-other-weekly group had a reported history of allergic conjunctivitis coming into the study.
These 1-year results from the CHRONOS study further suggested dupilumab impacts the aberrant activation of the interleukin-4/13 pathway and results in significant efficacy without the side effects associated with immune-suppressing therapies.
In this regard, and very importantly, we have not observed an increase in overall infections or serious infections in our atopic dermatitis program to date. The U.S. BLA submission has been completed, and we look forward to working with the FDA to bringing this important breakthrough therapy to patients as soon as possible.
We are also developing dupilumab in other allergic diseases, such as asthma, nasal polyps, and eosinophilic esophagitis. As a reminder, our first pivotal study in asthma show that 2 doses of dupilumab, 200 milligram and 300 milligram every other week, in combination with inhaled steroids and long-acting beta-agonist, demonstrated a statistically significant 12% to 15% improvement in lung function as measured by FEV1 over placebo at week 12, and a 64% to 75% reduction in the annualized rate of severe asthma exacerbations over placebo. The most common adverse event was injection-site reaction, which are more frequent in the dupilumab dose groups at 13% to 25% compared to 12% in the placebo group. The incident of infections was balance across treatment groups at 42% to 45% of dupilumab arms and 46% in the placebo arm as was the incidence of serious adverse events, which were seen in 3% to 7% of the dupilumab groups and 5% in the placebo group. We expect our confirmatory 1-year Phase III study of dupilumab in this indication to complete enrollment in the third quarter of 2016.
As a reminder, we are the only late-stage biologic that targets both IL-4 and IL-13, and recent competitor [ph] developments in the late-stage asthma space are consistent with our preclinical data and our hypothesis that it is important to block both of these interleukins.
Turning to Praluent. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. As we had previously disclosed, the data-monitoring committee for this study completed the first interim analysis with 50% of the total events had accrued based on unblinded study data. In addition to reviewing the safety study, the DMC performed a futility assessment and recommended that the study continue with no changes. A second interim analysis for futility as well as for overwhelming efficacy when 75% of the targeted primary events has occurred is expected later this year.
As Len mentioned, we also have 3 other late-stage programs: Sarilumab, our interleukin-6 receptor antibody for rheumatoid arthritis, where we expect FDA action by October 30; fasinumab, our NGF antibody for pain associated with osteoarthritis; and the Regeneron 2222, for respiratory syncytial virus, or RSV.
Turning now to our earlier-stage pipeline. In May, we reported positive interim proof-of-concept data from a Phase II study of evinacumab and the antibody to angiopoietin-PTL3 in patients with homozygous form of familial hypercholesterolemia. These patients continue to have a major unmet need as they are typically not as responsive to standard lipid-lowering therapy, such as statins or even to PCSK9 inhibition. And some of the other treatment options available to them are limited by the accompanying safety and tolerability concerns. Although these data were from a small number of patients, we're encouraged by the additional 55% reduction in LDL cholesterol levels at week 4 on top of standard of care compared to baseline.
In this study, evinacumab was generally well tolerated and there were no adverse events leading to discontinuation. The most common drug-related adverse events were injection-site reactions, which were mild in severity.
Our Phase II study of EYLEA in a co-formulated combination with rinucumab, our PDGF-receptor antibody, in wet age-related macular degeneration, or wet AMD, which has been granted fast-track designation, is fully enrolled, and we expect top line data from the study in the fourth quarter of 2016. This is a 3-arm, 2-stage study with patients randomized to receive 1 of 3 dosing regimens: EYLEA alone; EYLEA in combination with low-dose PDGF-blocking antibody; or EYLEA in combination with high-dose PDGF-blocking antibody. The primary efficacy endpoint of the first stage of this study is the mean change in visual acuity at week 12 from baseline. The second stage of the study is designed to confirm and extend the findings from the first stage of the study. Our Phase II combination studies of EYLEA in a co-formulated combination with Nesvacumab, our antibody to angiopoietin-2, in AMD and DME, continue to enroll patients. We are very excited by our earlier-stage pipeline in immuno-oncology, where both our PD-1 antibody and our CD20 by CD3 bispecific antibody have demonstrated promising activity in early clinical trials. A potential pivotal study with our PD-1 antibody in cutaneous squamous cell carcinoma continues to enroll patients, and we hope to be investigating additional agents and combinations over the next 6 to 12 months. We have also expanded our capability in the area of precision immunotherapy with our recently announced collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapies. This collaboration takes advantage over our unique VelocImmune and Veloci-Next technologies that will allow us to use cell-based therapies to target tumor cells.
We also recently initiated Phase I study in healthy volunteers of Regeneron 2477, an Activin A antibody, being developed for the treatment of fibrodysplasia ossificans progressiva, or FOP, and other musculoskeletal disorders. We remain committed to using our technologies and approaches to help address emerging infectious diseases, such as Ebola, MERS and Zika. For Zika, we have identified several fully human monoclonal antibody candidates that we're able to potentially block the virus -- to potently block the virus from infecting cells in vitro, and early data indicates that these antibodies are protected in an animal model. We are now in the process of scaling up for human trials. We also recently initiated our first in-human study in healthy volunteers in our Ebola program, which has been granted orphan drug designation by the FDA.
With that, let me turn the call over to Bob Terifay."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or a",803,"Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or alirocumab, among U.S. payers. In addition, the European and Japanese launches for Praluent continue to progress. And we are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next year.
Starting with EYLEA. Second quarter U.S. net sales grew 27% year-over-year. Net U.S. EYLEA sales in the second quarter were $831 million. Net ex U.S. EYLEA sales in the second quarter were $486 million, which represents 44% growth year-over-year on a reported basis. We continue to have a strong position in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market in terms of injections as reported by 203 retinal specialists in our quarterly market research survey. According to our survey results, in the overall anti-VEGF market, EYLEA has a 37% share of injections as compared to 19% for ranibizumab and 44% for off-label repackaged bevacizumab. On the other hand, with our growing market share, our expenses to support reimbursement activities, including patient support services and reimbursement assistance, have also increased, impacting both our gross-to-net ratio as well as our profit margin. I should note that there are currently a series of proposals for the -- from the Centers for Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B buy-and-bill drugs, which could lead towards positions favoring the use of bevacizumab or, in large-volume retinal practices, ranibizumab due to the provision of increased direct-to-physician financial incentives from the manufacturer and group-purchasing organizations.
The impact of any changes is difficult to predict. Though we are monitoring this situation very closely. Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. We believe that physician choice should be preserved and alternative schemas to reduce health care cost should be explored.
Turning now to Praluent. As reported by Sanofi, net sales in the second quarter were $24 million worldwide, with the U.S. accounting for $21 million of the total. I'm pleased to share that as of July 1, approximately 74% of commercially insured lives and approximately 91% of Medicare-insured lives have access to Praluent. We continue to see improvement in the number of prescriptions that are successfully being filled, with both Praluent and evolocumab generally splitting market share evenly. However, only approximately 25% of our prescriptions written actually get dispensed. Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork that the pharmacy benefits managers and health plans have put in place, many patients who are eligible for treatment with the PCSK9 inhibitor have not had their prescriptions filled. We continue to focus our efforts on improving access -- improving the prescription process through the payers and the specialty pharmacies. Over the last several months, we've seen some payers loosen their utilization management criteria, removing the requirement for prior ezetimibe therapy. Others have streamlined the prior-authorization processes. ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of Praluent.
Outside of the United States, Praluent was approved in the EU in September of 2015, with the product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K. and Spain among others. It still remains a difficult reimbursement market with some countries awaiting OUTCOMES data. In the United States, we've submitted the supplemental BLA for the 300-milligram monthly dose of Praluent and have been granted a PDUFA date of January 24, 2017. We have also submitted a regulatory application for Praluent monthly dosing in the EU. Also in July, Praluent was approved in Japan. We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our IL-6 receptor inhibitor, for rheumatoid arthritis and have been granted a PDUFA date of October 30, 2016. Earlier this week, the European Marketing Authorization Application, or MAA, for sarilumab was accepted for review by the European Medicines Agency. We will be co-promoting sarilumab with Sanofi Genzyme in the United States, and we've completed hiring of our field-based team. Training began this week. Co-promotion decisions for other countries will be made over time. We're currently preparing for dupilumab commercialization with potential U.S. approval in the first half 2017. We'll be co-promoting dupilumab in the United States with Sanofi Genzyme and they have begun interviewing our sales management team. Co-promotion decisions for other countries will be made at a later date.
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented a",1438,"Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented an increase of 24% in both non-GAAP net income per diluted share as well as non-GAAP net income in the second quarter of 2016 compared to the second quarter of 2015.
Regeneron's second quarter 2016 non-GAAP net income excludes noncash share-based compensation expense and $75 million up-front payment made in connection with our April 2016 license and collaboration agreement with Intellia. It also includes the income tax effect of these non-GAAP adjustments. A full reconciliation of GAAP and non-GAAP earnings is set forth in our earnings release. I will describe in further detail shortly, effective this quarter, our non-GAAP net income is no longer includes in adjustment from GAAP tax expense to the amount of taxes that were estimated to be paid or payable in cash. Total revenues in the second quarter of 2016 were $1.2 billion, which represented a year-over-year growth of 21% over the second quarter of 2015. Net product sales were $834 million in the second quarter of 2016 compared to $658 million in the second quarter of 2015. EYLEA U.S. net product sales were $831 million compared to $655 million in the second quarter of 2015, representing a 27% year-over-year growth. Sequential quarter-over-quarter growth was 6%. EYLEA distributor inventory levels continue to be within our normal 1- to 2-week targeted range, and the June 30 levels were very similar to our large March 31, 2016 levels.
Please note that we are reaffirming our 2016 U.S. EYLEA net sales guidance to be year-over-year growth of between 20% and 25%.
Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $486 million in the second quarter of 2016 compared to $338 million in the second quarter of 2015, representing a 44% increase on a reported basis. On an operational basis, or constant currency basis, sales increased approximately 42%. In the second quarter of 2016, Regeneron recognized $167 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the second quarter of 2016 was $192 million.
As a reminder, for the EYLEA franchise, during May 2016, we stopped incurring the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. This benefited our cost to goods sold and cost of collaboration manufacturing line items.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $163 million for the second quarter of 2016. Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the second quarter of 2016, our share of the collaboration's losses in connection with commercialization of antibodies, primarily Praluent, was $122 million, which can be found in table 4 of our earnings release. Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $24 million for the second quarter of 2016.
Turning now to expenses. Non-GAAP R&D expense was $406 million for the second quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total GAAP R&D expense, less R&D reimbursements from our collaborators, R&D noncash share-based compensation expense and the Intellia up-front payment, was $222 million for the 3 months ended June 30, 2016. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. Given our forecasted spend in associate reimbursement level for the second half of 2016, we are increasing and tightening our full year guidance for non-GAAP unreimbursed R&D to be in the range of between $970 million to just over $1 billion from the previously provided range of $875 million to $950 million. This increase is a result of 2 factors: A forecasted increase in spending shift from partnered to unpartnered antibody development programs. We now have 7 antibodies that we're developing independently, including 2 that are in late stage, RSV and fasinumab; and a greater allocation of unreimbursed manufacturing cost within our Rensselaer, New York facility to R&D as opposed to inventory due to less demand for Praluent than was anticipated. Non-GAAP SG&A expense was $244 million for the second quarter of 2016. We are increasing and tightening non-GAAP SG&A expense in 2016 to $980 million to $1.02 billion from the range of $925 million to $1 billion. This increase is primarily driven by our expenses to support EYLEA reimbursement activities, including patient support services and reimbursement assistance along with additional investments in EYLEA's commercialization. This increase is partially offset by lower commercialization and prelaunch spend associated with our collaboration antibodies with Sanofi. As you may recall, last quarter, we introduced a new guidance component, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs that Regeneron incurs in connection with preparing to commercialize or commercializing as applicable, Praluent, sarilumab and dupilumab. Again, this is the line item found within Sanofi collaboration revenue and is referenced in table 4 of our press release.
For the second quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $86 million. We are lowering and tightening this guidance in 2016 to be in the range of $310 million and $340 million from $320 million to $370 million.
Turning now to taxes. Prior to the quarter ended June 30, 2016, our non-GAAP measures included an income tax expense adjustment from GAAP tax expense to the amount of taxes that were paid or payable in cash for the respective period. Historically, there was a significant difference between the company's GAAP-effective tax rate and the actual cash income taxes paid or payable primarily due to tax benefits related to employee exercises stock options. The tax benefits related to employee exercises stock options were historically recorded in additional paid in capital for GAAP-reporting purposes.
During the second quarter of 2016, the company early adopted accounting standards update 2016-09. The new standard requires companies to recognize tax benefits in connection with employee exercises of stock option in the income statement. In other words, we'll account for tax deductions related to stock option exercises in the period of exercise as a discrete item to the quarter. With the early adoption of the new standard, the company chose to discontinue its former non-GAAP income tax expense adjustment since by adopting the new standard and eliminated one of our primarily -- primary differences between the company's effective tax rate and cash income taxes paid or payable. As a result, our second quarter 2016 and 2015 non-GAAP financial results included in our earnings release for comparison now reflect discontinuance of our non-GAAP income tax expense adjustment.
This new standard will result in variability in our effective tax rate from quarter-to-quarter. As based on GAAP rules, these items are not forecasted in our estimated annual effective tax rate. These deductions are based on the company's stock price and individual employees' decisions on when to exercise their stock options. The current tax-related adjustment in our reconciliation of GAAP net income to non-GAAP net income, table 3 of our earnings release, solely represents the income tax effects related to our non-GAAP pretax adjustments. Our effective tax rate for the second quarter of 2016 was approximately 33%, which is 8% lower compared to the second quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings and share base compensation as compared to the same quarter of last year.
For 2016, our guidance for our GAAP effective tax rate for the full year will be 33% to 41%. Our capital expenditures for the second quarter of 2016 and for the 6 months ended June 30, 2016 was $139 million and $243 million, respectively. We are lowering our full year 2016 capital expenditure guidance to a range of $480 million to $530 million from the previously provided range of $550 million to $625 million. These 2016 expenditures include the expansion of our manufacturing capabilities in both Rensselaer, New York; in Limerick, Ireland; as well as growth in our Tarrytown, New York headquarters as we continue to grow our employee base. Regeneron's balance sheet had $1.64 billion of cash and marketable securities as of June 30, 2016. Less than $500,000 of our originally issued $400 million of convertible senior notes due October 1, 2016, remain outstanding.
With that, I would now like to turn the call back to Michael."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for qu",45,"Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for questions."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're ho",68,"This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're hoping to see with respect to efficacy in order to make a go, no- go decision on the Phase III?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the firs",215,"It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the first stage. As you know, even in studies with hundreds of patients in them, as we have of course seen, we have as much experience as anybody alone and with our collaborators doing these large studies, there can be a lot of variability in letters gained. So we designed the study to include a second stage as well that actually shows the effects of adding on therapy on top within the same group. That we predict to be a more powerful way of confirming if there are added benefits of the PDGF therapies. So we'll have the first type of comparison, which we consider perhaps to be slightly less powerful in the time frame that I just described, and then we will also be getting the second stage of data. So depending on how strong the first set of data is, we will either be able to make a decision at that point or we'll be awaiting the results from the second stage to help us make that decision."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hu",70,"I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hurdle for us to move forward isn't that great because there's no additional burden on patients having to take an additional injection."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Robyn Karnauskas from Citigroup.",9,"Our next question comes from Robyn Karnauskas from Citigroup."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring pr",99,"So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring prior auth or reduce the requirements for filling up forms, et cetera? And then going to that, what do you think the trigger point was for doing that? And what are the timing for these events, like the third quarter? What triggers these things and how do we think about that going forward?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at t",149,"So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice of some of their physician -- medical directors, they've removed the ezetimibe step at it. And that has happened in a few plans already. With regards to the prior authorization paperwork, some of the payers had prior authorizations that required 10s -- almost up to 40 questions. It became very tedious for the physicians. So some of the plans have begun to change their prior authorization to be simpler. And again, that is in place in a few payers now. I think the real driver that's going to change things is going to be when we get the OUTCOMES data for the product."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate th",252,"Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate the drug, this is not like hepatitis C market. Those should be long-term patients, so we begin to accumulate as opposed to constantly having to find to replace as you would, let's say in a hep C environment. Secondly, as Bob said, this is -- the cardiologists are not like the rheumatologists where they have people in their office, who are very experienced in dealing with the prior authorizations and paperwork, and I think that they are getting more efficient at it, they are somewhat frustrated by it for sure, and some of them are giving up. Some say, ""well, I'll wait for outcomes before I go to the mat with fights"" and things like that. But I do believe that the experience that the doctors in picking the patients that they know that each PBM for each patient or each payer, if you will, they kind of know -- are getting better at knowing how to get this done as they get more experience. And then, of course, finally, as George mentioned, we hope that the OUTCOMES data later this year will change the dynamic out there in terms of the feeling, the compelling need to go on these products if we show an OUTCOMES benefit."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ronny Gal from Bernstein.",9,"Our following question comes from Ronny Gal from Bernstein."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","One second.",2,"One second."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Do you have a question?",5,"Do you have a question?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Yes, right here. Sorry, actually never mind.",7,"Yes, right here. Sorry, actually never mind."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ying Huang from Bank of America Merrill Lynch.",13,"Our following question comes from Ying Huang from Bank of America Merrill Lynch."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does t",60,"Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that [indiscernible] apply in this case? And what are you expecting for the outcome?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early fiel",169,"Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early field. And based on a lot of the science, it's really very, very hard to predict what, if any, benefit will be seen here. Would you think that our unique two-stage design will end up giving us probably the best data in most convincing perspective on whether there is an added benefit or not, and as Len pointed out, the fact that if there is an added benefit, we'll be able to do it with a single injection. And assuming appropriate safety, we'll make it easier to deliver that benefit to patients with this approach. And remember, our approach here, we are combining 2 very similar antibody-like drugs into a single co-formulated injection as opposed to giving 2 very different types of drugs with separate injections."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Geoffrey Porges from Leerink.",9,"Our following question comes from Geoffrey Porges from Leerink."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook.",68,"Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook. What are the parallels or differences to the Praluent experience? And how much you get payers to let some patients through in this case?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical ste",642,"Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical steroids are used in the populations and so forth, and we have various ideas about why this may be the case. That said, even though it seems specific to the way the drug is being used in this particular patient population and perhaps with either the use or actually the less use of topical steroids in the treated patients. The comforting thing is that these patients do have -- as we pointed out in the call, they do have already a lot of history of conjunctivitis. So this is not really something brand-new to the patients. And the conjunctivitis that is seen here on dupilumab seems to be of mild-to-moderate severity and is limited. Most cases actually resolve during treatment. And very few, if any, cases actually lead to discontinuation. So it seems as if the benefit/risk is really maintained in the face of this. That said also, in terms of the second part of your question about dupilumab, we think it's a very different situation compared to Praluent. I mean there is a huge unmet need here. Patients are really suffering from ongoing symptomatology. And the data actually shows that this symptomatology is actually markedly improved with the dupilumab treatment. So that it seems to us that there's going to be a lot of patients who really are -- and we already know, who are going to be so positively impacted in their lives that they're going to be demanding this drug. And it seems to us that these patients will deserve to have this first systemic therapy that can really make a difference in their lives. Let me remind you that this is -- we're talking about the most moderate-to-severe class of the patients here, which are more than 1 million patients in the United States alone, and these patients really have very few other alternatives. And as you can see with our data in CHRONOS, where we treat on top of topical steroids, the standard of care, very few, only about 10% of the patients or so, become clear or almost clear with topical steroids as opposed to about 40% on the drug. And there's not only, of course, the cosmetic effects of having these skin lesions and so forth and the associated infections and so forth that you get, but there's an enormous amount of itch, which drives a lot of behavioral problems and so forth. There is associated depressive and psychological symptomatology here and so forth. And we've actually shown that much of this is actually impacted in our studies. So we think this can be a very important drug for this population of patients, and we think that there's going to be a very important opportunity to make a lot of difference in a lot of people's lives, which is what should count in this business. But beyond that, I think that we also have to remember that dupilumab is really a franchise onto itself. The data really suggest that we have hit upon here with blocking both interleukin-4 and 13, the critical drivers of allergic disease in general. We're hoping obviously to extend the findings from our first pivotal study in asthma by confirming them with the second pivotal study. And we'll also be continuing to study in other allergic diseases whereas you've already seen we already have some positive data in other allergic diseases in early-stage studies as well. So this can benefit not only the allergic and atopic disease of atopic dermatitis, but we hope to be able to have studies that confirm it to additional allergic diseases as well."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowe",156,"I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowering drug or I'll fix it with diet or take my statin or what have you. But patients with atopic dermatitis really suffer. It's really made its way into pop-culture. There's a new series on HBO. I don't know if any of you have seen, it's called The Night Of, and the actor, John Turturro, portrays this lawyer, who suffers terribly from atopic dermatitis. He has to wear sandals. He goes to groups to discuss all this. And really has a terrible impact on his life. And this -- I don't think this is just a TV portrayal. I think this is what we see, the people really suffer from this disease."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This",124,"I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This appears to be more of immunomodulators correcting an immune deviation. And actually, as we reported and as we summarized during this call, there is no increase in infections and in serious infections here. So once again, this is an important option that's being offered to the patients in contrast to other alternatives which were essentially immunosuppressing. And to have this sort of efficacy with a nonimmunosuppressing agent, I think, is also offering a lot of hope to patients."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Chris Raymond from Raymond James.",9,"Next question comes from Chris Raymond from Raymond James."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is",87,"So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is topical corticosteroids. But just curious, what has your work uncovered in terms of the use of other biologics' off-label and physician satisfaction with these agents? And maybe can you talk about how you're thinking about this as you formulate your launch plans?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other thera",129,"Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therapies, immunosuppressant agents, generally not biologics, but things like cyclosporine and methotrexate. The challenge with those therapies is you can't use them long term. They've got some toxicities that really interfere with the patient's long-term use of the therapy. And thus, their symptoms will come back, their itch will come back and their quality of life will decrease. So there is a huge opportunity for dupilumab in these uncontrolled moderate-to-severe patients. There's the pent-up demand among patients and physicians to get the patients on therapy and to improve their lives."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promis",69,"And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promising in this area. So this really has a chance to really be providing something to patients that don't really have any other alternatives at this point."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effe",146,"I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effect both on FEV1 and on exacerbations. And that -- no such drug has been forthcoming as yet, and we're excited that our first pivotal trial demonstrated in the broad population effect both on FEV1 and on exacerbation. So, hopefully, if we can confirm that in our trial that's just about to be completed in enrollment. So think ahead about 1 year for the trial and then the data, we could be onto something a whole new opportunity which people really are looking for. Something that can treat all the patients and that can treat both the FEV1 and the exacerbations."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosino",95,"As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosinophilic-type patients, and it's the only places where substantial efficacy has been noted. And as Len said, mostly only with exacerbations and not on lung functions. So if we can confirm the results of the first pivotal, it could provide another major hope for patients who really need these types of therapies."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. Thes",66,"And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlapping syndromes because they are scientifically related in -- if I should say pathophysiologically related, we think, to the IL-4/13 pathway."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Mark Schoenebaum from Evercore ISI.",9,"Next question comes from Mark Schoenebaum from Evercore ISI."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that a",70,"It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that are already in development, such as selective? And then I guess, maybe when can we see some of those assets entering the clinic?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think the...",4,"Well, I think the..."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified.",29,"Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. W",196,"I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. We have enormous respect for her, her capabilities, and so we really feel that we can work well together with her and her team. And number 2 is the synergies with our existing programs. This is why we make these sorts of deals. We believe that we have a lot of potential tools and starting points for making the sorts of targeting reagents that would be introduced into these cell therapies using our existing technologies, such our VelocImmune and our Veloci-Next technologies, which really nobody else in this field has access to right now. So we're hoping that we put together our unique capabilities that nobody else in the cell therapy space has, together with a pioneer and leader in this area, such as Aya Jakobovits and her team, that we could really do a special thing. And I think at this point that's what we want to say about this collaboration."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Adnan Butt from RBC Capital.",10,"Our next question comes from Adnan Butt from RBC Capital."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please.",33,"Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies,",90,"Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies, which is cutaneous squamous cell carcinoma. And so that is, for example, one setting. We've also identified additional setting that has been publicly disclosed. We've also identified additional settings that will be going into, we hope, both potentially with it as a monotherapy but also with new combinations."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we have time for one last question.",8,"And we have time for one last question."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Alethia Young from Crdit Suisse.",10,"Our final question comes from Alethia Young from Crdit Suisse."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or",63,"Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or increasing or group purchasing. Why did you specifically kind of bring that to our attention this quarter?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and w",66,"I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and we have responses prepared should they be necessary. Bob, you want to add anything there?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it.",22,"No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?",42,"Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?"
33715,372870908,1025383,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.I will now turn the call",50,"Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.Joining me on the call today are Dr. Leonar",317,"Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available in our website under Events and Presentations for 30 days.
Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer.
After our prepared remarks, we'll open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecast, financial forecast, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC this morning.
Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions.
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to gi",545,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to give you some broader perspective on Regeneron and our business. Regeneron continues to advance its mission to bring important new medicines to patients in need. EYLEA is our drug used to treating a number of potentially blinding diseases. And with millions of injections administered each year, it is one of our most important approved products and continuous grow well globally. EYLEA is now at an annual global net sales run rate that exceeds $5 billion. This has been driven both by the approval of EYLEA in new indications as well as new data that have further increased the confidence of physicians in this product. Thanks to our long-standing belief and investment in science and technology, we are now in the midst of a new product cycle, which has the potential to impact multiple disease settings. This investment in science has resulted in Praluent, our PCSK9 antibody, for lowering LDL cholesterol, and additional potential near-term approvals that could address rheumatoid arthritis and atopic dermatitis. Our late-stage pipeline also includes programs in asthma, pain, respiratory syncytial virus and the immunotherapy of cancer. Our earlier pipeline opportunities continue to grow with a total of 15 product candidates currently in clinical development, including 7 that we are developing independently, with several more expected to enter the clinic in the near term, making for pipeline that can address potential opportunities ranging from rare often diseases such as fibrodysplasia ossificans progressiva, or FOP, to emerging infectious diseases epidemic, such as Zika. George will provide specific details on some of these programs later in this call. All of these opportunities are the results of investments we made in science and technology over the last 20 years, yielding a pipeline that is entirely home-grown. Our commitment to the long-term is unwavering as we invest in the next generation of technologies to support our feature pipeline. For example, our Regeneron Genetics Center and our investment in technologies with companies in the areas of gene-editing and cell therapy, such as Intellia and Adicet, which are synergistic with our existing capabilities. I should also mention that we recognize that we operate in a rapidly changing environment that poses new challenges to the commercialization of our products, and we continue to try and develop innovative solutions to address these issues. Lastly, we believe it's absolutely essential to attract the best and brightest minds to scientific careers and to elevate the place of science in our society. Therefore, we were thrilled to announce in May that Regeneron was selected as the new sponsor of the Science Talent Search. Regeneron is only the third sponsor in this renowned 75-year history of this high school science talent competition, which was previously sponsored by Intel and before that, by Westinghouse. George and I are both alumni of the Science Talent Search, and we believe the program plays a vital role encouraging -- in encouraging talented young people to pursue a path in science and engineering.
With that introduction, let me turn the call over to George."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 bloc",1499,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.
In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and 13 blocker in patients with uncontrolled moderate to severe atopic dermatitis, which is a chronic inflammatory skin disease. Dupilumab is the first systemic therapy to show positive Phase III results in this indication.
On our last earnings call, we talked about the positive data from the first 2 Phase III studies, Solo-1 and Solo-2, which studied dupilumab as a monotherapy.
In June, we just recently reported the results from the third study, LIBERTY AD CHRONOS, which was a long-term study that investigated dupilumab in combination with topical corticosteroids, which are currently the standard of care in the United States for the treatment of this difficult disease. Overall, the efficacy observed in the CHRONOS study was very consistent with the previously reported positive Phase III Solo-1 and Solo-2 studies of dupilumab in the monotherapy setting. While the primary endpoint of the CHRONOS study was assessed at 16 weeks, the study continued until 52 weeks and efficacy was sustained in both the dupilumab 300-milligram weekly as well as the 300-milligram every-other-week dose groups through this 1-year mark. At 16 weeks, about 40% of the patients in both dupilumab dose groups achieved clear or almost clear skin status as measured by the investigator global assessment score compared to about 12% of the patients in the topical-steroid-only arm. Nearly 2/3 of the patients receiving dupilumab achieved a 75% improvement in the average improvement in the overall skin score as assessed by the eczema area and severity index or the EASI score, compared to about 23% of patients in the topical-steroid-only arm.
This was the first long-term Phase III study to show that dupilumab in combination with topical steroids was superior to topical steroids alone and provided sustained efficacy and significantly improved measures of overall disease severity, skin clearing, itching and quality of life through 1 year of treatment.
The overall rate of adverse events and serious adverse events was comparable between the groups treated with dupilumab in combination with topical steroid and the topical steroids alone. Serious and/or severe infections were numerically higher in the topical-steroid-alone group. Adverse events that were noted to have a higher rate with dupilumab treatment included injection-site reactions, which were seen in 20% of the patients on the dupilumab weekly arm, 16% of the patients in dupilumab every-2-week arm and 9% of the patients in the placebo plus topical-steroid-alone arm. And conjunctivitis, which was observed in 19% of the patients in the dupilumab weekly arm, 13% of patients in the dupilumab every-other-week arm and 8% of patients in the topical-steroid-alone arm. About 22% of the patients in the placebo group, 23% of the patients in the dupilumab weekly group and 28% in the dupilumab every-other-weekly group had a reported history of allergic conjunctivitis coming into the study.
These 1-year results from the CHRONOS study further suggested dupilumab impacts the aberrant activation of the interleukin-4/13 pathway and results in significant efficacy without the side effects associated with immune-suppressing therapies.
In this regard, and very importantly, we have not observed an increase in overall infections or serious infections in our atopic dermatitis program to date. The U.S. BLA submission has been completed, and we look forward to working with the FDA to bringing this important breakthrough therapy to patients as soon as possible.
We are also developing dupilumab in other allergic diseases, such as asthma, nasal polyps, and eosinophilic esophagitis. As a reminder, our first pivotal study in asthma show that 2 doses of dupilumab, 200 milligram and 300 milligram every other week, in combination with inhaled steroids and long-acting beta-agonist, demonstrated a statistically significant 12% to 15% improvement in lung function as measured by FEV1 over placebo at week 12, and a 64% to 75% reduction in the annualized rate of severe asthma exacerbations over placebo. The most common adverse event was injection-site reaction, which are more frequent in the dupilumab dose groups at 13% to 25% compared to 12% in the placebo group. The incident of infections was balance across treatment groups at 42% to 45% of dupilumab arms and 46% in the placebo arm as was the incidence of serious adverse events, which were seen in 3% to 7% of the dupilumab groups and 5% in the placebo group. We expect our confirmatory 1-year Phase III study of dupilumab in this indication to complete enrollment in the third quarter of 2016.
As a reminder, we are the only late-stage biologic that targets both IL-4 and IL-13, and recent competitor [ph] developments in the late-stage asthma space are consistent with our preclinical data and our hypothesis that it is important to block both of these interleukins.
Turning to Praluent. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. As we had previously disclosed, the data-monitoring committee for this study completed the first interim analysis with 50% of the total events had accrued based on unblinded study data. In addition to reviewing the safety study, the DMC performed a futility assessment and recommended that the study continue with no changes. A second interim analysis for futility as well as for overwhelming efficacy when 75% of the targeted primary events has occurred is expected later this year.
As Len mentioned, we also have 3 other late-stage programs: Sarilumab, our interleukin-6 receptor antibody for rheumatoid arthritis, where we expect FDA action by October 30; fasinumab, our NGF antibody for pain associated with osteoarthritis; and the Regeneron 2222, for respiratory syncytial virus, or RSV.
Turning now to our earlier-stage pipeline. In May, we reported positive interim proof-of-concept data from a Phase II study of evinacumab and the antibody to angiopoietin-PTL3 in patients with homozygous form of familial hypercholesterolemia. These patients continue to have a major unmet need as they are typically not as responsive to standard lipid-lowering therapy, such as statins or even to PCSK9 inhibition. And some of the other treatment options available to them are limited by the accompanying safety and tolerability concerns. Although these data were from a small number of patients, we're encouraged by the additional 55% reduction in LDL cholesterol levels at week 4 on top of standard of care compared to baseline.
In this study, evinacumab was generally well tolerated and there were no adverse events leading to discontinuation. The most common drug-related adverse events were injection-site reactions, which were mild in severity.
Our Phase II study of EYLEA in a co-formulated combination with rinucumab, our PDGF-receptor antibody, in wet age-related macular degeneration, or wet AMD, which has been granted fast-track designation, is fully enrolled, and we expect top line data from the study in the fourth quarter of 2016. This is a 3-arm, 2-stage study with patients randomized to receive 1 of 3 dosing regimens: EYLEA alone; EYLEA in combination with low-dose PDGF-blocking antibody; or EYLEA in combination with high-dose PDGF-blocking antibody. The primary efficacy endpoint of the first stage of this study is the mean change in visual acuity at week 12 from baseline. The second stage of the study is designed to confirm and extend the findings from the first stage of the study. Our Phase II combination studies of EYLEA in a co-formulated combination with Nesvacumab, our antibody to angiopoietin-2, in AMD and DME, continue to enroll patients. We are very excited by our earlier-stage pipeline in immuno-oncology, where both our PD-1 antibody and our CD20 by CD3 bispecific antibody have demonstrated promising activity in early clinical trials. A potential pivotal study with our PD-1 antibody in cutaneous squamous cell carcinoma continues to enroll patients, and we hope to be investigating additional agents and combinations over the next 6 to 12 months. We have also expanded our capability in the area of precision immunotherapy with our recently announced collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapies. This collaboration takes advantage over our unique VelocImmune and Veloci-Next technologies that will allow us to use cell-based therapies to target tumor cells.
We also recently initiated Phase I study in healthy volunteers of Regeneron 2477, an Activin A antibody, being developed for the treatment of fibrodysplasia ossificans progressiva, or FOP, and other musculoskeletal disorders. We remain committed to using our technologies and approaches to help address emerging infectious diseases, such as Ebola, MERS and Zika. For Zika, we have identified several fully human monoclonal antibody candidates that we're able to potentially block the virus -- to potently block the virus from infecting cells in vitro, and early data indicates that these antibodies are protected in an animal model. We are now in the process of scaling up for human trials. We also recently initiated our first in-human study in healthy volunteers in our Ebola program, which has been granted orphan drug designation by the FDA.
With that, let me turn the call over to Bob Terifay."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or a",803,"Thank you, George, and hello, everyone. We are pleased with the sales growth by EYLEA, or aflibercept, injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or alirocumab, among U.S. payers. In addition, the European and Japanese launches for Praluent continue to progress. And we are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next year.
Starting with EYLEA. Second quarter U.S. net sales grew 27% year-over-year. Net U.S. EYLEA sales in the second quarter were $831 million. Net ex U.S. EYLEA sales in the second quarter were $486 million, which represents 44% growth year-over-year on a reported basis. We continue to have a strong position in our U.S. market share leadership for EYLEA in the FDA-approved anti-VEGF market in terms of injections as reported by 203 retinal specialists in our quarterly market research survey. According to our survey results, in the overall anti-VEGF market, EYLEA has a 37% share of injections as compared to 19% for ranibizumab and 44% for off-label repackaged bevacizumab. On the other hand, with our growing market share, our expenses to support reimbursement activities, including patient support services and reimbursement assistance, have also increased, impacting both our gross-to-net ratio as well as our profit margin. I should note that there are currently a series of proposals for the -- from the Centers for Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B buy-and-bill drugs, which could lead towards positions favoring the use of bevacizumab or, in large-volume retinal practices, ranibizumab due to the provision of increased direct-to-physician financial incentives from the manufacturer and group-purchasing organizations.
The impact of any changes is difficult to predict. Though we are monitoring this situation very closely. Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. We believe that physician choice should be preserved and alternative schemas to reduce health care cost should be explored.
Turning now to Praluent. As reported by Sanofi, net sales in the second quarter were $24 million worldwide, with the U.S. accounting for $21 million of the total. I'm pleased to share that as of July 1, approximately 74% of commercially insured lives and approximately 91% of Medicare-insured lives have access to Praluent. We continue to see improvement in the number of prescriptions that are successfully being filled, with both Praluent and evolocumab generally splitting market share evenly. However, only approximately 25% of our prescriptions written actually get dispensed. Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork that the pharmacy benefits managers and health plans have put in place, many patients who are eligible for treatment with the PCSK9 inhibitor have not had their prescriptions filled. We continue to focus our efforts on improving access -- improving the prescription process through the payers and the specialty pharmacies. Over the last several months, we've seen some payers loosen their utilization management criteria, removing the requirement for prior ezetimibe therapy. Others have streamlined the prior-authorization processes. ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of Praluent.
Outside of the United States, Praluent was approved in the EU in September of 2015, with the product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K. and Spain among others. It still remains a difficult reimbursement market with some countries awaiting OUTCOMES data. In the United States, we've submitted the supplemental BLA for the 300-milligram monthly dose of Praluent and have been granted a PDUFA date of January 24, 2017. We have also submitted a regulatory application for Praluent monthly dosing in the EU. Also in July, Praluent was approved in Japan. We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our IL-6 receptor inhibitor, for rheumatoid arthritis and have been granted a PDUFA date of October 30, 2016. Earlier this week, the European Marketing Authorization Application, or MAA, for sarilumab was accepted for review by the European Medicines Agency. We will be co-promoting sarilumab with Sanofi Genzyme in the United States, and we've completed hiring of our field-based team. Training began this week. Co-promotion decisions for other countries will be made over time. We're currently preparing for dupilumab commercialization with potential U.S. approval in the first half 2017. We'll be co-promoting dupilumab in the United States with Sanofi Genzyme and they have begun interviewing our sales management team. Co-promotion decisions for other countries will be made at a later date.
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented a",1438,"Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented an increase of 24% in both non-GAAP net income per diluted share as well as non-GAAP net income in the second quarter of 2016 compared to the second quarter of 2015.
Regeneron's second quarter 2016 non-GAAP net income excludes noncash share-based compensation expense and $75 million up-front payment made in connection with our April 2016 license and collaboration agreement with Intellia. It also includes the income tax effect of these non-GAAP adjustments. A full reconciliation of GAAP and non-GAAP earnings is set forth in our earnings release. I will describe in further detail shortly, effective this quarter, our non-GAAP net income is no longer includes in adjustment from GAAP tax expense to the amount of taxes that were estimated to be paid or payable in cash. Total revenues in the second quarter of 2016 were $1.2 billion, which represented a year-over-year growth of 21% over the second quarter of 2015. Net product sales were $834 million in the second quarter of 2016 compared to $658 million in the second quarter of 2015. EYLEA U.S. net product sales were $831 million compared to $655 million in the second quarter of 2015, representing a 27% year-over-year growth. Sequential quarter-over-quarter growth was 6%. EYLEA distributor inventory levels continue to be within our normal 1- to 2-week targeted range, and the June 30 levels were very similar to our large March 31, 2016 levels.
Please note that we are reaffirming our 2016 U.S. EYLEA net sales guidance to be year-over-year growth of between 20% and 25%.
Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $486 million in the second quarter of 2016 compared to $338 million in the second quarter of 2015, representing a 44% increase on a reported basis. On an operational basis, or constant currency basis, sales increased approximately 42%. In the second quarter of 2016, Regeneron recognized $167 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the second quarter of 2016 was $192 million.
As a reminder, for the EYLEA franchise, during May 2016, we stopped incurring the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. This benefited our cost to goods sold and cost of collaboration manufacturing line items.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $163 million for the second quarter of 2016. Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron commercialization-related expenses and our share of profits or losses in connection with commercialization of antibodies. In the second quarter of 2016, our share of the collaboration's losses in connection with commercialization of antibodies, primarily Praluent, was $122 million, which can be found in table 4 of our earnings release. Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $24 million for the second quarter of 2016.
Turning now to expenses. Non-GAAP R&D expense was $406 million for the second quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total GAAP R&D expense, less R&D reimbursements from our collaborators, R&D noncash share-based compensation expense and the Intellia up-front payment, was $222 million for the 3 months ended June 30, 2016. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. Given our forecasted spend in associate reimbursement level for the second half of 2016, we are increasing and tightening our full year guidance for non-GAAP unreimbursed R&D to be in the range of between $970 million to just over $1 billion from the previously provided range of $875 million to $950 million. This increase is a result of 2 factors: A forecasted increase in spending shift from partnered to unpartnered antibody development programs. We now have 7 antibodies that we're developing independently, including 2 that are in late stage, RSV and fasinumab; and a greater allocation of unreimbursed manufacturing cost within our Rensselaer, New York facility to R&D as opposed to inventory due to less demand for Praluent than was anticipated. Non-GAAP SG&A expense was $244 million for the second quarter of 2016. We are increasing and tightening non-GAAP SG&A expense in 2016 to $980 million to $1.02 billion from the range of $925 million to $1 billion. This increase is primarily driven by our expenses to support EYLEA reimbursement activities, including patient support services and reimbursement assistance along with additional investments in EYLEA's commercialization. This increase is partially offset by lower commercialization and prelaunch spend associated with our collaboration antibodies with Sanofi. As you may recall, last quarter, we introduced a new guidance component, Sanofi reimbursement of Regeneron commercialization-related expenses, which represents reimbursement of internal and external costs that Regeneron incurs in connection with preparing to commercialize or commercializing as applicable, Praluent, sarilumab and dupilumab. Again, this is the line item found within Sanofi collaboration revenue and is referenced in table 4 of our press release.
For the second quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $86 million. We are lowering and tightening this guidance in 2016 to be in the range of $310 million and $340 million from $320 million to $370 million.
Turning now to taxes. Prior to the quarter ended June 30, 2016, our non-GAAP measures included an income tax expense adjustment from GAAP tax expense to the amount of taxes that were paid or payable in cash for the respective period. Historically, there was a significant difference between the company's GAAP-effective tax rate and the actual cash income taxes paid or payable primarily due to tax benefits related to employee exercises stock options. The tax benefits related to employee exercises stock options were historically recorded in additional paid in capital for GAAP-reporting purposes.
During the second quarter of 2016, the company early adopted accounting standards update 2016-09. The new standard requires companies to recognize tax benefits in connection with employee exercises of stock option in the income statement. In other words, we'll account for tax deductions related to stock option exercises in the period of exercise as a discrete item to the quarter. With the early adoption of the new standard, the company chose to discontinue its former non-GAAP income tax expense adjustment since by adopting the new standard and eliminated one of our primarily -- primary differences between the company's effective tax rate and cash income taxes paid or payable. As a result, our second quarter 2016 and 2015 non-GAAP financial results included in our earnings release for comparison now reflect discontinuance of our non-GAAP income tax expense adjustment.
This new standard will result in variability in our effective tax rate from quarter-to-quarter. As based on GAAP rules, these items are not forecasted in our estimated annual effective tax rate. These deductions are based on the company's stock price and individual employees' decisions on when to exercise their stock options. The current tax-related adjustment in our reconciliation of GAAP net income to non-GAAP net income, table 3 of our earnings release, solely represents the income tax effects related to our non-GAAP pretax adjustments. Our effective tax rate for the second quarter of 2016 was approximately 33%, which is 8% lower compared to the second quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings and share base compensation as compared to the same quarter of last year.
For 2016, our guidance for our GAAP effective tax rate for the full year will be 33% to 41%. Our capital expenditures for the second quarter of 2016 and for the 6 months ended June 30, 2016 was $139 million and $243 million, respectively. We are lowering our full year 2016 capital expenditure guidance to a range of $480 million to $530 million from the previously provided range of $550 million to $625 million. These 2016 expenditures include the expansion of our manufacturing capabilities in both Rensselaer, New York; in Limerick, Ireland; as well as growth in our Tarrytown, New York headquarters as we continue to grow our employee base. Regeneron's balance sheet had $1.64 billion of cash and marketable securities as of June 30, 2016. Less than $500,000 of our originally issued $400 million of convertible senior notes due October 1, 2016, remain outstanding.
With that, I would now like to turn the call back to Michael."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for qu",45,"Thank you, Bob. That concludes our prepared remarks. We'd now like to open the call for Q&A. [Operator Instructions] As always, our team will be available in our office after the call for any follow-up questions. Operator, you can now open the call for questions."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're ho",68,"This is Cameron Bradshaw filling in for Terence. I was wondering for the Phase II trials EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're hoping to see with respect to efficacy in order to make a go, no- go decision on the Phase III?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the firs",215,"It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone, with 2 doses of the blocker. That's the first stage. As you know, even in studies with hundreds of patients in them, as we have of course seen, we have as much experience as anybody alone and with our collaborators doing these large studies, there can be a lot of variability in letters gained. So we designed the study to include a second stage as well that actually shows the effects of adding on therapy on top within the same group. That we predict to be a more powerful way of confirming if there are added benefits of the PDGF therapies. So we'll have the first type of comparison, which we consider perhaps to be slightly less powerful in the time frame that I just described, and then we will also be getting the second stage of data. So depending on how strong the first set of data is, we will either be able to make a decision at that point or we'll be awaiting the results from the second stage to help us make that decision."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hu",70,"I will just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hurdle for us to move forward isn't that great because there's no additional burden on patients having to take an additional injection."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Robyn Karnauskas from Citigroup.",9,"Our next question comes from Robyn Karnauskas from Citigroup."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring pr",99,"So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the peers had higher restrictions initially this year? And then how did that change? And what percent of people are not requiring prior auth or reduce the requirements for filling up forms, et cetera? And then going to that, what do you think the trigger point was for doing that? And what are the timing for these events, like the third quarter? What triggers these things and how do we think about that going forward?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at t",149,"So there have been some payers that based upon the FDA decision, not to approve ezetimibe based upon their OUTCOMES data that I've said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice of some of their physician -- medical directors, they've removed the ezetimibe step at it. And that has happened in a few plans already. With regards to the prior authorization paperwork, some of the payers had prior authorizations that required 10s -- almost up to 40 questions. It became very tedious for the physicians. So some of the plans have begun to change their prior authorization to be simpler. And again, that is in place in a few payers now. I think the real driver that's going to change things is going to be when we get the OUTCOMES data for the product."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate th",252,"Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients get on the drug, get their cholesterol lowered and tolerate the drug, this is not like hepatitis C market. Those should be long-term patients, so we begin to accumulate as opposed to constantly having to find to replace as you would, let's say in a hep C environment. Secondly, as Bob said, this is -- the cardiologists are not like the rheumatologists where they have people in their office, who are very experienced in dealing with the prior authorizations and paperwork, and I think that they are getting more efficient at it, they are somewhat frustrated by it for sure, and some of them are giving up. Some say, ""well, I'll wait for outcomes before I go to the mat with fights"" and things like that. But I do believe that the experience that the doctors in picking the patients that they know that each PBM for each patient or each payer, if you will, they kind of know -- are getting better at knowing how to get this done as they get more experience. And then, of course, finally, as George mentioned, we hope that the OUTCOMES data later this year will change the dynamic out there in terms of the feeling, the compelling need to go on these products if we show an OUTCOMES benefit."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ronny Gal from Bernstein.",9,"Our following question comes from Ronny Gal from Bernstein."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","One second.",2,"One second."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Do you have a question?",5,"Do you have a question?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Yes, right here. Sorry, actually never mind.",7,"Yes, right here. Sorry, actually never mind."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ying Huang from Bank of America Merrill Lynch.",13,"Our following question comes from Ying Huang from Bank of America Merrill Lynch."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does t",60,"Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a whole lot of difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that [indiscernible] apply in this case? And what are you expecting for the outcome?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early fiel",169,"Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the studies, 4 letter differences easily go away. So we really consider this a very early field. And based on a lot of the science, it's really very, very hard to predict what, if any, benefit will be seen here. Would you think that our unique two-stage design will end up giving us probably the best data in most convincing perspective on whether there is an added benefit or not, and as Len pointed out, the fact that if there is an added benefit, we'll be able to do it with a single injection. And assuming appropriate safety, we'll make it easier to deliver that benefit to patients with this approach. And remember, our approach here, we are combining 2 very similar antibody-like drugs into a single co-formulated injection as opposed to giving 2 very different types of drugs with separate injections."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Geoffrey Porges from Leerink.",9,"Our following question comes from Geoffrey Porges from Leerink."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook.",68,"Just on dupilumab. George, could you just comment first on the conjunctivitis. Is that signal really seeing it in the other studies, for example in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook. What are the parallels or differences to the Praluent experience? And how much you get payers to let some patients through in this case?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical ste",642,"Okay. Well, the first part is very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical steroids are used in the populations and so forth, and we have various ideas about why this may be the case. That said, even though it seems specific to the way the drug is being used in this particular patient population and perhaps with either the use or actually the less use of topical steroids in the treated patients. The comforting thing is that these patients do have -- as we pointed out in the call, they do have already a lot of history of conjunctivitis. So this is not really something brand-new to the patients. And the conjunctivitis that is seen here on dupilumab seems to be of mild-to-moderate severity and is limited. Most cases actually resolve during treatment. And very few, if any, cases actually lead to discontinuation. So it seems as if the benefit/risk is really maintained in the face of this. That said also, in terms of the second part of your question about dupilumab, we think it's a very different situation compared to Praluent. I mean there is a huge unmet need here. Patients are really suffering from ongoing symptomatology. And the data actually shows that this symptomatology is actually markedly improved with the dupilumab treatment. So that it seems to us that there's going to be a lot of patients who really are -- and we already know, who are going to be so positively impacted in their lives that they're going to be demanding this drug. And it seems to us that these patients will deserve to have this first systemic therapy that can really make a difference in their lives. Let me remind you that this is -- we're talking about the most moderate-to-severe class of the patients here, which are more than 1 million patients in the United States alone, and these patients really have very few other alternatives. And as you can see with our data in CHRONOS, where we treat on top of topical steroids, the standard of care, very few, only about 10% of the patients or so, become clear or almost clear with topical steroids as opposed to about 40% on the drug. And there's not only, of course, the cosmetic effects of having these skin lesions and so forth and the associated infections and so forth that you get, but there's an enormous amount of itch, which drives a lot of behavioral problems and so forth. There is associated depressive and psychological symptomatology here and so forth. And we've actually shown that much of this is actually impacted in our studies. So we think this can be a very important drug for this population of patients, and we think that there's going to be a very important opportunity to make a lot of difference in a lot of people's lives, which is what should count in this business. But beyond that, I think that we also have to remember that dupilumab is really a franchise onto itself. The data really suggest that we have hit upon here with blocking both interleukin-4 and 13, the critical drivers of allergic disease in general. We're hoping obviously to extend the findings from our first pivotal study in asthma by confirming them with the second pivotal study. And we'll also be continuing to study in other allergic diseases whereas you've already seen we already have some positive data in other allergic diseases in early-stage studies as well. So this can benefit not only the allergic and atopic disease of atopic dermatitis, but we hope to be able to have studies that confirm it to additional allergic diseases as well."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowe",156,"I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol-lowering drug or I'll fix it with diet or take my statin or what have you. But patients with atopic dermatitis really suffer. It's really made its way into pop-culture. There's a new series on HBO. I don't know if any of you have seen, it's called The Night Of, and the actor, John Turturro, portrays this lawyer, who suffers terribly from atopic dermatitis. He has to wear sandals. He goes to groups to discuss all this. And really has a terrible impact on his life. And this -- I don't think this is just a TV portrayal. I think this is what we see, the people really suffer from this disease."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This",124,"I think one last point to just add as well is that unlike most other biologics that are immunomodulators where you see, in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This appears to be more of immunomodulators correcting an immune deviation. And actually, as we reported and as we summarized during this call, there is no increase in infections and in serious infections here. So once again, this is an important option that's being offered to the patients in contrast to other alternatives which were essentially immunosuppressing. And to have this sort of efficacy with a nonimmunosuppressing agent, I think, is also offering a lot of hope to patients."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Chris Raymond from Raymond James.",9,"Next question comes from Chris Raymond from Raymond James."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is",87,"So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is topical corticosteroids. But just curious, what has your work uncovered in terms of the use of other biologics' off-label and physician satisfaction with these agents? And maybe can you talk about how you're thinking about this as you formulate your launch plans?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other thera",129,"Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies, who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therapies, immunosuppressant agents, generally not biologics, but things like cyclosporine and methotrexate. The challenge with those therapies is you can't use them long term. They've got some toxicities that really interfere with the patient's long-term use of the therapy. And thus, their symptoms will come back, their itch will come back and their quality of life will decrease. So there is a huge opportunity for dupilumab in these uncontrolled moderate-to-severe patients. There's the pent-up demand among patients and physicians to get the patients on therapy and to improve their lives."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promis",69,"And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promising in this area. So this really has a chance to really be providing something to patients that don't really have any other alternatives at this point."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effe",146,"I would add also to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effect both on FEV1 and on exacerbations. And that -- no such drug has been forthcoming as yet, and we're excited that our first pivotal trial demonstrated in the broad population effect both on FEV1 and on exacerbation. So hopefully, if we can confirm that in our trial that's just about to be completed in enrollment. So think ahead about 1 year for the trial and then the data, we could be onto something a whole new opportunity which people really are looking for. Something that can treat all the patients and that can treat both the FEV1 and the exacerbations."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosino",95,"As Len briefly touched upon, a very important feature that, of course, we're hoping to confirming in our second pivotal study is this point about the broad population. I mean, so far biologics have been limited to the so-called the more allergic or eosinophilic-type patients, and it's the only places where substantial efficacy has been noted. And as Len said, mostly only with exacerbations and not on lung functions. So if we can confirm the results of the first pivotal, it could provide another major hope for patients who really need these types of therapies."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. Thes",66,"And the last point on that, which George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlapping syndromes because they are scientifically related in -- if I should say pathophysiologically related, we think, to the IL-4/13 pathway."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Mark Schoenebaum from Evercore ISI.",9,"Next question comes from Mark Schoenebaum from Evercore ISI."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that a",70,"It's John Scotti in for Mark. I will just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the of-the-shelf therapies there? And how -- I guess how does that approach differ from those that are already in development, such as selective? And then I guess, maybe when can we see some of those assets entering the clinic?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think the...",4,"Well, I think the..."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified.",29,"Before you answer that, George, I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. W",196,"I think an important point to make is we really believe in people, and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who is really leading Adicet. And obviously, she's been in areas that we've been in. We have enormous respect for her, her capabilities, and so we really feel that we can work well together with her and her team. And number 2 is the synergies with our existing programs. This is why we make these sorts of deals. We believe that we have a lot of potential tools and starting points for making the sorts of targeting reagents that would be introduced into these cell therapies using our existing technologies, such our VelocImmune and our Veloci-Next technologies, which really nobody else in this field has access to right now. So we're hoping that we put together our unique capabilities that nobody else in the cell therapy space has, together with a pioneer and leader in this area, such as Aya Jakobovits and her team, that we could really do a special thing. And I think at this point that's what we want to say about this collaboration."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Adnan Butt from RBC Capital.",10,"Our next question comes from Adnan Butt from RBC Capital."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please.",33,"Let me ask a 10-Q question. Less PD-1 is embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies,",90,"Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies, which is cutaneous squamous cell carcinoma. And so that is, for example, one setting. We've also identified additional setting that has been publicly disclosed. We've also identified additional settings that will be going into, we hope, both potentially with it as a monotherapy but also with new combinations."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And we have time for one last question.",8,"And we have time for one last question."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Alethia Young from Crdit Suisse.",10,"Our final question comes from Alethia Young from Crdit Suisse."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or",63,"Just going back to your prepared remarks. I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for EYLEA kind of -- the financial and sums that manufacturing is providing or increasing or group purchasing. Why did you specifically kind of bring that to our attention this quarter?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and w",66,"I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It has not been any drastic change. But it's just sort of to get in front of these things. We monitor them and we have responses prepared should they be necessary. Bob, you want to add anything there?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it.",22,"No. I mean, it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay.",1,"Okay."
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?",42,"Great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry, and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?"
33715,372870908,1026222,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.I will now turn the call",50,"Welcome to the Regeneron Pharmaceuticals' Second Quarter 2016 Earnings Conference Call. My name is Sylvia, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events and Presentations for 30 days. Joining me on the call today are Dr. Leonard",318,"Thank you, and good morning and welcome to Regeneron Pharmaceuticals' Second Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events and Presentations for 30 days. Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President, Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended June 30, 2016, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the IR team will be available to answer further questions.
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to gi",549,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. Before I turn the call over to my colleagues, who will discuss our scientific, commercial and financial performance, I'd like to take a few minutes to give you some broader perspective on Regeneron and our business. 
Regeneron continues to advance its mission to bring important new medicines to patients in need. EYLEA is our drug used to treat a number of potentially blinding diseases. And with millions of injections administered each year, it is one of our most important approved products and continues to grow well globally. EYLEA is now at an annual global net sales run rate that exceeds $5 billion. This has been driven both by the approval of EYLEA in new indications as well as new data that have further increased the confidence of physicians in this product. 
Thanks to our long-standing belief and investment in science and technology, we are now in the midst of a new product cycle, which has the potential to impact multiple disease settings. This investment in science has resulted in Praluent, our PCSK9 antibody, for lowering LDL cholesterol, and additional potential near-term approvals that could address rheumatoid arthritis and atopic dermatitis. Our late-stage pipeline also includes programs in asthma, pain, respiratory syncytial virus and the immunotherapy of cancer. 
Our earlier pipeline opportunities continue to grow with a total of 15 product candidates currently in clinical development, including 7 that we are developing independently, with several more expected to enter the clinic in the near term, making for a pipeline that can address potential opportunities ranging from rare orphan diseases such as fibrodysplasia ossificans progressiva, or FOP, to emerging infectious diseases, epidemic such as Zika. George will provide specific details on some of these programs later in this call. 
All of these opportunities are the results of investments we made in science and technology over the last 20 years, yielding a pipeline that is entirely home-grown. Our commitment to the long term is unwavering as we invest in the next generation of technologies to support our future pipeline. For example, our Regeneron Genetics Center and our investment in technologies with companies in the areas of gene editing and cell therapy, such as Intellia and Adicet, which are synergistic with our existing capabilities. I should also mention that we recognize that we operate in a rapidly changing environment that poses new challenges to the commercialization of our products, and we continue to try and develop innovative solutions to address these issues. 
Lastly, we believe it's absolutely essential to attract the best and brightest minds to scientific careers and to elevate the place of science in our society. Therefore, we were thrilled to announce in May that Regeneron was selected as the new sponsor of the Science Talent Search. Regeneron is only the third sponsor in this renowned 75-year history of this high school science talent competition, which was previously sponsored by Intel and before that by Westinghouse. George and I are both alumni of the Science Talent Search and we believe the program plays a vital role encouraging -- in encouraging talented young people to pursue a path in science and engineering.
With that introduction, let me turn the call over to George."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and -13 blo",1539,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with progress in our late-stage pipeline.
In the second quarter, we reported positive data from 3 Phase III studies of dupilumab, our interleukin-4 and -13 blocker in patients with uncontrolled moderate to severe atopic dermatitis, which is a chronic inflammatory skin disease. Dupilumab is the first systemic therapy to show positive Phase III results in this indication.
On our last earnings call, we talked about the positive data from the first 2 Phase III studies, SOLO 1 and SOLO 2, which studied dupilumab as a monotherapy. In June, we just recently reported the results from the third study, LIBERTY AD CHRONOS, which was a long-term study that investigated dupilumab in combination with topical corticosteroids, which are currently the standard of care in the United States for the treatment of this difficult disease. Overall, the efficacy observed in the CHRONOS study was very consistent with the previously reported positive Phase III SOLO 1 and SOLO 2 studies of dupilumab in the monotherapy setting. 
While the primary endpoint of the CHRONOS study was assessed at 16 weeks, the study continued until 52 weeks and efficacy was sustained in both the dupilumab 300-milligram weekly as well as the 300-milligram every other week dose groups through this 1-year mark. At 16 weeks, about 40% of the patients in both dupilumab dose groups achieved clear or almost clear skin status as measured by the Investigator Global Assessment score compared to about 12% of the patients in the topical steroid only arm. 
Nearly 2/3 of the patients receiving dupilumab achieved a 75% improvement in the average improvement in the overall skin score as assessed by the Eczema Area and Severity Index, or the EASI, score compared to about 23% of patients in the topical steroid only arm. This was the first long-term Phase III study to show that dupilumab in combination with topical steroids was superior to topical steroids alone and provided sustained efficacy and significantly improved measures of overall disease severity, skin clearing, itching and quality of life through 1 year of treatment.
The overall rate of adverse events and serious adverse events was comparable between the groups treated with dupilumab in combination with topical steroid and the topical steroids alone. Serious and/or severe infections were numerically higher in the topical steroid alone group. Adverse events that were noted to have a higher rate with dupilumab treatment included injection site reactions, which were seen in 20% of the patients on the dupilumab weekly arm, 16% of the patients in dupilumab every 2-week arm and 9% of the patients in the placebo plus topical steroid alone arm. And conjunctivitis, which was observed in 19% of patients in the dupilumab weekly arm, 13% of patients in the dupilumab every other week arm and 8% of patients in the topical steroid alone arm. About 22% of the patients in the placebo group, 23% of the patients in the dupilumab weekly group and 28% of the patients in the dupilumab every other weekly group had a reported history of allergic conjunctivitis coming into the study.
These 1-year results from the CHRONOS study further suggest that dupilumab impacts the aberrant activation of the interleukin-4, -13 pathway and results in significant efficacy without the side effects associated with immune suppressing therapies. In this regard, and very importantly, we have not observed an increase in overall infections or serious infections in our atopic dermatitis program to date. The U.S. BLA submission has been completed, and we look forward to work with the FDA to bring this important breakthrough therapy to patients as soon as possible.
We are also developing dupilumab in other allergic diseases, such as asthma, nasal polyps, and eosinophilic esophagitis. As a reminder, our first pivotal study in asthma show that 2 doses of dupilumab, 200-milligram and 300-milligram every other week, in combination with inhaled steroids and long-acting beta agonist, demonstrated a statistically significant 12% to 15% improvement in lung function as measured by FEV1 over placebo at week 12, and a 64% to 75% reduction in the annualized rate of severe asthma exacerbations over placebo. 
The most common adverse event was injection site reaction, which was more frequent in the dupilumab dose groups at 13% to 25% compared to 12% in the placebo group. The incident of infections was balanced across treatment groups at 42% to 45% in dupilumab arms and 46% in the placebo arm as was the incidence of serious adverse events, which were seen in 3% to 7% of the dupilumab groups and 5% in the placebo group. We expect our confirmatory 1-year Phase III study of dupilumab in this indication to complete enrollment in the third quarter of 2016. As a reminder, we are the only late-stage biologic that targets both IL-4 and IL-13, and recent competitor developments in the late-stage asthma space are consistent with our preclinical data and our hypotheses that it is important to block both of these interleukins.
Turning to Praluent. Our 18,000-patient ODYSSEY OUTCOMES study is ongoing. As we have previously disclosed, the data monitoring committee for this study completed the first interim analysis when 50% of the total events had accrued based on unblinded study data. In addition to reviewing the safety study, the DMC performed a futility assessment and recommended that the study continue with no changes. A second interim analysis for futility as well as for overwhelming efficacy when 75% of the targeted primary events has occurred is expected later this year.
As Len mentioned, we also have 3 other late-stage programs: sarilumab, our interleukin-6 receptor antibody for rheumatoid arthritis, where we expect FDA action by October 30; fasinumab, our NGF antibody for pain associated with osteoarthritis; and Regeneron 2222 for respiratory syncytial virus, or RSV.
Turning now to our earlier stage pipeline. In May, we reported positive interim proof-of-concept data from a Phase II study of evinacumab, an antibody to angiopoietin PTL3 in patients with a homozygous form of familial hypercholesterolemia. These patients continue to have a major unmet need as they are typically not as responsive to standard lipid lowering therapy, such as statins or even to PCSK9 inhibition. And some of the other treatment options available to them are limited by the accompanying safety and tolerability concerns. 
Although these data were from a small number of patients, we are encouraged by the additional 55% reduction in LDL cholesterol levels at week 4 on top of standard of care compared to baseline. In this study, evinacumab was generally well tolerated and there were no adverse events leading to discontinuation. The most common drug related adverse events were injection site reactions, which were mild in severity.
Our Phase II study of EYLEA in a co-formulated combination with rinucumab, our PDGF-receptor antibody, in wet age related macular degeneration, or wet AMD, which has been granted fast track designation, is fully enrolled, and we expect top line data from this study in the fourth quarter of 2016. This is a 3-arm, 2-stage study with patients randomized to receive 1 of 3 dosing regimens: EYLEA alone; EYLEA in combination with low dose PDGF blocking antibody; or EYLEA in combination with high dose PDGF blocking antibody. 
The primary efficacy endpoint of the first stage of this study is the mean change in visual acuity at week 12 from baseline. The second stage of the study is designed to confirm and extend the findings from the first stage of the study. Our Phase II combination studies of EYLEA in a co-formulated combination with nesvacumab, our antibody to angiopoietin-2 in AMD and DME, continue to enroll patients. We are very excited by our earlier stage pipeline in immuno-oncology, where both our PD-1 antibody and our CD20 by CD3 bispecific antibody have demonstrated promising activity in early clinical trials. Our potentially pivotal study with our PD-1 antibody in cutaneous squamous cell carcinoma continues to enroll patients, and we hope to be investigating additional agents and combinations over the next 6 to 12 months. 
We have also expanded our capability in the area of precision immunotherapy with our recently announced collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapies. This collaboration takes advantage over our unique VelocImmune and Veloci-Next technologies that will allow us to use cell-based therapies to target tumor cells.
We also recently initiated a Phase I study in healthy volunteers of Regeneron 2477, an activin antibody being developed for the treatment of fibrodysplasia ossificans progressiva, or FOP, and other musculoskeletal disorders. We remain committed to using our technologies and approaches to help address emerging infectious diseases, such as Ebola, MERS and Zika. For Zika, we have identified several fully human monoclonal antibody candidates that are able to potentially block the virus -- to potently block the virus from infecting cells in vitro, and early data indicate that these antibodies are protective in an animal model. We are now in the process of scaling up for human trials. We also recently initiated our first in human study in healthy volunteers in our Ebola program, which has been granted orphan drug designation by the FDA.
With that, let me turn the call over to Bob Terifay."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and hello, everyone. We're pleased with the sales growth of EYLEA, or aflibercept injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or ali",812,"Thank you, George, and hello, everyone. We're pleased with the sales growth of EYLEA, or aflibercept injection, both in the United States and ex U.S. in the first half of 2016. We've made progress in improving access and reimbursement for Praluent, or alirocumab, among U.S. payers. In addition, the European and Japanese launches for Praluent continue to progress. And we are now preparing for the potential U.S. launches of sarilumab and dupilumab over the next year.
Starting with EYLEA. Second quarter U.S. net sales grew 27% year-over-year. Net U.S. EYLEA sales in the second quarter were $831 million. Net ex U.S. EYLEA sales in the second quarter were $486 million, which represents 44% growth year-over-year on a reported basis. We continue to have a strong position in our U.S. market share leadership for EYLEA in the FDA approved anti-VEGF market in terms of injections as reported by 203 retinal specialists in our quarterly market research survey. According to our survey results, in the overall anti-VEGF market, EYLEA has a 37% share of injections as compared to 19% for ranibizumab and 44% for off-label repackaged bevacizumab. 
On the other hand, with our growing market share, our expenses to support reimbursement activities, including patient support services and reimbursement assistance, have also increased, impacting both our gross to net ratio as well as our profit margin. I should note that there are currently a series of proposals for the -- from the Centers for Medicare & Medicaid Services regarding physician reimbursement for physician administered Medicare Part B buy-and-bill drugs, which could lead towards physicians favoring the use of bevacizumab or, in large volume retinal practices, ranibizumab due to the provision of increased direct-to-physician financial incentives from the manufacturer and group purchasing organizations.
The impact of any changes is difficult to predict, though we are monitoring the situation very closely. Regeneron believes that EYLEA is clearly differentiated from both bevacizumab and ranibizumab. Physicians and patients should not be denied access to any drug therapy that is deemed appropriate. We believe that physician choice should be preserved and alternative schemas to reduce health care costs should be explored.
Turning now to Praluent. As reported by Sanofi, net sales in the second quarter were $24 million worldwide, with the U.S. accounting for $21 million of the total. I'm pleased to share that as of July 1, approximately 74% of commercially insured lives and approximately 91% of Medicare insured lives have access to Praluent. We continue to see improvement in the number of prescriptions that are successfully being filled, with both Praluent and evolocumab generally splitting market share evenly. However, only approximately 25% of our prescriptions written actually get dispensed. Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork that the pharmacy benefits managers at health plans have put in place, many patients who are eligible for treatment with a PCSK9 inhibitor have not had their prescriptions filled. 
We continue to focus our efforts on improving access -- improving the prescription process through the payers and the specialty pharmacies. Over the last several months, we've seen some payers loosen their utilization management criteria, removing a requirement for prior ezetimibe therapy. Others have streamlined the prior authorization processes. ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of Praluent.
Outside of the United States, Praluent was approved in the EU in September of 2015, with the product now available in several countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K. and Spain among others. It still remains a difficult reimbursement market with some countries awaiting OUTCOMES data. 
In the United States, we've submitted the supplemental BLA for the 300-milligram monthly dose of Praluent and have been granted a PDUFA date of January 24, 2017. We have also submitted a regulatory application for Praluent monthly dosing in the EU. Also in July, Praluent was approved in Japan. We've submitted a BLA to the U.S. Food and Drug Administration for sarilumab, our IL-6 receptor inhibitor for rheumatoid arthritis and have been granted a PDUFA date of October 30, 2016. 
Earlier this week, the European Marketing Authorization Application, or MAA, for sarilumab was accepted for review by the European Medicines Agency. We will be co-promoting sarilumab with Sanofi Genzyme in the United States, and we have completed hiring of our field based team. Training began this week. Co-promotion decisions for other countries will be made over time. We're currently preparing for dupilumab commercialization with potential U.S. approval in the first half of 2017. We'll be co-promoting dupilumab in the United States with Sanofi Genzyme and have begun interviewing our sales management team. Co-promotion decisions for other countries will be made at a later date.
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented a",1442,"Thanks, Bob, and good morning to everyone. I have several financial updates to provide this morning. Let me start with our top line second quarter earnings. In the second quarter of 2016, non-GAAP net income per diluted share was $2.82. This represented an increase of 24% in both non-GAAP net income per diluted share as well as non-GAAP net income in the second quarter of 2016 compared to the second quarter of 2015.
Regeneron's second quarter 2016 non-GAAP net income excludes noncash share-based compensation expense and $75 million upfront payment made in connection with our April 2016 license and collaboration agreement with Intellia. It also includes the income tax effect of these non-GAAP adjustments. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. I will describe in further detail shortly, effective this quarter, our non-GAAP net income is no longer includes an adjustment from GAAP tax expense to the amount of taxes that were estimated to be paid or payable in cash. 
Total revenues in the second quarter of 2016 were $1.2 billion, which represented a year-over-year growth of 21% over the second quarter of 2015. Net product sales were $834 million in the second quarter of 2016 compared to $658 million in the second quarter of 2015. EYLEA U.S. net product sales were $831 million compared to $655 million in the second quarter of 2015, representing a 27% year-over-year growth. Sequential quarter-over-quarter growth was 6%. EYLEA distributor inventory levels continue to be within our normal 1- to 2-week targeted range, and the June 30 levels were very similar to our March 31, 2016 levels. Please note that we are reaffirming our 2016 U.S. EYLEA net sales guidance to be year-over-year growth of between 20% and 25%.
Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $486 million in the second quarter of 2016 compared to $338 million in the second quarter of 2015, representing a 44% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 42%. In the second quarter of 2016, Regeneron recognized $167 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the second quarter of 2016 was $192 million. As a reminder, for the EYLEA franchise, during May 2016, we stopped incurring the royalty expense in connection with our agreement with Genentech related to global EYLEA sales. This benefited our cost of goods sold and cost of collaboration manufacturing line items.
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $163 million for the second quarter of 2016. Sanofi collaboration revenue line primarily consists of reimbursement of Regeneron incurred R&D expenses, reimbursement of Regeneron commercialization related expenses and our share of profits or losses in connection with commercialization of antibodies. In the second quarter of 2016, our share of the collaborations losses in connection with commercialization of antibodies, primarily Praluent, was $122 million, which can be found in table 4 of our earnings release. Netted within the collaboration losses were the global sales of Praluent as recognized by our collaborator, Sanofi, of $24 million for the second quarter of 2016.
Turning now to expenses. Non-GAAP R&D expense was $406 million for the second quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total GAAP R&D expense less R&D reimbursements from our collaborators, R&D noncash share-based compensation expense and the Intellia upfront payment, was $222 million for the 3 months ended June 30, 2016. Our press release includes all the information that is required to calculate unreimbursed non-GAAP R&D expense. Given our forecasted spend and associated reimbursement level for the second half of 2016, we are increasing and tightening our full year guidance for non-GAAP unreimbursed R&D to be in the range of between $970 million to just over $1 billion from the previously provided range of $875 million to $950 million. This increase is a result of 2 factors: A forecasted increase in spending shift from partnered to unpartnered antibody development programs. We now have 7 antibodies that we are developing independently including 2 that are in late stage, RSV and fasinumab; and a greater allocation of unreimbursed manufacturing costs within our Rensselaer, New York facility to R&D as opposed to inventory due to less demand for Praluent than was anticipated. 
Non-GAAP SG&A expense was $244 million for the second quarter of 2016. We are increasing and tightening non-GAAP SG&A expense in 2016 to $980 million to $1.02 billion from the range of $925 million to $1 billion. This increase is primarily driven by our expenses to support EYLEA reimbursement activities, including patient support services and reimbursement assistance along with additional investments in EYLEA's commercialization. This increase is partially offset by lower commercialization and prelaunch spend associated with our collaboration antibodies with Sanofi. 
As you may recall, last quarter, we introduced a new guidance component, Sanofi reimbursement of Regeneron commercialization related expenses, which represents reimbursement of internal and external costs that Regeneron incurs in connection with preparing to commercialize or commercializing, as applicable, Praluent, sarilumab and dupilumab. Again, this is the line item found within Sanofi collaboration revenue and is referenced in table 4 of our press release. For the second quarter of 2016, the reimbursement of Regeneron commercialization-related expenses was $86 million. We are lowering and tightening this guidance in 2016 to be in the range of $310 million and $340 million from $320 million to $370 million.
Turning now to taxes. Prior to the quarter ended June 30, 2016, our non-GAAP measures included an income tax expense adjustment from GAAP tax expense to the amount of taxes that were paid or payable in cash for the respective period. Historically, there was a significant difference between the company's GAAP-effective tax rate and the actual cash income taxes paid or payable primarily due to tax benefits related to employee exercises stock options. The tax benefits related to employee exercises stock options were historically recorded in additional paid in capital for GAAP reporting purposes.
During the second quarter of 2016, the company early adopted accounting standards update 2016-09. The new standard requires companies to recognize tax benefits in connection with employee exercises stock options in the income statement. In other words, we will account for tax deductions related to stock option exercises in the period of exercise as a discrete item to the quarter. With the early adoption of the new standard, the company chose to discontinue its former non-GAAP income tax expense adjustment since, by adopting the new standard, it eliminated one of our primarily -- primary differences between the company's effective tax rate and cash income taxes paid or payable. 
As a result, our second quarter 2016 and 2015 non-GAAP financial results included in our earnings release for comparison now reflect discontinuance of our non-GAAP income tax expense adjustment. This new standard will result in variability in our effective tax rate from quarter-to-quarter. As based on GAAP rules, these items are not forecasted in our estimated annual effective tax rate. These deductions are based on the company's stock price and individual employees' decisions on when to exercise their stock options. The current tax related adjustment in our reconciliation of GAAP net income to non-GAAP net income, table 3 of our earnings release, solely represents the income tax effects related to our non-GAAP pretax adjustment. 
Our effective tax rate for the second quarter of 2016 was approximately 33%, which is 8% lower compared to the second quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings and share-based compensation as compared to the same quarter of last year. For 2016, our guidance for our GAAP effective tax rate for the full year will be 33% to 41%. 
Our capital expenditures for the second quarter of 2016 and for the 6 months ended June 30, 2016 were $139 million and $243 million, respectively. We are lowering our full year 2016 capital expenditure guidance to a range of $480 million to $530 million from the previously provided range of $550 million to $625 million. These 2016 expenditures include the expansion of our manufacturing capabilities in both Rensselaer, New York and Limerick, Ireland as well as growth in our Tarrytown, New York headquarters as we continue to grow our employee base. Regeneron's balance sheet had $1.64 billion of cash and marketable securities as of June 30, 2016. Less than $500,000 of our originally issued $400 million of convertible senior notes due October 1, 2016, remain outstanding.
With that, I would now like to turn the call back to Michael."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. That concludes our prepared remark. We'd now like to open the call for Q&A. [Operator Instructions] Our team will be available in our office after the call for any follow-up questions. Operator, if you can now open the call for questions.",44,"Thank you, Bob. That concludes our prepared remark. We'd now like to open the call for Q&A. [Operator Instructions] Our team will be available in our office after the call for any follow-up questions. Operator, if you can now open the call for questions."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs.",13,"[Operator Instructions] And our first question comes from Terence Flynn from Goldman Sachs."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is Cameron Bradshaw filling in for Terence. I was wondering, for the Phase II trials, EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're",68,"This is Cameron Bradshaw filling in for Terence. I was wondering, for the Phase II trials, EYLEA combined with your PDGF, looks like we're going to see data in the second half of this year. Can you just remind us of the trial design? And then what you're hoping to see with respect to efficacy in order to make a go, no go decision on the Phase III?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone with 2 doses of the blocker. That's the first",216,"It's George. The study design really has 2 stages. The first is a head-to-head-to-head between the 3 groups that we described in our call. The combination of the PDGF blocker on top of EYLEA versus EYLEA alone with 2 doses of the blocker. That's the first stage. As you know, even in studies with hundreds of patients in them, as we've of course seen, we have as much experience as anybody alone and with our collaborators in doing these large studies, there can be a lot of variability in letters gained. So we designed the study to include a second stage as well that actually shows the effects of adding on therapy on top within the same groups. That we predict to be a more powerful way of confirming if there are added benefits of the PDGF therapy. So we will have the first type of comparison, which we consider perhaps to be slightly less powerful, in the time frame that I just described, and then we will also be getting the second stage of data. So depending on how strong the first set of data is, we will either be able to make a decision at that point or we'll be awaiting the results from the second stage to help us make that decision."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the h",70,"I would just add in terms of helping you think about it. For us, since this is a single injection of the 2 antibodies by the physician that -- we don't have to have a gigantic benefit, we just have to have something that's clearly beneficial because the hurdle for us to move forward isn't that great because there's no additional burden on patients having to take an additional injection."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Robyn Karnauskas from Citigroup.",9,"Our next question comes from Robyn Karnauskas from Citigroup."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the payers had higher restrictions initially this year? And then how did that change, like what percentage of people are not requiri",100,"So you mentioned that access is opening up a little bit for the PCSK9s. Can you talk a little bit about what percentage of the payers had higher restrictions initially this year? And then how did that change, like what percentage of people are not requiring prior auth or reduced the requirements for filling out forms, et cetera? And then going to that, what do you think the trigger point was for doing that? And what are the timing for these events, like is it third quarter? What triggers these things and how do we think about that going forward?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob?",1,"Bob?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So there have been some payers that based upon the FDA decision not to approve ezetimibe based upon their OUTCOMES data that have said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at th",151,"So there have been some payers that based upon the FDA decision not to approve ezetimibe based upon their OUTCOMES data that have said since ezetimibe does not have an FDA indication for the prevention of cardiovascular outcomes that on their own or at the advice of some of their physician -- medical directors, they've removed the ezetimibe step at it [ph]. And that has happened in a few plans already. With regards to the prior authorization paperwork, some of the payers had prior authorizations that required 10s -- or almost up to 40 questions. It became very tedious for the physicians. So some of the plans have begun to change their prior authorization to be simpler. And again, that is in place in a few payers now. I think the real driver that's going to change things is going to be when we get the OUTCOMES data for the product."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So yes. Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients who get on the drug, get their cholesterol lowered and",255,"So yes. Thanks, Bob. It's Len. Just to amplify on that. It seems to me there are 3 ways -- 3 important factors you can consider. Assuming that we have a relatively high satisfaction rate that patients who get on the drug, get their cholesterol lowered and tolerate the drug, this is not like hepatitis C market. Those should be long-term patients. So we begin to accumulate as opposed to constantly having to find to replace, as you would, let's say, in a hep C environment. Secondly, as Bob said, this is -- the cardiologists are not like the rheumatologists where they have people in their office who are very experienced in dealing with these prior authorizations and paperwork. And I think that they are getting more efficient at it. They are somewhat frustrated by it for sure and some of them are giving up. Some say, ""well, I'll wait for outcomes before I go to the mat with fights"" and things like that. But I do believe that the experience of the doctors in picking the patients that they know that each PBM for each patient or each payer, if you will, they kind of know -- are getting better at knowing how to get this done as they get more experience. And then, of course, finally, as George mentioned, we hope that the OUTCOMES data later this year will change the dynamic out there in terms of the feeling, the compelling need to go on these products if we show an OUTCOMES benefit."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ronny Gal from Bernstein.",9,"Our following question comes from Ronny Gal from Bernstein."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","One second.",2,"One second."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Do you have a question?",5,"Do you have a question?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Yes, right here. Okay, sorry. Actually, never mind.",8,"Yes, right here. Okay, sorry. Actually, never mind."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Ying Huang from Bank of America Merrill Lynch.",13,"Our following question comes from Ying Huang from Bank of America Merrill Lynch."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a 4-letter difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that",59,"Just one more on PDGF. So if you look at Fovista plus Lucentis, it seems that there's a 4-letter difference. Can you help us frame the expectations for your co-formulated EYLEA plus PDGF antibody? I know you're comparing to EYLEA, of course. So does that 4 letter apply in this case? And what are you expecting from the outcome?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the study, 4-letter differences easily go away. So we really consider this a very early field.",169,"Well, we consider it very hard to interpret these sort of existing studies. Because as I said, we've actually seen with larger studies, when you actually repeat the study, 4-letter differences easily go away. So we really consider this a very early field. And based on a lot of the science, it's really very, very hard to predict what, if any, benefit will be seen here. We do you think that our unique 2-stage design will end up giving us probably the best data and most convincing perspective on whether there is an added benefit or not. And as Len pointed out, the fact that if there is an added benefit, we'll be able to do it with a single injection. And assuming appropriate safety, we'll make it easier to deliver that benefit to patients with this approach. And remember, our approach here, we're combining 2 very similar antibody like drugs into a single co-formulated injection as opposed to giving 2 very different types of drugs with separate injections."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our following question comes from Geoffrey Porges from Leerink.",9,"Our following question comes from Geoffrey Porges from Leerink."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just on dupilumab. George, could you just comment first on the conjunctivitis? Is that signal real, and are you seeing it in the other studies, for example, in asthma or esophagitis? And then related to that, could you just talk a little bit about the lau",71,"Just on dupilumab. George, could you just comment first on the conjunctivitis? Is that signal real, and are you seeing it in the other studies, for example, in asthma or esophagitis? And then related to that, could you just talk a little bit about the launch outlook? What are the parallels or differences to the Praluent experience? And how might you get payers to let some patients through in this case?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay. Well, the first part, very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical stero",645,"Okay. Well, the first part, very interesting in terms of the conjunctivitis. We have consistently seen it in our atopic dermatitis studies. We have not seen it in our asthma studies. As you know, there's differences, for examples, in the way topical steroids are used in the populations and so forth, and we have various ideas about why this may be the case. That said, even though it seems specific to the way the drug is being used in this particular patient population and perhaps with either the use or actually the less use of topical steroids in the treated patients, the comforting thing is that these patients do have, as we pointed out in the call, they do have already a lot of history of conjunctivitis. So this is not really something brand-new to the patients. And the conjunctivitis that is seen here on dupilumab seems to be of mild to moderate severity and is limited. Most cases actually resolve during treatment and very few, if any, cases actually lead to discontinuation. So it seems as if the benefit/risk is really maintained in the face of this. That said, also, in terms of the second part of your question about dupilumab, we think it's a very different situation compared to Praluent. I mean there is a huge unmet need here. Patients are really suffering from ongoing symptomatology. And the data actually shows that this symptomatology is actually markedly improved with the dupilumab treatment. So that it seems to us that there's going to be a lot of patients who really are -- and we already know, who are going to be so positively impacted in their life that they're going to be demanding this drug. And it seems to us that these patients will deserve to have this first systemic therapy that can really make a difference in their lives. Let me remind you that this is -- we're talking about the most moderate to severe class of the patients here, which are more than 1 million patients in the United States alone, and these patients really have very few other alternatives. And as you see with our data in CHRONOS, where we treat on top of topical steroids, the standard of care, very few, only about 10% of the patients or so, become clear or almost clear with topical steroids as opposed to about 40% on the drug. And there's not only, of course, the cosmetic effects of having these skin lesions and so forth and the associated infections and so forth that you get, but there's an enormous amount of itch, which drives a lot of behavioral problems and so forth. There's associated depressive and psychological symptomatology here and so forth. And we've actually shown that much of this is actually impacted in our studies. So we think this can be a very important drug for this population of patients, and we think that there's going to be a very important opportunity to make a lot of difference in a lot of peoples' lives, which is what should count in this business. But beyond that, I think that we also have to remember that dupilumab is really a franchise onto itself. The data really suggest that we have hit upon here with blocking both interleukin-4 and -13, the critical drivers of allergic disease in general. We're hoping ODYSSEY to extend the findings from our first pivotal study in asthma by confirming them with the second pivotal study. And we will also be continuing to study in other allergic diseases where, as you've already seen, we already have some positive data in other allergic diseases in early stage studies as well. So this can benefit, not only the allergic and atopic disease of atopic dermatitis, but we hope to be able to have studies that confirm it to additional allergic diseases as well."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol lowe",160,"I just wanted to add one thing, Geoff. In terms about the difference between Praluent, just to reemphasize what George already said, which is that most people don't like to think of themselves as sick and they don't like to have to take a cholesterol lowering drug, oh, I'll fix it with diet or I'll take my statin or what have you. But patients with atopic dermatitis really suffer. It's really made its way into pop culture. There's a new series on HBO. I don't know if any of you have seen it, called The Night Of. And the actor, John Turturro, portrays this lawyer who suffers terribly from atopic dermatitis. He has to wear sandals. He goes to group to discuss all this. And it really has a terrible impact on his life. And this -- I don't think this is just a TV portrayal. I think this is what we see, that people really suffer from this disease."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think one last point to just add as well is that unlike most other biologics that are immunomodulators, where you see in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This",127,"I think one last point to just add as well is that unlike most other biologics that are immunomodulators, where you see in general, whether it's the TNFs or a variety of other classes, you generally see a doubling of the serious infection risk rate. This appears to be more of a immunomodulator that is correcting an immune deviation. And actually, as we reported and as we summarized during this call, there is no increase in infections and in serious infections here. So once again, this is an important option that's being offered to the patients in contrast to other alternatives which were essentially immunosuppressing. And to have this sort of efficacy with a nonimmunosuppressing agent, I think is also offering a lot of hope to patients."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Chris Raymond from Raymond James.",9,"Next question comes from Chris Raymond from Raymond James."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is",88,"So just another question here, I guess, on dupilumab. So in atopic dermatitis, so -- maybe for Bob, if possible. So I'd imagine your marketing prep's pretty underway now with the BLA submitted, and I know we know the vast majority of intervention here is topical corticosteroids. But just curious, what has your work uncovered in terms of the use of other biologics off label in physician satisfaction with these agents? And maybe can you talk about how you're thinking about this as you formulate your launch plans?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therap",131,"Sure. So as George pointed out, there are approximately 1.6 million patients in the United States who are uncontrolled on topical therapies who have moderate to severe atopic dermatitis. A very small proportion of those patients have received other therapies, immunosuppressant agents, generally not biologics, but things like cyclosporine and methotrexate. The challenge with those therapies is you can't use them long term. They've got some toxicities that really interfere with the patient's long-term use of the therapy. And thus, their symptoms will come back, their itch will come back and their quality of life will decrease. So there is a huge opportunity for dupilumab in these uncontrolled moderate to severe patients. There's a pent-up demand among patients and physicians to get the patients on therapy and to improve their lives."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promis",69,"And to add to that, in terms of biologics, we do not believe that there's any convincing evidence with any available approved biologics that show efficacy in this disease setting. And as you know, there's also no other late-stage biologics that are promising in this area. So this really has a chance to really be providing something to patients that don't really have any other alternatives at this point."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would add also that to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an",147,"I would add also that to make sure you think about these other diseases as other significant opportunities. There's been a desire to have a drug like a biologic that could affect -- in asthma, for example, that could treat all patients, that could have an effect both on FEV1 and on exacerbations. And that -- no such drug has been forthcoming as yet, and we're excited that our first pivotal trial demonstrated in the broad population effect both on FEV1 and on exacerbation. So hopefully, if we can confirm that in our trial that's just about to be completed in enrollment. So think ahead about a year for the trial and then the data, we could be onto something a whole new opportunity which people really are looking for, something that can treat all the patients and that can treat both the FEV1 and the exacerbations."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","All right. As Len briefly touched upon, a very important feature that, of course, we're hoping to confirm in our second pivotal study is this point about the broad population. I mean, so far, biologics have been limited to the so-called the more allergic",98,"All right. As Len briefly touched upon, a very important feature that, of course, we're hoping to confirm in our second pivotal study is this point about the broad population. I mean, so far, biologics have been limited to the so-called the more allergic or eosinophilic-type patients and is the only places where substantial efficacy has been noted. And it's, as Len said, mostly only with exacerbations and not on lung function. So if we can confirm the results of the first pivotal, it could provide another major hope for patients who really need these types of therapies."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And the last point on that, which I know George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthm",69,"And the last point on that, which I know George likes to make when he speaks about this at meetings, is that we can't forget the fact that people who have asthma frequently have atopic dermatitis and people who have atopic dermatitis frequently have asthma. These are overlapping syndromes because they are scientifically related in -- if I should say pathophysiologically related, we think through the IL-4, -13 pathway."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next question comes from Mark Schoenebaum from Evercore ISI.",9,"Next question comes from Mark Schoenebaum from Evercore ISI."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's John Scotti in for Mark. Maybe I'll just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the off-the-shelf therapies there? And how -- I guess how does that approach differ from those t",70,"It's John Scotti in for Mark. Maybe I'll just ask a quick one on the Adicet collaboration. Could you just elaborate a little bit more on the technology behind the off-the-shelf therapies there? And how -- I guess how does that approach differ from those that are already in development, such as Cellectis? And then I guess maybe when could we see some of those assets entering the clinic?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, I think...",3,"Well, I think..."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Wait, before you answer that, George. I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified.",30,"Wait, before you answer that, George. I just wanted to make one comment that is, if I went to Broadway and had so many stand-in actors, I would be mortified."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think an important point to make is we really believe in people and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who's really leading Adicet. And obviously, she's been in areas that we've been in. We",197,"I think an important point to make is we really believe in people and we believe in synergies. And we've had long-standing interests to be working with Aya Jakobovits, who's really leading Adicet. And obviously, she's been in areas that we've been in. We have enormous respect for her, her capabilities, and so we really feel that we can work well together with her and her team. And number two is the synergies with our existing programs. This is why we make these sorts of deals. We believe that we have a lot of potential tools and starting points for making the sorts of targeting reagents that would be introduced into these cell therapies using our existing technologies, such as our VelocImmune and our Veloci-Next technologies, which really nobody else in this field has access to right now. So we're hoping that we put together our unique capabilities that nobody else in the cell therapy space has, together with a pioneer and a leader in this area, such as Aya Jakobovits and her team, that we could really do a special thing. And I think at this point that's what we want to say about this collaboration."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Adnan Butt from RBC Capital.",10,"Our next question comes from Adnan Butt from RBC Capital."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Let me ask a 10-Q question. It lists PD-1 as embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please.",34,"Let me ask a 10-Q question. It lists PD-1 as embarking on potentially pivotal studies over the next year. Are there unique indications or combinations that you've selected already? Any details there, please."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies,",90,"Yes. So it's already been publicly disclosed that we're already in a potentially registration study in a unique indication that we think has a lot of promise for various reasons and where we've already seen early clinical activity in our earlier studies, which is cutaneous squamous cell carcinoma. And so that is, for example, one setting. We've also identified additional setting that has been publicly disclosed. We've also identified additional setting that we'll be going into, we hope, both potentially with it as a monotherapy but also with new combinations."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Alethia Young from Crdit Suisse.",10,"Our final question comes from Alethia Young from Crdit Suisse."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just going back to your prepared remarks, I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for why EYLEA kind of -- the financial incentives that manufacturers providing",63,"Just going back to your prepared remarks, I was just wondering with EYLEA, like is it something that you're kind of starting to experience just as -- like what are the dynamics for why EYLEA kind of -- the financial incentives that manufacturers providing are increasing or group purchasing, like why did you specifically kind of bring that to our attention this quarter?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It's not been any drastic change. But it's just sort of to get in front of these things. We monitor them and we",64,"I think that Bob is highlighting for you what's going on in the marketplace, and we're seeing more of these things than we have in years past. It's not been any drastic change. But it's just sort of to get in front of these things. We monitor them and we have responses prepared should they be necessary. Bob, want to add anything there?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","No. I mean it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it.",22,"No. I mean it's a dynamic in the marketplace that impacts the growth of EYLEA and we just wanted to discuss it."
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Okay, great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?",43,"Okay, great. Well, that concludes today's call. I want to thank everyone for joining. As we said, myself, Bob Landry and the IR team will be available for follow-up questions. If you have any, please e-mail us or give us a call. Operator?"
33715,372870908,1035143,"Regeneron Pharmaceuticals, Inc., Q2 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you. Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you. Ladies and gentlemen, this concludes today's conference. Thank you for participating. You may now disconnect."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr.",46,"Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today a",324,"Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are: Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for questions-and-answers.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2016, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the rest of the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  EYLEA, our flagship anti-VEGF, continues",746,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  
EYLEA, our flagship anti-VEGF, continues to remain a key financial driver for Regeneron. We are pleased with the continued growth of EYLEA and are committed to maintaining our leadership position in the branded anti-VEGF market by pursuing both additional indications for EYLEA, such as diabetic retinopathy, where we currently have a Phase III study ongoing. And we are also looking at ways in which we can improve upon the high efficacy bar set by EYLEA to combinations with an antibody to ANG2, where we currently have 2 Phase II studies ongoing. 
While EYLEA remains very important to our business, we are equally focused on the ongoing launch of PRALUENT, our PCSK9 antibody, for lowering LDL cholesterol as well as advancing our pipeline. For PRALUENT, we believe that if outcomes data are positive, it will drive greater use of this class. As mentioned in our press release, we expect the second interim analysis by the end of this month. 
Moving on to sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis. As you heard last week, we received a Complete Response Letter from the FDA. This was due to certain manufacturing deficiencies not specific to sarilumab that were observed during a routine inspection of a Sanofi fill and finish plant in France. Sanofi has provided comprehensive responses and is working closely with the FDA to address the deficiencies as expeditiously as possible. It has only been a week since we received the Complete Response Letter. And we are preparing to engage in meaningful discussions with the FDA. So it is too early for us to comment on the expected time line for potential sarilumab approval. 
We do not expect these manufacturing deficiencies will impact dupilumab or as it is now known by its brand name, Dupixent, where our Biologics License Application, or BLA, is currently under FDA priority review for the treatment of moderate-to-severe atopic dermatitis in adults. The FDA action date for the BLA is at the end of March. Dupixent is a very important pipeline product candidate for us. And we believe that atopic dermatitis represents an area of high unmet need. As a reminder, we received breakthrough designation in this indication. In addition to atopic dermatitis, we are also investigating Dupixent in other indications, including asthma, where we recently completed enrollment in our second pivotal study. 
In the mid-term, we are looking to important clinical progress from several of our Phase II and III programs, which span a variety of therapeutic areas, such as allergic diseases, pain, viral diseases, ophthalmology, oncology, cardiometabolic disease, inflammatory and rare diseases. These programs have the potential to drive the next wave of growth for Regeneron. You will hear more about the key current developments from some of these programs from George. 
At Regeneron, we've always been committed to long-term science and innovation. In fact, today's marketed products as well as the 16 product candidates in clinical development were all home-grown in our internal R&D engine. We will continue to invest in science and technology that can provide sustainable innovation and growth well into the future. This unique long-term focus on science is at the heart of why we have been able to attract top talent, which is key to our continuing success. Through that end, last week, we were thrilled to be named by Science Magazine as the #1 company in the biotech or pharmaceutical industry to work for, a recognition we have received for 4 of the last 6 years. 
We know that our industry has faced many important questions regarding pricing of drugs. This is not the forum to discuss the complex issue of drug pricing. But I think it is important to note that Regeneron is in a unique position. As a company founded on science and committed to the research and development of important new products, we are well positioned to succeed even in a difficult and constrained pricing environment. In fact, we have never raised prices on any of our drugs, choosing instead to grow through the optimization of currently marketed products by pursuing new indications as well as the introduction of new medicines. Our future potential growth will be driven by this strategy. 
With that, let me turn the call over to George."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a",1262,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a wide variety of allergic diseases. The most advanced of which is uncontrolled moderate-to-severe atopic dermatitis. 
Just last month, we had the opportunity to present detailed results from SOLO 1 and SOLO 2, which were 2 identical Phase III studies that investigated Dupixent in the monotherapy setting at the annual EADV conference. These data were also concurrently published in the New England Journal of Medicine. These were the first large pivotal studies where a systemic investigational therapy demonstrated significant reduction in the signs and symptoms of atopic dermatitis with an average reduction in skin scores of about 70%, accompanied by a marked reduction in the usually unrelenting itch associated with this disease and almost 40% of these patients achieving clearing or near-clearing of the skin lesions. 
Unlike other immune modulating therapies, there was no evidence of increased immunosuppression. And the most common adverse events in the 2 trials were injection site reactions and conjunctivitis. We were encouraged by the excitement with which these data were received by the physician community as well as by patients. And we believe that this speaks to the current unmet need and frustration with currently available therapies for this severely debilitating disease. As Len mentioned, our BLA for Dupixent for the treatment of adults with moderate-to-severe atopic dermatitis is currently under FDA review and has been given priority review status and an action date of March 29, 2017. 
While the SOLO studies were in the monotherapy setting, we have also reported positive 1-year top line data from the CHRONOS Phase III study, which explored Dupixent in combination with topical corticosteroids. The safety and efficacy findings from the long-term CHRONOS study were consistent with those observed in SOLO 1 and 2. I'm also pleased to share that LIBERTY AD CAF, a Phase III study of Dupixent with concomitant topical corticosteroids in adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to or ineligible for oral cyclosporine, is now fully enrolled. We, along with our collaborator Sanofi, expect to complete the regulatory resubmission in Europe and Japan in the fourth quarter of 2016. We also plan to initiate a Phase III study in the pediatric severe atopic dermatitis population in the first quarter of 2017 in patients between the ages of 12 and 17. We are pleased that similar to the adult indications, Dupixent has received breakthrough designation for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. 
While atopic dermatitis is the most advanced indication in development for Dupixent, we are making headway with our asthma program as well. We have previously announced positive results from our first pivotal study in uncontrolled persistent asthma despite treatment with inhaled steroids and long-acting beta agonists. As a reminder, these data demonstrated improvements in both lung function as measured by FEV and exacerbations in all patients regardless of baseline eosinophil status. There was a 15% improvement above placebo in FEV1 and a 75% reduction in exacerbations in the overall population treated with the 300-milligram, every 2-week dose. The most common adverse events associated with treatment in this study was injection site reaction. 
In September, we announced completion of enrollment in LIBERTY ASTHMA QUEST, which is our confirmatory Phase III pivotal study of Dupixent in this indication. The primary endpoint of this study is at 52 weeks. And we, therefore, expect to make a regulatory submission in the U.S. towards the end of 2017. We also expect to initiate a Phase III study in the pediatric asthma patients in early 2017. We are also exploring the use of Dupixent in several other allergic indications, such as nasal polyps, where we expect to initiate a Phase III study early next year. And in eosinophilic esophagitis, we are currently in a Phase II. 
Turning to fasinumab, our Nerve Growth Factor antibody for pain. In October, we provided an update on this program. Following the observation of a case of rapidly progressive osteoarthritis in a patient receiving high-dose fasinumab, who had a history of advanced osteoarthritis of the knee, the FDA placed our Phase II study in chronic lower back pain patients on clinical hold. This event prompted an unplanned interim analysis of the study, which had already completed 70% of its targeted enrollment. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups compared to placebo at 8- and 12-week time points with p-value of less than 0.01. Preliminary safety results were also generally consistent with those observed previously with this class. The FDA has since communicated that we can continue development of fasinumab in chronic lower back pain by excluding patients who have advanced osteoarthritis. We are also continuing our pivotal program in osteoarthritis with final design elements still receiving regulatory feedback. The fasinumab program will contain safety data from approximately 10,000 patients overall.
Moving to PRALUENT. The recent news on the discontinuation of development of bococizumab obviously has a major impact on the PCSK9 landscape. This further underscores the very high bar in terms of safety and efficacy for this class. This example also highlights to us the value of our fully human VelocImmune-based antibody technology. In terms of our PRALUENT program, our 18,000-patient ODYSSEY OUTCOMES study, remains ongoing. We expect the second interim analysis for futility and overwhelming efficacy by the end of this month. We, and our collaborator Sanofi, have also completed regulatory submissions for the once-monthly dosing formulation of PRALUENT in the Europe and Japan territories as well as in the United States, where we have been granted an FDA action date of January 24, 2017. 
Our immuno-oncology program continues to advance and expand. We believe that these are still early days in the area of immuno-oncology with the collective knowledge of this field evolving rapidly and the competitive landscape changing continuously. Evidence of this includes the recent surprising failure of the market-leading PD-1 antibody in first-line lung cancer. Regarding our PD-1 program, our potentially pivotal study in cutaneous squamous cell carcinoma is ongoing and we plan to announce additional studies in the near future. In addition, we're also studying PD-1 in combination with our bispecific CD20xCD3 molecule. At the end of this year, at the American Society of Hematology or ASH conference, we will be presenting monotherapy data from the CD20xCD3 program. Lastly, we plan to advance Regeneron 3767 [ph], an antibody LAG3, into clinical development by the end 2016. 
In October, we announced top line results from a Phase II combination study of EYLEA with rinucumab, our PDGF receptor antibody in wet age-related macular degeneration or wet AMD, where the data demonstrated no improvement in best corrected visual acuity or BCVA, the primary endpoint of the study, versus EYLEA alone. We think these study results demonstrate the high hurdle that has been set by the well-established efficacy and safety of EYLEA. That said, we are looking for ways in which we can strengthen our EYLEA franchise. To that end, we are conducting a Phase II study of EYLEA in a co-formulated combination with nesvacumab, our antibody to ANG2, in AMD and DME. The DME study is full enrolled while the study in wet AMD continues to enroll patients. We are also exploring longer-acting approaches with this class. 
And with that summary, let me turn the call over to Bob Terifay."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the",817,"Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the third quarter were $471 million, which represents 27% year-over-year growth, unadjusted for currency fluctuations. Net ex U.S. year-to-date sales were $1.4 billion. EYLEA is the market-leading product among FDA-approved anti-VEGF agents for all of its proven indications in the United States. In the U.S., we are seeing increased competitor discounts and rebates. We are carefully assessing these actions. As I'm sure you are well aware, there's a pending proposal for the Centers of Medicare Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B or buy-and-build drugs. We worked hard on the policy and legislative front on this issue, and we will be prepared to respond on the commercial front as needed to make sure that patients continue to have full and complete access to EYLEA.
Turning now to Praluent or alirocumab. As reported by Sanofi, net sales in the third quarter were $38 million worldwide, with the U.S. accounting for $32 million of the total. Sales data and IMS total prescription data indicate that Praluent and alirocumab market shares are roughly 50-50 in the United States. As reported by IMS, U.S. total prescriptions of Praluent increased sequentially 60% versus second quarter 2016. The challenge for the PCSK9 inhibitor class continues to be the significant reimbursement hurdles for the physicians, offices and patients, resulting in a low volume of prescriptions being dispensed. This has resulted in physician offices reserving their initial prescriptions to a limited pool of patients. We continue to focus our efforts in improving access and improving the prescription process to the payers and specialty pharmacies. We're gradually seeing more payers losing their utilization management criteria, including removing the requirement for prior therapy. In addition, we're now seeing some patients shortening the number of months that a patient needs to be on a maximum-tolerated statin therapy and eliminating a specialist only prescribing our consultation requirement. Others have streamlined the prior authorization process. ODYSSEY OUTCOMES data if positive are anticipated to be a key driver in shaping the future success of Praluent. Outside of the United States, Praluent was approved in the EU in September of 2015, with the product now approved in 41 countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K., Spain, Norway and The Netherlands. It still remains a challenging reimbursement situation with some countries awaiting cardiovascular OUTCOMES data. We continue to plan for the potential launch of sarilumab in the United States. As an example, we have a major presence at the upcoming American College of Rheumatology meeting this month in Washington, D.C. We'll be presenting data from our MONARCH Study of sarilumab as monotherapy in patients who are [indiscernible] responders as well as subset analysis from our pivotal U.S. registration studies. We'll have a display floor present highlighting the central role of IL-6 in rheumatoid arthritis. European marketing authorization application for sarilumab is currently under review by the European Medicines Agency, with a potential decision on the application expected in mid-2017. Co-promotion decisions for Europe and other x U.S. countries will be made over time.
We're currently preparing for Dupixent or dupilumab commercialization, with an FDA PDUFA date of March 29, 2017. We will be co-promoting Dupixent with Sanofi Genzyme in the United States. Co-promotion decisions for other countries will be made at a later date. We are aware that Kaiser, payers and pharmacy benefits managers are proactively evaluating the cost-effectiveness of emerging therapies for atopic dermatitis in the United States. We want to take a moment to discuss how we're thinking about the Dupixent commercial opportunity, which differs in many important respects in the situation we faced with Praluent. Dupixent has already demonstrated efficacy on the most important outcomes. Consistent efficacy on rash severity, itching and quality of my life measures. In the United States, there are 1.6 million patients with uncontrolled moderate-to-severe atopic dermatitis. The majority of which will not likely receive Dupixent therapy. We estimate that approximately 300,000 of these patients have exhausted all approved therapies and have failed or unable to tolerate unapproved use of immunosuppressant therapies. Many of these advanced patients are suffering from a host of related issues, including sleep disturbances, anxiety and depression. These atopic dermatitis patients should not be denied therapy. We hope payers and insurers will provide appropriate and timely access to Dupixent should it be approved, and the patients should not have to step through unapproved immunosuppressant therapies, many of which have brought black box warnings. We plan to work closely with all stakeholders, including patients, physicians and payers to achieve this goal. With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We were also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAA",1331,"Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We were also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP SG&A, our effective tax rate and capital expenditures. Let me start with our top line third quarter earnings. In the third quarter 2016, non-GAAP net income was $365 million and non-GAAP net income per diluted share was $3.13. This represents an increase of 32% in both non-GAAP net income per diluted share as well as non-GAAP net income in the third quarter 2016 compared to the third quarter of 2015. Regeneron's third quarter 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and the $25 million up front payment made in connection with our third quarter 2016 license, in collaboration agreement with and includes the income tax effect of these non-GAAP reconciling items. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the third quarter of 2016 were $1.2 billion, which represents year-over-year growth of 7% over the third quarter of 2015. Net product sales were $857 million in the third quarter of 2016 compared to $738 million in the third quarter of 2015. EYLEA U.S. net product sales were $854 million compared to $734 million in the third quarter of 2015, representing 16% year-over-year growth; sequential quarter-over-quarter growth was approximately 3%. 
During the third quarter of 2016, EYLEA experienced a slight increase in U.S. distributor inventory levels as compared to the second quarter of 2016 but continues to be within our normal 1 to 2 weeks targeted range.
As mentioned in our press release issued this morning, we're tightening our full year 2016 U.S. EYLEA net sales guidance to be year-over-year growth of 23% to 25%. X U.S. EYLEA sales, where were product revenues are recorded by our collaborator, Bayer, were $471 million in third quarter of 2016 compared to $371 million in the third quarter of 2015, representing a 27% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 25%. In the third quarter of 2016, Regeneron recognized $171 million from our share in net profits of EYLEA sales outside the U.S. Total Bayer collaboration revenue for the third quarter of 2016 was $191 million. 
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $144 million for the third quarter of 2016. The Sanofi collaboration revenue line item primarily consist of reimbursement average entering-incurred R&D expenses, reimbursement of Regeneron-incurred commercialization-related expenses and our share of profits and losses in connection with the commercialization of antibodies. In the third quarter of 2016, our share of the collaborations losses in connection with commercialization of antibodies, which includes Praluent and pre-commercialization activities and cost in connection with sarilumab, Dupixent was $112 million, which can be found in Table 4 of our earnings release. Netted within this collaboration losses were a global sales of Praluent as recognized by our collaborator Sanofi of $38 million for the third quarter of 2016. Before moving to expenses, I'd like to highlight 2 third quarter business development transactions. The first is the collaboration we entered into with Teva to develop and commercialize our NGF antibody, fasinumab. Under the terms of the agreement, Teva paid Regeneron a $250 million upfront payment that we will equally share on an ongoing basis R&D expenses of approximately $1 billion under a global development plan, we plan to radically recognize the upfront payment as revenue over the related performance bearded. The signing of this agreement did not have a material P&L impact in the third quarter of 2016. As a reminder, the intellectual property associated with our late-stage pipeline, including fasinumab, has been migrated offshore. Thus, expenses associated with the program will be recognized in foreign jurisdictions with tax rates lower than the U.S. statutory rate. 
The other 2016 third quarter business development transaction was a collaboration with Adicet, which will allow us to discover and develop engineered next-generation immuned cell therapeutics. In accordance with this agreement, we paid Adicet a $25 million upfront payment in the third quarter of 2016, which we have recorded as GAAP R&D expense in our consolidated statement of operations but have excluded from our non-GAAP net income. 
Turning now to expenses. Non-GAAP R&D expense, which is calculated as the total GAAP R&D expense, less R&D noncash share-based compensation expense as well as the upfront payment we made to collaborator, Adicet, was $437 million for the third quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total non-GAAP R&D expense less R&D reimbursements from our collaborators was $256 million for the 3 months ended September 30, 2016. Our press release includes all the information as required to calculate unreimbursed non-GAAP R&D expense. As a result of the recently executed collaboration with Teva regarding fasinumab, we are lowering and tightening our full year 2016 guidance for non-GAAP unreimbursed R&D, to be in the range of $945 million to $975 million from our previous guidance range of $970 million to just over $1 billion. Non-GAAP SG&A expense was $221 million for the third quarter 2016. We're tightening and lowering our full year 2016 guidance for non-GAAP SG&A to $965 million to $995 million from our previous guidance range of $980 million to $1.02 billion. Note that even after lowering and tightening our full year guidance, we do not expect to see any material prelaunch cost savings from the PDUFA delay of sarilumab. We will be co-promoting sarilumab with Sanofi , and our sales forces is already on board. And as you heard earlier from Bob Terifay, we continue to prepare for the launch and anticipation of the resolution of matters with the FDA. Sanofi reimbursement of the Regeneron commercialization-related expenses, the line item found within Sanofi collaboration revenue, was $66 million for the third quarter of 2016. We are tightening our full year 2016 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to be in the range of $310 million to $335 million from $310 million to $340 million. 
Turning now to taxes. Effective tax rate for the third quarter of 2016 was 27.6% as compared to 46.5% in the third quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings, inclusion of the tax benefit of share-based compensation and the impact of the domestic manufacturing deduction as compared to the same quarter of last year as well as the discrete impact to this quarter of a change in our assessment of reserves for uncertain tax positions. 
For 2016, we are lowering and tightening guidance for our full year GAAP effective tax rate to be 29% to 33% from the previously provided range of 33% to 41%. Our capital expenditures for the 9 months ended September 30, 2016, we're $361 million. 
For the full year 2016, we are lowering and tightening our guidance for capital expenditures to be  in the range of $480 million to $510 million from the previously provided range of $480 million to $530 million. 2016 capital expenditures primarily include costs in connection with renovations of our Limerick Ireland manufacturing facility; tenant improvement and associated costs at our Tarrytown, New York facilities; renovations and addition store in Rensselaer, New York manufacturing facilities; and the purchase of an office building near our Rensselaer manufacturing facility. We ended the third quarter of 2016 with cash and marketable securities of $2.2 billion, which includes the Teva upfront payment of $250 million. As we have reported in previous quarters, we have opportunistically reduced the number of warrants that we issued in 2011 in connection with our convertible debt issuance through repurchases from the warrant counter parties. Depending on market and other conditions we may spend up to $450 million to repurchase or settle these outstanding warrants. With that, I'd now like to turn the call over to Michael."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob.  [Operator Instructions] With that, operator, can we please open up for Q&A?",15,"Thank you, Bob.  [Operator Instructions] With that, operator, can we please open up for Q&A?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup.",12,"[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","And I'll fix it to one question. So if I heard you correctly, it sounded like the ANG2 and [indiscernible] enrollment 12-week study? Is it possible we think it was in the first quarter? And if so, or when we get results, how are you -- remind us how you r",61,"And I'll fix it to one question. So if I heard you correctly, it sounded like the ANG2 and [indiscernible] enrollment 12-week study? Is it possible we think it was in the first quarter? And if so, or when we get results, how are you -- remind us how you release them [indiscernible] maybe some color and expectations around that?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","First, since think you're talking about timing, we really don't give guidance on timing. And as we have typically look at this and give the top line press releases is our typical practice.",33,"First, since think you're talking about timing, we really don't give guidance on timing. And as we have typically look at this and give the top line press releases is our typical practice."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","But one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is a top bar and we're possibly looking on trying to improve on that. And so when we get the data, we certainly give you a top line assessment.",47,"But one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is a top bar and we're possibly looking on trying to improve on that. And so when we get the data, we certainly give you a top line assessment."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn from Goldman Sachs.",10,"Our next question comes from Terence Flynn from Goldman Sachs."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just 2 parts. First, just maybe just walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year? And then Bob, just maybe last year, at  that time, you highlighted  2016 were shaping up to be an important inv",63,"Just 2 parts. First, just maybe just walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year? And then Bob, just maybe last year, at  that time, you highlighted  2016 were shaping up to be an important investment year. Any thoughts here as we head into '17 for the particular dupilumab launch?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to",81,"So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to happen in the marketplace. There's both potential for ups and downs there. And obviously, additional indications, diabetic retinopathy. Those are the 3 places where we would be focusing and looking to drive growth off of a very large base, obviously."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Terence, it's Bob. Yes, we'll go out with our SG&A guidance upcoming. We're not in the position right now to talk to that. But again, we've spent time on this call, and you've heard us previously with regards to the excitement we have around Dupixent. So",151,"Terence, it's Bob. Yes, we'll go out with our SG&A guidance upcoming. We're not in the position right now to talk to that. But again, we've spent time on this call, and you've heard us previously with regards to the excitement we have around Dupixent. So with the March 29 PDUFA date coming, we need to ensure that we are ready with regards to our marketing and our sales team, and everything to be able to hit the road very quickly on that. And again, we're still investing behind Praluent as we wait for the OUTCOMES data. In sarilumab, as I mentioned on the call, we are putting our promotional dollars behind that in our marketing and spend and when the FDA lifts we get regulatory approval on that and then we will be in a position to ensure that the product is fully supported from a marketing and sales perspective."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ying Huang from Bank of America Merrill Lynch.",11,"Next, we have Ying Huang from Bank of America Merrill Lynch."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming to stop is has a ratio of less than 0.802 with a p value of less than 0.0001. Can you elaborate? Do you need to see consistency in every composite of the primary",83,"I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming to stop is has a ratio of less than 0.802 with a p value of less than 0.0001. Can you elaborate? Do you need to see consistency in every composite of the primary endpoint, [indiscernible] the primary endpoint? And also can you tell us how confident -- how much confidence you have in terms of being able to meet that endpoint by end of this month?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. This is George. In some ways, this decision is out of our hands, and it's very subjective. In terms of there's independent monitoring board that without us, is going to look at the data regardless of even if we hit the numbers that you stated in term",170,"Yes. This is George. In some ways, this decision is out of our hands, and it's very subjective. In terms of there's independent monitoring board that without us, is going to look at the data regardless of even if we hit the numbers that you stated in terms of for over efficacy. They have to make a decision about not only consistency and so forth that they're going to take into account whether there was rationale and it's worthwhile because maybe they want to look at this subgroup or another to get the complete data set. And so it'll be -- it's very hard to predict something like that. And as I said, it's up to 1 independent data monitoring board completely out of our hands. And they could simply decide, for example, if they want to follow and get more depth in 1 particular subgroup even though the overall population was very clear. So the end result is I can't really answer your question because we just don't know."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Chris Raymond from Raymond James.",8,"Next, we have Chris Raymond from Raymond James."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On sarilumab, just putting the manufacturing delay for the drug aside. There's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out if it's sort of pricing runway. And we'd actually seen from some of",126,"On sarilumab, just putting the manufacturing delay for the drug aside. There's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out if it's sort of pricing runway. And we'd actually seen from some of our own work pretty strong evidence that other sort of newer biologics have been gaining traction for some time. And I wonder if you could maybe describe at a high level your views of maybe the changing landscape with respect to access and PDM market power and how you think sarilumab, once it is ultimately approved, is positioned, not just necessarily from a political standpoint but how you think for commercial landscape's changing in ways that may or may not favor the drug."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure. This is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because, obviously, we have to get to market. It is a tough environment and the people who are paying the bills have seen what I would consider, in some c",265,"Sure. This is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because, obviously, we have to get to market. It is a tough environment and the people who are paying the bills have seen what I would consider, in some cases, almost outrageous increases in the price of at least on the price of the whole site position cost of drugs rheumatoid arthritis with people taking double-digit increases sometimes twice a year. To me, that suggests some sort of tone deafness in this environment. We think that we have to compete in 2 ways. We have to compete with a very good drug, which we think sarilumab will be be -- of course, we have to get over this feeling glitch and get the market as quickly as we can. But we think that the class is doing very well. There's some data out there from the first-class where monotherapy against the leading the IL-6 receptor class performed better. And there were some people who simply don't like to take methotrexate. We have a date out of our own which probably first filing similar types of results outperforming in monotherapy. But given a solid entry with good properties is not going to be enough here, and we have to compete with an offering that payers will find attractive. I think Regeneron is not -- is willing to break some of the mold here, and I'm getting some sort of hinge from my colleagues that I probably said enough. So I'll leave it at that."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Lyn, it's Bob. I think it's important though to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is that after a patient receives 1 TNF inhibitor, if they move to a second, we see diminishing effi",117,"Lyn, it's Bob. I think it's important though to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is that after a patient receives 1 TNF inhibitor, if they move to a second, we see diminishing efficacy over time. We have an obligation from a sales and marketing perspective when we get approved to stop the TNF cycling. And IL-6 inhibition plays a central role in RA. It plays central role not only the symptoms but in terms of the progression of joint damage. And we have to educate physicians on that. So we're anxious to have the product get approved to get that message out there."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Geoffrey Porges from Leerink Partners.",8,"Next, we have Geoffrey Porges from Leerink Partners."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternate facility was included in the original BLA? And whether it is s",91,"Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternate facility was included in the original BLA? And whether it is straightforward to switch the fill finish alternative facility? And the secondly, could you tell us whether the inventory of Praluent, sarilumab and dupilumab, which presumably have already pre-launched, is embargoed? Or is it likely to be usable? And can you be selling Praluent from that inventory already?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, Geoff. As usual you asked some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, h",294,"Yes, Geoff. As usual you asked some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, how they're going to be resolved, the strategy, , what's in filings and what it is in so on and so forth. We can summarize by saying that we -- Sanofi is working very hard, and they believe they can quickly remedy the deficiencies that were not related to sarilumab per se but rather some general GMP deficiencies which they are, frankly, well on their way to remedy. Of course, we have to work with the agency and they have to be satisfied. In terms of products that are already manufactured there, I think you should think of -- the FDA sort of take a risk-based approach here to have sort of a maybe frozen and place those things that are actually being -- assuming that they don't think of plan is way out of whack and nothing can be shipped and filled. They continue to fill and use product from that facility for approved products. It's a new product such as sarilumab, which gets sort of shut out, obviously and unfortunately. We're working with them on sarilumab and we're also working with a different group on Dupixent, which is a breakthrough product which has a whole different set of approaches to it. So it's complicated. You can imagine there's a tremendous amount of work. A week seems like a long time maybe in your world. But in the world of regulatory interactions and manufacturing remedies and so on, it's still a relatively short time."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Rannie Goal from Bernstein.",7,"Next, we have Rannie Goal from Bernstein."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just very quickly, following on Jeff. Just looking at generic industry when it comes to fill finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives the conviction that in this case, it wi",95,"So just very quickly, following on Jeff. Just looking at generic industry when it comes to fill finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives the conviction that in this case, it will be a relatively short one? And then if I could sneak a second one. 340B, there's been some discussions in the forum for that program. If you could just let us know how you think -- if you can just give us an update about this program? And how it impacts EYLEA sales?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We're going to give you only 1 question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a relati",146,"We're going to give you only 1 question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a relatively short period of time, that Sanofi feels that they can get the plant in full GMP compliance. In fact, they've already brought in all sorts of efforts and resources. They've already submitted a detailed plan. They've already submitted their first -- or second progress reports against that plan. And so we feel we feel that the strategy is the right one and the approach is the right one. Obviously, we just have to work with the agency and see how quickly they can feel comfortable that the plan is ready to go. Next question?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Alethia Young from Credit Suisse.",8,"Next, we have Alethia Young from Credit Suisse."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on the pediatric population. I know you quantified a little bit more about the adult pedestrian, the 300,000 a day. Can you kind of frame that in similar or likely nature or similar nature as to the pediatric population please?",42,"Just one on the pediatric population. I know you quantified a little bit more about the adult pedestrian, the 300,000 a day. Can you kind of frame that in similar or likely nature or similar nature as to the pediatric population please?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob, do you want to comment at all on the...",10,"Bob, do you want to comment at all on the..."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now.",28,"I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Adnan Butt from RBC Capital Markets.",9,"Next, we have Adnan Butt from RBC Capital Markets."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Maybe for Bob. On EYLEA, pricing aside, as EYLEA growth tempering a bit, we have thought that DME would be bigger what are the individual market dynamics if you could give any color on that?",35,"Maybe for Bob. On EYLEA, pricing aside, as EYLEA growth tempering a bit, we have thought that DME would be bigger what are the individual market dynamics if you could give any color on that?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to and fasinumab on its primary endpoint.",189,"Yes. We have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to and fasinumab on its primary endpoint. The challenge with continuing growth in DME is that there are a number of patients that never make it to the retinal specialist's office. They go to an ophthalmologist who do laser therapy. Laser is a revenue driver in the ophthalmologist office. And they don't make it and the retina physician's office where they can get access to anti-VEGF therapy. This has been a focus for us. We are educating. We're trying to educate patients that if they do have DME, they ought to get themselves to a retinal specialist. But this is chipping away at a habit among the ophthalmologists is going to take some time. But we continue to see that the DME market does offers substantial growth opportunities in the future. And as Len mentioned earlier, if and when we get the diabetic retinopathy indication, that would be a further driver."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from John Scotti from Evercore ISI.",10,"Our next question comes from John Scotti from Evercore ISI."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross net? And I was just wondering if you're still seeing that steady increase in the and potentially a small erosion on the price? And if so, what's the magnitude",62,"On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross net? And I was just wondering if you're still seeing that steady increase in the and potentially a small erosion on the price? And if so, what's the magnitude of that? And whether or not you see this trend stabilizing or continuing in 2017."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters.",25,"Yes. I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Cory Kasimov from JPMorgan.",7,"Next, we have Cory Kasimov from JPMorgan."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So with the PDUFA date for monthly Praluent early next year, can you just talk a little bit about extended dosing in this study? Clearly, this is a payer-constraint market today. But what might monthly dosing mean a little bit down the road, and how do yo",66,"So with the PDUFA date for monthly Praluent early next year, can you just talk a little bit about extended dosing in this study? Clearly, this is a payer-constraint market today. But what might monthly dosing mean a little bit down the road, and how do you think about even maybe longer-term dosing options potentially entering this market from competition at some point in the future?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the outcomes data that we hope will support the LD",123,"Yes. I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the outcomes data that we hope will support the LDL hypothesis and continue to support its, and largely driven by payers. They've already demonstrated that they will not pay for convenience. If you look at the hepatitis C class, they put much less convenient regiment up against the much more expensive regiment. So I don't think convenience per se is going to drive the market. On the other hand, we like to come up with offerings that is convenient as possible for patients."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just to add to that, so far, patients who have received Praluent on an every 2-week basis, have been happy with the dosing sequence. Perhaps convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patie",65,"And just to add to that, so far, patients who have received Praluent on an every 2-week basis, have been happy with the dosing sequence. Perhaps convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who do want monthly convenience. But this is not an issue in the marketplace at the current time."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Jim Birchenough from Wells Fargo.",8,"Next, we have Jim Birchenough from Wells Fargo."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","This is a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual components whether it's viscosity and ability to i",90,"This is a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual components whether it's viscosity and ability to inject the full dose? Probably the amount of protein you're giving to the back of the eye? I'm just trying to see if there's any learnings from the PDGF program that might inform how we should think about the co-formulation part of this for the ANG2 product?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We have no reason to think that there's any issue whatsoever with that or that, that would have contributed all to the results and the results we believe simply reflect the biology or the lack of biology here for the PDGF pathway.",43,"We have no reason to think that there's any issue whatsoever with that or that, that would have contributed all to the results and the results we believe simply reflect the biology or the lack of biology here for the PDGF pathway."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Yatin Suneja from SunTrust.",7,"Next, we have Yatin Suneja from SunTrust."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","A question on Praluent. Could you comment on the value-based contract? We know Amgen mentioned that they are inching into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?",40,"A question on Praluent. Could you comment on the value-based contract? We know Amgen mentioned that they are inching into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can",62,"Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can do it, we are working with those plans to establish a value-based contract where appropriate."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Brian Amin from Jefferies.",7,"Next, we have Brian Amin from Jefferies."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear the community all typically follow easier score at scales. But if that look at those service area to determine severity of disease.",37,"How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear the community all typically follow easier score at scales. But if that look at those service area to determine severity of disease."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think it varies by geography in Europe. EASI-75 or PASI-75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on and they're already preparing themselves for that. In the U",79,"I think it varies by geography in Europe. EASI-75 or PASI-75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on and they're already preparing themselves for that. In the United States, you're correct. EASI scores are not relevant to the physicians and IGA scores are not specific enough. So we're working right now on plans with payers on how to better define the disease. George?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We should, Jeff, let you know that obviously in our studies, on average, the patients that we study have more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients have 85% or more of their body covered with this dise",321,"We should, Jeff, let you know that obviously in our studies, on average, the patients that we study have more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients have 85% or more of their body covered with this disease. This just shows how severely these patients are. And it's not just that their skin is covered with this rash but this is a weepy, itchy, horrific rash that they just can't escape. And remarkably, enough as we said, despite the heavy burden of disease at baseline, almost 40% of these patients achieved a clearer, almost clear status. Rarely in this business do you have a privilege to be involved in a story like this that can make such a difference in patients lives. We've been lucky here in Regeneron that we've done this a couple of times already. But we think that Dupixent is really a once-in-a-lifetime story where you can really impact such an important disease so dramatically, have an average 70% improvement among all patients. And the thing that's also so stunning to us about dupilumab is that it looks like it might have the promise to do likewise in a host of related allergic disease, including the overall asthma population where there again in the most uncontrolled severe population. Once again, the results are very impressive from our first pivotal study. And we think the same is being the case and a host of other allergic settings. So the short answer to your question is, unfortunately, there's a lot of patients who have more than 50% of their body surface covered. Those patients are certainly, by any category, considered severe patients. As Bob already told you, many of them have exhausted all other options. And we just hope that the -- all the other ancillary things don't keep these important patients from getting access to this important life-changing drug."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would just amplify a tiny bit on what George has said, which is contrasted to Praluent. We knew that with Praluent, of course, that we can lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the details of thei",404,"I would just amplify a tiny bit on what George has said, which is contrasted to Praluent. We knew that with Praluent, of course, that we can lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the details of their care, which some are. But many, to them, that isn't the end-all be-all or something they wake up everyday wondering how to get that cholesterol down. Of course, if they have an art that and everybody to family does and they do pay attention to that. And then there was the push back well, you don't really know do you that it improves outcomes. We're just going on a hypothesis even know there's a quite a deal of data to certainly support that hypothesis. So it's not a disease that people are clamoring to get treated and is not outcomes that are readily in hand. Contrast that with Praluent where these patients are desperate for treatment, truly desperate for treatment. And we're not talking about the topical treatments that are available such as steroids that might become available when you're dealing with small areas of relatively mild to moderate disease. We're talking about the kind of patients George referred to, which are really quite significant. And these patients can see the outcome themselves. They can tell that they're doing better. And we see it in our studies, we see it in our questionnaires. We see it in whether or not they're sleeping because they can scratch themselves so badly. I heard a story the other day which practically it was but as all to tears where a little boy who was visiting his grandparents and so is cuddling and sleeping on the same bed  with very bad atopic dermatitis, said to his grand parents, can you each hold one of my hands when I sleep so I don't scratch myself so badly. I mean, think about that. This is a disease that people really are looking for treatments. And if we can get this drug approved, first, for adults and, hopefully, down the road, for children, we can really provide something that they can tangibly feel. We're passionate about making sure that we remove all the barriers out there, and we expect to work with patients, with doctors, with payers, with organizations to make sure that people are aware of this treatment and can get access to it. Next question?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. I think we have time for one more question.",10,"Yes. I think we have time for one more question."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Phil Nadeau from Cowen and Company.",11,"Our final question comes from Phil Nadeau from Cowen and Company."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I want to understand the dynamics there a bit more. Is there a set cycle for when discounts are",74,"Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I want to understand the dynamics there a bit more. Is there a set cycle for when discounts are negotiated? Or are there any signs that you're saying that this is something that's demanded by payers? Or is this something that the competition is taking upon themselves to do?"
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","There's really not -- remember, this is a Part D drug, and it's really not the same kind of environment. We have a timing and a cycle with patients. For the most part, there is some small amount of that, that goes on. But for the most part, the discounts",143,"There's really not -- remember, this is a Part D drug, and it's really not the same kind of environment. We have a timing and a cycle with patients. For the most part, there is some small amount of that, that goes on. But for the most part, the discounts and rebates that have been offered have been sort of directly back to the physicians offices, et cetera, et cetera. We continually reevaluate that situation. We look at what the impact. We're very sensitive to doctors not having to make a choice of what to give their patients, what they might think the best drug would be because of a rebate situation or something like that. We think most retinal physicians don't do that. But we certainly understand the real world. And as the market  suggests, we're prepared to react if necessary."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today.",42,"Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today."
33715,404125717,1073787,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr.",46,"Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today a",324,"Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are: Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for questions-and-answers.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2016, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the rest of the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  EYLEA, our flagship anti-VEGF, continues",746,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  
EYLEA, our flagship anti-VEGF, continues to remain a key financial driver for Regeneron. We are pleased with the continued growth of EYLEA and are committed to maintaining our leadership position in the branded anti-VEGF market by pursuing both additional indications for EYLEA, such as diabetic retinopathy, where we currently have a Phase III study ongoing. And we are also looking at ways in which we can improve upon the high efficacy bar set by EYLEA to combinations with an antibody to ANG2, where we currently have 2 Phase II studies ongoing. 
While EYLEA remains very important to our business, we are equally focused on the ongoing launch of PRALUENT, our PCSK9 antibody, for lowering LDL cholesterol as well as advancing our pipeline. For PRALUENT, we believe that if OUTCOMES data are positive, it will drive greater use of this class. As mentioned in our press release, we expect the second interim analysis by the end of this month. 
Moving on to sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis. As you heard last week, we received a Complete Response Letter from the FDA. This was due to certain manufacturing deficiencies not specific to sarilumab that were observed during a routine inspection of a Sanofi fill and finish plant in France. Sanofi has provided comprehensive responses and is working closely with the FDA to address the deficiencies as expeditiously as possible. It has only been a week since we received the Complete Response Letter. And we are preparing to engage in meaningful discussions with the FDA. So it is too early for us to comment on the expected time line for potential sarilumab approval. 
We do not expect these manufacturing deficiencies will impact dupilumab or as it is now known by its brand name, Dupixent, where our Biologics License Application, or BLA, is currently under FDA priority review for the treatment of moderate-to-severe atopic dermatitis in adults. The FDA action date for the BLA is at the end of March. Dupixent is a very important pipeline product candidate for us. And we believe that atopic dermatitis represents an area of high unmet need. As a reminder, we received breakthrough designation in this indication. In addition to atopic dermatitis, we are also investigating Dupixent in other indications, including asthma, where we recently completed enrollment in our second pivotal study. 
In the mid-term, we are looking to important clinical progress from several of our Phase II and III programs, which span a variety of therapeutic areas, such as allergic diseases, pain, viral diseases, ophthalmology, oncology, cardiometabolic disease, inflammatory and rare diseases. These programs have the potential to drive the next wave of growth for Regeneron. You will hear more about the key current developments from some of these programs from George. 
At Regeneron, we've always been committed to long-term science and innovation. In fact, today's marketed products as well as the 16 product candidates in clinical development were all home-grown in our internal R&D engine. We will continue to invest in science and technology that can provide sustainable innovation and growth well into the future. This unique long-term focus on science is at the heart of why we have been able to attract top talent, which is key to our continuing success. Through that end, last week, we were thrilled to be named by Science Magazine as the #1 company in the biotech or pharmaceutical industry to work for, a recognition we have received for 4 of the last 6 years. 
We know that our industry has faced many important questions regarding pricing of drugs. This is not the forum to discuss the complex issue of drug pricing. But I think it is important to note that Regeneron is in a unique position. As a company founded on science and committed to the research and development of important new products, we are well positioned to succeed even in a difficult and constrained pricing environment. In fact, we have never raised prices on any of our drugs, choosing instead to grow through the optimization of currently marketed products by pursuing new indications as well as the introduction of new medicines. Our future potential growth will be driven by this strategy. 
With that, let me turn the call over to George."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a",1262,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a wide variety of allergic diseases. The most advanced of which is uncontrolled moderate-to-severe atopic dermatitis. 
Just last month, we had the opportunity to present detailed results from SOLO 1 and SOLO 2, which were 2 identical Phase III studies that investigated Dupixent in the monotherapy setting at the annual EADV conference. These data were also concurrently published in the New England Journal of Medicine. These were the first large pivotal studies where a systemic investigational therapy demonstrated significant reduction in the signs and symptoms of atopic dermatitis with an average reduction in skin scores of about 70%, accompanied by a marked reduction in the usually unrelenting itch associated with this disease and almost 40% of these patients achieving clearing or near-clearing of the skin lesions. 
Unlike other immune modulating therapies, there was no evidence of increased immunosuppression. And the most common adverse events in the 2 trials were injection site reactions and conjunctivitis. We were encouraged by the excitement with which these data were received by the physician community as well as by patients. And we believe that this speaks to the current unmet need and frustration with currently available therapies for this severely debilitating disease. As Len mentioned, our BLA for Dupixent for the treatment of adults with moderate-to-severe atopic dermatitis is currently under FDA review and has been given priority review status and an action date of March 29, 2017. 
While the SOLO studies were in the monotherapy setting, we have also reported positive 1-year top line data from the CHRONOS Phase III study, which explored Dupixent in combination with topical corticosteroids. The safety and efficacy findings from the long-term CHRONOS study were consistent with those observed in SOLO 1 and 2. I'm also pleased to share that LIBERTY AD CAF, a Phase III study of Dupixent with concomitant topical corticosteroids in adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to or ineligible for oral cyclosporine, is now fully enrolled. We, along with our collaborator Sanofi, expect to complete the regulatory resubmission in Europe and Japan in the fourth quarter of 2016. We also plan to initiate a Phase III study in the pediatric severe atopic dermatitis population in the first quarter of 2017 in patients between the ages of 12 and 17. We are pleased that similar to the adult indications, Dupixent has received breakthrough designation for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. 
While atopic dermatitis is the most advanced indication in development for Dupixent, we are making headway with our asthma program as well. We have previously announced positive results from our first pivotal study in uncontrolled persistent asthma despite treatment with inhaled steroids and long-acting beta agonists. As a reminder, these data demonstrated improvements in both lung function as measured by FEV and exacerbations in all patients regardless of baseline eosinophil status. There was a 15% improvement above placebo in FEV1 and a 75% reduction in exacerbations in the overall population treated with the 300-milligram, every 2-week dose. The most common adverse events associated with treatment in this study was injection site reaction. 
In September, we announced completion of enrollment in LIBERTY ASTHMA QUEST, which is our confirmatory Phase III pivotal study of Dupixent in this indication. The primary endpoint of this study is at 52 weeks. And we, therefore, expect to make a regulatory submission in the U.S. towards the end of 2017. We also expect to initiate a Phase III study in the pediatric asthma patients in early 2017. We are also exploring the use of Dupixent in several other allergic indications, such as nasal polyps, where we expect to initiate a Phase III study early next year. And in eosinophilic esophagitis, we are currently in a Phase II. 
Turning to fasinumab, our Nerve Growth Factor antibody for pain. In October, we provided an update on this program. Following the observation of a case of rapidly progressive osteoarthritis in a patient receiving high-dose fasinumab, who had a history of advanced osteoarthritis of the knee, the FDA placed our Phase II study in chronic lower back pain patients on clinical hold. This event prompted an unplanned interim analysis of the study, which had already completed 70% of its targeted enrollment. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups compared to placebo at 8- and 12-week time points with p-value of less than 0.01. Preliminary safety results were also generally consistent with those observed previously with this class. The FDA has since communicated that we can continue development of fasinumab in chronic lower back pain by excluding patients who have advanced osteoarthritis. We are also continuing our pivotal program in osteoarthritis with final design elements still receiving regulatory feedback. The fasinumab program will contain safety data from approximately 10,000 patients overall.
Moving to PRALUENT. The recent news on the discontinuation of development of bococizumab obviously has a major impact on the PCSK9 landscape. This further underscores the very high bar in terms of safety and efficacy for this class. This example also highlights to us the value of our fully human VelocImmune-based antibody technology. In terms of our PRALUENT program, our 18,000-patient ODYSSEY OUTCOMES study, remains ongoing. We expect the second interim analysis for futility and overwhelming efficacy by the end of this month. We, and our collaborator Sanofi, have also completed regulatory submissions for the once-monthly dosing formulation of PRALUENT in the Europe and Japan territories as well as in the United States, where we have been granted an FDA action date of January 24, 2017. 
Our immuno-oncology program continues to advance and expand. We believe that these are still early days in the area of immuno-oncology with the collective knowledge of this field evolving rapidly and the competitive landscape changing continuously. Evidence of this includes the recent surprising failure of the market-leading PD-1 antibody in first-line lung cancer. Regarding our PD-1 program, our potentially pivotal study in cutaneous squamous cell carcinoma is ongoing and we plan to announce additional studies in the near future. In addition, we're also studying PD-1 in combination with our bispecific CD20xCD3 molecule. At the end of this year, at the American Society of Hematology or ASH conference, we will be presenting monotherapy data from the CD20xCD3 program. Lastly, we plan to advance Regeneron 3767 [ph], an antibody LAG3, into clinical development by the end 2016. 
In October, we announced top line results from a Phase II combination study of EYLEA with rinucumab, our PDGF receptor antibody in wet age-related macular degeneration or wet AMD, where the data demonstrated no improvement in best corrected visual acuity or BCVA, the primary endpoint of the study, versus EYLEA alone. We think these study results demonstrate the high hurdle that has been set by the well-established efficacy and safety of EYLEA. That said, we are looking for ways in which we can strengthen our EYLEA franchise. To that end, we are conducting a Phase II study of EYLEA in a co-formulated combination with nesvacumab, our antibody to ANG2, in AMD and DME. The DME study is full enrolled while the study in wet AMD continues to enroll patients. We are also exploring longer-acting approaches with this class. 
And with that summary, let me turn the call over to Bob Terifay."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the",817,"Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the third quarter were $471 million, which represents 27% year-over-year growth, unadjusted for currency fluctuations. Net ex U.S. year-to-date sales were $1.4 billion. 
EYLEA is the market-leading product among FDA-approved anti-VEGF agents for all of its approved indications in the United States. In the U.S., we are seeing increased competitor discounts and rebates. We are carefully assessing these actions. As I'm sure you're well aware, there's a pending proposal from the Centers of Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B or buy-and-bill drugs. We've worked hard on the policy and legislative front on this issue. And we'll be prepared to respond on the commercial front as needed to make sure that patients continue to have full and complete access to EYLEA.
Turning now to PRALUENT or alirocumab. As reported by Sanofi, net sales in the third quarter were $38 million worldwide with U.S. accounting for $32 million of the total. Sales data and IMS total prescription data indicate that PRALUENT and evolocumab market share are roughly 50-50 in the United States. As reported by IMS, U.S. total prescriptions for PRALUENT increased sequentially 60% versus second quarter 2016. 
The challenge for the PCSK9 inhibitor class continues to be the significant reimbursement hurdles for the physicians' offices and patients, resulting in a low volume of prescriptions being dispensed. This has resulted in physicians' offices reserving their initial prescriptions to a limited pool of patients. We continue to focus our efforts in improving access and improving the prescription process through the payers and the specialty pharmacies. We're gradually seeing more payers loosen their utilization management criteria, including removing their requirement for prior ezetimibe therapy. In addition, we are now seeing some patients shortening the number of months that a patient needs to be on a maximally tolerated statin therapy and eliminating a specialist-only prescribing or consultation requirement. Others have streamlined the prior authorization process. 
ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of PRALUENT. Outside of the United States, PRALUENT was approved in the EU in September of 2015 with the product now approved in 41 countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K., Spain, Norway and the Netherlands. It still remains a challenging reimbursement situation with some countries awaiting cardiovascular OUTCOMES data. 
We continue to plan for the potential launch of sarilumab in the United States. As an example, we have a major presence at the upcoming American College of Rheumatology meeting this month in Washington, D.C. We'll be presenting data from our MONARCH study of sarilumab as monotherapy in patients who are DMARD responders as well as subset analysis from our pivotal U.S. registrational studies. We'll have a display floor presence highlighting the central role of IL-6 in rheumatoid arthritis. The European Marketing Authorization Application for sarilumab is currently under review by the European Medicines Agency with a potential decision on the application expected in mid-2017. Co-promotion decisions for Europe and other ex U.S. countries will be made over time.
We're currently preparing for Dupixent or dupilumab commercialization with an FDA PDUFA date of March 29, 2017. We will be co-promoting Dupixent with Sanofi-Genzyme in the United States. Co-promotion decisions for other countries will be made at a later date. We are aware that ICER, payers and pharmacy benefits managers are proactively evaluating the cost-effectiveness of emerging therapies for atopic dermatitis in the United States. We want to take a moment to discuss how we are thinking about the Dupixent commercial opportunity, which differs in many important respects from the situation we faced with PRALUENT. 
Dupixent has already demonstrated efficacy on the most important outcomes: consistent efficacy on rash severity, itching and quality of life measures. In the United States, there are 1.6 million patients with uncontrolled moderate-to-severe atopic dermatitis, the majority of which will not likely receive Dupixent therapy. We estimate that approximately 300,000 of these patients have exhausted all approved therapies and have failed or unable to tolerate unapproved use of immunosuppressant therapies. Many of these advanced patients are suffering from a host of related issues, including sleep disturbances, anxiety and depression. These atopic dermatitis patients should not be denied therapy. We hope payers and insurers will provide appropriate and timely access to Dupixent, should it be approved, and that patients will not have to step through unapproved immunosuppressant therapies, many of which have black box warnings. We plan to work closely with all stakeholders, including patients, physicians and payers to achieve this goal. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP",1331,"Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP SG&A, our effective tax rate and capital expenditures. 
Let me start with our top line third quarter earnings. In the third quarter 2016, non-GAAP net income was $365 million and non-GAAP net income per diluted share was $3.13. This represents an increase of 32% in both non-GAAP net income per diluted share as well as non-GAAP net income in the third quarter 2016 compared to the third quarter of 2015. Regeneron's third quarter 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and the $25 million upfront payment made in connection with our third quarter 2016 license and collaboration agreement with Adicet and includes the income tax effect of these non-GAAP reconciling items. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the third quarter of 2016 were $1.2 billion, which represents year-over-year growth of 7% over the third quarter of 2015. Net product sales were $857 million in the third quarter of 2016 compared to $738 million in the third quarter of 2015. EYLEA U.S. net product sales were $854 million compared to $734 million in the third quarter of 2015, representing 16% year-over-year growth. Sequential quarter-over-quarter growth was approximately 3%. During the third quarter of 2016, EYLEA experienced a slight increase in U.S. distributor inventory levels as compared to the second quarter of 2016 but continues to be within our normal 1- to 2-week targeted range.
As mentioned in our press release issued this morning, we're tightening our full year 2016 U.S. EYLEA net sales guidance to be year-over-year growth of 23% to 25%. Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $471 million in third quarter of 2016 compared to $371 million in the third quarter of 2015, representing a 27% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 25%. In the third quarter of 2016, Regeneron recognized $171 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the third quarter of 2016 was $191 million. 
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $144 million for the third quarter of 2016. The Sanofi collaboration revenue line item primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron-incurred commercialization-related expenses and our share of profits or losses in connection with the commercialization of antibodies. In the third quarter of 2016, our share of the collaboration's losses in connection with the commercialization of antibodies, which includes PRALUENT and pre-commercialization activities and costs in connection with sarilumab and Dupixent, was $112 million, which can be found in Table 4 of our earnings release. Netted within these collaboration losses were the global sales of PRALUENT as recognized by our collaborator Sanofi of $38 million for the third quarter of 2016. 
Before moving to expenses, I'd like to highlight 2 third quarter business development transactions. The first is the collaboration we entered into with Teva to develop and commercialize our NGF antibody, fasinumab. Under the terms of the agreement, Teva paid Regeneron a $250 million upfront payment and we will equally share on an ongoing basis R&D expenses of approximately $1 billion under a global development plan. We plan to ratably recognize the upfront payment as revenue over the related performance period. The signing of this agreement did not have a material P&L impact on the third quarter of 2016. As a reminder, the intellectual property associated with our late-stage pipeline, including fasinumab, has been migrated offshore, thus expenses and revenues associated with the program will be recognized in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. The other 2016 third quarter business development transaction was a collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapeutics. In accordance with this agreement, we paid Adicet a $25 million upfront payment in the third quarter of 2016, which we have recorded as GAAP R&D expense in our consolidated statement of operations but have excluded from our non-GAAP net income. 
Turning now to expenses. Non-GAAP R&D expense, which is calculated as the total GAAP R&D expense less R&D noncash share-based compensation expense as well as the upfront payment we made to collaborator Adicet, was $437 million for the third quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total non-GAAP R&D expense less R&D reimbursements from our collaborators, was $256 million for the 3 months ended September 30, 2016. Our press release includes all the information as required to calculate unreimbursed non-GAAP R&D expense. As a result of the recently executed collaboration with Teva regarding fasinumab, we are lowering and tightening our full year 2016 guidance for non-GAAP unreimbursed R&D to be in the range of $945 million to $975 million from our previous guidance range of $970 million to just over $1 billion. 
Non-GAAP SG&A expense was $221 million for the third quarter 2016. We are tightening and lowering our full year 2016 guidance for non-GAAP SG&A to $965 million to $995 million from our previous guidance range of $980 million to $1.02 billion. Note that even after lowering and tightening our full year guidance, we do not expect to see any material prelaunch cost savings from the PDUFA delay of sarilumab, we will be co-promoting sarilumab with Sanofi-Genzyme and our sales force is already onboard. And as you heard earlier from Bob Terifay, we continue to prepare for the launch in anticipation of the resolution of matters with the FDA. Sanofi reimbursement of the Regeneron commercialization-related expenses, a line item found within Sanofi collaboration revenue, was $66 million for the third quarter of 2016. We are tightening our full year 2016 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to be in the range of $310 million to $335 million from $310 million to $340 million. 
Turning now to taxes. Our effective tax rate for the third quarter 2016 was 27.6% as compared to 46.5% in the third quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings, inclusion of the tax benefit of share-based compensation and the impact of the domestic manufacturing deduction as compared to the same quarter of last year as well as the discrete impact to this quarter of a change in our assessment of reserves for uncertain tax positions. For 2016, we are lowering and tightening guidance for our full year GAAP effective tax rate to be 29% to 33% from the previously provided range of 33% to 41%. 
Our capital expenditures for the 9 months ended September 30, 2016, were $361 million. For the full year 2016, we are lowering and tightening our guidance for capital expenditures to be in the range of $480 million to $510 million from the previously provided range of $480 million to $530 million. 2016 capital expenditures primarily include costs in connection with renovations of our Limerick, Ireland manufacturing facility; tenant improvement and associated costs at our Tarrytown, New York facility; renovations and additional store at Rensselaer, New York manufacturing facility; and the purchase of an office building near our Rensselaer manufacturing facility. 
We ended the third quarter 2016 with cash and marketable securities of $2.2 billion, which includes the Teva upfront payment of $250 million. As we have reported in previous quarters, we have opportunistically reduced the number of warrants that we issued in 2011 in connection with our convertible debt issuance through repurchases from the warrant counterparties. Depending on market and other conditions, we may spend up to $450 million to repurchase or settle these outstanding warrants. 
With that, I'd now like to turn the call over to Michael."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?",15,"Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup.",12,"[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, h",80,"And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, how are -- remind us how you typically release them. [indiscernible] we'd have to wait for 2 weeks for a conference, and maybe some color and expectations around that."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice.",38,"First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment.",49,"So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn from Goldman Sachs.",10,"Our next question comes from Terence Flynn from Goldman Sachs."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an",68,"It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an important investment year. Any thoughts here as we head into '17, particularly for the dupilumab launch?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to",81,"So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to happen in the marketplace. There's both potential for ups and downs there, and obviously additional indications, diabetic retinopathy. Those are the 3 places where we would be focusing and looking to drive growth off of a very large base, obviously."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent",156,"Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent. So with the March 29 PDUFA date coming, we need to ensure that we are ready with regards to our marketing and our sales teams and everything to be able to hit the road very quickly on that. And again, we're still investing behind PRALUENT as we wait for the OUTCOMES data. In sarilumab, as I mentioned on the call, I mean, we are putting our promotional dollars behind that in our marketing and spend. And when the FDA lifts the -- we get regulatory approval on that, then we will be in a position to ensure that the product is fully supported from a marketing and sales perspective."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ying Huang from Bank of America Merrill Lynch.",11,"Next, we have Ying Huang from Bank of America Merrill Lynch."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every co",87,"I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every composite of the primary endpoint, overall composite of the primary endpoint? And also can you tell us how confident -- how much confidence you have in terms of being able to meet that endpoint by end of this month?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in te",172,"Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in terms of for overwhelming efficacy, they have to make a decision about not only consistency and so forth that they're going to take into account, whether there's rationale and it's worthwhile because maybe they want to look within this subgroup or another to get the complete data set. And so it will be -- it's very hard to predict something like that. And as I said, it's up to an independent data monitoring board, it's completely out of our hands. And they could simply decide, for example, if they want to follow and get more deaths in one particular subgroup even though the overall population was very clear. So the end result is I can't really answer your question because we just don't know."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Chris Raymond from Raymond James.",8,"Next, we have Chris Raymond from Raymond James."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from so",128,"So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from some of our own work, pretty strong evidence that other sort of newer biologics have been gaining traction for some time. I wonder if you could maybe describe at a high level your views maybe of the changing landscape with respect to access and PBM market power and how you think sarilumab, once it is ultimately approved, is positioned not just necessarily from a clinical standpoint, but how you think the commercial landscape is changing in ways that may or may not favor the drug."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some ca",268,"Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some cases, almost outrageous increases in the price of -- at least on the WAC price, the wholesale acquisition cost of drugs for rheumatoid arthritis with people taking double-digit increases sometimes twice a year. To me, that suggests some sort of tone deafness in this environment. We think that we have to compete in 2 ways. We have to compete with a very good drug, which we think sarilumab will be. Of course, we have to get over this filling glitch and get to market as quickly as we can. But we think that the class is doing very well. There's some data out there from the first [indiscernible] class, where monotherapy against the leading anti-TNF, the anti-IL-6 receptor class performed better. And there are some people who simply don't like to take methotrexate. We have data of our own, which probably won't be in our first filing, similar types of results with outperforming in monotherapy. But giving a solid entry with good properties is not going to be enough here. And we have to compete with an offering that payers will find attractive. I think Regeneron is not -- is willing to break some of the mold here. And I'm getting some hints from my colleagues that I've probably said enough. So I'll leave it at that."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminish",119,"Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminishing efficacy over time. We have an obligation from a sales and marketing perspective, when we get approved, to stop the TNF cycling. And IL-6 inhibition plays a central role in RA. It plays a role in not only the symptoms but in terms of the progression of joint damage. And we have to educate physicians on that. So we're anxious to have the product get approved and get that message out there."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Geoffrey Porges from Leerink Partners.",8,"Next, we have Geoffrey Porges from Leerink Partners."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and wh",96,"Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and whether it's straightforward to switch the fill-finish for dupi to that alternative facility? And then secondly, could you just tell us whether the inventory of PRALUENT, sarilumab and dupilumab, which presumably you have already prelaunched, is embargoed? Or is it likely to be usable? And can you be selling PRALUENT from that inventory already?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, ho",292,"Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, how they're going to be resolved, the strategy of redundancy, what's in filings, what isn't and so on and so forth. We can summarize by saying that we -- Sanofi is working very hard. And they believe they can quickly remedy the deficiencies that were not related to sarilumab per se but rather some general GMP deficiencies, which they're frankly well on their way to remedying. Of course, we have to work with the agency and they have to be satisfied. In terms of products that are already manufactured there, I think you should think of the FDA sort of takes a risk-based approach here to have sort of a -- maybe a frozen in place, those things that are actually being -- assuming that they don't think a plant is way out of whack and nothing can be shipped and filled, they continue to fill and use product from that facility for approved products. It's a new product, such as sarilumab, which gets sort of shutout, obviously and unfortunately. We're working with them on sarilumab and we're also working with a different group on Dupixent, which is a breakthrough product which has a whole different set of approaches to it. So it's complicated. You can imagine there's a tremendous amount of work. A week seems like a long time maybe in your world. But in the world of regulatory interactions and manufacturing remedies and so on, it's still a relatively short time."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ronny Gal from Bernstein.",7,"Next, we have Ronny Gal from Bernstein."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in th",94,"So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in this case, it will be a relatively short one? And then if I can sneak a second one, 340B, there's been some discussions, reform for that program. If you could just let us know how you think -- if you can just give us an update about this program and how it impacts EYLEA sales."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a rela",141,"We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a relatively short period of time that Sanofi feels that they can get the plant in full GMP compliance. In fact, they've already brought in all sorts of efforts and resources. They've already submitted a detailed plan. They've already submitted their first or second progress reports against that plan. And so we feel that the strategy is the right one and the approach is the right one. Obviously, we'll just have to work with the agency and see how quickly they can feel comfortable that the plan is ready to go."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Alethia Young from Crdit Suisse.",8,"Next, we have Alethia Young from Crdit Suisse."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?",43,"Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob, do you want to comment a little on the...",10,"Bob, do you want to comment a little on the..."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now.",28,"Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Adnan Butt from RBC Capital Markets.",9,"Next, we have Adnan Butt from RBC Capital Markets."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Maybe for Bob, on EYLEA, pricing issue aside, as EYLEA growth tempering a bit, we had thought that DME would be a bigger [indiscernible]. What are the individual market dynamics if you can give any color on that?",38,"Maybe for Bob, on EYLEA, pricing issue aside, as EYLEA growth tempering a bit, we had thought that DME would be a bigger [indiscernible]. What are the individual market dynamics if you can give any color on that?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its pri",192,"Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its primary endpoint. The challenge with continuing growth in DME is that there are a number of patients that never make it to the retinal specialist's office. They go to an ophthalmologist who do laser therapy. Laser is a revenue driver in the ophthalmologist office. And they don't make it to the retina physician's office, where they could get access to anti-VEGF therapy. This has been a focus for us. We are educating. We're trying to educate patients that if they do have DME, they ought to get themselves to a retinal specialist. But this is chipping away at a habit among the ophthalmologists and it's going to take some time. But we continue to see that the DME market does offer substantial growth opportunities in the future. And as Len mentioned earlier, if and when we get the diabetic retinopathy indication, that would be a further driver."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from John Scotti from Evercore ISI.",10,"Our next question comes from John Scotti from Evercore ISI."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's",66,"On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's the magnitude of that and whether or not you see this trend is stabilizing or continuing into 2017?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters.",25,"Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Cory Kasimov from JPMorgan.",7,"Next, we have Cory Kasimov from JPMorgan."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit do",71,"So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit down the road? And how do you think about even maybe longer-term dosing options potentially entering this market from competition at some point in the future?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LD",124,"Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LDL hypothesis, continue to support it, and largely driven by payers. They've already demonstrated that they will not pay for convenience. If you look at the hepatitis C class, they've put a much less convenient regimen up against a much more expensive regimen. So I don't think convenience per se is going to drive the market. On the other hand, we like to come up with offerings that are as convenient as possible for patients."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who d",64,"And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who do want monthly convenience. But this is not an issue in the marketplace at the current time."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Jim Birchenough from Wells Fargo.",8,"Next, we have Jim Birchenough from Wells Fargo."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inje",88,"Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inject the full dose, the amount of protein you're giving to the back of the eye? I'm just trying to see if there's any learnings from the PDGF program that might inform how we should think about the co-formulation part of this for the ANG2 product?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway.",45,"Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Yatin Suneja from SunTrust.",7,"Next, we have Yatin Suneja from SunTrust."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?",42,"A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can",62,"Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can do it, we are working with those plans to establish a value-based contract, where appropriate."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Biren Amin from Jefferies.",7,"Next, we have Biren Amin from Jefferies."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease.",38,"How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the",80,"I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the United States, you're correct. EASI scores are not relevant to the physicians and IGA scores are not specific enough. So we're working right now on plans with payers on how to better define the disease. George?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this dis",323,"Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this disease. This just shows how severely these patients are. And it's not just that their skin is covered with this rash, but this is a weepy, itchy, horrific rash that they just can't escape. And remarkably, enough as we said, despite the heavy burden of disease at baseline, almost 40% of these patients achieved a clearer, almost clear status. Rarely in this business do you have a privilege to be involved in a story like this that can make such a difference in patients' lives. And we've been lucky here at Regeneron that we've done this a couple of times already. But we think that Dupixent is really a once-in-a-lifetime story, where you can really impact such an important disease so dramatically, have an average 70% improvement among all patients. And the thing that's also so stunning to us about dupilumab is that it looks like it might have the promise to do likewise in a host of related allergic diseases, including the overall asthma population, where there again in the most uncontrolled severe population, once again the results are very impressive from our first pivotal study. And we think the same may be the case in a host of other allergic settings. So the short answer to your question is, unfortunately, there's a lot of patients who have more than 50% of their body surface covered. Those patients are certainly, by any category, considered severe patients. As Bob already told you, many of them have exhausted all other options. And we just hope that the -- all the other ancillary things don't keep these important patients from getting access to this important life-changing drug."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the de",407,"I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the details of their care, which some are, but many, to them, that isn't the end-all, be-all, something they wake up every day wondering how to get that cholesterol down. Of course, if they've had a heart attack and everybody in their family does, and they do pay attention to that. But then there was the pushback, ""Well, you don't really know, do you, that it improves outcomes?"" We're just going on a hypothesis, even through there's a great deal of data to certainly support that hypothesis. So it's not a disease that people are clamoring to get treated and it's not outcomes that are readily in hand. Contrast that with PRALUENT, where these patients are desperate for treatment, truly desperate for treatment. And we're not talking about the topical treatments that are available, such as steroids that might become available when you're dealing with small areas of relatively mild to moderate disease. We're talking about the kind of patients George referred to, which are really quite significant. And these patients can see the outcome themselves. They can tell that they're doing better. And we see it in our studies, we see it in our questionnaires. We see it whether or not they're sleeping because they can scratch themselves so badly. I heard a story the other day, which practically -- it was group of us that practically brought us all to tears, where a little boy who was visiting his grandparents and so is cuddling and sleeping on the same bed with very bad atopic dermatitis said to his grandparents, ""Can you each hold one of my hands when I sleep, so I don't scratch myself so badly?"" I mean, think about that. This is a disease that people really are looking for treatments. And if we can get this drug approved, first, for adults and hopefully down the road for children, we can really provide something that they can tangibly feel. We're passionate about making sure that we remove all the barriers out there and we expect to work with patients, with doctors, with payers, with organizations to make sure that people are aware of this treatment and can get access to it."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Phil Nadeau from Cowen and Company.",11,"Our final question comes from Phil Nadeau from Cowen and Company."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there such cycle for when discounts ar",74,"Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there such cycle for when discounts are negotiated? And are there any signs that you're seeing that this is something that's demanded by payers? Or is this something that the competition is taking it upon themselves to do?"
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the disco",143,"There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the discounts and rebates that have been offered have been sort of directly back to the physicians' offices, et cetera, et cetera. We continually reevaluate that situation. We look at what the impact. We're very sensitive to doctors not have to make a choice of what to give their patients, what they might think the best drug would be because of a rebate situation or something like that. We think most retinal physicians don't do that. But we certainly understand the real world. And as the market shifts, we're prepared to react if necessary."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today.",42,"Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today."
33715,404125717,1074102,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr.",46,"Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today a",324,"Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are: Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for questions-and-answers.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2016, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the rest of the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  EYLEA, our flagship anti-VEGF, continues",746,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  
EYLEA, our flagship anti-VEGF, continues to remain a key financial driver for Regeneron. We are pleased with the continued growth of EYLEA and are committed to maintaining our leadership position in the branded anti-VEGF market by pursuing both additional indications for EYLEA, such as diabetic retinopathy, where we currently have a Phase III study ongoing. And we are also looking at ways in which we can improve upon the high efficacy bar set by EYLEA to combinations with an antibody to ANG2, where we currently have 2 Phase II studies ongoing. 
While EYLEA remains very important to our business, we are equally focused on the ongoing launch of PRALUENT, our PCSK9 antibody, for lowering LDL cholesterol as well as advancing our pipeline. For PRALUENT, we believe that if OUTCOMES data are positive, it will drive greater use of this class. As mentioned in our press release, we expect the second interim analysis by the end of this month. 
Moving on to sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis. As you heard last week, we received a Complete Response Letter from the FDA. This was due to certain manufacturing deficiencies not specific to sarilumab that were observed during a routine inspection of a Sanofi fill and finish plant in France. Sanofi has provided comprehensive responses and is working closely with the FDA to address the deficiencies as expeditiously as possible. It has only been a week since we received the Complete Response Letter. And we are preparing to engage in meaningful discussions with the FDA. So it is too early for us to comment on the expected time line for potential sarilumab approval. 
We do not expect these manufacturing deficiencies will impact dupilumab or as it is now known by its brand name, Dupixent, where our Biologics License Application, or BLA, is currently under FDA priority review for the treatment of moderate-to-severe atopic dermatitis in adults. The FDA action date for the BLA is at the end of March. Dupixent is a very important pipeline product candidate for us. And we believe that atopic dermatitis represents an area of high unmet need. As a reminder, we received breakthrough designation in this indication. In addition to atopic dermatitis, we are also investigating Dupixent in other indications, including asthma, where we recently completed enrollment in our second pivotal study. 
In the mid-term, we are looking to important clinical progress from several of our Phase II and III programs, which span a variety of therapeutic areas, such as allergic diseases, pain, viral diseases, ophthalmology, oncology, cardiometabolic disease, inflammatory and rare diseases. These programs have the potential to drive the next wave of growth for Regeneron. You will hear more about the key current developments from some of these programs from George. 
At Regeneron, we've always been committed to long-term science and innovation. In fact, today's marketed products as well as the 16 product candidates in clinical development were all home-grown in our internal R&D engine. We will continue to invest in science and technology that can provide sustainable innovation and growth well into the future. This unique long-term focus on science is at the heart of why we have been able to attract top talent, which is key to our continuing success. Through that end, last week, we were thrilled to be named by Science Magazine as the #1 company in the biotech or pharmaceutical industry to work for, a recognition we have received for 4 of the last 6 years. 
We know that our industry has faced many important questions regarding pricing of drugs. This is not the forum to discuss the complex issue of drug pricing. But I think it is important to note that Regeneron is in a unique position. As a company founded on science and committed to the research and development of important new products, we are well positioned to succeed even in a difficult and constrained pricing environment. In fact, we have never raised prices on any of our drugs, choosing instead to grow through the optimization of currently marketed products by pursuing new indications as well as the introduction of new medicines. Our future potential growth will be driven by this strategy. 
With that, let me turn the call over to George."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a",1261,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a wide variety of allergic diseases. The most advanced of which is uncontrolled moderate-to-severe atopic dermatitis. 
Just last month, we had the opportunity to present detailed results from SOLO 1 and SOLO 2, which were 2 identical Phase III studies that investigated Dupixent in the monotherapy setting at the annual EADV conference. These data were also concurrently published in the New England Journal of Medicine. These were the first large pivotal studies where a systemic investigational therapy demonstrated significant reduction in the signs and symptoms of atopic dermatitis with an average reduction in skin scores of about 70%, accompanied by a marked reduction in the usually unrelenting itch associated with this disease and almost 40% of these patients achieving clearing or near-clearing of the skin lesions. 
Unlike other immune modulating therapies, there was no evidence of increased immunosuppression. And the most common adverse events in the 2 trials were injection site reactions and conjunctivitis. We were encouraged by the excitement with which these data were received by the physician community as well as by patients. And we believe that this speaks to the current unmet need and frustration with currently available therapies for this severely debilitating disease. As Len mentioned, our BLA for Dupixent for the treatment of adults with moderate-to-severe atopic dermatitis is currently under FDA review and has been given priority review status and an action date of March 29, 2017. 
While the SOLO studies were in the monotherapy setting, we have also reported positive 1-year top line data from the CHRONOS Phase III study, which explored Dupixent in combination with topical corticosteroids. The safety and efficacy findings from the long-term CHRONOS study were consistent with those observed in SOLO 1 and 2. I'm also pleased to share that LIBERTY AD CAF, a Phase III study of Dupixent with concomitant topical corticosteroids in adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to or ineligible for oral cyclosporine, is now fully enrolled. We, along with our collaborator Sanofi, expect to complete the regulatory resubmission in Europe and Japan in the fourth quarter of 2016. We also plan to initiate a Phase III study in the pediatric severe atopic dermatitis population in the first quarter of 2017 in patients between the ages of 12 and 17. We are pleased that similar to the adult indications, Dupixent has received breakthrough designation for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. 
While atopic dermatitis is the most advanced indication in development for Dupixent, we are making headway with our asthma program as well. We have previously announced positive results from our first pivotal study in uncontrolled persistent asthma despite treatment with inhaled steroids and long-acting beta agonists. As a reminder, these data demonstrated improvements in both lung function as measured by FEV and exacerbations in all patients regardless of baseline eosinophil status. There was a 15% improvement above placebo in FEV1 and a 75% reduction in exacerbations in the overall population treated with the 300-milligram, every 2-week dose. The most common adverse events associated with treatment in this study was injection site reaction. 
In September, we announced completion of enrollment in LIBERTY ASTHMA QUEST, which is our confirmatory Phase III pivotal study of Dupixent in this indication. The primary endpoint of this study is at 52 weeks. And we, therefore, expect to make a regulatory submission in the U.S. towards the end of 2017. We also expect to initiate a Phase III study in the pediatric asthma patients in early 2017. We are also exploring the use of Dupixent in several other allergic indications, such as nasal polyps, where we expect to initiate a Phase III study early next year. And in eosinophilic esophagitis, we are currently in a Phase II. 
Turning to fasinumab, our Nerve Growth Factor antibody for pain. In October, we provided an update on this program. Following the observation of a case of rapidly progressive osteoarthritis in a patient receiving high-dose fasinumab, who had a history of advanced osteoarthritis of the knee, the FDA placed our Phase II study in chronic lower back pain patients on clinical hold. This event prompted an unplanned interim analysis of the study, which had already completed 70% of its targeted enrollment. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups compared to placebo at 8- and 12-week time points with p-value of less than 0.01. Preliminary safety results were also generally consistent with those observed previously with this class. The FDA has since communicated that we can continue development of fasinumab in chronic lower back pain by excluding patients who have advanced osteoarthritis. We are also continuing our pivotal program in osteoarthritis with final design elements still receiving regulatory feedback. The fasinumab program will contain safety data from approximately 10,000 patients overall.
Moving to PRALUENT. The recent news on the discontinuation of development of bococizumab obviously has a major impact on the PCSK9 landscape. This further underscores the very high bar in terms of safety and efficacy for this class. This example also highlights to us the value of our fully human VelocImmune-based antibody technology. In terms of our PRALUENT program, our 18,000-patient ODYSSEY OUTCOMES study, remains ongoing. We expect the second interim analysis for futility and overwhelming efficacy by the end of this month. We, and our collaborator Sanofi, have also completed regulatory submissions for the once-monthly dosing formulation of PRALUENT in the Europe and Japan territories as well as in the United States, where we have been granted an FDA action date of January 24, 2017. 
Our immuno-oncology program continues to advance and expand. We believe that these are still early days in the area of immuno-oncology with the collective knowledge of this field evolving rapidly and the competitive landscape changing continuously. Evidence of this includes the recent surprising failure of the market-leading PD-1 antibody in first-line lung cancer. Regarding our PD-1 program, our potentially pivotal study in cutaneous squamous cell carcinoma is ongoing and we plan to announce additional studies in the near future. In addition, we're also studying PD-1 in combination with our bispecific CD20xCD3 molecule. At the end of this year, at the American Society of Hematology or ASH conference, we will be presenting monotherapy data from the CD20xCD3 program. Lastly, we plan to advance Regeneron 3767, an antibody LAG3, into clinical development by the end 2016. 
In October, we announced top line results from a Phase II combination study of EYLEA with rinucumab, our PDGF receptor antibody in wet age-related macular degeneration or wet AMD, where the data demonstrated no improvement in best corrected visual acuity or BCVA, the primary endpoint of the study, versus EYLEA alone. We think these study results demonstrate the high hurdle that has been set by the well-established efficacy and safety of EYLEA. That said, we are looking for ways in which we can strengthen our EYLEA franchise. To that end, we are conducting a Phase II study of EYLEA in a co-formulated combination with nesvacumab, our antibody to ANG2, in AMD and DME. The DME study is full enrolled while the study in wet AMD continues to enroll patients. We are also exploring longer-acting approaches in this class. 
And with that summary, let me turn the call over to Bob Terifay."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the",818,"Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the third quarter were $471 million, which represents 27% year-over-year growth, unadjusted for currency fluctuations. Net ex U.S. year-to-date sales were $1.4 billion. 
EYLEA is the market-leading product among FDA-approved anti-VEGF agents for all of its approved indications in the United States. In the U.S., we are seeing increased competitor discounts and rebates. We are carefully assessing these actions. As I'm sure you're well aware, there's a pending proposal from the Centers of Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B or buy-and-bill drugs. We've worked hard on the policy and legislative front on this issue. And we'll be prepared to respond on the commercial front as needed to make sure that patients continue to have full and complete access to EYLEA.
Turning now to PRALUENT or alirocumab. As reported by Sanofi, net sales in the third quarter were $38 million worldwide with U.S. accounting for $32 million of the total. Sales data and IMS total prescription data indicate that PRALUENT and evolocumab market share are roughly 50-50 in the United States. As reported by IMS, U.S. total prescriptions for PRALUENT increased sequentially 60% versus second quarter 2016. 
The challenge for the PCSK9 inhibitor class continues to be the significant reimbursement hurdles for the physicians' offices and patients, resulting in a low volume of prescriptions being dispensed. This has resulted in physicians' offices reserving their initial prescriptions to a limited pool of patients. We continue to focus our efforts in improving access and improving the prescription process through the payers and the specialty pharmacies. We're gradually seeing more payers loosen their utilization management criteria, including removing their requirement for prior ezetimibe therapy. In addition, we are now seeing some patients shortening the number of months that a patient needs to be on a maximally tolerated statin therapy and eliminating a specialist-only prescribing or consultation requirement. Others have streamlined the prior authorization process. 
ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of PRALUENT. Outside of the United States, PRALUENT was approved in the EU in September of 2015 with the product now approved in 41 countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K., Spain, Norway and the Netherlands. It still remains a challenging reimbursement situation with some countries awaiting cardiovascular OUTCOMES data. 
We continue to plan for the potential launch of sarilumab in the United States. As an example, we have a major presence at the upcoming American College of Rheumatology meeting this month in Washington, D.C. We'll be presenting data from our MONARCH study of sarilumab as monotherapy in patients who are DMARD responders as well as subset analysis from our pivotal U.S. registrational studies. We'll have a display floor presence highlighting the central role of IL-6 in rheumatoid arthritis. The European Marketing Authorization Application for sarilumab is currently under review by the European Medicines Agency with a potential decision on the application expected in mid-2017. Co-promotion decisions for Europe and other ex U.S. countries will be made over time.
We're currently preparing for Dupixent or dupilumab commercialization with an FDA PDUFA date of March 29, 2017. We will be co-promoting Dupixent with Sanofi-Genzyme in the United States. Co-promotion decisions for other countries will be made at a later date. We are aware that ICER, payers and pharmacy benefits managers are proactively evaluating the cost-effectiveness of emerging therapies for atopic dermatitis in the United States. We want to take a moment to discuss how we are thinking about the Dupixent commercial opportunity, which differs in many important respects from the situation we faced with PRALUENT. 
Dupixent has already demonstrated efficacy on the most important outcomes: consistent efficacy on rash severity, itching and quality of life measures. In the United States, there are 1.6 million patients with uncontrolled moderate-to-severe atopic dermatitis, the majority of which will not likely receive Dupixent therapy. We estimate that approximately 300,000 of these patients have exhausted all approved therapies and have failed or are unable to tolerate unapproved use of immunosuppressant therapies. Many of these advanced patients are suffering from a host of related issues, including sleep disturbances, anxiety and depression. These atopic dermatitis patients should not be denied therapy. We hope payers and insurers will provide appropriate and timely access to Dupixent, should it be approved, and that patients will not have to step through unapproved immunosuppressant therapies, many of which have black box warnings. We plan to work closely with all stakeholders, including patients, physicians and payers to achieve this goal. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP",1331,"Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP SG&A, our effective tax rate and capital expenditures. 
Let me start with our top line third quarter earnings. In the third quarter 2016, non-GAAP net income was $365 million and non-GAAP net income per diluted share was $3.13. This represents an increase of 32% in both non-GAAP net income per diluted share as well as non-GAAP net income in the third quarter 2016 compared to the third quarter of 2015. Regeneron's third quarter 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and the $25 million upfront payment made in connection with our third quarter 2016 license and collaboration agreement with Adicet and includes the income tax effect of these non-GAAP reconciling items. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the third quarter of 2016 were $1.2 billion, which represents year-over-year growth of 7% over the third quarter of 2015. Net product sales were $857 million in the third quarter of 2016 compared to $738 million in the third quarter of 2015. EYLEA U.S. net product sales were $854 million compared to $734 million in the third quarter of 2015, representing 16% year-over-year growth. Sequential quarter-over-quarter growth was approximately 3%. During the third quarter of 2016, EYLEA experienced a slight increase in U.S. distributor inventory levels as compared to the second quarter of 2016 but continues to be within our normal 1- to 2-week targeted range.
As mentioned in our press release issued this morning, we're tightening our full year 2016 U.S. EYLEA net sales guidance to be year-over-year growth of 23% to 25%. Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $471 million in third quarter of 2016 compared to $371 million in the third quarter of 2015, representing a 27% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 25%. In the third quarter of 2016, Regeneron recognized $171 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the third quarter of 2016 was $191 million. 
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $144 million for the third quarter of 2016. The Sanofi collaboration revenue line item primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron-incurred commercialization-related expenses and our share of profits or losses in connection with the commercialization of antibodies. In the third quarter of 2016, our share of the collaboration's losses in connection with the commercialization of antibodies, which includes PRALUENT and pre-commercialization activities and costs in connection with sarilumab and Dupixent, was $112 million, which can be found in Table 4 of our earnings release. Netted within these collaboration losses were the global sales of PRALUENT as recognized by our collaborator Sanofi of $38 million for the third quarter of 2016. 
Before moving to expenses, I'd like to highlight 2 third quarter business development transactions. The first is the collaboration we entered into with Teva to develop and commercialize our NGF antibody, fasinumab. Under the terms of the agreement, Teva paid Regeneron a $250 million upfront payment and we will equally share on an ongoing basis R&D expenses of approximately $1 billion under a global development plan. We plan to ratably recognize the upfront payment as revenue over the related performance period. The signing of this agreement did not have a material P&L impact on the third quarter of 2016. As a reminder, the intellectual property associated with our late-stage pipeline, including fasinumab, has been migrated offshore, thus expenses and revenues associated with the program will be recognized in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. The other 2016 third quarter business development transaction was a collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapeutics. In accordance with this agreement, we paid Adicet a $25 million upfront payment in the third quarter of 2016, which we have recorded as GAAP R&D expense in our consolidated statement of operations but have excluded from our non-GAAP net income. 
Turning now to expenses. Non-GAAP R&D expense, which is calculated as the total GAAP R&D expense less R&D noncash share-based compensation expense as well as the upfront payment we made to collaborator Adicet, was $437 million for the third quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total non-GAAP R&D expense less R&D reimbursements from our collaborators, was $256 million for the 3 months ended September 30, 2016. Our press release includes all the information as required to calculate unreimbursed non-GAAP R&D expense. As a result of the recently executed collaboration with Teva regarding fasinumab, we are lowering and tightening our full year 2016 guidance for non-GAAP unreimbursed R&D to be in the range of $945 million to $975 million from our previous guidance range of $970 million to just over $1 billion. 
Non-GAAP SG&A expense was $221 million for the third quarter 2016. We are tightening and lowering our full year 2016 guidance for non-GAAP SG&A to $965 million to $995 million from our previous guidance range of $980 million to $1.02 billion. Note that even after lowering and tightening our full year guidance, we do not expect to see any material prelaunch cost savings from the PDUFA delay of sarilumab, we will be co-promoting sarilumab with Sanofi-Genzyme and our sales force is already onboard. And as you heard earlier from Bob Terifay, we continue to prepare for the launch in anticipation of the resolution of matters with the FDA. Sanofi reimbursement of the Regeneron commercialization-related expenses, a line item found within Sanofi collaboration revenue, was $66 million for the third quarter of 2016. We are tightening our full year 2016 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to be in the range of $310 million to $335 million from $310 million to $340 million. 
Turning now to taxes. Our effective tax rate for the third quarter 2016 was 27.6% as compared to 46.5% in the third quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings, inclusion of the tax benefit of share-based compensation and the impact of the domestic manufacturing deduction as compared to the same quarter of last year as well as the discrete impact to this quarter of a change in our assessment of reserves for uncertain tax positions. For 2016, we are lowering and tightening guidance for our full year GAAP effective tax rate to be 29% to 33% from the previously provided range of 33% to 41%. 
Our capital expenditures for the 9 months ended September 30, 2016, were $361 million. For the full year 2016, we are lowering and tightening our guidance for capital expenditures to be in the range of $480 million to $510 million from the previously provided range of $480 million to $530 million. 2016 capital expenditures primarily include costs in connection with renovations of our Limerick, Ireland manufacturing facility; tenant improvement and associated costs at our Tarrytown, New York facilities; renovations and additional store at Rensselaer, New York manufacturing facility; and the purchase of an office building near our Rensselaer manufacturing facility. 
We ended the third quarter 2016 with cash and marketable securities of $2.2 billion, which includes the Teva upfront payment of $250 million. As we have reported in previous quarters, we have opportunistically reduced the number of warrants that we issued in 2011 in connection with our convertible debt issuance through repurchases from the warrant counterparties. Depending on market and other conditions, we may spend up to $450 million to repurchase or settle these outstanding warrants. 
With that, I'd now like to turn the call over to Michael."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?",15,"Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup.",12,"[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, h",80,"And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, how are -- remind us how you typically release them. [indiscernible] we'd have to wait for 2 weeks for a conference, and maybe some color and expectations around that."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice.",38,"First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment.",49,"So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn from Goldman Sachs.",10,"Our next question comes from Terence Flynn from Goldman Sachs."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an",68,"It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an important investment year. Any thoughts here as we head into '17, particularly for the dupilumab launch?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to",81,"So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to happen in the marketplace. There's both potential for ups and downs there, and obviously additional indications, diabetic retinopathy. Those are the 3 places where we would be focusing and looking to drive growth off of a very large base, obviously."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent",156,"Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent. So with the March 29 PDUFA date coming, we need to ensure that we are ready with regards to our marketing and our sales teams and everything to be able to hit the road very quickly on that. And again, we're still investing behind PRALUENT as we wait for the OUTCOMES data. In sarilumab, as I mentioned on the call, I mean, we are putting our promotional dollars behind that in our marketing and spend. And when the FDA lifts the -- we get regulatory approval on that, then we will be in a position to ensure that the product is fully supported from a marketing and sales perspective."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ying Huang from Bank of America Merrill Lynch.",11,"Next, we have Ying Huang from Bank of America Merrill Lynch."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every co",87,"I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every composite of the primary endpoint, overall composite of the primary endpoint? And also can you tell us how confident -- how much confidence you have in terms of being able to meet that endpoint by end of this month?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in te",172,"Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in terms of for overwhelming efficacy, they have to make a decision about not only consistency and so forth that they're going to take into account, whether there's rationale and it's worthwhile because maybe they want to look within this subgroup or another to get the complete data set. And so it will be -- it's very hard to predict something like that. And as I said, it's up to an independent data monitoring board, it's completely out of our hands. And they could simply decide, for example, if they want to follow and get more deaths in one particular subgroup even though the overall population was very clear. So the end result is I can't really answer your question because we just don't know."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Chris Raymond from Raymond James.",8,"Next, we have Chris Raymond from Raymond James."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from so",128,"So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from some of our own work, pretty strong evidence that other sort of newer biologics have been gaining traction for some time. I wonder if you could maybe describe at a high level your views maybe of the changing landscape with respect to access and PBM market power and how you think sarilumab, once it is ultimately approved, is positioned not just necessarily from a clinical standpoint, but how you think the commercial landscape is changing in ways that may or may not favor the drug."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some ca",268,"Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some cases, almost outrageous increases in the price of -- at least on the WAC price, the wholesale acquisition cost of drugs for rheumatoid arthritis with people taking double-digit increases sometimes twice a year. To me, that suggests some sort of tone deafness in this environment. We think that we have to compete in 2 ways. We have to compete with a very good drug, which we think sarilumab will be. Of course, we have to get over this filing glitch and get to market as quickly as we can. But we think that the class is doing very well. There's some data out there from the first [indiscernible] class, where monotherapy against the leading anti-TNF, the anti-IL-6 receptor class performed better. And there are some people who simply don't like to take methotrexate. We have data of our own, which probably won't be in our first filing, similar types of results with outperforming in monotherapy. But giving a solid entry with good properties is not going to be enough here. And we have to compete with an offering that payers will find attractive. I think Regeneron is not -- is willing to break some of the mold here. And I'm getting some hints from my colleagues that I've probably said enough. So I'll leave it at that."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminish",119,"Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminishing efficacy over time. We have an obligation from a sales and marketing perspective, when we get approved, to stop the TNF cycling. And IL-6 inhibition plays a central role in RA. It plays a role in not only the symptoms but in terms of the progression of joint damage. And we have to educate physicians on that. So we're anxious to have the product get approved and get that message out there."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Geoffrey Porges from Leerink Partners.",8,"Next, we have Geoffrey Porges from Leerink Partners."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and wh",96,"Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and whether it's straightforward to switch the fill-finish for dupi to that alternative facility? And then secondly, could you just tell us whether the inventory of PRALUENT, sarilumab and dupilumab, which presumably you have already prelaunched, is embargoed? Or is it likely to be usable? And can you be selling PRALUENT from that inventory already?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, ho",292,"Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, how they're going to be resolved, the strategy of redundancy, what's in filings, what isn't and so on and so forth. We can summarize by saying that we -- Sanofi is working very hard. And they believe they can quickly remedy the deficiencies that were not related to sarilumab per se but rather some general GMP deficiencies, which they're frankly well on their way to remedying. Of course, we have to work with the agency and they have to be satisfied. In terms of products that are already manufactured there, I think you should think of the FDA sort of takes a risk-based approach here to have sort of a -- maybe a frozen in place, those things that are actually being -- assuming that they don't think a plant is way out of whack and nothing can be shipped and filled, they continue to fill and use product from that facility for approved products. It's a new product, such as sarilumab, which gets sort of shutout, obviously and unfortunately. We're working with them on sarilumab and we're also working with a different group on Dupixent, which is a breakthrough product which has a whole different set of approaches to it. So it's complicated. You can imagine there's a tremendous amount of work. A week seems like a long time maybe in your world. But in the world of regulatory interactions and manufacturing remedies and so on, it's still a relatively short time."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ronny Gal from Bernstein.",7,"Next, we have Ronny Gal from Bernstein."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in th",94,"So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in this case, it will be a relatively short one? And then if I can sneak a second one, 340B, there's been some discussions, reform for that program. If you could just let us know how you think -- if you can just give us an update about this program and how it impacts EYLEA sales."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a rela",141,"We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a relatively short period of time that Sanofi feels that they can get the plant in full GMP compliance. In fact, they've already brought in all sorts of efforts and resources. They've already submitted a detailed plan. They've already submitted their first or second progress reports against that plan. And so we feel that the strategy is the right one and the approach is the right one. Obviously, we'll just have to work with the agency and see how quickly they can feel comfortable that the plan is ready to go."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Alethia Young from Crdit Suisse.",8,"Next, we have Alethia Young from Crdit Suisse."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?",43,"Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob, do you want to comment at all on the...",10,"Bob, do you want to comment at all on the..."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now.",28,"Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Adnan Butt from RBC Capital Markets.",9,"Next, we have Adnan Butt from RBC Capital Markets."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Maybe for Bob, on EYLEA, pricing issue aside, is EYLEA growth tempering a bit, we had thought that DME;  would be as big as DME. What are the individual market dynamics if you can give any color on that?",39,"Maybe for Bob, on EYLEA, pricing issue aside, is EYLEA growth tempering a bit, we had thought that DME;  would be as big as DME. What are the individual market dynamics if you can give any color on that?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its pri",192,"Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its primary endpoint. The challenge with continuing growth in DME is that there are a number of patients that never make it to the retinal specialist's office. They go to an ophthalmologist who do laser therapy. Laser is a revenue driver in the ophthalmologist office. And they don't make it to the retina physician's office, where they could get access to anti-VEGF therapy. This has been a focus for us. We are educating. We're trying to educate patients that if they do have DME, they ought to get themselves to a retinal specialist. But this is chipping away at a habit among the ophthalmologists and it's going to take some time. But we continue to see that the DME market does offer substantial growth opportunities in the future. And as Len mentioned earlier, if and when we get the diabetic retinopathy indication, that would be a further driver."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from John Scotti from Evercore ISI.",10,"Our next question comes from John Scotti from Evercore ISI."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's",66,"On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's the magnitude of that and whether or not you see this trend is stabilizing or continuing into 2017?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters.",25,"Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Cory Kasimov from JPMorgan.",7,"Next, we have Cory Kasimov from JPMorgan."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit do",71,"So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit down the road? And how do you think about even maybe longer-term dosing options potentially entering this market from competition at some point in the future?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LD",124,"Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LDL hypothesis, continue to support it, and largely driven by payers. They've already demonstrated that they will not pay for convenience. If you look at the hepatitis C class, they've put a much less convenient regimen up against a much more expensive regimen. So I don't think convenience per se is going to drive the market. On the other hand, we like to come up with offerings that are as convenient as possible for patients."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who d",64,"And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who do want monthly convenience. But this is not an issue in the marketplace at the current time."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Jim Birchenough from Wells Fargo.",8,"Next, we have Jim Birchenough from Wells Fargo."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inje",88,"Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inject the full dose, the amount of protein you're giving to the back of the eye? I'm just trying to see if there's any learnings from the PDGF program that might inform how we should think about the co-formulation part of this for the ANG2 product?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway.",45,"Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Yatin Suneja from SunTrust.",7,"Next, we have Yatin Suneja from SunTrust."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?",42,"A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can",62,"Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can do it, we are working with those plans to establish a value-based contract, where appropriate."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Biren Amin from Jefferies.",7,"Next, we have Biren Amin from Jefferies."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease.",38,"How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the",80,"I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the United States, you're correct. EASI scores are not relevant to the physicians and IGA scores are not specific enough. So we're working right now on plans with payers on how to better define the disease. George?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this dis",323,"Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this disease. This just shows how severely these patients are. And it's not just that their skin is covered with this rash, but this is a weepy, itchy, horrific rash that they just can't escape. And remarkably, enough as we said, despite the heavy burden of disease at baseline, almost 40% of these patients achieved a clearer, almost clear status. Rarely in this business do you have a privilege to be involved in a story like this that can make such a difference in patients' lives. And we've been lucky here at Regeneron that we've done this a couple of times already. But we think that Dupixent is really a once-in-a-lifetime story, where you can really impact such an important disease so dramatically, have an average 70% improvement among all patients. And the thing that's also so stunning to us about dupilumab is that it looks like it might have the promise to do likewise in a host of related allergic diseases, including the overall asthma population, where there again in the most uncontrolled severe population, once again the results are very impressive from our first pivotal study. And we think the same may be the case in a host of other allergic settings. So the short answer to your question is, unfortunately, there's a lot of patients who have more than 50% of their body surface covered. Those patients are certainly, by any category, considered severe patients. As Bob already told you, many of them have exhausted all other options. And we just hope that the -- all the other ancillary things don't keep these important patients from getting access to this important life-changing drug."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the de",407,"I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the details of their care, which some are, but many, to them, that isn't the end-all, be-all, something they wake up every day wondering how to get that cholesterol down. Of course, if they've had a heart attack and everybody in their family does, and they do pay attention to that. But then there was the pushback, ""Well, you don't really know, do you, that it improves outcomes?"" We're just going on a hypothesis, even through there's a great deal of data to certainly support that hypothesis. So it's not a disease that people are clamoring to get treated and it's not outcomes that are readily in hand. Contrast that with PRALUENT, where these patients are desperate for treatment, truly desperate for treatment. And we're not talking about the topical treatments that are available, such as steroids that might become available when you're dealing with small areas of relatively mild to moderate disease. We're talking about the kind of patients George referred to, which are really quite significant. And these patients can see the outcome themselves. They can tell that they're doing better. And we see it in our studies, we see it in our questionnaires. We see it whether or not they're sleeping because they can scratch themselves so badly. I heard a story the other day, which practically -- it was group of us that practically brought us all to tears, where a little boy who was visiting his grandparents and so is cuddling and sleeping on the same bed with very bad atopic dermatitis said to his grandparents, ""Can you each hold one of my hands when I sleep, so I don't scratch myself so badly?"" I mean, think about that. This is a disease that people really are looking for treatments. And if we can get this drug approved, first, for adults and hopefully down the road for children, we can really provide something that they can tangibly feel. We're passionate about making sure that we remove all the barriers out there and we expect to work with patients, with doctors, with payers, with organizations to make sure that people are aware of this treatment and can get access to it."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think we have time for one last question.",9,"I think we have time for one last question."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Phil Nadeau from Cowen and Company.",11,"Our final question comes from Phil Nadeau from Cowen and Company."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there a set cycle for when discounts a",75,"Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there a set cycle for when discounts are negotiated? And are there any signs that you're seeing that this is something that's demanded by payers? Or is this something that the competition is taking it upon themselves to do?"
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the disco",143,"There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the discounts and rebates that have been offered have been sort of directly back to the physicians' offices, et cetera, et cetera. We continually reevaluate that situation. We look at what the impact. We're very sensitive to doctors not have to make a choice of what to give their patients, what they might think the best drug would be because of a rebate situation or something like that. We think most retinal physicians don't do that. But we certainly understand the real world. And as the market shifts, we're prepared to react if necessary."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today.",42,"Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today."
33715,404125717,1074384,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr.",46,"Welcome to the Regeneron Pharmaceuticals' Q3 2016 Earnings Conference Call. My name is Jason, and I will be your operator. [Operator Instructions] And please note this conference is being recorded. I will now turn the call over to Dr. Michael Aberman. Dr. Aberman, you may begin."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today a",324,"Thank you very much, and good morning, everyone. Welcome to Regeneron Pharmaceuticals' Third Quarter 2016 Conference Call. An archive of this webcast will be available on our website under Events & Presentations for 30 days. Joining me on the call today are: Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer; Bob Terifay, Executive Vice President of Commercial; and Bob Landry, Chief Financial Officer. After our prepared remarks, we will open the call for questions-and-answers.
I would also like to remind you that remarks made on this call include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, sales and expense forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, coverage and reimbursement matters, intellectual property, litigation matters and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-Q for the quarter ended September 30, 2016, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. 
In addition, please note that GAAP and non-GAAP measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website at www.regeneron.com. Once our call concludes, Bob Landry and the rest of the IR team will be available to answer further questions. 
With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  EYLEA, our flagship anti-VEGF, continues",746,"Thanks, Michael, and a very good morning to everyone who has joined us on the call and webcast today. I'd like to begin by giving you a high-level sense of our near-term and longer-term priorities at Regeneron.  
EYLEA, our flagship anti-VEGF, continues to remain a key financial driver for Regeneron. We are pleased with the continued growth of EYLEA and are committed to maintaining our leadership position in the branded anti-VEGF market by pursuing both additional indications for EYLEA, such as diabetic retinopathy, where we currently have a Phase III study ongoing. And we are also looking at ways in which we can improve upon the high efficacy bar set by EYLEA to combinations with an antibody to ANG2, where we currently have 2 Phase II studies ongoing. 
While EYLEA remains very important to our business, we are equally focused on the ongoing launch of PRALUENT, our PCSK9 antibody, for lowering LDL cholesterol as well as advancing our pipeline. For PRALUENT, we believe that if OUTCOMES data are positive, it will drive greater use of this class. As mentioned in our press release, we expect the second interim analysis by the end of this month. 
Moving on to sarilumab, our IL-6 receptor antibody for the treatment of rheumatoid arthritis. As you heard last week, we received a Complete Response Letter from the FDA. This was due to certain manufacturing deficiencies not specific to sarilumab that were observed during a routine inspection of a Sanofi fill and finish plant in France. Sanofi has provided comprehensive responses and is working closely with the FDA to address the deficiencies as expeditiously as possible. It has only been a week since we received the Complete Response Letter. And we are preparing to engage in meaningful discussions with the FDA. So it is too early for us to comment on the expected time line for potential sarilumab approval. 
We do not expect these manufacturing deficiencies will impact dupilumab or as it is now known by its brand name, Dupixent, where our Biologics License Application, or BLA, is currently under FDA priority review for the treatment of moderate-to-severe atopic dermatitis in adults. The FDA action date for the BLA is at the end of March. Dupixent is a very important pipeline product candidate for us. And we believe that atopic dermatitis represents an area of high unmet need. As a reminder, we received breakthrough designation in this indication. In addition to atopic dermatitis, we are also investigating Dupixent in other indications, including asthma, where we recently completed enrollment in our second pivotal study. 
In the mid-term, we are looking to important clinical progress from several of our Phase II and III programs, which span a variety of therapeutic areas, such as allergic diseases, pain, viral diseases, ophthalmology, oncology, cardiometabolic disease, inflammatory and rare diseases. These programs have the potential to drive the next wave of growth for Regeneron. You will hear more about the key current developments from some of these programs from George. 
At Regeneron, we've always been committed to long-term science and innovation. In fact, today's marketed products as well as the 16 product candidates in clinical development were all home-grown in our internal R&D engine. We will continue to invest in science and technology that can provide sustainable innovation and growth well into the future. This unique long-term focus on science is at the heart of why we have been able to attract top talent, which is key to our continuing success. Through that end, last week, we were thrilled to be named by Science Magazine as the #1 company in the biotech or pharmaceutical industry to work for, a recognition we have received for 4 of the last 6 years. 
We know that our industry has faced many important questions regarding pricing of drugs. This is not the forum to discuss the complex issue of drug pricing. But I think it is important to note that Regeneron is in a unique position. As a company founded on science and committed to the research and development of important new products, we are well positioned to succeed even in a difficult and constrained pricing environment. In fact, we have never raised prices on any of our drugs, choosing instead to grow through the optimization of currently marketed products by pursuing new indications as well as the introduction of new medicines. Our future potential growth will be driven by this strategy. 
With that, let me turn the call over to George."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a",1261,"Thank you, Len, and a very good morning to everyone who has joined us today. I'd like to begin with Dupixent, our IL-4/13 blocker, which we believe is one of the most exciting late-stage drug candidates in the industry. We are investigating Dupixent in a wide variety of allergic diseases. The most advanced of which is uncontrolled moderate-to-severe atopic dermatitis. 
Just last month, we had the opportunity to present detailed results from SOLO 1 and SOLO 2, which were 2 identical Phase III studies that investigated Dupixent in the monotherapy setting at the annual EADV conference. These data were also concurrently published in the New England Journal of Medicine. These were the first large pivotal studies where a systemic investigational therapy demonstrated significant reduction in the signs and symptoms of atopic dermatitis with an average reduction in skin scores of about 70%, accompanied by a marked reduction in the usually unrelenting itch associated with this disease and almost 40% of these patients achieving clearing or near-clearing of the skin lesions. 
Unlike other immune modulating therapies, there was no evidence of increased immunosuppression. And the most common adverse events in the 2 trials were injection site reactions and conjunctivitis. We were encouraged by the excitement with which these data were received by the physician community as well as by patients. And we believe that this speaks to the current unmet need and frustration with currently available therapies for this severely debilitating disease. As Len mentioned, our BLA for Dupixent for the treatment of adults with moderate-to-severe atopic dermatitis is currently under FDA review and has been given priority review status and an action date of March 29, 2017. 
While the SOLO studies were in the monotherapy setting, we have also reported positive 1-year top line data from the CHRONOS Phase III study, which explored Dupixent in combination with topical corticosteroids. The safety and efficacy findings from the long-term CHRONOS study were consistent with those observed in SOLO 1 and 2. I'm also pleased to share that LIBERTY AD CAF, a Phase III study of Dupixent with concomitant topical corticosteroids in adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to or ineligible for oral cyclosporine, is now fully enrolled. We, along with our collaborator Sanofi, expect to complete the regulatory resubmission in Europe and Japan in the fourth quarter of 2016. We also plan to initiate a Phase III study in the pediatric severe atopic dermatitis population in the first quarter of 2017 in patients between the ages of 12 and 17. We are pleased that similar to the adult indications, Dupixent has received breakthrough designation for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. 
While atopic dermatitis is the most advanced indication in development for Dupixent, we are making headway with our asthma program as well. We have previously announced positive results from our first pivotal study in uncontrolled persistent asthma despite treatment with inhaled steroids and long-acting beta agonists. As a reminder, these data demonstrated improvements in both lung function as measured by FEV and exacerbations in all patients regardless of baseline eosinophil status. There was a 15% improvement above placebo in FEV1 and a 75% reduction in exacerbations in the overall population treated with the 300-milligram, every 2-week dose. The most common adverse events associated with treatment in this study was injection site reaction. 
In September, we announced completion of enrollment in LIBERTY ASTHMA QUEST, which is our confirmatory Phase III pivotal study of Dupixent in this indication. The primary endpoint of this study is at 52 weeks. And we, therefore, expect to make a regulatory submission in the U.S. towards the end of 2017. We also expect to initiate a Phase III study in the pediatric asthma patients in early 2017. We are also exploring the use of Dupixent in several other allergic indications, such as nasal polyps, where we expect to initiate a Phase III study early next year. And in eosinophilic esophagitis, we are currently in a Phase II. 
Turning to fasinumab, our Nerve Growth Factor antibody for pain. In October, we provided an update on this program. Following the observation of a case of rapidly progressive osteoarthritis in a patient receiving high-dose fasinumab, who had a history of advanced osteoarthritis of the knee, the FDA placed our Phase II study in chronic lower back pain patients on clinical hold. This event prompted an unplanned interim analysis of the study, which had already completed 70% of its targeted enrollment. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups compared to placebo at 8- and 12-week time points with p-value of less than 0.01. Preliminary safety results were also generally consistent with those observed previously with this class. The FDA has since communicated that we can continue development of fasinumab in chronic lower back pain by excluding patients who have advanced osteoarthritis. We are also continuing our pivotal program in osteoarthritis with final design elements still receiving regulatory feedback. The fasinumab program will contain safety data from approximately 10,000 patients overall.
Moving to PRALUENT. The recent news on the discontinuation of development of bococizumab obviously has a major impact on the PCSK9 landscape. This further underscores the very high bar in terms of safety and efficacy for this class. This example also highlights to us the value of our fully human VelocImmune-based antibody technology. In terms of our PRALUENT program, our 18,000-patient ODYSSEY OUTCOMES study, remains ongoing. We expect the second interim analysis for futility and overwhelming efficacy by the end of this month. We, and our collaborator Sanofi, have also completed regulatory submissions for the once-monthly dosing formulation of PRALUENT in the Europe and Japan territories as well as in the United States, where we have been granted an FDA action date of January 24, 2017. 
Our immuno-oncology program continues to advance and expand. We believe that these are still early days in the area of immuno-oncology with the collective knowledge of this field evolving rapidly and the competitive landscape changing continuously. Evidence of this includes the recent surprising failure of the market-leading PD-1 antibody in first-line lung cancer. Regarding our PD-1 program, our potentially pivotal study in cutaneous squamous cell carcinoma is ongoing and we plan to announce additional studies in the near future. In addition, we're also studying PD-1 in combination with our bispecific CD20xCD3 molecule. At the end of this year, at the American Society of Hematology or ASH conference, we will be presenting monotherapy data from the CD20xCD3 program. Lastly, we plan to advance Regeneron 3767, an antibody LAG3, into clinical development by the end 2016. 
In October, we announced top line results from a Phase II combination study of EYLEA with rinucumab, our PDGF receptor antibody in wet age-related macular degeneration or wet AMD, where the data demonstrated no improvement in best corrected visual acuity or BCVA, the primary endpoint of the study, versus EYLEA alone. We think these study results demonstrate the high hurdle that has been set by the well-established efficacy and safety of EYLEA. That said, we are looking for ways in which we can strengthen our EYLEA franchise. To that end, we are conducting a Phase II study of EYLEA in a co-formulated combination with nesvacumab, our antibody to ANG2, in AMD and DME. The DME study is full enrolled while the study in wet AMD continues to enroll patients. We are also exploring longer-acting approaches in this class. 
And with that summary, let me turn the call over to Bob Terifay."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the",818,"Thank you, George, and good morning, everyone. Third quarter U.S. EYLEA or aflibercept net sales grew 16% year-over-year. Net U.S. EYLEA sales in the third quarter were $854 million and year-to-date sales were $2.5 billion. Net ex U.S. EYLEA sales in the third quarter were $471 million, which represents 27% year-over-year growth, unadjusted for currency fluctuations. Net ex U.S. year-to-date sales were $1.4 billion. 
EYLEA is the market-leading product among FDA-approved anti-VEGF agents for all of its approved indications in the United States. In the U.S., we are seeing increased competitor discounts and rebates. We are carefully assessing these actions. As I'm sure you're well aware, there's a pending proposal from the Centers of Medicare & Medicaid Services regarding physician reimbursement for physician-administered Medicare Part B or buy-and-bill drugs. We've worked hard on the policy and legislative front on this issue. And we'll be prepared to respond on the commercial front as needed to make sure that patients continue to have full and complete access to EYLEA.
Turning now to PRALUENT or alirocumab. As reported by Sanofi, net sales in the third quarter were $38 million worldwide with U.S. accounting for $32 million of the total. Sales data and IMS total prescription data indicate that PRALUENT and evolocumab market share are roughly 50-50 in the United States. As reported by IMS, U.S. total prescriptions for PRALUENT increased sequentially 60% versus second quarter 2016. 
The challenge for the PCSK9 inhibitor class continues to be the significant reimbursement hurdles for the physicians' offices and patients, resulting in a low volume of prescriptions being dispensed. This has resulted in physicians' offices reserving their initial prescriptions to a limited pool of patients. We continue to focus our efforts in improving access and improving the prescription process through the payers and the specialty pharmacies. We're gradually seeing more payers loosen their utilization management criteria, including removing their requirement for prior ezetimibe therapy. In addition, we are now seeing some patients shortening the number of months that a patient needs to be on a maximally tolerated statin therapy and eliminating a specialist-only prescribing or consultation requirement. Others have streamlined the prior authorization process. 
ODYSSEY OUTCOMES data, if positive, are anticipated to be a key driver in shaping the future success of PRALUENT. Outside of the United States, PRALUENT was approved in the EU in September of 2015 with the product now approved in 41 countries. Reimbursement discussions are currently underway with several governments across Europe. Positive reimbursement decisions have been issued in the U.K., Spain, Norway and the Netherlands. It still remains a challenging reimbursement situation with some countries awaiting cardiovascular OUTCOMES data. 
We continue to plan for the potential launch of sarilumab in the United States. As an example, we have a major presence at the upcoming American College of Rheumatology meeting this month in Washington, D.C. We'll be presenting data from our MONARCH study of sarilumab as monotherapy in patients who are DMARD responders as well as subset analysis from our pivotal U.S. registrational studies. We'll have a display floor presence highlighting the central role of IL-6 in rheumatoid arthritis. The European Marketing Authorization Application for sarilumab is currently under review by the European Medicines Agency with a potential decision on the application expected in mid-2017. Co-promotion decisions for Europe and other ex U.S. countries will be made over time.
We're currently preparing for Dupixent or dupilumab commercialization with an FDA PDUFA date of March 29, 2017. We will be co-promoting Dupixent with Sanofi-Genzyme in the United States. Co-promotion decisions for other countries will be made at a later date. We are aware that ICER, payers and pharmacy benefits managers are proactively evaluating the cost-effectiveness of emerging therapies for atopic dermatitis in the United States. We want to take a moment to discuss how we are thinking about the Dupixent commercial opportunity, which differs in many important respects from the situation we faced with PRALUENT. 
Dupixent has already demonstrated efficacy on the most important outcomes: consistent efficacy on rash severity, itching and quality of life measures. In the United States, there are 1.6 million patients with uncontrolled moderate-to-severe atopic dermatitis, the majority of which will not likely receive Dupixent therapy. We estimate that approximately 300,000 of these patients have exhausted all approved therapies and have failed or are unable to tolerate unapproved use of immunosuppressant therapies. Many of these advanced patients are suffering from a host of related issues, including sleep disturbances, anxiety and depression. These atopic dermatitis patients should not be denied therapy. We hope payers and insurers will provide appropriate and timely access to Dupixent, should it be approved, and that patients will not have to step through unapproved immunosuppressant therapies, many of which have black box warnings. We plan to work closely with all stakeholders, including patients, physicians and payers to achieve this goal. 
With that, let me turn the call over to our Chief Financial Officer, Bob Landry."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP",1331,"Thanks, Bob, and good morning. Regeneron posted strong financial results in the third quarter of 2016 as well as entered into 2 new exciting collaborations. We are also lowering and tightening full year 2016 guidance on non-GAAP unreimbursed R&D, non-GAAP SG&A, our effective tax rate and capital expenditures. 
Let me start with our top line third quarter earnings. In the third quarter 2016, non-GAAP net income was $365 million and non-GAAP net income per diluted share was $3.13. This represents an increase of 32% in both non-GAAP net income per diluted share as well as non-GAAP net income in the third quarter 2016 compared to the third quarter of 2015. Regeneron's third quarter 2016 non-GAAP net income primarily excludes noncash share-based compensation expense and the $25 million upfront payment made in connection with our third quarter 2016 license and collaboration agreement with Adicet and includes the income tax effect of these non-GAAP reconciling items. A full reconciliation of GAAP to non-GAAP earnings is set forth in our earnings release. 
Total revenues in the third quarter of 2016 were $1.2 billion, which represents year-over-year growth of 7% over the third quarter of 2015. Net product sales were $857 million in the third quarter of 2016 compared to $738 million in the third quarter of 2015. EYLEA U.S. net product sales were $854 million compared to $734 million in the third quarter of 2015, representing 16% year-over-year growth. Sequential quarter-over-quarter growth was approximately 3%. During the third quarter of 2016, EYLEA experienced a slight increase in U.S. distributor inventory levels as compared to the second quarter of 2016 but continues to be within our normal 1- to 2-week targeted range.
As mentioned in our press release issued this morning, we're tightening our full year 2016 U.S. EYLEA net sales guidance to be year-over-year growth of 23% to 25%. Ex U.S. EYLEA sales, where product revenue is recorded by our collaborator, Bayer, were $471 million in third quarter of 2016 compared to $371 million in the third quarter of 2015, representing a 27% increase on a reported basis. On an operational basis or constant currency basis, sales increased approximately 25%. In the third quarter of 2016, Regeneron recognized $171 million from our share of net profits from EYLEA sales outside the U.S. Total Bayer collaboration revenue for the third quarter of 2016 was $191 million. 
Turning now to our Sanofi collaboration. Total Sanofi collaboration revenue was $144 million for the third quarter of 2016. The Sanofi collaboration revenue line item primarily consists of reimbursement of Regeneron-incurred R&D expenses, reimbursement of Regeneron-incurred commercialization-related expenses and our share of profits or losses in connection with the commercialization of antibodies. In the third quarter of 2016, our share of the collaboration's losses in connection with the commercialization of antibodies, which includes PRALUENT and pre-commercialization activities and costs in connection with sarilumab and Dupixent, was $112 million, which can be found in Table 4 of our earnings release. Netted within these collaboration losses were the global sales of PRALUENT as recognized by our collaborator Sanofi of $38 million for the third quarter of 2016. 
Before moving to expenses, I'd like to highlight 2 third quarter business development transactions. The first is the collaboration we entered into with Teva to develop and commercialize our NGF antibody, fasinumab. Under the terms of the agreement, Teva paid Regeneron a $250 million upfront payment and we will equally share on an ongoing basis R&D expenses of approximately $1 billion under a global development plan. We plan to ratably recognize the upfront payment as revenue over the related performance period. The signing of this agreement did not have a material P&L impact on the third quarter of 2016. As a reminder, the intellectual property associated with our late-stage pipeline, including fasinumab, has been migrated offshore, thus expenses and revenues associated with the program will be recognized in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. The other 2016 third quarter business development transaction was a collaboration with Adicet, which will allow us to discover and develop engineered next-generation immune cell therapeutics. In accordance with this agreement, we paid Adicet a $25 million upfront payment in the third quarter of 2016, which we have recorded as GAAP R&D expense in our consolidated statement of operations but have excluded from our non-GAAP net income. 
Turning now to expenses. Non-GAAP R&D expense, which is calculated as the total GAAP R&D expense less R&D noncash share-based compensation expense as well as the upfront payment we made to collaborator Adicet, was $437 million for the third quarter of 2016. Our non-GAAP unreimbursed R&D expense, which is calculated as the total non-GAAP R&D expense less R&D reimbursements from our collaborators, was $256 million for the 3 months ended September 30, 2016. Our press release includes all the information as required to calculate unreimbursed non-GAAP R&D expense. As a result of the recently executed collaboration with Teva regarding fasinumab, we are lowering and tightening our full year 2016 guidance for non-GAAP unreimbursed R&D to be in the range of $945 million to $975 million from our previous guidance range of $970 million to just over $1 billion. 
Non-GAAP SG&A expense was $221 million for the third quarter 2016. We are tightening and lowering our full year 2016 guidance for non-GAAP SG&A to $965 million to $995 million from our previous guidance range of $980 million to $1.02 billion. Note that even after lowering and tightening our full year guidance, we do not expect to see any material prelaunch cost savings from the PDUFA delay of sarilumab, we will be co-promoting sarilumab with Sanofi-Genzyme and our sales force is already onboard. And as you heard earlier from Bob Terifay, we continue to prepare for the launch in anticipation of the resolution of matters with the FDA. Sanofi reimbursement of the Regeneron commercialization-related expenses, a line item found within Sanofi collaboration revenue, was $66 million for the third quarter of 2016. We are tightening our full year 2016 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to be in the range of $310 million to $335 million from $310 million to $340 million. 
Turning now to taxes. Our effective tax rate for the third quarter 2016 was 27.6% as compared to 46.5% in the third quarter of 2015. This decrease was primarily due to the impact of changes in the geographic mix of earnings, inclusion of the tax benefit of share-based compensation and the impact of the domestic manufacturing deduction as compared to the same quarter of last year as well as the discrete impact to this quarter of a change in our assessment of reserves for uncertain tax positions. For 2016, we are lowering and tightening guidance for our full year GAAP effective tax rate to be 29% to 33% from the previously provided range of 33% to 41%. 
Our capital expenditures for the 9 months ended September 30, 2016, were $361 million. For the full year 2016, we are lowering and tightening our guidance for capital expenditures to be in the range of $480 million to $510 million from the previously provided range of $480 million to $530 million. 2016 capital expenditures primarily include costs in connection with renovations of our Limerick, Ireland manufacturing facility; tenant improvement and associated costs at our Tarrytown, New York facilities; renovations and additional store at Rensselaer, New York manufacturing facility; and the purchase of an office building near our Rensselaer manufacturing facility. 
We ended the third quarter 2016 with cash and marketable securities of $2.2 billion, which includes the Teva upfront payment of $250 million. As we have reported in previous quarters, we have opportunistically reduced the number of warrants that we issued in 2011 in connection with our convertible debt issuance through repurchases from the warrant counterparties. Depending on market and other conditions, we may spend up to $450 million to repurchase or settle these outstanding warrants. 
With that, I'd now like to turn the call over to Michael."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?",15,"Thank you, Bob. [Operator Instructions] With that, operator, can we please open up for Q&A?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup.",12,"[Operator Instructions] And our first question comes from Robyn Karnauskas from Citigroup."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, h",80,"And I'll stick to the one question. So if I heard you correctly, it sounded like the ANG2 DNA study was completed enrollment and it's a 12-week study? So is it possible that we could get results in the first quarter? And if so -- or when we get results, how are -- remind us how you typically release them. [indiscernible] we'd have to wait for 2 weeks for a conference, and maybe some color and expectations around that."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice.",38,"First, I mean, since you're talking about timing, we really don't give guidance on timing. And as we have with our PDGF, we typically look at this and give the top line press releases is our typical practice."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment.",49,"So but one general comment, Robyn. We would say that -- and George might want to amplify this, EYLEA is the top bar. And we're constantly looking to try and improve on that. And so when we get the data, we certainly will give you a top line assessment."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from Terence Flynn from Goldman Sachs.",10,"Our next question comes from Terence Flynn from Goldman Sachs."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an",68,"It's just one with 2 parts. So first, just maybe walk us through some of the key drivers of EYLEA growth that we should consider as we head into next year here? And then Bob, maybe just last year at this time, you highlighted 2016 was shaping up to be an important investment year. Any thoughts here as we head into '17, particularly for the dupilumab launch?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to",81,"So it's Len. I'll let Bob amplify if he likes. But the obvious potential growth drivers for EYLEA come from demographics, aging population, more patients with diabetic eye disease, potentially would come from market share, depending upon what continues to happen in the marketplace. There's both potential for ups and downs there, and obviously additional indications, diabetic retinopathy. Those are the 3 places where we would be focusing and looking to drive growth off of a very large base, obviously."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent",156,"Terence, it's Bob. Yes, I mean, we'll go out with our SG&A guidance upcoming. We're not in a position right now to talk to that. But again, we've spent time on this call and you've heard us previously with regards to the excitement we have around Dupixent. So with the March 29 PDUFA date coming, we need to ensure that we are ready with regards to our marketing and our sales teams and everything to be able to hit the road very quickly on that. And again, we're still investing behind PRALUENT as we wait for the OUTCOMES data. In sarilumab, as I mentioned on the call, I mean, we are putting our promotional dollars behind that in our marketing and spend. And when the FDA lifts the -- we get regulatory approval on that, then we will be in a position to ensure that the product is fully supported from a marketing and sales perspective."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ying Huang from Bank of America Merrill Lynch.",11,"Next, we have Ying Huang from Bank of America Merrill Lynch."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every co",87,"I have a question on the ODYSSEY OUTCOMES study here. So we know the hurdles for overwhelming efficacy to stop the trial is a hazard ratio of less than 0.802 with a p-value of less than 0.0001. Can you elaborate? Do you need to see consistency in every composite of the primary endpoint, overall composite of the primary endpoint? And also can you tell us how confident -- how much confidence you have in terms of being able to meet that endpoint by end of this month?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in te",172,"Yes, this is George. In some ways, this decision is out of our hands and it's very subjective. In terms of there's an independent monitoring board that without us is going to look at the data. Regardless of even if we hit the numbers that you stated in terms of for overwhelming efficacy, they have to make a decision about not only consistency and so forth that they're going to take into account, whether there's rationale and it's worthwhile because maybe they want to look within this subgroup or another to get the complete data set. And so it will be -- it's very hard to predict something like that. And as I said, it's up to an independent data monitoring board, it's completely out of our hands. And they could simply decide, for example, if they want to follow and get more deaths in one particular subgroup even though the overall population was very clear. So the end result is I can't really answer your question because we just don't know."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Chris Raymond from Raymond James.",8,"Next, we have Chris Raymond from Raymond James."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from so",128,"So on sarilumab, so just putting the manufacturing delay for the drug aside, there's been some news in the biologics space in inflammation recently with Amgen sort of talking about running out of its sort of pricing runway. And we've actually seen from some of our own work, pretty strong evidence that other sort of newer biologics have been gaining traction for some time. I wonder if you could maybe describe at a high level your views maybe of the changing landscape with respect to access and PBM market power and how you think sarilumab, once it is ultimately approved, is positioned not just necessarily from a clinical standpoint, but how you think the commercial landscape is changing in ways that may or may not favor the drug."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some ca",268,"Sure, this is Len. At the risk of unveiling a little bit of our strategy here but not too much of it because obviously we have to get to market, it is a tough environment. And the people who are paying the bills have seen what I would consider, in some cases, almost outrageous increases in the price of -- at least on the WAC price, the wholesale acquisition cost of drugs for rheumatoid arthritis with people taking double-digit increases sometimes twice a year. To me, that suggests some sort of tone deafness in this environment. We think that we have to compete in 2 ways. We have to compete with a very good drug, which we think sarilumab will be. Of course, we have to get over this filing glitch and get to market as quickly as we can. But we think that the class is doing very well. There's some data out there from the first [indiscernible] class, where monotherapy against the leading anti-TNF, the anti-IL-6 receptor class performed better. And there are some people who simply don't like to take methotrexate. We have data of our own, which probably won't be in our first filing, similar types of results with outperforming in monotherapy. But giving a solid entry with good properties is not going to be enough here. And we have to compete with an offering that payers will find attractive. I think Regeneron is not -- is willing to break some of the mold here. And I'm getting some hints from my colleagues that I've probably said enough. So I'll leave it at that."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminish",119,"Well, Len, it's Bob. I think it's important though also to keep in mind that the market has been characterized by a significant amount of TNF cycling. And the reality is after a patient receives one TNF inhibitor, if they move to a second, we see diminishing efficacy over time. We have an obligation from a sales and marketing perspective, when we get approved, to stop the TNF cycling. And IL-6 inhibition plays a central role in RA. It plays a role in not only the symptoms but in terms of the progression of joint damage. And we have to educate physicians on that. So we're anxious to have the product get approved and get that message out there."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Geoffrey Porges from Leerink Partners.",8,"Next, we have Geoffrey Porges from Leerink Partners."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and wh",96,"Perhaps a question on the manufacturing issue. And it's been a week since the Sanofi conference call, so I presume you both have a lot more information. Could you confirm whether the alternative fill-finish facility was included in the original BLA and whether it's straightforward to switch the fill-finish for dupi to that alternative facility? And then secondly, could you just tell us whether the inventory of PRALUENT, sarilumab and dupilumab, which presumably you have already prelaunched, is embargoed? Or is it likely to be usable? And can you be selling PRALUENT from that inventory already?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, ho",292,"Yes. Geoff, as usual, you ask some of the best and most penetrating questions. And as usual, we'll give you our -- we'd love to give you an answer, but we really are not in a position to discuss the details of discussions that are ongoing with the FDA, how they're going to be resolved, the strategy of redundancy, what's in filings, what isn't and so on and so forth. We can summarize by saying that we -- Sanofi is working very hard. And they believe they can quickly remedy the deficiencies that were not related to sarilumab per se but rather some general GMP deficiencies, which they're frankly well on their way to remedying. Of course, we have to work with the agency and they have to be satisfied. In terms of products that are already manufactured there, I think you should think of the FDA sort of takes a risk-based approach here to have sort of a -- maybe a frozen in place, those things that are actually being -- assuming that they don't think a plant is way out of whack and nothing can be shipped and filled, they continue to fill and use product from that facility for approved products. It's a new product, such as sarilumab, which gets sort of shutout, obviously and unfortunately. We're working with them on sarilumab and we're also working with a different group on Dupixent, which is a breakthrough product which has a whole different set of approaches to it. So it's complicated. You can imagine there's a tremendous amount of work. A week seems like a long time maybe in your world. But in the world of regulatory interactions and manufacturing remedies and so on, it's still a relatively short time."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Ronny Gal from Bernstein.",7,"Next, we have Ronny Gal from Bernstein."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in th",94,"So just very quickly, following on Geoff, just looking at generic industry history here when it comes to fill-finish facilities. The cycles for improving facilities and getting product approvals is actually quite long. What gives you conviction that in this case, it will be a relatively short one? And then if I can sneak a second one, 340B, there's been some discussions, reform for that program. If you could just let us know how you think -- if you can just give us an update about this program and how it impacts EYLEA sales."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a rela",141,"We're going to give you only one question. So the first question has to do with how do we know how quickly this is going to be remedied. Well, we don't know how quickly it's going to be remedied for sure, obviously. We know how quickly, which is in a relatively short period of time that Sanofi feels that they can get the plant in full GMP compliance. In fact, they've already brought in all sorts of efforts and resources. They've already submitted a detailed plan. They've already submitted their first or second progress reports against that plan. And so we feel that the strategy is the right one and the approach is the right one. Obviously, we'll just have to work with the agency and see how quickly they can feel comfortable that the plan is ready to go."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Alethia Young from Crdit Suisse.",8,"Next, we have Alethia Young from Crdit Suisse."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?",43,"Just one on the pediatric population, I know you quantified a little bit more about the adult with the 300,000 a day. Can you kind of frame that in a similar, likely nature or a similar nature as to the pediatric population, please?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Bob, do you want to comment at all on the...",10,"Bob, do you want to comment at all on the..."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now.",28,"Yes, I don't think we're prepared to sort of go into the numbers in the pediatric population, especially since we just embarked on our Phase III program now."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Adnan Butt from RBC Capital Markets.",9,"Next, we have Adnan Butt from RBC Capital Markets."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Maybe for Bob, on EYLEA, pricing issue aside, is EYLEA growth tempering a bit, we had thought that DME;  would be as big as DME. What are the individual market dynamics if you can give any color on that?",39,"Maybe for Bob, on EYLEA, pricing issue aside, is EYLEA growth tempering a bit, we had thought that DME;  would be as big as DME. What are the individual market dynamics if you can give any color on that?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its pri",192,"Yes. So we have done very, very well with EYLEA in DME. That has been the driver of growth over the last couple of years, primarily driven by the impressive Protocol T results, which indicated that EYLEA was superior to LUCENTIS and ranibizumab on its primary endpoint. The challenge with continuing growth in DME is that there are a number of patients that never make it to the retinal specialist's office. They go to an ophthalmologist who do laser therapy. Laser is a revenue driver in the ophthalmologist office. And they don't make it to the retina physician's office, where they could get access to anti-VEGF therapy. This has been a focus for us. We are educating. We're trying to educate patients that if they do have DME, they ought to get themselves to a retinal specialist. But this is chipping away at a habit among the ophthalmologists and it's going to take some time. But we continue to see that the DME market does offer substantial growth opportunities in the future. And as Len mentioned earlier, if and when we get the diabetic retinopathy indication, that would be a further driver."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our next question comes from John Scotti from Evercore ISI.",10,"Our next question comes from John Scotti from Evercore ISI."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's",66,"On EYLEA, I think you previously mentioned that you're seeing a bit of an increase in your gross to net. And I was just wondering if you're still seeing that steady increase in the gross to net and potentially small erosion in net price. And if so, what's the magnitude of that and whether or not you see this trend is stabilizing or continuing into 2017?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters.",25,"Yes, I don't think there's been much sequential change at all in the gross to net. It's been flat sequentially in the last 2 quarters."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Cory Kasimov from JPMorgan.",7,"Next, we have Cory Kasimov from JPMorgan."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit do",71,"So with the PDUFA date for monthly PRALUENT early next year, can you just talk a little bit about the importance of extended dosing in this study? I mean, clearly this is a payer-constrained market today. But what might monthly dosing mean a little bit down the road? And how do you think about even maybe longer-term dosing options potentially entering this market from competition at some point in the future?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LD",124,"Yes, I'm not convinced that the driver of this market is whether or not you have something every other week or every month or what have you. I do believe that people will be driven by the LDL lowering, by the OUTCOMES data that we hope will support the LDL hypothesis, continue to support it, and largely driven by payers. They've already demonstrated that they will not pay for convenience. If you look at the hepatitis C class, they've put a much less convenient regimen up against a much more expensive regimen. So I don't think convenience per se is going to drive the market. On the other hand, we like to come up with offerings that are as convenient as possible for patients."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who d",64,"And just to add to that, so far, patients who have received PRALUENT on an every 2-week basis have been happy with the dosing sequence. Convenience is not a big issue. But as Len pointed out, we'd like to offer another dosing form for those patients who do want monthly convenience. But this is not an issue in the marketplace at the current time."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Jim Birchenough from Wells Fargo.",8,"Next, we have Jim Birchenough from Wells Fargo."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inje",88,"Just a question on the co-formulated ANG2 EYLEA product and referencing the data for the PDGF program. Is there anything in the co-formulation of the 2 drugs that limits the efficacy of each individual component, whether it's viscosity and ability to inject the full dose, the amount of protein you're giving to the back of the eye? I'm just trying to see if there's any learnings from the PDGF program that might inform how we should think about the co-formulation part of this for the ANG2 product?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway.",45,"Yes, we have no reason to think that there's any issues whatsoever with that or that, that would have contributed at all to the results and that the results, we believe, simply reflect the biology or the lack of biology here for the PDGF pathway."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Yatin Suneja from SunTrust.",7,"Next, we have Yatin Suneja from SunTrust."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?",42,"A question on PRALUENT. Could you comment on the value-based contract? I mean, we know Amgen mentioned that they are entering into value-based contract for their PCSK9. Is that happening with you? How do you see that impacting the dynamics going forward?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can",62,"Well, one thing I should mention is many plans do not have the ability at the present time to enter into these types of arrangements. So it's going to be a rarity that a plan is able to implement value-based price contracting. However, for those that can do it, we are working with those plans to establish a value-based contract, where appropriate."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Next, we have Biren Amin from Jefferies.",7,"Next, we have Biren Amin from Jefferies."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease.",38,"How do you think payers will define moderate-to-severe atopic dermatitis patients? Because we hear that community of derms don't typically follow EASI score at scales but instead look at value surface area to determine severity of disease."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the",80,"I think it varies by geography in Europe. EASI-75 or PASI 75 is the driver of definition of disease in psoriasis. And we anticipate that EASI-75 will be something we have to educate physicians on. And they're already preparing themselves for that. In the United States, you're correct. EASI scores are not relevant to the physicians and IGA scores are not specific enough. So we're working right now on plans with payers on how to better define the disease. George?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this dis",323,"Yes. We should just let you know that obviously in our studies, on average, the patients that we study had more than 50% of their body surface at baseline covered by this disease. And 1/4 of the patients had 85% or more of their body covered with this disease. This just shows how severely these patients are. And it's not just that their skin is covered with this rash, but this is a weepy, itchy, horrific rash that they just can't escape. And remarkably, enough as we said, despite the heavy burden of disease at baseline, almost 40% of these patients achieved a clearer, almost clear status. Rarely in this business do you have a privilege to be involved in a story like this that can make such a difference in patients' lives. And we've been lucky here at Regeneron that we've done this a couple of times already. But we think that Dupixent is really a once-in-a-lifetime story, where you can really impact such an important disease so dramatically, have an average 70% improvement among all patients. And the thing that's also so stunning to us about dupilumab is that it looks like it might have the promise to do likewise in a host of related allergic diseases, including the overall asthma population, where there again in the most uncontrolled severe population, once again the results are very impressive from our first pivotal study. And we think the same may be the case in a host of other allergic settings. So the short answer to your question is, unfortunately, there's a lot of patients who have more than 50% of their body surface covered. Those patients are certainly, by any category, considered severe patients. As Bob already told you, many of them have exhausted all other options. And we just hope that the -- all the other ancillary things don't keep these important patients from getting access to this important life-changing drug."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the de",407,"I would just amplify a tiny bit on what George has said, which is that contrasted to PRALUENT, where we knew that with PRALUENT, of course, that we could lower cholesterol rather dramatically. But to most patients, unless they're highly involved in the details of their care, which some are, but many, to them, that isn't the end-all, be-all, something they wake up every day wondering how to get that cholesterol down. Of course, if they've had a heart attack and everybody in their family does, and they do pay attention to that. But then there was the pushback, ""Well, you don't really know, do you, that it improves outcomes?"" We're just going on a hypothesis, even through there's a great deal of data to certainly support that hypothesis. So it's not a disease that people are clamoring to get treated and it's not outcomes that are readily in hand. Contrast that with PRALUENT, where these patients are desperate for treatment, truly desperate for treatment. And we're not talking about the topical treatments that are available, such as steroids that might become available when you're dealing with small areas of relatively mild to moderate disease. We're talking about the kind of patients George referred to, which are really quite significant. And these patients can see the outcome themselves. They can tell that they're doing better. And we see it in our studies, we see it in our questionnaires. We see it whether or not they're sleeping because they can scratch themselves so badly. I heard a story the other day, which practically -- it was group of us that practically brought us all to tears, where a little boy who was visiting his grandparents and so is cuddling and sleeping on the same bed with very bad atopic dermatitis said to his grandparents, ""Can you each hold one of my hands when I sleep, so I don't scratch myself so badly?"" I mean, think about that. This is a disease that people really are looking for treatments. And if we can get this drug approved, first, for adults and hopefully down the road for children, we can really provide something that they can tangibly feel. We're passionate about making sure that we remove all the barriers out there and we expect to work with patients, with doctors, with payers, with organizations to make sure that people are aware of this treatment and can get access to it."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Our final question comes from Phil Nadeau from Cowen and Company.",11,"Our final question comes from Phil Nadeau from Cowen and Company."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Analysts","Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there a set cycle for when discounts a",75,"Just one question on some of your prepared remarks. You mentioned that your competition for EYLEA is beginning to increase the discounts that they're offering. I wanted to understand the dynamics there a bit more. Is there a set cycle for when discounts are negotiated? And are there any signs that you're seeing that this is something that's demanded by payers? Or is this something that the competition is taking it upon themselves to do?"
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the disco",143,"There's really not -- remember, this is a Part B drug and it's really not the same kind of environment, where you have a timing and a cycle with patients. For the most part, there's some small amount of that, that goes on. But for the most part, the discounts and rebates that have been offered have been sort of directly back to the physicians' offices, et cetera, et cetera. We continually reevaluate that situation. We look at what the impact. We're very sensitive to doctors not have to make a choice of what to give their patients, what they might think the best drug would be because of a rebate situation or something like that. We think most retinal physicians don't do that. But we certainly understand the real world. And as the market shifts, we're prepared to react if necessary."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Executives","Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today.",42,"Great. Thank you all for joining the call today. As we mentioned before, the IR team and Bob, the Chief Financial Officer, will be available to answer any questions that didn't make it on the call. That ends the call for today."
33715,404125717,1076730,"Regeneron Pharmaceuticals, Inc., Q3 2016 Earnings Call, Nov 04, 2016",2016-11-04,"Earnings Calls","Regeneron Pharmaceuticals, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.",17,"Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect."
